a journey from

good to great



ANNUAL REPORT 2025-26

IBN SINA

The **IBN SINA**
Pharmaceutical Industry PLC

Quality We Assure



In the name of Allah
the most gracious, the most merciful

01 INTRODUCTION

04 About Us
05 Letter of Transmittal
06 Cover Story
08 বিজ্ঞপ্তি
10 Notice
12 Vision and Mission Statements
14 Forward Looking Statement
15 Strategic Objectives
16 Core Values and Code of Corporate Philosophy
17 Our Guiding Principles
18 Awards and Recognitions
20 Board of Directors
21 Corporate Management
22 Quality Policy
23 Corporate Profile
24 Directors' Profile

34 MANAGEMENT REPORT

34 Chairman's Address
37 চেয়ারম্যানের বিবৃতি
39 Directors' Report
53 পরিচালনা পর্ষদের প্রতিবেদন
66 Statement from the Managing Director
72 Financial Highlights
73 Horizontal and Vertical Analysis
74 Value Added Statement
75 Market Value Added Statement
76 Economic Value Added Statement
77 Performance Indicators
85 Shareholders' Information
86 Share Performance
87 Pattern of Shareholdings

88 SUSTAINABILITY INITIATIVES

88 Our Approach to Sustainability
92 Sustainable Development Goals
94 Integrated Report
98 Business Model
103 Financial Capital
104 Human Capital
108 Manufactured Capital
118 Intellectual Capital
129 Social and Relationship Capital
141 Natural Capital
146 Human Resource Accounting
148 Health, Safety and Environment

Contents

149 THE GOVERNANCE

149 Corporate Governance
158 Report of the Audit Committee
162 Nomination and Remuneration Policy and Evaluation Criteria
164 Nomination and Remuneration Committee (NRC) Report
165 Code of Conduct for the Board
169 Declaration on Financial Statements by MD and CFO
170 Statement of Directors Responsibilities for Financial Report
171 Dividend Distribution Policy
173 Unclaimed Dividend Information
174 Internal Control and Risk Management
177 Our Stakeholders Relation Policy
180 Organizational Chart
181 Certificate of Compliance
182 Compliance Status on Corporate Governance Code of BSEC

194 AUDITORS' REPORT AND FINANCIAL STATEMENTS

195 Independent Auditors' Report
199 Consolidated Statement of Financial Position
200 Consolidated Statement of Profit or Loss & Other Comprehensive Income
201 Consolidated Statement of Changes in Equity
202 Consolidated Statement of Cash Flows
203 Statement of Financial Position
204 Statement of Profit or Loss & Other Comprehensive Income
205 Statement of Changes in Equity
206 Statement of Cash Flows
207 Notes to the Consolidated Financial Statements

246 REPORTS OF THE SUBSIDIARY COMPANIES

246 The IBN SINA Natural Medicine Ltd.
257 The IBN SINA API Industry Ltd.
267 The IBN SINA Polymer Industry Ltd.

278 MISCELLANEOUS

278 Excerpts from 41st Annual General Meeting
279 Virtual Annual General Meeting (AGM) Logistics
280 প্রক্সি ফরম এবং হাজিরা পত্র



About us

The IBN SINA Pharmaceutical Industry PLC is committed to making sustainability an integral part to continually enable the people in good health for better life, improving the environmental and social performance through mainstream operations of health services ensuring availability of quality medicines which we commonly refer to as our corporate footprint.

The sustainability strategy articulates the company strategic commitment to sustainable development and is an integral part of our approach to a healthy life for human being as a whole.

The Companys' priority as a good corporate citizen is to earn money in ethical manner that is both socially and ecologically responsible and of obviously sustainable.



Letter of Transmittal

To
The Respected Shareholders;
Bangladesh Securities and Exchange Commission (BSEC);
Registrar of Joint Stock Companies and Firms (RJSC);
Dhaka Stock Exchange PLC (DSE);
Chittagong Stock Exchange PLC (CSE); and
Other Stakeholders of The IBN SINA Pharmaceutical Industry PLC.

Disclosures of Annual Report for the year ended June 30, 2026

Dear Sir(s)

Enclosed please find a copy of the Annual Report together with the Audited Statement of Financial Position as on June 30, 2026, Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year ended June 30, 2026 along with the Notes to the Consolidated Financial Statements and the Directors' Report, thereon of The IBN SINA Pharmaceutial Industry PLC for your kind information and record.

Thank you,
Yours sincerely,

Md. Kabir Hossain
Company Secretary

Dated: September 30, 2026

Cover Story

-a journey from good to great


The year 2025–26 marked a landmark chapter for The IBN SINA Pharmaceutical Industry PLC. In an increasingly dynamic and competitive pharmaceutical environment, the Company advanced with confidence, driven by the inspiring philosophy, to be great from good emphasizing prestigious market dominance. This theme reflects our unwavering commitment to excellence, continuous advancement, and the collective spirit that strengthens our contribution to healthcare and society.

Throughout the year, the Company attained notable achievements by integrating modern technologies, enhancing research and development capabilities, and elevating quality standards to ensure the uninterrupted supply of essential medicines to the people who rely on them. These accomplishments were made possible through the dedication and professionalism of our employees, the enduring support of our stakeholders, and the trust placed in us by millions of patients and healthcare professionals.

Despite prevailing global and domestic challenges, our financial performance demonstrated remarkable resilience, sustainable growth, and operational strength. More significantly, it highlighted the competence of our human capital, the solidity of our partnerships, and the unified vision that continues to guide our journey. Together, we expanded our presence across Bangladesh and further reinforced our reputation as one of the nation's dependable and progressive pharmaceutical manufacturers.

We believe that true success is not measured solely by financial achievements, but also creating the valued focusing in legacy and resilience as center future readiness and innovation. Taking the targets of reaching the absolutely peck of the industry, The IBN SINA Pharmaceutical Industry PLC of course, by the grace of Almighty Allah continue to overcome challenges, foster innovation, and contribute towards building a healthier and more sustainable future for generations to come.




Our Industry
• Pharma
• Natural
• Polymer
• API
New Product Launched
8 (Pharma)
4 (Natural)
Earnings Per Share (EPS) 25.43
Contribution to National Exchequer
2,487,757,631
Net Asset Value (NAV) Per Share
144.56
Net Profit after Tax
792,927,301
42
Years of Excellence

৪২তম বার্ষিক সাধারণ সভার বিজ্ঞপ্তি

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি-এর সম্মানিত শেয়ারহোল্ডারগণকে জানানো যাচ্ছে যে, আগামী ২৩ নভেম্বর ২০২৬, সোমবার সকাল ৯:৩০ টায় কোম্পানীর ৪২তম বার্ষিক সাধারণ সভা বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের আদেশ নং বিএসইসি/আইসিএডি/২০২৪/৩১৮/৮৭, তারিখ: ২৭ মার্চ ২০২৪ অনুসারে ডিজিটাল (ভার্চুয়াল) প্লাটফর্মের মাধ্যমে অনুষ্ঠিত হবে। সভায় নিম্ন বর্ণিত বিষয়সমূহ আলোচনা করা হবে :

আলোচ্যসূচি:

১. ৩০ জুন ২০২৬ সমাপ্ত অর্থ বছরের নিরীক্ষিত হিসাব এবং তার ওপর নিরীক্ষক ও কোম্পানীর পরিচালনা পর্ষদের প্রতিবেদন গ্রহণ ও অনুমোদন।

২. ২০২৫-২৬ অর্থ বছরের লভ্যাংশ অনুমোদন।

৩. পরিচালক নিয়োগ/নির্বাচন।

৪. ২০২৬-২৭ অর্থ বছরের জন্য নিরীক্ষক নিয়োগ এবং তাঁদের পারিশ্রমিক নির্ধারণ।

৫. ২০২৬-২৭ অর্থ বছরের জন্য কমপ্লায়ান্স অডিটর নিয়োগ এবং তাঁদের পারিশ্রমিক নির্ধারণ।

৬. সাবসিডিয়ারি কোম্পানী, দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি. এ বিনিয়োগ অনুমোদন।

৭. সাবসিডিয়ারি কোম্পানী, দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এ বিনিয়োগ অনুমোদন।

কোম্পানীর সম্মানিত শেয়ারহোল্ডারগণকে উক্ত সভায় যথাসময়ে অংশগ্রহণ করার জন্য অনুরোধ করা যাচ্ছে।

বোর্ডের আদেশক্রমে

তারিখ:
৩০ সেপ্টেম্বর ২০২৬

(মো. কবীর হোসেন)
কোম্পানী সেক্রেটারী

টীকা:

ক. রেকর্ড ডেট (২৬ অক্টোবর ২০২৬, সোমবার) এ কোম্পানীর শেয়ার রেজিস্টার অথবা ডিপোজিটরি রেজিস্টারে যে সকল শেয়ারহোল্ডারগণের নাম রেকর্ডভুক্ত থাকবে তাঁরাই কেবল বার্ষিক সাধারণ সভায় অংশগ্রহণ, ভোট প্রদান এবং লভ্যাংশ পাওয়ার যোগ্য বলে বিবেচিত হবেন;

খ. সভায় অংশগ্রহণ ও ভোট প্রদানে উপযুক্ত কোন শেয়ারহোল্ডার তাঁর পক্ষে অন্য কোন ব্যক্তিকে সভায় অংশগ্রহণ ও ভোটদানের জন্য প্রক্সি নিয়োগ করতে পারবেন। সভা অনুষ্ঠানের নির্ধারিত সময়ের অন্তত পক্ষে ৭২ ঘন্টা পূর্বে প্রক্সি ফরম ১০০.০০ টাকার রেভিনিউ স্ট্যাম্প সহকারে যথাযথভাবে পূরণ করে কোম্পানীর রেজিস্টার্ড অফিসে সরাসরি অথবা ই-মেইল shareipi@ibnsinapharma.com এর মাধ্যমে জমা দিতে হবে;

গ. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের আদেশ নং বিএসইসি/সিএমআরআরসিডি/২০০৬-১৫৮/২০৮/এডমিন/৮১, তারিখ ২০ জুন ২০১৮ অনুসারে, বার্ষিক প্রতিবেদন ২০২৫-২৬ এর সফট কপি শেয়ারহোল্ডারগণের কোম্পানীতে সংরক্ষিত স্ব-স্ব ই-মেইলের মাধ্যমে প্রেরণ করা হবে এবং কোম্পানীর ওয়েবসাইটেও (www.ibnsinapharma.com) পাওয়া যাবে;

ঘ. শেয়ারহোল্ডারগণ বার্ষিক সাধারণ সভা শুরুর ২৪ ঘন্টা পূর্ব থেকে এবং সভা চলাকালীন সময়ে ভার্চুয়াল লিংক (https://ibnsinapharma.bdvirtualagm.com) অথবা ই-মেইল (shareipi@ibnsinapharma.com) এর মাধ্যমে প্রশ্ন ও মন্তব্য এবং ভোটাধিকার প্রয়োগ করতে পারবেন। শেয়ারহোল্ডারগণ ১৬ সংখ্যার বিও আইডি/৫ সংখ্যার ফলিও নাম্বার সহ সংশ্লিষ্ট পরিচয় নির্দেশক তথ্য নিশ্চিত করে উক্ত লিংক এ লগইন করতে পারবেন;

ঙ. ২৩ নভেম্বর ২০২৬, সোমবার সকাল ৯:৩০ টায় মিটিং শুরুর পূর্বেই শেয়ারহোল্ডাগণকে 'সিস্টেমে লগইন' করার অনুরোধ করা যাচ্ছে। উল্লেখ্য সকাল ৯:১৫ টায় সরাসরি সম্প্রচার কার্যক্রম শুরু হবে। ভার্চুয়াল সভায় যুক্ত হতে প্রয়োজনে ০১৭০৯-৬৪৫০৮১ নাম্বারে যোগাযোগ করুন; এবং

চ. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিজ্ঞপ্তি নং এসইসি/সিএমআরআরসিডি/২০০৯-১৯৩/১৫৪, তারিখ ২৪ অক্টোবর ২০১৩ এবং ঢাকা স্টক এক্সচেঞ্জ লিস্টিং রেগুলেশনস, ২০১৫ ও চট্টগ্রাম স্টক এক্সচেঞ্জ লিস্টিং রেগুলেশনস, ২০১৫ মোতাবেক ৪২তম বার্ষিক সাধারণ সভায় কোন ধরনের উপহার/উপহার কুপন/খাদ্য বক্স বিতরণ করা হবে না।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর মুদ্রিত বার্ষিক প্রতিবেদন, ২০২৫-২৬ এর সফট কপির জন্য দয়া করে উপরের "কিউআর কোডটি" স্ক্যান করুন।

Notice of The 42nd Annual General Meeting

Notice is hereby given that the **42nd ANNUAL GENERAL MEETING** of the Shareholders of **The IBN SINA Pharmaceutical Industry PLC** will be held on **Monday, November 23, 2026** at 9:30 AM using **Digital Platform** pursuant to the BSEC's Directive BSEC/ICAD/2024/318/87, dated March 27, 2024 to transact the following businesses:

Agenda:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended 30 June, 2026 together with the Auditors' Report and the Directors' Report thereon.
2. To approve dividend for the year 2025-26.
3. To appoint/re-elect Directors.
4. To appoint Statutory Auditors for the Financial Year 2026-27 and to fixup their remuneration.
5. To appoint Compliance Auditors for the Financial Year 2026-27 and to fixup their remuneration.
6. To approve investment in the Subsidiary Company, The IBN SINA API Industry Ltd.
7. To approve investment in the Subsidiary Company, The IBN SINA Polymer Industry Ltd.

The respected Shareholders of the Company are requested to participate the meeting in time.

By Order of the Board of Directors

Md. Kabir Hossain
Company Secretary

Dated :
September 30, 2026

Notes:

1. The Shareholders whose names will appear in the Share Register of the Company or Depository Register (CDBL) on the "Record Date" i.e., Monday, October 26, 2026 are eligible to attend/participate and vote at the Annual General Meeting (AGM) and entitled to the Dividend;
2. A Member entitled to attend and vote at the Annual General Meeting, may appoint a proxy to attend and vote in his/her stead. The Proxy Form must be affixed with the revenue stamp of Tk. 100.00 and be sent physically at the Registered Office of the Company or through email: shareipi@ibnsinapharma.com at least 72 hours before the scheduled time of the AGM;
3. Pursuant to the BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, dated June 20, 2018, soft copy of the Annual Report, 2025-26will be sent to the Shareholders' respective e-mail addresses as available with us. The Annual Report, 2025-26 will also be available in the Company's website at: www.ibnsinapharma.com;
4. The Shareholders will be able to submit their questions/comments through virtual link (https://ibnsinapharma.bdvirtualagm.com) or e-mail (shareipi@ibnsinapharma.com) 24 hours before commencement of the AGM and during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficiary Owner (BO) ID/5-digit Folio Number and other credentials as proof of their identity in visiting the said link;
5. The Shareholders are requested to login to the system prior to starting the meeting at 09:30 AM on Monday, November 23, 2026. The webcast will start at 09:15 AM. Please contact at +8801709-645081 for any queries in accessing the virtual meeting; and
6. In compliance with the Bangladesh Securities and Exchange Commission's Circular No. SEC/CMRRCD/2009-193/154, dated October 24, 2013 and The Listing Regulations, 2015 of Dhaka Stock Exchange and Chittagong Stock Exchange, no Gift/Gift Coupon/Food Box shall be distributed at the ensuing 42nd AGM.

**Please scan the given "QR Code" instead of printing the report.
It contains the soft copy of the Annual Report, 2025-26 of
The IBN SINA Pharmaceutical Industry PLC**



Vision and Mission Statements




The IBN SINA Pharmaceutical Industry PLC's vision is to become a premier speciality pharmaceutical company, with a balanced focus in complementary therapeutic areas. Our primary responsibility lies towards the people of Bangladesh and ultimate responsibility towards humanity at large.



The IBN SINA Pharmaceutical Industry PLC is working for the nation as a whole with pertinacious incitement and firm determination to ensure the quality and ethical standing attributing the sustainable growth and development to serve the mankind.


The Board approved vision and mission statements of the Company. The Board of Directors at its 45th meeting redefined the Company's vision and mission. We are driving towards our vision.



Forward Looking


This forward looking statement predicts our outlook to the future actions as expectations or possibilities. Information in the Annual Report reveals the management's thinking and views based on commercial operation, business and economy during the year under review and future events and its proposition. However, these statements do not give assurance against certain probable risks and uncertainties. Therefore, actual future outcome and trends forecasted in the enterprising statements may differ significantly due to the following reasons:

- Changes in national economic and financial conditions;
- Changes in Government policy issues;
- Fluctuations in international prices which impact the foreign exchange rate;
- Instability of capital market;
- Changes in corporate tax structure and VAT in Pharmaceutical sector;
- Changes in the competitive markets of the country;
- Unusual forex volatality;
- Sudden ecological and demographical changes;
- Inconsistency of the factors regarding market competitors, suppliers and pricing;
- Global Supply Chain interruption for Geopolitical Issues.



Strategic Objectives

- To serve humanity by providing the highest quality of products and services;
- To maintain the ethical standard in all its functions;
- To contribute to the national SDGs Goals' indicators by adopting necessary policies for sustainable manufacturing, waste management, and economy principles;
- To follow WHO-cGMP requirements from procurement to finished goods;
- To march onward for sustainable growth and continuous improvements;
- To ensure consumers' satisfaction;
- Ensuring welfare oriented health services;
- To establish a set of managerial succession and adopting technological changes to ensure sustainable development of the Company;
- To invest in the thrust and priority sectors of the economy;
- To pay more importance in human resources as well as financial capital;
- To follow doctrine of lucrative career path, attractive facilities and excellent working environment;
- To ensure the compliance requirements with the regulatory issues;
- To provide impeccable and progressively better customer services adopting changed technologies;
- To train and develop human resources continuously;
- To motivate team members taking part in the job with sense of belongingness;
- To strengthen corporate governance best practice culture;
- To ensure Corporate Social Responsibilities (CSR) through all activities;
- Positive changes such as reversing climate and other environmental change and its related disclosures.



Core Values and Code of Corporate Philosophy

01. Trust in Almighty Allah;
02. Highest Principle of Honesty, Integrity and Conscience;
03. Equity and Justice;
04. Environmental Consciousness;
05. Adoption of Changed Technology and Advancement;
06. Proper Delegation, Transparency and Accountability;
07. Human interest is the first priority that is attached to the country's growth and prosperity;
08. Employees are trained with the object of developing leaders to be next successors;
09. Emphasize on creativity and innovation to achieve organizational excellence;
10. Employees have an obligation to know and understand not only the guidance contained in the Code of Conduct but also the spirit on which it is built;
11. Recognize the rights of shareholders in creating wealth, jobs and the sustainability of a financially sound enterprise;
12. Ensure timely and accurate disclosure of all material information regarding the entity;
13. Ensure strategic guidance of the company, effective monitoring of management and the Board's accountability to the company and the shareholders;
14 Monitor and assess how risk is minimized and how performance is maximized;
15. Customers Satisfaction;
16. Team Work in adherence with the truth and transparency;
17. In accordance with the agreed Code of Conducts, the Company;

a. Acts with integrity, competence, dignity and ethical manner while dealing with the stakeholders as a whole;

b. Acts and encourages others to behave in a professional and ethical manner;

c. Endeavors to maintain and improve the competence of all in the business;

d. Uses reasonable cart and exercise independent professional judgment;

e. Not restrains others from responding their professional obligations.

Ethical Principles

- Trustworthiness
- Legitimacy
- Integrity
- Objectivity
- Professional competence and diligence
- Faith-driven conduct
- Loyalty
- Law abiding


Our Guiding Principles


Commitments

- Regulators
- Community
- Environment
- Stakeholders
- Shareholders
- Customers
- Employees
- Patrons


Awards
and Recognitions


















ICSB
Institute of Chartered Secretaries of Bangladesh
ICSB National Award 2020
BRONZE AWARD
This is to Certify


ICSB
Institute of Chartered Secretaries of Bangladesh
ICSB National Award 2024
This is to Certify


ICSB
Institute of Chartered Secretaries of Bangladesh
ICSB National Award 2019
GOLD AWARD
This is to Certify


CERTIFICATE
OF APPRECIATION
15
CORPORATE AWARD
Pharmaceuticals Manufacturing
BRONZE AWARD
This is to Certify
The IBN SINA Pharmaceutical Industry PLC.
ICMAB


The Institute of Cost and Management Accountants of Bangladesh
ICMAB Best Corporate Award-2012
Certificate of Merit
To
The IBN SINA Pharmaceutical Industry Ltd.
Sector : Pharmaceutical


জাতীয় রাজস্ব বোর্ড
সম্মাননাপত্র


The Institute of Chartered Accountants of Bangladesh
Certificate of Appreciation

IBN SINA

Board of Directors

- **Kazi Harun or Rashid**
  Chairman
- **Prof. ANMA Zaher**
  Director
- **Prof. Dr. A K M Sadrul Islam**
  Managing Director
- **Prof. Dr. Choudhury Mahmood Hasan**
  Director
- **Prof. Col. (Retd.) Dr. Zehad Khan**
  Director
- **Dr. Mohammad Ayub Miah**
  Director
- **Md. Rafiqul Islam Khan** FCA
  Independent Director
- **Abdus Sadeque Bhuiyan**
  Independent Director
- **Ms. Parsa Begum**
  Independent Director

Corporate Management

Executive Committee

Prof. Dr. Choudhury Mahmood Hasan	Chairman
Prof. Dr. A K M Sadrul Islam	Member
Dr. Mohammad Ayub Miah	Member
Md. Kabir Hossain	Secretary

Audit Committee

Md. Rafiqul Islam Khan, FCA	Chairman
Dr. Mohammad Ayub Miah	Member
Abdus Sadeque Bhuiyan	Member
Md. Kabir Hossain	Secretary

Nomination And Remuneration Committee

Abdus Sadeque Bhuiyan	Chairman
Prof. Col. (Retd.) Dr. Zehad Khan	Member
Ms. Parsa Begum	Member
Md. Kabir Hossain	Secretary

CSR Committee

Prof. Dr. Shah Md. Bulbul Islam	Chairman
Prof. Dr. A K M Sadrul Islam	Member
Kazi Harun or Rashid	Member
Md. Kabir Hossain	Secretary

Chief Financial Officer

Md. Jasim Uddin, FCA

Company Secretary

Md. Kabir Hossain

Head of Internal Audit and Compliance

Abdur Rakib

Head of Share Department

Md. Aminur Rahman

Statutory Auditors

Malek Siddiqui Wali
Chartered Accountants
9-G, Motijheel C/A
Dhaka-1000

Compliance Auditors

SA Rashid & Associates
(Chartered Secretaries)
Noakhali Tower (12th Floor, 13-D)
55/B Purana Paltan, Dhaka-1000
Bangladesh

Bankers

Al-Arafah Islami Bank PLC
Islami Bank Bangladesh PLC
Sammilito Islami Bank PLC
Prime Bank PLC
Sonali Bank PLC
Pubali Bank PLC
Shimanto Bank PLC
City Bank PLC
Standard Bank PLC
Standard Chartered Bank


Registered Office

Tanin Center, 3 Asad Gate
Mirpur Road, Mohammadpur
Dhaka-1207, Bangladesh.

Corporate Website

www.ibnsinapharma.com

Quality Policy



The IBN SINA Pharmaceutical Industry PLC
is committed to

serve humanity by manufacturing and providing quality pharmaceutical products and services to its customers.

maintaining ethical standards in all its functions following the requirements of cGMP and regulatory authorities.

marching onward for sustainable growth and continual improvement.

Corporate Profile

Nature of Business:
Manufacturing and Marketing of
Pharmaceutical Products and Natural Medicine

	Subscription Opened on Initial Public Offerings (IPO) 15 July 1989	Authorized Capital Tk. 500,000,000	Company Crossed the Number of Products to 100 December 2003	OSD Production in a Distinct Compliant Plant 2019
Status Publicly Listed Company	Subscription Closed 14 September 1989	Paid up Capital Tk. 312,436,270	Started production and marketing of injectable products December 2004	ISO 9001:2015 Certification 19 October 2020
Certificate of Incorporation as Private Ltd. Company 22 December 1983	Listed in DSE 17 July 1990	No. of Securities (Shares) 31,243,627	Commercial Production in the state-of-art Natural Medicine Plant 2006	Recognized as Highest VAT Payer Company for 2020-21 from NBR 2022
Commercial Production Started May 1986	First Dividend Declared (After IPO) 31 March 1993 in the 7th AGM	Face Value Tk. 10	Registered as Depository Participant of CDBL 03 January 2009	Commencement of Natural Medicine business as subsidiary Company The IBN SINA Natural Medicine Ltd. 2022
Certificate of Commencement of Business 22 October 1988	Started production and marketing of Ophthalmic products 1995	Market Catagory "A"	Dematerialized Securities trading Started on 04 January 2009	API Products Trial Production Started December 2023
Converted into Public Ltd. Company 1989	Listed in CSE 24 December 1996	Electronic Share "Y"	Commercial Production in the state-of-art Cephalosporin Plant 2016	Pharma Unit-2 Under Validation 2026



Directors' Profile



Kazi Harun or Rashid
Chairman

Kazi Harun or Rashid comes from a noble family on 1st April, 1950. He is an M. Com. in Accounting He did his graduation from the University of Dhaka.

Kazi Harun or Rashid has been working The IBN SINA Pharmaceutical Industry PLC in different capacity as Director since 2016. He served the Company as Finance Director, Member, Executive Committee and Audit Committee with dedication and integrity. Presently he is working as the Chairman of the Company from June 16, 2021 to till now.

Kazi Harun or Rashid is a former Chairman, Board of Directors, of Islami Bank Bangladesh PLC and Chairman, Audit Committee of IBB PLC.

Kazi Harun or Rashid is also Director of The IBN SINA API Industry Ltd., Managing Director of The IBN SINA Natural Medicine Ltd.; Managing Director of The IBN SINA Polymer Industry Ltd., Managing Director of The IBN SINA Consumer Products Ltd., Chairman of Madaripur Adarsha Dakhil Madrasah, Vice Chairman of Uddam Foundation, and Member Finance of Board of Trustees, The IBN SINA Trust.

Kazi Harun or Rashid has 42 years of versatile professional and business expertise.



Prof. ANMA Zaher
Director

Prof. Abu Nasser Muhammad Abduz Zaher was born in a respectable Muslim family of Companygonj, Noakhali in the year 1948.

Prof. Zaher has been serving as Director of The IBN SINA Pharmaceutical Industry PLC since 1983.

He achieved his Master's Degree in English Literature. He started his professional life with teaching at Khandaker Mosharrof Hossain Degree College in the early seventies. Later he joined at the Royal Embassy of Kingdom of Saudi Arabia in Dhaka, Bangladesh as the Secretary of the Embassy and Ambassador and performed duties for about 13 years. He joined The IBN SINA Pharmaceutical Industry PLC in 1989 as Managing Director of the Company.

Prof. Zaher was Chairman of Islami Bank Bangladesh PLC, Chairman of Islami Banks Consultative Forum (IBCF), Chairman of Islami Bank Foundation, Chairman of Industrialists and Businessmen Welfare Foundation (IBWF), Vice Chairman of Bangladesh Association of Banks (BAB) and Board Member of General Council for Islami Banks and Financial Institutions (CIBAFI). He was the former Advisor and Vice Chairman of the Advisory Committee of the Bangladesh Association of Pharmaceutical Industries (BAPI). He was the former Member of The Accounting and Auditing Organization for Islamic Financial Institutions (AAOIFI), Islamic Financial Services Board (IFSB) and The International Association of Islamic Banks (IAIB); the former Country Head of World Islamic Economic Forum (WIEF) and Director, Board of Governors Independent Industrialists and Businessmen's Association (MUSIAD). He is the Founder of The IBN SINA Trust (IST) and Tamirul Millat Madrasah, Dhaka.

He is the Chairman of Badsha Faisal Trust and Founder Member of Fouad Foundation, Badshah Faisal Institute, Manarat International School and College, Ibn Tymia College, Islamic Education Society, Bangladesh Islamic Centre, Al Jamiatul Falahia, Jamia Quasimia; Founder, Board Member and Syndicate Member of Manarat International University of Bangladesh. He is also a Director of The IBN SINA Natural Medicine Ltd.



Prof. Dr. A K M Sadrul Islam
Managing Director

Prof. Dr. A K M Sadrul Islam was born on 7th April 1955 in Jashore. He did Ph.D in Mechanical Engineering from University of London, U.K. in 1988. He served BUET and Islamic University of Technology (a subsidiary organ of OIC) for 36 years as Professor and Head of Department from 1980 to 2016. He was a Visiting Professor of University Technology Malaysia; a Guest Professor of Institute of Ocean Energy, Saga University, Japan.

Prof. Islam is also Ex- Chairman, Mechanical Engineering Division, Institution of Engineers Bangladesh (IEB) and Vice-Chairman, Bangladesh Society of Mechanical Engineers (BSME). He served as a Director of Islami Bank Bangladesh PLC.

He has been serving the Company in different levels as Director, since 2003; Member, Executive Committee since 2005; and formerly Director, Finance, Chairman of the Audit Committee and Managing Director from 2014 to till now.

Prof. Islam is also a Director, The IBN SINA API Industry Ltd., The IBN SINA Natural Medicine Ltd., The IBN SINA Polymer Industry Ltd., IBN SINA Hospital Sylhet Ltd., IBN SINA Diagnostic Center, Lalbag Ltd. and Member of Board of Trustees of The IBN SINA Trust.



Prof. Dr. Choudhury Mahmood Hasan
Director and Chairman, Executive Committee

Prof. Dr. Choudhury Mahmood Hasan was born on 31st August 1953, in Chittagong District of Bangladesh. He obtained B. Pharm. (Hons) and M. Pharm. (Thesis group) degree from the Dhaka University, securing First position in First Class in both the examinations. He received his Ph.D. in 1982 from the Dept. of Pharmaceutical Chemistry at the University of Strathclyde, Glasgow, United Kingdom. He was awarded Commonwealth Scholarship for doing Ph.D. (1978-1981) in the University of Strathclyde, Glasgow, Commonwealth Academic Staff Fellowship (1990-1991) to work as a visiting scientist in the same university and Japan Society for the Promotion of Science (JSPS) Senior Fellowship (Nov-Dec, 2004) for doing research in Tokushima Bunri University, Tokushima, Japan.

Dr. Hasan joined the Department of Pharmacy, DU, in 28th January, 1978 and progressed through the ranks to Professor in the same department in March, 1992 and retired on 30th June 2019. He was the Chairman of this Dept. from 1992 to 1993. He was the Director of Drug Administration, Ministry of Health and Family Welfare, from July 1993 to January 1997. He was elected as the Dean of the Faculty of Pharmacy for two terms from 1999 to 2003. He was the Chairman of BCSIR (Bangladesh Council of Scientific and Industrial Research) from 11th August 2005 to 10th August 2008. He was the Vice-Chancellor of Manarat International University for four years from 13th October, 2012 to 12th October, 2016.

He was the member of Pharmacy Council (1993-1997, 2001-2008) and also the Chairman of Accreditation and Education Committee. Dr. Hasan, as a member of expert committee, played the pivotal role for the inclusion of "herbal drugs" in the National Drug Policy 2005 and which later on incorporated in the Drug Ordinance 2005.

Prof. Dr. Choudhury Mahmood Hasan is Emeritus Professor, Department of Pharmaceutical Chemistry, Dhaka University, from 2nd February 2026 to present. His research focuses on the chemical and biological studies of local medicinal plants with emphasis on structure elucidation of the secondary metabolites by spectroscopic techniques (UV, IR, NMR, MS etc.). So far he supervised/co-supervised the research of 14 Ph.D and more than 65 M.Pharm. students of Dhaka University. At present he is supervisor/co-supervisor of 8 Ph.D and 3 M.Pharm students. He is the main/co-author of 318 peer-reviewed papers published in international and national scientific journals. He was the chairman/ co-chairman/ plenary lecturer/ presenter/ participator in 66 international seminars/symposium/workshop held in 25 countries of the world (including UK, USA, Japan, Canada, Germany, Sweden, Spain, Australia etc.). He has more than 5315 (h-index 38, i10-index 143) citations in Google Scholar.

For his outstanding contribution in medicinal plant research and in biological science he was awarded Habibur Rahman Gold Medal 2003, Bangladesh Academy of Science Gold Medal 2006 (senior group), Chandrabati Gold Medal 2007 and Atish Dipankar Gold Medal 2008.

Dr. Hasan is a member of American Chemical Society (ACS), American Society of Pharmacognosy (ASP), Fellow of Bangladesh Academy of Sciences (FBAS) and Fellow of Royal Society of Chemistry (FRCS). Vice-President of Bangladesh Academy of Sciences (FBAS) from 2019 -2025.

He was a Director of Essential Drug Company Ltd (EDCL) owned by Government of Bangladesh. (1993-1997). Dr. Hasan is also a Director of The IBN SINA API Industry Ltd., The IBN SINA Natural Medicine Ltd. and The IBN SINA Polymer Industry Ltd. Prof. Dr. Choudhury Mahmood Hasan is the Chairman of the Board of Trustees of The IBN SINA Trust (IST).



Professor Col. (Retd.) Dr. Zehad Khan
Director

Professor Col. Dr. Zehad Khan (Retd.) was born in a noble family in the district of Kishoreganj in the year 1957. He secured 21st position in SSC examination from Dhaka Board in 1976. He got admitted in Dhaka Medical College in 1978. But he was awarded the scholarship of ex. Soviet Union and obtained MD degree from Abu Ali IBN SINA Medical College, Tajikistan in 1986.

Dr. Khan received MCPS in 1997 and FCPS in 1998. After working at Cardiology Department in Combined Military Hospital (CMH), Dhaka for three years, he went to Germany for one and half year. He completed advanced training in Interventional Cardiology under renowned Professor KH KUCK there. Due to his significant contribution in medical treatment, he received FRCP from Royal College of Physicians and Surgeons (Glasgow) and FACC from Amirican College of Cardiology.

Dr. Khan joined in Bangladesh Army Medical Corps in 1988. He worked in different Combined Military Hospitals (CMH), Chittagong Hill Tracts and United Nation's Hospital in Ivory Coast. He also worked as a Professor in Armed Forces Medical College, Dhaka.

Dr. Khan retired from Bangladesh Army in 2014. Now, he is working as a Senior Consultant Cardiology in IBN SINA Cardiac Center, IBN SINA Hospital, Dhanmondi. He is also working as a visiting Professor in Abdul Hamid Medical College and as an honorary Professor in IBN SINA Medical College.

Dr. Khan introduced Transradial Intervention (Angiogram and through hand Arteries) in Combined Military Hospital (CMH), Dhaka. He also introduced Electrophysiology in that Hospital with successful treatment of arrhythmia.

Dr. Zehad Khan served as Director of The IBN SINA Pharmaceutical Industry PLC since 2016 to 2018.

He is a member of Cardiac Interventional Society, Bangladesh, Chairman of various Social Welfare Associations like AN Foundation, PRAC. He is member of governing body of Tamirul Millat Kamil Madrasah, Tongi.

He is also a Director of The IBN SINA Natural Medicine Ltd., The IBN SINA API Industry Ltd. and Member of Board of Trustees of The IBN SINA Trust.



Dr. Mohammad Ayub Miah
Director

Dr. Mohammad Ayub Miah is a specialist in Institutionalization of Zakat Management, Policy and Administrative Reforms, Agriculture, Food and Industrial Policy Reforms, SME Development, Islamic Social Finance Specialist, Corporate Governance, Poverty Alleviation Strategies etc.

Dr. Mohammad Ayub Miah has got a brilliant and ornamental career in the Bangladesh civil service for long 30 years. He served in as many as 15 Ministries and attached Departments of the Government of Bangladesh in different capacities. Before retirement he worked as Secretary in the Ministry of Food & Disaster Management and Ministry of Water Resources. He acted as the founder Managing Director of Small & Medium Enterprise (SME) Foundation under Ministry of Industries.

He represented the Government of Bangladesh in the Board of Directors of different public and private sector enterprises including Unilever Bangladesh, Reckit & Bankiser, Shilpa Bank, Atlas Bangladesh, Bangladesh Sugar & Food Industries Corporation, Bangladesh Steel Mills Corporation, Bangladesh Small & Cottage Industries Corporation, and Triple Super Phosphate Company.

After his retirement from the civil service he has been working as Chief Executive Officer (CEO) of Center for Zakat Management (CZM) for last seventeen years. CZM is a non-profit organization promoting Zakat, Islamic Social Finance and advocating for institutionalizing zakat for poverty alleviation and human development.

Dr. Miah is the Chairman of The IBN SINA Natural Medicine Ltd. and Director of The IBN SINA Polymer Industry Ltd., Subsidiary Company of The IBN SINA Pharmaceutical Industry PLC and Member of Board of Trustees of The IBN SINA Trust.

Dr. Mohammad Ayub Miah obtained his Bachelor and Master's degree in Political Science and Ph.D. in Public Administration from the University of Dhaka. He was awarded Post Graduate Certificate on Advanced Studies in Economic and Social Studies from Victoria University of Manchester, U.K. He completed a senior management training course from Birmingham University and Civil Service College, London. He obtained various trainings in foreign countries including USA, UK, Japan, Switzerland, China, Singapore etc. He was born in 02 December 1954 at Patuakhali.

During the Interim Government in 2025-26, he made significant contribution as a member of Public Administration Reform Commission and National Consensus Commission.



Md. Rafiqul Islam Khan FCA
Independent Director and Chairman, Audit Committee

Md. Rafiqul Islam Khan FCA was born on 25th March, 1952 in a noble muslim family. He qualified as chartered Accountant from the Institute of chartered Accountants of Bangladesh (ICAB) in the year 1978 and also awarded as fellow member of ICAB in the year 1986.

Md. Rafiqul Islam Khan FCA took Bachelor of Commerce from University of Dhaka in 1970. He was Director of Dhaka Chamber of Commerce and Industry (DCCI) and was a councillor of the Institute of Chartered Accountants of Bangladesh (ICAB).

Mr. Khan was the Chief Officer (Finance & Accounts) of Trading Corporation of Bangladesh (TCB) for six years and General Manager, Desh Group for five years. He was founder chairman and Managing Director of Aman knitting Ltd. a sweater factory and Sub Cherry Body Fashion MFTY Ltd. (a fashion wear factory).

Mr. Khan is a Member National Council, Diabetic Association of Bangladesh (BADAS), Member, Board of Management BIRDEM and Member, Board of Management, Bangladesh Institute of Health Services (BIHS). He is also Independent Director of The IBN SINA Polymer Industry Ltd.

He has about 43 years of experience in the arena of Auditing, Taxation, Project Consultancy, Investment and Foreign Investment Promotion, etc.



Abdus Sadeque Bhuiyan

Independent Director and Chairman, Nomination and Remuneration Committee (NRC)

Bachelor and Master's Degree in Social Welfare from the University of Dhaka. He has completed the Diplomaed Associate of the Institute of Bankers, Bangladesh (DAIBB). Mr. Bhuiyan, former Deputy Managing Director of Islami Bank Bangladesh Limited commenced his career by joining IBBL on February 07, 1984.

He has 34 years of versatile professional experience and expert in Banking, Finance, Human Resource and Administration etc. Now he is serving as Independent Director and Chairman of the Nomination and Remuneration Committee (NRC) of The IBN SINA Pharmaceutical Industry PLC from 16th January 2022 to till now.

During his long professional career, he attended various national and international training and participated in seminars, workshops & symposiums on Banking and Finance in USA, UK, Canada, Singapore, China, Australia, Malaysia, Hong Kong, UAE, Thailand and Nigeria.

He was Chief Anti Money Laundering Compliance Officer (CAMLCO) and Head of Risk Management Wing (RMW) of Islami Bank Bangladesh Ltd. during his service period.

He also acted as the Treasurer of Association of Anti Money Laundering Compliance Officer's of Banks in Bangladesh (AACOBB).

Abdus Sadeque Bhuiyan has attachment with different associations like Member of the Association of Bankers Bangladesh (ABB) and also life Member of Registered Graduate of Dhaka University & Member of Alumni Association of University of Dhaka.

Abdus Sadeque Bhuiyan is also Independent Director of The IBN SINA API Industry Ltd. and The IBN SINA Natural Medicine Ltd. Subsidiary Companies of The IBN SINA Pharmaceutical Industry PLC.



Ms. Parsa Begum
Independent Director

Parsa Begum is an accomplished professional with over three decades of experience in tax and revenue administration of People's Republic of Bangladesh. She has started her professional career as Assistant Commissioner of Taxes in 1981. She joined as a First Secretary (Income Tax Law) in 2000 and upgraded as Commissioner of Taxes in 2001. She has held various prominent positions, including President of the Taxes Appellate Tribunal and Member of the National Board of Revenue (NBR) in Bangladesh.

Mrs. Begum holds a Master of Arts in English and a Bachelor of Laws (LLB.) from the University of Dhaka. She has accrued a Higher Diploma in Arabic language (Junior, Senior Diploma, Higher Diploma-four years course) from the Modern Language Institute, University of Dhaka. She completed a training on Tax Policy for Asian and Pacific countries on Tax Incentives (2008) from International Monetary Fund, Japan. She obtained various trainings in foreign countries including Harvard University USA, UK, Japan, Malaysia etc.



Kazi Harun or Rashid
Chairman, IPI

Chairman's Address

Bismillahir Rahmanir Rahim

The Respected Shareholders

Assalamu Alaikum Wa Rahmatullah

We are delighted to welcome you all at the 42nd Annual General Meeting of The IBN SINA Pharmaceutical Industry PLC (IPI). In this auspicious occasion we would like to present to you the Annual Report for the year 2025-26 showing the financial position, achievement and the notable performance of the Company.

Business Overview

The year 2025–26 marked a period of steady progress and strategic resilience for The IBN SINA Pharmaceutical Industry PLC, as the Company continued to strengthen its position within Bangladesh's competitive pharmaceutical landscape. Amid evolving global economic uncertainties, supply chain adjustments, and inflationary pressures, the Company demonstrated operational agility, ensuring uninterrupted production and consistent market supply of quality medicines.

In Bangladesh, the pharmaceutical sector maintained robust growth, driven by rising healthcare awareness, expanding access to medical services, and supportive regulatory frameworks promoting local manufacturing. Capitalizing on these favorable dynamics, The IBN SINA Pharmaceutical Industry PLC expanded its product portfolio, enhanced production efficiency, and reinforced its commitment to quality compliance and innovation.

Globally, the pharmaceutical industry experienced moderate growth influenced by cost pressures, regulatory complexities, and increasing demand for affordable healthcare solutions in emerging markets. Aligning with these trends, the Company focused on sustainable growth strategies, export diversification, and technological advancement to remain competitive in international markets.

With a strong emphasis on research, operational excellence, and human capital development, the Company continues to uphold its mission of delivering safe, effective, and affordable healthcare solutions. Looking ahead, it remains well-positioned to achieve long-term growth and create sustainable value for all stakeholders.

Financial Performance

I am pleased to report that despite the volatility in the foreign currency rate, high inflation, and liquidity crisis in the Banking System, IBN SINA Pharma has achieved steady growth of financial performance in 2025-26. To ascertain promising future our people worked diligently forwards lasting program in all areas and parameters for our stakeholders.

The key performances achieved during the year:

Revenue 13,899,792,434	Operating Profit 1,160,166,625
Profit after Tax 792,927,301	Earnings per Share 25.43

All the indicators mentioned above show that the Company is progressing and doing well. We are hopeful to perform even better in the years to come as well.

Outlook for FY, 2026-27

With the continuous focus on rigorous marketing, growing portfolio of 40 products of 25 generics increasing global registrations for new international markets and developing well-trained sales work force, we expect to see continued revenue growth both locally and globally.

Operational efficiency

To enhance optimization of operational efficiency in FY 2025–26, The IBN SINA Pharmaceutical Industry PLC is advancing a comprehensive operational excellence agenda focused on productivity, quality, and sustainable growth. The company is leveraging data-driven insights from the production floor to optimize resource utilization and minimize process variability. Capacity utilization across manufacturing facilities has been systematically analyzed to strengthen output efficiency and support ongoing expansion initiatives. These strategic initiatives are enabling higher operational agility, cost efficiency, and long-term value creation for stakeholders across value chain.

Permanent Corporate Office

You will be happy to know that Company is going to shift its Corporate Head Office in a state-of-art building-, "Concord Lily Heights", Plot-08, Road-16, Dhanmondi, Dhaka to secure a centralized anchor for its legal status, operational governance, and long-term brand identity which is our long cherished expectation for a permanent foundation for growth and stability. The matter will duly be informed to all concerned upon completion of required formalities in this regard.

Today's initiatives for brighter future

Looking ahead, we remain optimistic and well-suited to adapt the changing market condition, and the strategic initiatives to reach planned destination expecting to keep continuation of sustainable growth.

The future is of great opportunities, the Board is vigilant to look forward with a sense of direction and concern for better future of the Company. To ensure competitiveness in the market, we are now in track to expand our domestic market through redesigning the distribution system, enriching and diversifying our product portfolio and the manufacturing capacities in different technical aspects.

I am confident the company will continue its success with the support from all its stakeholders.

Appreciation

Dear Brother and Sister (s),

We hope the year 2026-27 will continue to be another successful year for The IBN SINA Pharmaceutical Industry PLC. We remain confident that we are taking the right actions to continue to grow the businesses and deliver value-for-money to our shareholders. Thank you very much for your continued trust on us.

The Board of Directors accepts with gratitude the reviews, criticism and suggestions of our valued shareholders and consider them as a catalytic factor in attainment of the success and continued progress of the Company.

I sincerely show my immense impression for the dedication, commitment and skills of the employees of all levels and acknowledge for the contributions made by the management to bring this success. It is their efforts that drive the business forward, delivering excellent performance and strong growth across our businesses. The success we have achieved is only possible because of the collective efforts of all concerned. I thankfully acknowledge their contributions to the Company.

We are grateful to our valued customers, well-wishers, healthcare professionals, bankers, suppliers, Bangladesh Securities and Exchanges Commission, Dhaka Stock Exchange PLC, Chittagong Stock Exchange PLC, Central Depository Bangladesh Ltd., Bangladesh Association of Publicly Listed Companies (BAPLC), Registrar of Joint Stock Companies and Firms, National Board of Revenue (NBR), Government Agencies and all other concerned.

Lastly, I pray to the Almighty Allah (swt) to bless us with success and help us in our endeavor marching towards a bright future and benevolence to our people as a whole, and also show our profound gratitude recalling the memories of the founding directors, promoters of the Company for their significant contributions in the health sector until their death. Let us all please join praying to the Almighty Allah (swt) for their eternal peace and place in the Jannatual Ferdous, Ameen.



Kazi Harun or Rashid
Chairman

চেয়ারম্যানের বিবৃতি

বিসমিল্লাহির রাহমানির রাহীম

সম্মানিত শেয়ারহোল্ডারগণ,

আসসালামু আলাইকুম ওয়া রাহ্‌মাতুল্লাহ।

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর ৪২তম বার্ষিক সাধারণ সভায় আপনাদের সবাইকে জানাই আন্তরিক শুভেচ্ছা ও মোবারকবাদ। আজকের এ মহতী অনুষ্ঠানে ২০২৫-২৬ অর্থ বছরে কোম্পানীর আর্থিক অবস্থা, গৃহীত অর্জন সমূহ এবং উল্লেখযোগ্য তৎপরতার বিবরণ আপনাদের সামনে পেশ করা হলো।

সংক্ষিপ্ত ব্যবসায়িক বিবরণ

২০২৫-২৬ অর্থ বছরটি দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি-এর জন্য ছিল অগ্রগতি, স্থিতিশীলতা ও কৌশলগত সক্ষমতার বছর। বৈশ্বিক অর্থনৈতিক অনিশ্চয়তা, মূল্যস্ফীতি ও সরবরাহ ব্যবস্থার নানা চ্যালেঞ্জের মধ্যেও কোম্পানী উৎপাদন কার্যক্রম সচল রেখে বাজারে মানসম্মত ও নিরবচ্ছিন্ন ওষুধ সরবরাহ নিশ্চিত করেছে।

দেশে ক্রমবর্ধমান স্বাস্থ্য সচেতনা বৃদ্ধি, চিকিৎসা সেবার প্রসার এবং স্থানীয় উৎপাদনকে উৎসাহ দান সহায়ক নীতিমালা প্রণয়নের ফলে ওষুধ শিল্পখাত শক্তিশালী প্রবৃদ্ধি অর্জন করতে সক্ষম হয়েছে। চলমান অনুকূল পরিবেশকে কাজে লাগিয়ে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি তাদের পণ্যের পরিসর আরও বিস্তৃত করেছে। উদ্ভাবনী দক্ষতা ও উৎপাদন সক্ষমতা বৃদ্ধির পাশাপাশি পণ্যের গুনগত মান সংক্রান্ত বিধি-বিধান আপোসহীনভাবে পরিপালন করা হচ্ছে।

সাশ্রয়ী স্বাস্থ্য সেবার ক্রমবর্ধমান চাহিদা, বাড়তি ব্যয় এবং নিয়ন্ত্রণ ব্যবস্থা সহজতর না হবার কারণে বৈশ্বিক ভাবে ওষুধ শিল্পখাতের প্রবৃদ্ধি কাঙ্ক্ষিত মানে পৌছাতে পারেনি। কোম্পানী আন্তর্জাতিক প্রতিযোগিতামূলক বাজারে রপ্তানী কার্যক্রমে ক্রমবর্ধমান প্রবৃদ্ধি অর্জনের লক্ষে পণ্যে বৈচিত্র আনয়ন এবং প্রযুক্তির সর্বোত্তম ব্যবহারের প্রতি গুরুত্বারোপ করেছে।

কোম্পানী নিরাপদ, কার্যকর ও সাশ্রয়ী স্বাস্থ্যসেবা প্রদানের লক্ষ্যে গবেষণা, পরিচালনাগত উৎকর্ষ এবং মানব সম্পদের উন্নয়ন ও যথাযথ ব্যবহারের প্রতি গুরুত্ব আরোপের মাধ্যমে দীর্ঘমেয়াদী টেকসই প্রবৃদ্ধি অর্জন এবং সকল অংশীজনের স্বার্থ সংরক্ষণে দৃঢ় প্রতিজ্ঞ রয়েছে।

আর্থিক অর্জন

বৈদেশিক মুদ্রার অপ্রতুলতা, উচ্চ মূল্যস্ফীতি ও তারল্য সংকট সত্ত্বেও কোম্পানী ২০২৫-২৬ অর্থ বছরে কাঙ্ক্ষিত আর্থিক ফলাফল অর্জনের ধারাবাহিকতা ধরে রাখতে সক্ষম হয়েছে। সুন্দর ভবিষ্যৎ বিনির্মাণের লক্ষ্যে সামগ্রিক মূল্যবোধকে ধারণ করে সকল অংশীজনের জন্য প্রত্যাশিত ফলাফল অর্জনের স্বার্থে আমাদের কর্মীগণের ক্লান্তিহীন পরিশ্রম অব্যাহত রয়েছে।

আলোচ্য অর্থ বছরে কোম্পানীর উল্লেখযোগ্য অগ্রগতি ও অর্জন সমূহের বিবরণ নিম্নে উপস্থাপন করছি :

বিক্রয় ১৩,৮৯৯,৭৯২,৪৩৪	পরিচালনা মুনাফা ১,১৬০,১৬৬,৬২৫
কর পরবর্তী মুনাফা ৭৯২,৯২৭,৩০১	শেয়ার প্রতি আয় ২৫.৪৩

ওপরের সূচক সমূহ কোম্পানীর উন্নয়নের সংক্ষিপ্ত চিত্র প্রকাশ করছে। আরও সমৃদ্ধি আনয়নের ইপ্সিত লক্ষ্যে আমাদের নিরবচ্ছিন্ন প্রচেষ্টা অব্যাহত আছে। আগামীতে অধিকতর সাফল্য অর্জনের ব্যাপারে আমরা দৃঢ় প্রতিজ্ঞ ও আশাবাদী।

২০২৬-২৭ অর্থবছরের সম্ভাবনা

ক্রমবর্ধমান ভাবে পণ্য বাজারজাতকরণের ওপর বিশেষ গুরুত্ব প্রদান অব্যাহত রয়েছে। আগামী বছর আমাদের পণ্য তালিকায় ২৫টি জেনেরিক এর আরও ৪০টি নতুন পণ্য যুক্ত হবে ইনশাআল্লাহ। বৈদেশিক নিবন্ধন সম্প্রসারণ এবং সুদক্ষ সেলস

ফোর্স গঠনের মাধ্যমে আমরা দেশীয় ও আন্তর্জাতিক বাজারে কাঙ্ক্ষিত রাজস্ব আহরণের ব্যাপারে আশাবাদী। যা কোম্পানীর দীর্ঘমেয়াদি টেকসই প্রবৃদ্ধিকে আরও বিস্তৃত করবে।

কার্যক্রমের দক্ষতা বৃদ্ধি

কোম্পানী উৎপাদন সক্ষমতাকে সামনে রেখে সম্পদের সর্বোত্তম ব্যবহার নিশ্চিত পূর্বক উৎপাদন ব্যয় যৌক্তিক পর্যায়ে রাখার জন্য সদা সচেষ্ট রয়েছে। চলমান সম্প্রসারিত কার্যক্রম পুঙ্খানুপুঙ্খ বিশ্লেষণের মাধ্যমে উৎপাদন সক্ষমতার আকার বর্ধিতকরণের কৌশল অবলম্বন করা হয়েছে। কৌশলগত এই উদ্যোগগুলো ব্যয় সাশ্রয়ে অধিকতর কার্যকরের ফলে সকল অংশীজনের দীর্ঘমেয়াদী কাঙ্ক্ষিত স্বার্থ সংরক্ষণে সহায়ক হবে।

কোম্পানীর স্থায়ী কর্পোরেট অফিস

আপনারা জেনে আনন্দিত হবেন যে, কোম্পানী শীঘ্রই তার কর্পোরেট অফিস ধানমন্ডিতে দৃষ্টি নন্দন ভবনে স্থানান্তর করতে যাচ্ছে। নিজস্ব অফিস থেকে কোম্পানীর ব্যবসায়িক কার্যক্রম পরিচালনা করা ছিল আমাদের দীর্ঘদিনের লালিত স্বপ্ন। এ সংক্রান্ত প্রয়োজনীয় কার্যাদি সম্পন্ন হওয়ার পর যথারীতি সংশ্লিষ্ট সকলকে বিষয়টি অবগত করা হবে, ইনশাআল্লাহ।

ভবিষ্যৎ মজবুত অবস্থানের জন্য গৃহীত উদ্যোগ সমূহ

বৈশ্বিক অর্থনীতির অনিশ্চয়তা বিরাজমান থাকা সত্ত্বেও আমাদের সতর্ক ও কৌশলী পদক্ষেপ সমূহ কোম্পানীকে দৃঢ়তার সাথে সামনের দিকে এগিয়ে নেয়ার ব্যাপারে গুরুত্বপূর্ণ ভূমিকা পালন করবে বলে আমরা আশাবাদী। বাজারের পরিবর্তিত পরিস্থিতিকে সামনে রেখে পরিকল্পিতভাবে গন্তব্যে পৌঁছার জন্য পরিচালনা পর্ষদ কর্তৃক গৃহীত উদ্যোগ সমূহ টেকসই উন্নয়নের ধারাবাহিকতা অক্ষুণ্ণ রাখবে।

পরিচালনা পর্ষদ ইবনে সিনা ফার্মার উজ্জ্বল ভবিষ্যৎ বিনির্মাণের জন্য সকল সুযোগের পূর্ণ সদ্ব্যবহার করতে সদা সতর্ক। বিতরণ ব্যবস্থায় আধুনিক প্রযুক্তির সর্বোত্তম ব্যবহার করায় অভ্যন্তরীণ বাজারে কোম্পানীর অবস্থানের ক্রমশ দ্রুত বিস্তৃতি ঘটছে।

সংশ্লিষ্ট অংশীজনের সম্প্রসারিত সহযোগিতার অদম্য প্রয়াস আমাদের উন্নয়নের অগ্রযাত্রাকে আরও বেগবান করবে বলে আমরা দৃঢ়ভাবে প্রত্যাশা করি।

প্রিয় ভাই ও বোনেরা,

২০২৬-২৭ অর্থ বছর কোম্পানীর জন্য আরও সুসংবাদ বয়ে আনার ব্যাপারে আমরা আশাবাদী। আমরা দৃঢ়তার সাথে বলতে চাই যে, ব্যবসায়িক প্রবৃদ্ধি অর্জন ও স্টেকহোল্ডারগণের স্বার্থ সংরক্ষণের লক্ষ্যে আমরা উপযুক্ত পদক্ষেপ গ্রহণ করেছি। আমাদের প্রতি আপনাদের গভীর আস্থা ও বিশ্বাসের জন্য আন্তরিক ধন্যবাদ জ্ঞাপন করছি।

শেয়ারহোল্ডারগণের মতামত, গঠনমূলক সমালোচনা ও পরামর্শকে পরিচালনা পর্ষদ গুরুত্ব সহকারে গ্রহণ এবং এটিকে অগ্রগতি ও সাফল্য অর্জনের মূল চালিকাশক্তি হিসেবে গণ্য করে।

আমি সাফল্য অর্জনে অবদান রাখার জন্য কোম্পানীর ব্যবস্থাপনা কর্তৃপক্ষ ও সর্বস্তরের দক্ষ কর্মকর্তা-কর্মচারী-শ্রমিকগণের অর্থবহ সহযোগিতার জন্য আন্তরিক ধন্যবাদ ও কৃতজ্ঞতা জানাচ্ছি। সকলের আন্তরিক প্রচেষ্টা ব্যবসায়িক প্রবৃদ্ধি অর্জনকে শক্তিশালী করেছে। আমরা যে সাফল্য অর্জন করেছি তা মহান আল্লাহর রহমতে সকলের সম্মিলিত প্রচেষ্টার কারণেই সম্ভব হয়েছে। আমি সংশ্লিষ্ট সকলের অবদানের কথা কৃতজ্ঞতার সাথে স্বীকার করছি।

আমি আরও কৃতজ্ঞতা জ্ঞাপন করছি, আমাদের সম্মানিত ক্রেতাসাধারণ, শুভাকাঙ্ক্ষী, চিকিৎসক, ব্যাংকার, সরবরাহকারী, বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন, ঢাকা স্টক এক্সচেঞ্জ পিএলসি, চট্টগ্রাম স্টক এক্সচেঞ্জ পিএলসি, সেন্ট্রাল ডিপোজিটরি বাংলাদেশ লিমিটেড, বাংলাদেশ এসোসিয়েশন অব পাবলিকলী লিস্টেট কোম্পানিজ, রেজিস্ট্রার অব জয়েন্ট স্টক কোম্পানিজ এন্ড ফার্মস, জাতীয় রাজস্ব বোর্ড, শ্রম অধিদপ্তর, কলকারখানা ও প্রতিষ্ঠান পরিদর্শন অধিদপ্তর, ভোক্তা অধিকার সংরক্ষণ অধিদপ্তর, নিরাপদ খাদ্য কর্তৃপক্ষ, বিভিন্ন জেলা প্রশাসন, পুলিশ প্রশাসন, বিভিন্ন আইনজীবী সমিতি সহ সরকারি বিভিন্ন সংস্থাসমূহ এবং কোম্পানীর ব্যবসার সাথে সংশ্লিষ্ট সবাইকে তাঁদের অব্যাহত সহযোগিতার জন্য।

আমি কোম্পানীর ভবিষ্যৎ উন্নয়ন, উন্নতি ও অগ্রগতি এবং সর্বোপরি দেশ ও জাতির কল্যাণের জন্য মহান আল্লাহ পাকের দরবারে দোয়া করছি।

পরিশেষে আমি গভীর শ্রদ্ধার সাথে স্মরণ করছি কোম্পানীর প্রতিষ্ঠাকালীন পরিচালকগণকে যাঁরা আমৃত্যু স্বাস্থ্যখাতে অসামান্য অবদান রেখে গেছেন। মহান আল্লাহ পাক তাঁদেরকে জান্নাতুল ফেরদাউস নসীব করুন, আমীন।

কাজী হারুন অর রশিদ
চেয়ারম্যান



Directors' Report

Bismillahir Rahmanir Rahim

Distinguished Shareholders,

Assalamu Alaikum Wa Rahmatullah

We have the pleasure to welcome you on behalf of the Board of Directors at the 42nd Annual General Meeting of The IBN SINA Pharmaceutical Industry PLC (IPI) and present before you to receive, consider and adopt the Audited Financial Statements of the Company for the year ended on June 30, 2026 together with the Auditors' Report and Directors' Report thereon, for your valuable guidance, opinion and consideration. The Directors' report will enable our shareholders, users and other readers to get a sound insight into our business and performance for the year, 2025-26 and our future outlook. We express our gratitude to Almighty Allah (swt) for the Company's business achievement in 2025-26.

This report has been prepared in compliance with Section 184 of the Companies Act, 1994, Rule 12 of The Securities and Exchange Commission Rules, 1987, Corporate Governance Code June 3, 2018 of Bangladesh Securities and Exchange Commission, International Accounting Standards and The International Financial Reporting Standards as issued by Financial Reporting Council, Bangladesh and The Dhaka and The Chittagong Stock Exchange (Listing) Regulations, 2015.

Main Objective of the Company

The primary objective of The IBN SINA Pharmaceutical Industry PLC is to enhance healthcare by providing medicines of the highest quality through the manufacturing and marketing of Allopathic (Pharmaceutical), Unani, and Herbal products, serving patients across Bangladesh and international markets.

Outlook

IBN SINA Pharma tried to maintain the continuity of its productivity and best ethical standard of business affairs preferring to the principles of sustainable development in the year under review. The activities initiated for sustainable development of the Company viewing its future outlook may be seen in the page no. 69 of the Annual Report.

Overview: Management's Discussion and Business Analysis

The Company has attained revenue growth of 16.97% over the previous year. This growth reflects resilience amid continued currency depreciation, shortages of power supply, and inflationary pressures on essential goods. The people of IPI made an untiring effort to overcome these difficulties. The organization had to implement several internal process adjustments and enhance chemist-focused offerings to navigate the macroeconomic challenges.

In the FY 2025-26, inflation soared to 9.16%, Taka devaluation to Taka 121-123 per US Dollar increased cost of goods and contributed to the high inflation. Export-import imbalance, dependency on imported fuel, import payment settlement, and foreign debt servicing continued to be among major economic challenges. The cost of borrowing increased from 11% to 13% over the fiscal year. Higher interest rate affected profitability across business segments. Gas supply shortages impacted in the production plant.

To meet the demand and lift sales that led to the steady growth of the sales, IPI focused on refining the systems and processes to adapt the evolving market conditions, strategic changes, optimized cost structures that offer the highest potential for growth and resilience. This approach enabled us to maintain strong connections with our diverse customer base while staying relevant in the market.

In the fiscal year 2025-26, the Bangladesh pharma market witnessed a growth of 10.6% reaching a value of approximately $ 3.32 Billion as per IQVIA data. The top 20 pharmaceutical companies have dominated about 90% of the total market share. IBN SINA Pharma business grew around by 16.97% amid of export-import imbalance, dependency on imported oil and gas, decreasing remittance flow, growing import payment settlement, and foreign debt servicing were the major factors which contributed to this challenging situation.

However, during the year the Company undertook some significant market restructuring initiatives to make its sales operation more effective, dynamic and accountable. Management remains confident that the benefits of these initiatives will become increasingly visible in the days ahead, Insha-Allah.

The year 2025-26, EPS stood Tk. 25.43 which was Tk. 20.27 in 2024-25. In the year under review, Net Asset Value per share is Tk. 144.56 which was Tk. 125.69 in 2024-25, Net Asset Value stood Tk. 4,516,608,247 which was Tk. 3,926,901,664 over the last corresponding year. NOCFPS stood Tk. 37.97 which was previously Tk. 23.16.

Bangladesh Pharma Market

Pharmaceutical companies have emerged as the game-changer by contributing more than 90% of the overall available medicines in the market yet the Bangladesh pharmaceutical market largely dependent on the imports. The government of Bangladesh is playing a major role in the rapid growth of the pharmaceutical market by providing favorable policies for easy drug approval, production and marketing of new products. Focusing to reduce the dependence over the import of raw material, API Park will act as a turning point for this purpose and help in the production of patented and already opened active pharmaceuticals ingredients and thereby reducing the expenditure related to the import of raw material.

Achievement in Revenue Growth

The company had registered a noteworthy growth simply focusing on quality prescription, cash sales, proper utilization of resources and manpower and productivity as well. During the year 16.97% sales growth (Pharma = 15.78% & Natural Medicine =

27.93%) was achieved compared to the preceding year. In the year 2025-2026 total sales achievement stood at Tk.13,899.80 million which was Tk.11,883.59 million in the last year. This was attained by coordinated efforts of all employees.

Industrial Prospects and Future Sustainable Development

We have a confident outlook on our future prospects. Keeping such in view multi-dimensional actions have been taken to enhance productivity and revenue not only from local sales but also from the export.

For a brighter tomorrow ahead with sustainable growth and provide the healthcare facility locally and globally, new strategies have been formulated to explore the project diversifications. The Company's outlook in terms of "a general review of forward-looking perspective" has been mentioned in the page no. 69 of the Annual Report.

Investment in The IBN SINA API Industry Ltd.

As of 30 June 2026, out of total authorized capital of Tk. 100 (hundred) Crore, IBN SINA Pharma invested Tk. 79,99,99,800 for holding of 99.99% Shares of The IBN SINA API Industry Ltd. as reported in Note no. 07 of the Audited Report and Financial Statements of the Company. This investment stands 10.18% of tangible assets of Tk. 7,424,347,745 (Property, Plant and Equipment and Capital Work-in-Progress) of the holding Company, therefore, it is recommended by the Board of The IBN SINA Pharmaceutical Industry PLC that approval of Shareholders at this AGM is required pursuant to BSEC's Notification No. BSEC/ CMRRCD / 2009-193 /10/ Admin / 118, dated March 22, 2021 for capital investment exceeding 1% of total tangible assets of The IBN SINA Pharmaceutical Industry PLC to its subsidiary Company, The IBN SINA API Industry Ltd. as shown in Note no. 04.A and 05.A of the Statement of Financial Position as at the end of the Financial Year, 2025-26.

Investment in The IBN SINA Polymer Industry Ltd.

As of 30 June 2026, out of total authorized capital of Tk. 40.00 (Forty) Crore, IBN SINA Pharma invested Tk. 20.00 (Twenty) Core Taka for holding of 65% Shares held by the Company (IPI) and 35% shares held by The IBN SINA Trust (IST) of The IBN SINA Polymer Industry Ltd. as reported in Note no. 07 of the Audited Report and Financial Statements of the Company. This investment stands 2.69% of tangible assets of Tk. 7,424,347,745 (Property, Plant and Equipment and Capital Work-in-Progress) of the holding Company, therefore, it is recommended by the Board of The IBN SINA Pharmaceutical Industry PLC that approval of Shareholders at this AGM is required pursuant to BSEC's Notification No. BSEC's Notification No. BSEC/ CMRRCD / 2009-193 /10/ Admin / 118, dated March 22, 2021 for capital investment exceeding 1% of total tangible assets of The IBN SINA Pharmaceutical Industry PLC to its subsidiary Company, The IBN SINA Polymer Industry Ltd. as shown in Note no. 04.A and 05.A of the Statement of Financial Position as at the end of the Financial Year, 2025-26.

Fixed Assets

As part of continual development program, The IBN SINA Pharmaceutical Industry PLC has achieved overall progress in:

1. Acquisition of Land and Land Development;

2. Building Construction Works of new projects and

3. Procurement and Commissioning of new capital machineries for production, QC and utility purpose.

[As per IPI's strategic perspective plan "Mawna Project", IPI Unit-2 for production of Oral Solid Dosage (OSD), Sterile and Oncology is considered to be priority projects. Accordingly, project implementation of "Mawna Project" is about to be complited aiming to synergistic effect to the desired sales growth of the Company, Commencement of commercial production will be resumed by this year end, InshaAllah.

The construction of another Polymer Project (located at Chalkpara, Mawna, Gazipur) works of a two-storied admin building, having total floor area of 7,750 sqf., four-storied Production Building, having total floor area of 122,236 sqf., along with two-storied Generator building, having 6785 sqf., have been completed. Installation and commissioning of production machine is in progress full-swing and hopefully trial production will commence by January 2027.

Financial Results

The financial results of 2025-26 are summarized below:

Profit Before Tax

2025-26	2024-25
1,014,580,738	839,974,353

Net Asset Value

2025-26	2024-25
4,516,608,247	3,926,901,664

Income Tax

2025-26	2024-25
221,653,436	206,718,125

Earnings Per Share (EPS)

2025-26	2024-25
25.43	20.27

Profit After Tax

2025-26	2024-25
792,927,301	633,256,228

Net Operating Cash Flow Per Share (NOCFPS)

2025-26	2024-25
37.95	23.16


Retained Earnings

2025-26	2024-25
4,220,291,576	3,625,617,615


Net Asset Value (NAV) Per Share

2025-26	2024-25
144.56	125.69


Earnings Per Share (EPS)



NOCFPS



Net Asset Value (NAV) Per Share



All these new project works and the new capital machineries are in fact adding value to fixed assets of the Company. Detailed particulars of the fixed assets added during the year under review is stated in the page no. 243 of the Annual Report.

Technology Integration with Production Capacity

Procurement of modern technology, research and training are being continued to enrich the production capacity of the factory by increasing efficiency and skills in terms of quality and quantity as well. The investments for capital machineries, etc., for Pharma, Cepha, OSD, API and Natural Medicine factories made during the year under review were funded from own sources and banking institutions to yield the benefits balanced financial leverage.

Qualitative Standard of Medicine and Raw Materials

The Company is committed to maintain the qualitative standard of medicine. Highest efforts are given to identify genuine sources, collecting best quality raw materials and their proper storing and also producing prescribed standard medicine for which there is an effective Total Quality Management (TQM) system in the Company. Relentless endeavor is being given to deliver the quality medicine with competitive price at the door steps of the customers.

Marketing of New Medicines

Pharma Medicine

The IBN SINA Pharmaceutical Industry PLC is regularly introducing new products along with

existing products which contributed remarkably in the achievement of company's sales growth. In consequences of such IPI launched 8 new products of 7 generics in 2025-26 which includes Finotab 10 tablet, Colostat 40 tablet, Bioton IV injection, Stuvec injection, Sinatide 50/500 cozycap dry powder inhaler (DPI), Fantagesic injection, Eggikal-D tablet, Eggikal-DX tablet.

Among these products Bioton IV injection, Eggikal-D tablet and Eggikal-DX tablet were well accepted by physician.

Natural Medicine

The market of natural medicine is growing significantly both in Bangladesh and worldwide, compared to synthetic (allopathic) medicine. The IBN SINA Natural Medicine Ltd. has earned trust and credibility among physicians, as well as consumers. The company continues to introduce innovative products alongside its existing portfolio, contributing notably to consistent sales growth.

During the fiscal year 2025-26, The IBN SINA Natural Medicine Ltd. launched 4 new products: Moringa LX Capsule 500 mg, Sinasoy Tablet 500 mg, Colagen Plus Capsule 500 mg and Bacigut 9 Capsule 500 mg. Moringa LX is enriched with 90 nutrients, 46 amino acids and key phytochemicals. It improves nutrition, energy and immunity, heals iron deficiency anemia, enhances breast milk production and helps slow the progression of diabetes. Sinasoy is a fermented non-GMO soy supplement (fermented by Lactobacillus delbrueckii ssp., also known as Rosell-187). It is effective in managing gastric and duodenal ulcers, chronic gastritis, hyperacidity, heartburn and acidity. Colagen Plus is a combination supplement targeting multiple pathways involved in osteoarthritis (OA) management. It also supports joint health in rheumatoid arthritis (RA) by modulating inflammation and immune response. Bacigut 9 is a probiotic blend containing 9 billion CFUs that restores gut microflora balance, relieves symptoms of IBS, flatulence constipation, improves digestion and strengthens immunity.

Distribution

Distribution is time befitting and well-equipped and futuristic Department of the Company. The manpower employed in this department are experienced, skilled having knowledge of modern distribution channel management technology serving diligently. There are about 100 vehicles of various types to distribute the medicine countrywide. Besides, timely distribution of the life-saving medicines at the doorsteps of the consumers is being ensured through 21 Sales Depots. Smooth communication and customer service has been accelerated adding modern technology like software, automation and networking facilities. This department is ready and committed as always to achieve the desired sales target upgraded depots management system.

Export Activities

With a vision to amplify bilateral business tie in terms of providing healthcare facilities, The IBN SINA always adopts precise plant inspection by foreign buyers as well as regulatory authorities and thereby attributes to expanding its access to different countries. At this moment The IBN SINA Pharma is exporting more than 100 products in different dosage forms to Guatemala and Venezuela in Central America; Philippines, Cambodia, Myanmar, Sri Lanka, and Maldives in Asia; Kenya, Mali, Somalia and Sierra Leone in Africa and many more countries are under contact for future business development.

In order to grab more opportunities in global generic market, The IBN SINA Pharmaceutical Industry PLC. is now focusing on capacity building to get the manufacturing units approved by various international regulatory authorities.

Human Resources Development

The HR Department is endeavoring to create an emphatic balanced complimentary working environment having the belief in equal and meritocratic employment towards attracting, retaining, developing and promoting the most qualified and competent employees regardless of their race, ethnicity, religion, gender or any other such characteristics. This policy is applicable to our recruitment, placement, promotion, training and retention strategy resulting of which ensuring the development of diverse workforce with skills and integrity giving their diligent efforts to run the total activities of the Company effectively and efficiently.

Legal Affairs and Estate

Legal Affairs and Estate Department is vigilant all the time to properly maintain land properties of the Company and also face the litigations sued against the Company, legally mitigation of industrial disputes, keeping the Company compliant of overall legal management activities. In addition to these activities, the Estate Department carefully catalogs and professionally manages all movable and immovable assets of the head office, factory, sales depots, and field offices, ensuring their legal safeguards and official procedures.

Training and Skills Development

The Training and Skill Development Department has successfully initiated various professional training and skill-related programs to develop skills, competency and increase the efficiency of all levels of employees. Last year, around 4300 employees in different levels were taken under in-house training programs and in different local and foreign professional training organizations. Effective action was taken to bring the total manpower of the Company in the same platform gradually of the "Need-based Training" Manual adopting an appropriate training policy.

Information Technology

Being an ever-expanding pharmaceutical Company, IBN SINA Pharma is producing quality products maintaining accuracy in every step applying the updated Information Technology and know-how. ERP System is in place where Procurement, Inventory, Production, Costing, HR, Admin, Accounts, Marketing, Sales, Survey and Distribution modules are being incorporated. This system accelerates to take real time decision and action as required. Company is vigilant for more modernization and time benefiting IT system to cope up with the growing demand of the competitive challenging markets.

Corporate Governance Compliance Report

The Corporate Governance Compliance Auditors issued a "SATISFACTORY" Report on the overall level of compliance of the Company. The Company is committed to run the organization in adherence to the Code of Corporate Governance (Notification No. BSEC / CMRRCD / 2006 -158 / 207 / Admin / 80, dated: 3 June 2018) issued by the Bangladesh Securities and Exchange Commission (BSEC). In the year under review, 2025-26 the code applicable for the Company was duly followed. The compliance of the Corporate Governance Code certified by the Compliance Auditors and status of compliance of the Company are reflected respectively page no. 181 and 182.

Management Discussion and Analysis

Detailed discussion on the operating and financial performances of the Company along with other disclosures as required under Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) through Notification No. BSEC / CMRRCD / 2006-158 / 207 / Admin / 80, dated June 3, 2018 has been separately reported by the Managing Director in page no. 67 of the Annual Report.

Additional Disclosures and Information

The objective of Corporate Good Governance is to run the Company effectively and legitimately with a sense of accountability and transparency to the shareholders and the society as a whole. The Company is complying with the Condition No. 1(5) of "Corporate Governance Code" of Bangladesh Securities and Exchange Commission since it's promulgation.

The Board of Directors has confirmed the standard of corporate good governance incorporating the following additional statements in the Annual Report:

(i) An industry outlook and possible future development of the Company is stated in the page no. 69 of the Annual Report;

(ii) The information about the segment-wise or product-wise performance is stated in the page no. 80 and 81 of the Annual Report;

(iii) The report regarding the risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment is stated in the page no. 174 of the Annual Report;

(iv) A discussion on the cost of goods sold, gross profit margin and net profit margin is stated in the page no. 72 of the Annual Report;

(v) There is no extraordinary gain or loss during the year;

(vi) A detailed discussion on related party transaction along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions of the Company is stated in the page no. 239 of the Annual Report;

(vii) There is no significant variance between Quarterly Financial performances and Annual Financial Statements.

(viii) A statement of remuneration paid to the Directors including Independent Directors is stated in the page no 232 of the Annual Report;

(ix) A statement that the financial statements prepared by the management present fairly the state of affairs of the Company, the result of its operations, cash flows and changes in equity has duly been given;

(x) The Books of Accounts of the Company have been properly maintained.

(xi) Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;

(xii) A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;

(xiii) The system of internal control is sound in design and has been effectively implemented and monitored;

(xiv) Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;

(xv) There is no significant doubt upon the Company's ability to continue as a going concern;

(xvi) There have been no significant deviations from the last year's operating results of the Company;

(xvii) Preceding 5 (five) years' key operating and financial data have been summarized in page 72.

(xviii) The total number of Board meetings held during the year and attendance by each director has been described in page 155.

(xix) A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details) held has been presented in the prescribed format in page 87 and 223.

(xx) The disclosures on the appointment or reappointment of Directors' as prescribed information to the Shareholders have been given in the page no. 50.

(xxi) A Management's Discussion and Analysis signed by MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on the information [(xxv) (a), (b), (c), (d), (e), (f), (g)] is stated in the page no. 67 of the Annual Report.

(xxii) Declaration or Certification by the Managing Director and Chief Financial Officer to the Board of Directors as required under condition No. 3(3) is disclosed as per Annexure-A in the page no. 169 of the Annual Report.

(xxiii) The report as well as certificate regarding compliance of conditions of the Corporate Governance Code of BSEC as required under condition No. 9 is disclosed in the page 181 and 182 of Annual Report.

Implementation of IAS, IFRS and Other Applicable Laws and Regulations

The Board of Directors of the Company is entrusted to ensure the disclosure of actual financial position and preparation and maintenance of all types of Statutory Statements as per the Securities and Exchange Commission Rules, 1987, Companies Act, 1994 and Bangladesh Financial Reporting Act, 2015. The Board of Directors is absolutely responsible to prepare all types of financial reports in line with the International Accounting Standard (IAS), International Financial Reporting Standard (IFRS) and other applicable rules and regulations. The roles and responsibilities of the Directors in presentation of the financial report has been stated in page 170 of the Annual Report.

Financial Reports, Accountability and Transparency

The Board of Directors discharged their due responsibilities through timely preparation and publication of 1st quarter, half yearly, 3rd quarter and Annual Financial Statements at the end of each financial period and the affairs of the Company performed in the year under review. Audit Committee, a sub-committee of the Board reviewed the true and fair view of the activities, accountability and completeness of these reports before placement of the same to the Board for their approval.

The Company published the report (un-audited accounts) of 1st quarter, half yearly and 3rd quarter accounts as per notification of Bangladesh Securities and Exchange Commission (BSEC) and the Listing Regulations, 2015 of Dhaka Stock Exchange PLC (DSE) and The Chittagong Stock Exchange PLC (CSE) through Company's Website, Newspapers and Online News Portal and submitted the same timely to BSEC, DSE, CSE and other regulatory authorities.

Related Party Transactions

The business-related party transactions of the Company are being made based on the business principle and as per International Accounting Standard IAS: 24. During the year, the standard, nature and the manner of related party transactions in the ordinary course of business carried out arm's length basis at commercial rates with its related parties were reflected transparently in the financial statements in note No-36 which is given in the page no. 239 of the Annual Report.

Minority Shareholders' Interest Protection

In the year 2025-26, the Minority Shareholders' interest as articulated in the Section 233 of the Companies Act, 1994 "Power of Court to give direction for protecting interest of the minority" has duly been adhered to as effective means of redress. No abusive actions either directly or indirectly with regard to the interest of minority shareholders was observed.

Unusual Profit or Loss

In the year 2025-26, there is no unusual profit or loss being observed.

Directors' Shareholding Position

Pattern of Shareholdings as against the name of the Directors of the Company has been stated in the page no. 87 of the Annual Report.

Beneficiary Insider Trading Prohibition

The Company has outlined the beneficiary insider trading prohibition policy regarding the trading of Company's share for its directors, employees and concerned persons. The policy is being followed accordingly.

Adherence to the Laws

The laws of the Bangladesh and other applicable rules and regulations of the Company and the affairs thereon, have duly been complied with the highest preference and timely actions on the same have been ensured. The Company is committed to abide by the rules of regulatory bodies and other legislative authorities, as always.

Compliance to the Labour Laws

In order to maintain labour friendly atmosphere in all the aspects, the Company duly complied with the Bangladesh Labour Act, 2006 (As amended upto 2026), Bangladesh Labour Rules, 2015 (amended 2022) and other relevant laws and regulations applicable to the Company.

Pollution Free Environment

In order to protect from risk of human health and environment, caused by increasing man-made pollution; the Company is trying its best to keep pollution free environment through Effluent Treatment Plant (ETP) and follow the required laws and rules of The Directorate General of Drug Administration (DGDA) and Department of Environment of the Government in the factory and its surrounding, as well.

Statutory Payments

All statutory payments in relation to the employees and the government have duly been made up-to-date.

Compliance to the Laws of the Capital Market

Since listing in both the Stock Exchanges of the Country, the Company strictly abides by all the laws, regulations and directions circulated from time to

time by Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange PLC (DSE) and the Chittagong Stock Exchange PLC (CSE) and other related authorities.

Key Information of the Financial Statements

As per direction of the Bangladesh Securities and Exchange Commission (BSEC), the key information of the financial statements of preceding five years' including current year has been summarized in the page no. 72 of the Annual Report.

Welfare Activities for the Company's Officers and Workers

The welfare activities for the Company's officers and workers taken in the year 2025-26, are briefly presented in the page no. 129 of the Annual Report.

Workers' Profit Participation Fund and the Welfare Fund

The year under review 5% of the Company's profit i.e. Tk. 52,979,904 will be transferred to the Workers' Profit Participation Fund (WPPF) and Welfare Fund as per The Bangladesh Labour Laws 2006 (As amended upto 2026).

Mentionable that Tk. 4,335,839 (which is 10% of approved WPPF as of June 30, 2026) has been transferred to the Director General, Bangladesh Sromik Kallyan Foundation, Labour and Employment Ministry, Government of Bangladesh.

A Going Concern

By the grace of the Almighty Allah, the Board of Directors after analysis of the business trend of the Company has confirmed that the Company has enough ability to carry on business activities in the foreseeable future as a going concern and the financial statements have been prepared on the basis of going concern assumption basis. As per management assessment there is no material uncertainty related to events or conditions which may cast significant doubt upon the Company's ability to continue as a going concern. The statutory auditors following its evaluation in its audit reports issued a confirmation on the continuity of the Company.

Contribution to the National Exchequer

The Company had made a significant contribution in the year 2025-26 towards the National Exchequer by paying Tk. 2,487,757,631 as Income Tax and VAT.

Internal Control System and Risk Management

In order to control all matters involving risks and uncertainties, the Company has a strong risk mitigation process and internal control system. This has been described in details in page. 174 of this Annual Report.

Principles of Disclosure of Material Information and Price Sensitive Information

To protect the interest of minority shareholders and other stakeholders getting them notified with the significantly changed information as disclosure, the Board of Directors of IBN SINA Pharma has formulated "Principles of Disclosure of Material Information and Price Sensitive Information" pursuant to the Bangladesh Securities and Exchange Commissions' (BSEC) rule vide ref: BSEC / CMRRCD / 2021-396 / 52 / Admin / 140, dated: 28.12.2022. This is disclosed in the Company's website at www.ibnsinapharma.com as a guiding framework for the shareholders to allow the Stakeholders making them informed about the principles of disclosure policy of material information and price sensitive information.

Material information and price sensitive information means those significantly changes information relating to decision, occasion, circumstances, situation, conditions, events, financials or otherwise, any other changes in the affairs of the Company and its defined insiders that can have impact on investment decision of the holders of the securities or potential investors or otherwise users of such material information/significant changes.

Directors' Code of Conduct

The Board of the Company approved a separate Code of Conduct for its Directors in compliance with the requirement of Bangladesh Securities and Exchange Commission (BSEC) Corporate Governance Code, June 03, 2018 under condition 1(7) which is stated in the page no. 165 of the Annual Report. This Code of Conduct was duly uploaded in the Company's official website (www.ibnsinapharma.com)

Code of Ethics and its Implementation

Highest emphasis is given on the implementation of code of ethics and principles so that the concerned officials and personnel can take appropriate decision complying the required laws and applicable standards.

Directors' Remuneration

This information is incorporated in the Note no. 27.01 of the Notes to the Financial Statements in the page no. 230 of Annual Report with reference to the "Directors Fees and Remuneration" figures relating to the Board of Directors including Independent Directors.

Remuneration Policy: Salaries and Wages

The salary and wages of the employees are usually determined considering the prevailing inflation, price index and commensurate with the existing salary structure with other competitors' companies.

The procedure of evaluation and determining the honorarium of the Executive Directors are being followed within the criteria recommended by the Nomination and Remuneration Committee (NRC) duly approved by the Board as per Corporate Governance Code of BSEC.

Events after the Reporting Period

Events after the reporting period for the year 2025-26, no necessity arose for subsequent adjustment or no pecuniary issues thereto happened which is mentionable in the financial statements excepting as provided in the note No. 47 of the Notes to the Financial Statements in the page no. 242 of the Annual Report.

Dividend Distribution Policy

In compliance with the Directive No. BSEC / CMRRCD / 2021-386 / 03, dated 14 January, 2021 of the Bangladesh Securities and Exchange Commission (BSEC), the Board of Directors of the Company formulated "The Dividend Distribution Policy" about dividend declaration, pay off, disbursement and compliance and disclosed the same publishing in the Company's Annual Report and official website at www.ibnsinapharma.com as a guiding framework for the shareholders to allow the Shareholders to make informed investment decisions. Company's Dividend Distribution Policy is stated in the page no. 171 of the Annual Report.

Reserves and Surplus

In the year 2025-26, Company's reserves and surplus rose to Tk. 4,224,683,686 which was Tk.3,630,009,725 in the previous year.

Internal Control and Audit

Internal control and audit system of the Company is founded on specified code approved by the Board. The Board of Directors incorporates necessary norms and practices of internal control and audit system for development of control management. An effective internal control system is in action to ensure the transparency, highest productivity and maximum utilization of resources.

Company's Position in the Capital Market

In the year 2025-26, the market share of the Company did not face ups and downs significantly in either Dhaka Stock Exchange PLC (DSE) or Chittagong Stock Exchange PLC (CSE). The shareholders had always been confident on the Company shares. From July 01, 2025 to June 30, 2026, the Company's shares were traded in both stock exchanges at minimum of Tk. 273.00 to maximum of Tk. 371.00 as against the face value of Tk.10.

Whistle Blowing Policy

Company's Whistle Blowing Policy ensures to establish transparency in all aspects and also in terms of minimizing the risk management and detecting any forgery or embezzlement.

Independent Scrutinizer

As per BSEC's Directive No. BSEC / CMRRCD / 2009-193 / 08, Dated-March 10, 2021, the Board has appointed an Independent Scrutinizer to observe the 42nd AGM of the Company to be held on November 23, 2026 through Virtual Platform ensuring the facility to exercise the shareholders (holders of paper shares or dematerialized shares) voting rights on the resolution proposed to be considered at the general meeting.

The due process of election and the detailed information of voting results shall be authenticated by Independent Scrutinizer M. Mohashin & Co., Chartered Secretaries in Practice and reported the same to the BSEC within 48 hours of concluding the AGM.

Employee Relationships

There exists devotion to work and harmonious relationships among all levels of officers and employees in the Company, which has accelerated the Company's progress and productivity.

Transferring the Unclaimed Dividend to Capital Market Stabilization Fund (CMSF)

Pursuant to the Bangladesh Securities and Exchange Commission's (BSEC) Directive No. BSEC / CMRRCD / 2021-386 / 03 Dated, January 14, 2021 and Bangladesh Securities and Exchange Commission Capital Market Stabilization Fund Rules, 2021, the Company transferred Tk. 92,08,819.14 (Taka Ninety Two Lakh Eight Thousand Eight Hundred Nineteen and Paisa Forteen) only held against unclaimed or undistributed or unsettled dividend for the year 2021-22 to the Bank Account No. SND A/C 0010311521301 titled "Capital Market Stabilization Fund (CMSF)" maintained with Community Bank Bangladesh PLC, Gulshan Corporate Branch, Dhaka.

Year wise unclaimed / undistributed / unsettled dividend amount is stated in the page no. 173 of the Annual Report and Company's website link at http: // www.ibnsinapharma.com / investors / corporate-governance / unclaimed - dividend - information /

Dividend

Based on the overall performance as reflected in the Financial Statements for the year 2025-26 of the Company, the Board of Directors proposed cash dividend @ 77.00% as against per share of Tk.10. The directors state that no bonus share or stock dividend has been declared during the year 2025-26 or shall be declared in future as interim dividend.

Audit Committee

As per condition no. 5 of BSEC's notification no. BSEC / CMRRCD / 2006-158 /207 / Admin /80 dated 3 June, 2018, the Audit Committee consisting of three members including two Independent Directors having prominent reputation and versatile knowledge and experience have been working prudently.

The Audit Committee had detailed discussion and analysis on its report as directed by BSEC and the Board with regards to internal audit system, preparation of unaudited periodical accounts, annual financial report and the observations of external auditors. As there was no evidence of mistakes, dissemblance or information contrary to the truth, the financial report was considered as realistic and transparent. Report of the Audit Committee is presented in the page no. 158 of the Annual Report.

Nomination and Remuneration Committee

In accordance with the condition no. 6 of Bangladesh Securities and Exchange Commission's Code of Corporate Governance, BSEC / CMRRCD / 2006 -158 / 207 / Admin / 80 dated 3 June 2018, the Nomination and Remuneration Committee (NRC) a sub-committee of the Board is working. as per NRC Policy shown in page no. 162 of Annual Report The report from the Nomination and Remuneration Committee (NRC) about their activities performed during the year under review is mentioned in the page no. 164 of the Annual Report.

Corporate Social Responsibility (CSR)

In view of the corporate social responsibility of the Company, the Board of Directors has approved corporate social responsibility policy as part of accountability to the society. A 3-Members' Committee formed by the Board has been working to implement this policy. The CSR activities taken by the Company in the year, 2025-26 is stated in the page no. 129 of the Annual Report.

Independent Directors

As per notification no. BSEC / CMRRCD / 2006 -158 / 207 / Admin / 80 dated 3 June, 2018 of Bangladesh Securities and Exchange Commission (BSEC), professionals respectively Md. Rafiqul Islam Khan, FCA Practicing Chartered Accountants, Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU, Ex-Deputy Managing Director of Islami Bank Bangladesh PLC and Ms. Parsa Begum MA (English), LL. B, DU have been performing the duties as Independent Directors with integrity and diligently.

The brief profile of three professional Independent Directors of the Company has been stated in the Directors' profile of the Annual Report.

Election of Directors

Directors of the Company, Prof. ANMA Zaher and Prof. Dr. Choudhury Mahmood Hasan shall retire from the office at this Annual General Meeting as per Article 28 of Articles of Association of the Company and Section 91 (2) of the Companies Act, 1994. As per law, the retiring directors are eligible to be re-elected to act as Director. The brief resume along with the required information of the directors is given in the Directors' Profile of this Annual Report.

Appointment of Statutory Auditors

Malek Siddiqui Wali & Co., Chartered Accountants, statutory auditors of the Company, audited the Accounts of the Company for the year 2025-26. Malek Siddiqui Wali & Co., Chartered Accountants retire at this meeting. As per BSEC/CMRRCD/ 2009-193/104/Admn, Date- 27 July, 2011, the existing Auditors are eligible for re-appointment as statutory auditors. Malek Siddiqui Wali & Co., Chartered Accountants has given their expression of interest to be re-appointed as Statutory Auditors.

The Audit Committee reviewed the audit works performed in the last year and the profile of the said Audit Firms and recommended in favour of Malek Siddiqui Wali & Co., Chartered Accountants for reappointment as Statutory Auditors of the Company for the year, 2026-27.

Being eligible as per Companies Act, 1994 the Board of Directors has concurred with the recommendation of the Audit Committee to re-appoint Malek Siddiqui Wali & Co., Chartered Accountants as statutory auditors of the Company and recommended remuneration of Tk. 400,000/- (Four Lac) Taka only subject to approval by the Shareholders at this AGM of the Company.

Compliance Auditors Appointment

As per Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC), SARashid & Associates, Chartered Secretaries, Compliance Auditors of the Company audited the compliance status of the Company for the year 2025-26. SARashid & Associates, Chartered Secretaries retire at this AGM.

The Company has received Expression of Interest (EOI) to be appointed as Compliance Auditors from two (2) recognized Chartered Secretaries firms. The profile of these two audit firms was reviewed by the Audit Committee and recommended to appoint M. Mohashin & Co. Chartered Secretaries in practice as Compliance Auditors of the Company for the financial year, 2026-27.

After review and discussion over the profile and particulars of the said Firms and being eligible as per law, the Board of Directors has concurred with the recommendation of the Audit Committee to appoint M. Mohashin & Co. Chartered Secretaries in practice as Compliance Auditors of the Company for the financial year 2026-27 with a remuneration of Tk.80,000/- (Taka Eighty Thousand) only subject to approval at this AGM of the Company.

Governance of Board of Directors of Subsidiary Companies

The Company's representation in the Subsidiary Company's Board was in line with the Corporate Governance Code and accordingly, one Independent Director from The IBN SINA Pharmaceutical Industry PLC was nominated in the Board of every subsidiary Company The IBN SINA Natural Medicine Ltd., The IBN SINA API Industry Ltd. and The IBN SINA Polymer Industry Ltd. Minutes of the Board meetings of the Subsidiary Companies were placed before the Board of the holding Company, The IBN SINA Pharmaceutical Industry PLC and then duly reviewed and recorded. Board of Directors of the holding Company also reviewed the periodical and annual financial statements of the subsidiaries.

Company wise disclosures are as follows: -

The IBN SINA Natural Medicine Ltd.

Considering the global rise in the adoption of natural and traditional (like herbal medicine), complementary, and integrative medicine (TCIM), we are working with the objective of conducting manufacturing of all kinds of natural medicine- Unani, Ayurvedic and Herbal, nutritional, nutraceutical products and dietary supplements, health food products, medicated consumer products, cosmetics and toiletries.

The activities performed in the year, 2025-26 has been stated in the Directors' Report of The IBN SINA Natural Medicine Ltd. of the Annual Report page no. 246.

The IBN SINA API Industry Ltd.

Given that the upcoming LDC graduation and its "impact under TRIPS agreement"- TRIPS compliance transition, and the demand of Active Pharmaceutical Ingredients (API) product eventually in the domestic as well as new export frontiers, steps being taken to create production facility of Pharma Active Raw

materials. Resonating with the excellent success in the growth of Pharma sectors in Bangladesh, the backward linkage of raw materials supply has become the vital issue.

The disclosures in this respect, in the form of Directors' Report of The IBN SINA API Industry Ltd. for the year 2025-26 may be seen in the page no. 257 of the Annual Report.

The IBN SINA Polymer Industry Ltd.

Aiming to produce major polymer products includes PET bottles, Eye drops Vials, different containers, and PVC Films etc., the basic primary packaging materials for pharma Production, The IBN SINA Polymer Industry Ltd. was formed.

The necessary disclosures as Directors' Report of The IBN SINA Polymer Industry Ltd. are stated in the page no. 267 of the Annual Report, 2025-26.

Relation and Communication with the Shareholders

The Company has been arranging regular Annual General Meetings (AGM) as per Companies Act, 1994 through which shareholders are informed about the Company's progress, important development activities undertaken in the year under review. As a result, the shareholders, concerned organizations and the stakeholders as a whole get the various information about the Company in due time. The shareholders of the Company are able to collect all required information from our Share Department through physically, land phone, mobile phone, e-mail service and website: www.ibnsinapharma.com, as well.

Recognition and Compliments

The Board of Directors extends its' heart felt gratitude to the Ministry of Health, Directorate General of Drug Administration, National Board of Revenue (NBR), Ministry of Labour Employment, Labour Directorate, respected Doctors, Chemists, Patrons and all concerned with the pharmaceutical industry for their all-out support to us. The Board of Directors acknowledges gratefully the co-operation of Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange PLC (DSE), Chittagong Stock Exchange PLC (CSE) and other regulatory agencies of the Government of Bangladesh. The Board thanks the Banks and the Financial Institutions for their support.

The Board of Directors wishes all levels of officers, employees, buyers, consumers, patrons, well-wishers and all concerned for their sincere contributions towards our business success. We are also grateful to our respected shareholders for their relentless support to the Company.

The shareholders' trustworthiness to the Board of Directors makes them confident and deeply inspired. The management and employees of all levels are committed to uphold this as we march ahead to take The IBN SINA Pharmaceutical Industry PLC forward as a leading partner in Bangladesh's business community.

May Allah Subhanahu WaTaa'la accept all our endeavors for the development of our Company, Nation and the Country at large. We pray to the Almighty Allah for His blessings for inspiring the overall progress and prosperity of our beloved Country, The People's Republic of Bangladesh.

Allah Hafiz

Approved by the Board of Directors and signed on its behalf,



Prof. Dr. A K M Sadrul Islam
Managing Director



Kazi Harun or Rashid
Chairman

পরিচালনা পর্ষদের প্রতিবেদন

বিসমিল্লাহির রাহমানির রাহীম

সম্মানিত শেয়ারহোল্ডারগণ,

আসসালামু আলাইকুম ওয়া রাহমাতুল্লাহ।

কোম্পানীর পরিচালনা পর্ষদের পক্ষ থেকে আপনাদের সবাইকে ৪২তম বার্ষিক সাধারণ সভায় আন্তরিক শুভেচ্ছা ও স্বাগত জানাচ্ছি। ০১ জুলাই ২০২৫ থেকে ৩০ জুন ২০২৬ সমাপ্ত অর্থ বছরের কার্যক্রমের ওপর পরিচালনা পর্ষদের প্রতিবেদন এবং নিরীক্ষক কর্তৃক নিরীক্ষিত আর্থিক বিবরণী সমূহ আপনাদের মূল্যবান দিক নির্দেশনা, মতামত ও সদয় বিবেচনার জন্য পেশ করা হল। ২০২৫-২৬ অর্থবছরের ব্যবসায়িক অর্জন এবং ভবিষ্যৎ দৃষ্টিভঙ্গি সম্পর্কে পরিচালনা পর্ষদের প্রতিবেদনে সম্মানিত শেয়ারহোল্ডারগণ ও সংশ্লিষ্টরা একটি সম্যক ধারণা পাবেন। আলোচ্য অর্থ বছরে কোম্পানীর ব্যবসায়িক সাফল্যের জন্য মহান রাব্বুল আলামীনের দরবারে শুকরিয়া আদায় করছি।

এ প্রতিবেদনটি কোম্পানী আইন, ১৯৯৪ (সংশোধিত, ২০২০) এর ধারা ১৮৪ এবং বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন বিধি, ১৯৮৭, বিএসইসি কর্পোরেট গভর্নেন্স কোড ৩ জুন, ২০১৮, ফাইনান্সিয়াল রিপোর্টিং কাউন্সিল, বাংলাদেশ কর্তৃক গৃহিত ইন্টারন্যাশনাল একাউন্টিং স্ট্যান্ডার্ড, ইন্টারন্যাশনাল ফাইনান্সিয়াল রিপোর্টিং স্ট্যান্ডার্ড এবং ঢাকা স্টক এক্সচেঞ্জ লিষ্টিং রেগুলেশনস, ২০১৫ ও চট্টগ্রাম স্টক এক্সচেঞ্জ লিষ্টিং রেগুলেশনস, ২০১৫ মোতাবেক প্রস্তুত করা হয়েছে।

কোম্পানীর মূল কার্যক্রম

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসির (আইপিআই) মূল কার্যক্রম সর্বোচ্চ মান সম্পন্ন এলোপ্যাথিক ও ন্যাচারাল মেডিসিন (ইউনানী ও হারবাল) ওষুধ উৎপাদন ও বিতরণের মাধ্যমে বাংলাদেশ ও বহির্বিশ্বে প্রত্যাশিত মানের সেবা প্রদানের লক্ষ্যে অগ্রণী ভূমিকা পালন করা।

দৃষ্টিভঙ্গি

আলোচ্য অর্থ বছরে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি সর্বক্ষেত্রে উৎপাদনশীলতা ও ব্যবসা পরিচালনায় উত্তম নীতিবোধ সংরক্ষণ এবং উন্নয়নকে অগ্রাধিকার দেয়ার নীতিতে অবিচল থাকার চেষ্টা অব্যাহত রেখেছে। কোম্পানীর টেকসই উন্নয়নের জন্য গৃহিত পদক্ষেপ সমূহের একটি চিত্র ভবিষ্যৎ দৃষ্টিভঙ্গি আকারে বার্ষিক প্রতিবেদনের ৬৯ পৃষ্ঠায় বর্ণিত হয়েছে।

ব্যবস্থাপনা ও ব্যবসায়িক পর্যালোচনা

কোম্পানী বিগত বছরের তুলনায় এবছর প্রায় ১৬.৯৭% বর্ধিত রাজস্ব অর্জন করতে সক্ষম হয়েছে। এ প্রবৃদ্ধি প্রমাণ করে যে, মুদ্রার অবমূল্যায়ন, জ্বালানি ঘাটতি এবং নিত্যপ্রয়োজনীয় পণ্যের মূল্যস্ফীতি চাপের মধ্যেও প্রতিষ্ঠানটি দৃঢ়তা ও স্থিতিশীলতা বজায় রেখেছে। আইপিআই-এর নিবেদিত প্রাণ জনশক্তি পারিপার্শ্বিক সকল সমস্যা অতিক্রম করে সফলতার সাথে সামনে এগিয়ে যেতে হিম্মত দেখিয়েছে। এ লক্ষ্যে কোম্পানী অভ্যন্তরীণ প্রক্রিয়া সমূহ সমন্বয়ের মাধ্যমে গ্রাহকবান্ধবতা অক্ষুণ্ন রেখে অর্থনৈতিক চ্যালেঞ্জ সমূহ মোকাবেলা করতে সমর্থ হয়েছে। আলহামদুলিল্লাহ।

২০২৫-২৬ অর্থবছরে দেশের অর্থনীতিতে একাধিক চ্যালেঞ্জ বিরাজিত ছিল। মুদ্রাস্ফীতি বেড়ে দাঁড়ায় ৯.১৬%, আর টাকার মান এক ডলারের বিপরীতে নেমে আসে ১২১-১২৩ টাকায়, যা আমদানির খরচ বৃদ্ধি ও মূল্যস্ফীতি তীব্রতর করে। আমদানি-রপ্তানির ভারসাম্যহীনতা, জ্বালানি আমদানির ওপর নির্ভরশীলতা, আমদানি ব্যয় নিষ্পত্তি ও বৈদেশিক ঋণ পরিশোধ এখনও একটি বড় চ্যালেঞ্জ হিসেবে রয়েছে। এ বছর ঋণ মেটানোর ব্যয় বেড়ে ১১% থেকে ১৫% দাঁড়িয়েছে। ব্যবসায়িক ক্ষেত্রে উচ্চ সুদহার মুনাফা অর্জনে বেশ প্রভাব ফেলেছে। চাহিদামত গ্যাস সরবরাহ না থাকায় উৎপাদন বিঘ্নিত হয়েছে।

বিক্রয় বৃদ্ধির লক্ষ্যে আইপিআই নবতর পদ্ধতি গ্রহণ করেছে যা পরিবর্তনশীল বাজারের সাথে খাপ খাইয়ে নিতে সক্ষম। ব্যয় সংকোচনের জন্য গৃহীত নীতিমালা ধারাবাহিক টেকসই প্রবৃদ্ধি অর্জনে সহায়ক ভূমিকা পালন করবে।

আইপিআই বাজার পরিস্থিতির সাথে সমন্বয় করে চলার জন্য নিজস্ব পদ্ধতি ও প্রক্রিয়াগুলো সাজিয়েছে। আমরা কৌশলী পদক্ষেপ গ্রহণের মাধ্যমে ব্যয় সংকোচন কাঠামো বিনির্মাণ এবং সম্ভাবনাময় ক্ষেত্রগুলোতে বিনিয়োগের মাধ্যমে টেকসই প্রবৃদ্ধির দ্বার উন্মোচন করার চেষ্টা অব্যাহত রেখেছি। আমাদের সম্মানিত গ্রাহকদের বৈচিত্রময় চাহিদা যথাসময়ে সম্মানের সাথে পূরণের জন্য আমাদের ব্যবসায় নতুন পদক্ষেপ অভিযোজিত করেছি। এর ফলে আমাদের গ্রাহকদের সাথে মজবুত সম্পর্ক স্থাপন এবং গতিশীল বাজারের সাথে তাল মিলিয়ে চলার দৃঢ়তা সৃষ্টি হয়েছে। বছর জুড়ে আইপিআই আর্থিক স্থিতিশীলতা বজায় রাখা এবং কর্ম দক্ষতার উপর অপরিসীম নজর দিয়েছে যাতে গ্রাহকদের আস্থা আরও দৃঢ় হয় এবং সেবার মান উন্নত করার প্রতিশ্রুতি বজায় থাকে।

আই কিউ ভি আই এ এর তথ্য অনুসারে ২০২৫-২৬ অর্থবছরে বাংলাদেশ ফার্মা মার্কেট ১০.৬০% সম্প্রসারিত হয়েছে যা প্রায় $ 3.32 বিলিয়ন মার্কিন ডলারের সমান। সম্মুখ সারির ২০টি ফার্মাসিউটিক্যাল কোম্পানী সমুদয় বাজার শেয়ারের ৯০% এ আধিপত্য বিস্তার করে আছে। ইবনে সিনা ফার্মার বর্ধিত ব্যবসার পরিমাণ ১৬.৯৭%। এ খাতে ভারসাম্যহীন আমদানী-রপ্তানী, আমদানীকৃত গ্যাস ও জ্বালানীর ওপর নির্ভরতা, রেমিটেন্স প্রবাহের নিম্নগামিতা, ক্রমবর্ধমান আমদানী ব্যয় নিষ্পত্তি এবং বৈদেশিক ঋণ গ্রহণ কঠিন পরিস্থিতি সৃষ্টিতে সহায়ক ভূমিকা রেখেছে।

চলতি বছরে কোম্পানী তার বিক্রয় কার্যক্রমকে আরও গতিশীল কার্যকর ও জবাবদিহি মূলক করার জন্য বিপণন ব্যবস্থাপনা পুনর্গঠনের লক্ষ্যে গুরুত্বপূর্ণ উদ্যোগ গ্রহণ করেছে। আগামী দিনগুলোতে এই উদ্যোগ সমূহের সুফল ক্রমশ দৃশ্যমান হবার ব্যাপারে ব্যবস্থাপনা কর্তৃপক্ষ খুবই আশাবাদী।

২০২৫-২০২৬ অর্থ বছরে শেয়ার প্রতি আয় দাঁড়িয়েছে ২৫.৪৩ টাকা যা ২০২৪-২৫ অর্থ বছরে ছিল ২০.২৭ টাকা এবং আলোচ্য অর্থ বছরে শেয়ার প্রতি নীট সম্পদ মূল্য (NAVPS) ১৪৪.৫৬ টাকা, যা পূর্ববর্তী অর্থ বছরে ছিল ১২৫.৬৯ টাকা। নীট সম্পদ মূল্য (NAV) ৪,৫১৬,৬০৮,২৪৭ টাকা, যা পূর্ববর্তী অর্থ বছরে ছিল ৩,৯২৬,৯০১,৬৬৪ টাকা। শেয়ার প্রতি নীট চলতি নগদ প্রবাহ (NOCFPS) -৩৭.৯৫ টাকা, যা পূর্ববর্তী অর্থ বছরে ছিল ২৩.১৬ টাকা।

বাংলাদেশ ফার্মা মার্কেট

বাংলাদেশের ফার্মাসিউটিক্যাল মার্কেট বহুলাংশে আমদানী নির্ভরশীল। তদুপরি ওষুধ কোম্পানীসমুহ সামগ্রিকভাবে মার্কেটের সর্বপ্রকার সহজলভ্য ওষুধে ৯০% এর বেশি অবদান রেখে গেম চেঞ্জার হিসেবে আবির্ভূত হয়েছে। বিজ্ঞান

এবং গবেষণা ও উন্নয়ন সেক্টরে নতুনত্ব উদ্ভাবনে বৈশ্বিক মার্কেটে এক উল্লেখযোগ্য পরিবর্তন সূচিত হয়েছে। বাংলাদেশের ওষুধ বাজার আন্তর্জাতিক স্তরে সামগ্রিক অনুপাতে আশাব্যাঞ্জক পরিবর্তন ঘটিয়েছে।

ফার্মাসিউটিক্যাল মার্কেট দ্রুত বিস্তারের জন্য বাংলাদেশ সরকার সহজে ড্রাগ অনুমোদন প্রাপ্তি, উৎপাদন এবং নতুন পণ্য বাজারজাতকরণের লক্ষ্যে অনুকূল নীতিমালা প্রণয়নে উল্লেখযোগ্য ভূমিকা পালন করেছে। বিদেশ থেকে ওষুধের কাঁচামাল আমদানী নির্ভরতা হ্রাস করণের জন্য "এপিআই পার্ক" টার্নিং পয়েন্ট হিসেবে কাজ করছে। পেটেন্ট উৎপাদনে ভূমিকা পালনসহ ইতোমধ্যে "একটিভ ফার্মাসিউটিক্যাল ইনগ্রিডিয়েন্টস" উন্মুক্ত করা হয়েছে। এর ফলে কাঁচামাল আমদানী ব্যয় সংকুচিত হবে।

বিক্রয় প্রবৃদ্ধি অর্জন

আলোচ্য অর্থ বছরে কোম্পানী বিপণন ও বিতরণ বিভাগের জনশক্তি অপরিবর্তিত রেখে বাজার উপযোগী কর্মকৌশল গ্রহণ ও উৎপাদনশীলতা বৃদ্ধির মাধ্যমে কাঙ্ক্ষিত প্রবৃদ্ধি অর্জন করতে সক্ষম হয়েছে। আলোচ্য অর্থ বছরে ১৬.৯৭% (ফার্মা-১৫.৭৮% এবং ন্যাচারাল মেডিসিন-২৭.৯৩%) বিক্রয় প্রবৃদ্ধি অর্জিত হয়েছে। সর্বমোট বিক্রয় অর্জিত হয়েছে ১৩,৮৯৯.৮০ মিলিয়ন টাকা, বিগত বছরে বিক্রয় হয়েছিল ১১,৮৮৩.৫৯ মিলিয়ন টাকা। কোম্পানীর সকল পর্যায়ের জনশক্তির সমন্বিত আন্তরিক প্রচেষ্টার ফলে এ অর্জনের ধারাবাহিকতা অব্যাহত রাখা সম্ভব হয়েছে।

শিল্প সম্ভাবনা ও সম্ভাব্য ভবিষ্যৎ উন্নয়ন

আলোচ্য অর্থ বছরে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি সবক্ষেত্রে তথা উৎপাদনশীলতা ও ব্যবসা পরিচালনায় উত্তম নীতি সংরক্ষণ ও উন্নয়নকে অগ্রাধিকার দেয়ার প্রত্যয়ে অবিচল থাকার চেষ্টা অব্যাহত রেখেছে।

উন্নয়নের শীর্ষে পৌঁছার ব্যাপারে আমরা আপোসহীন। শুধুমাত্র স্থানীয় বাজার থেকে নয়, রপ্তানী খাত থেকেও আয় বর্ধনের লক্ষ্যে উৎপাদনশীলতা বৃদ্ধির জন্য নানাবিধ পদক্ষেপ গ্রহণ করা হয়েছে। ভবিষ্যৎ উন্নয়ন ও টেকসই প্রবৃদ্ধি এবং অভ্যন্তরীণ ও আন্তর্জাতিক পরিসরে স্বাস্থ্য সেবা প্রদান অব্যাহত রাখার লক্ষ্যে বহুমুখী প্রকল্প গ্রহণের নতুন কৌশল গ্রহণ করা হয়েছে।

একটি প্রতিযোগিতামূলক ব্যবসায়িক পরিবেশে কোম্পানী প্রতিযোগিতামূলক দরে সর্বোচ্চ গুণগত মানসম্পন্ন পণ্য দিয়ে ভোক্তা সাধারণের পাশে থাকতে সক্ষম হয়েছে। কোম্পানী উন্নত প্রযুক্তির সর্বোচ্চ ব্যবহার এবং ভবিষ্যৎ চ্যালেঞ্জ মোকাবিলা করে চাহিদামাফিক পণ্য পরিবেশনের মাধ্যমে ব্যবসা সম্প্রসারণের ওপর গুরুত্ব আরোপ করে থাকে। সম্ভাব্য ভবিষ্যৎ উন্নয়নের কোম্পানীর দৃষ্টিভঙ্গি প্রতিবেদনের ৬৯ পৃষ্ঠায় উল্লেখ করা হয়েছে।

দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি. এ বিনিয়োগ

কোম্পানীর ৩০ জুন, ২০২৬ সমাপ্ত অর্থ বছরের নিরীক্ষিত আর্থিক প্রতিবেদনের ০৭ নং নোটের রিপোর্ট মোতাবেক এপিআই এর ১০০.০০ কোটি টাকা অনুমোদিত মূলধনের ৯৯.৯৯% শেয়ারের ধারক হিসেবে আলোচ্য বছরে ইবনে সিনা ফার্মার বিনিয়োগের পরিমাণ ৭৯,৯৯,৯৯,৮০০ টাকা। হোল্ডিং কোম্পানী আইপিআই এর মোট ৭,৪২৪,৩৪৭,৭৪৫ টাকা প্রকৃত সম্পদের (সম্পত্তি, প্লান্ট, যন্ত্রপাতি, চলতি মূলধন) ১০.৭৮% টাকা, যা বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং বিএসইসি / সিএমআরআরসিডি/২০০৯-১৯৩/১০/এডমিন/১১৮, তারিখ মার্চ ২২, ২০২১ অনুসারে প্রকৃত সম্পদের ১% এর অধিক হওয়ায় পরিচালনা পরিষদের সুপারিশ শেয়ারহোল্ডারগণের অনুমোদনের জন্য অদ্যকার বার্ষিক সাধারণ সভায় পেশ করা হবে। সাবসিডিয়ারী কোম্পানী দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি. এর আলোচ্য বছরের আর্থিক বিবরণী 04A এবং 05A নং নোটে উল্লিখিত হয়েছে।

দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এ বিনিয়োগ

কোম্পানীর ৩০ জুন, ২০২৬ সমাপ্ত অর্থ বছরের নিরীক্ষিত আর্থিক প্রতিবেদনের ০৭ নং নোটের রিপোর্ট মোতাবেক দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর ৪০.০০ কোটি টাকা অনুমোদিত মূলধনের ৬৫% শেয়ারের ধারক হিসেবে আলোচ্য বছরে ইবনে সিনা ফার্মার বিনিয়োগের পরিমাণ ২০.০০ কোটি টাকা। হোল্ডিং কোম্পানী আইপিআই এর মোট ৭,৪২৪,৩৪৭,৭৪৫ টাকা প্রকৃত সম্পদের (সম্পত্তি, প্লান্ট, যন্ত্রপাতি, চলতি মূলধন) ২.৬৯ টাকা। যা বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং বিএসইসি / সিএমআরআরসিডি/ ২০০৯-১৯৩/ ১০/ এডমিন/ ১১৮, তারিখ মার্চ ২২, ২০২১ অনুসারে প্রকৃত সম্পদের ১% এর অধিক হওয়ায় এ সংক্রান্ত পরিচালনা পরিষদের ১টি সুপারিশ শেয়ারহোল্ডারগণের অনুমোদনের জন্য অদ্যকার বার্ষিক সাধারণ সভায় পেশ করা হবে। সাবসিডিয়ারী কোম্পানী দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর আলোচ্য বছরের আর্থিক বিবরণী 04A এবং 05A নং নোটে উল্লিখিত হয়েছে।

আর্থিক ফলাফল

০১ জুলাই ২০২৫ থেকে ৩০ জুন ২০২৬ অর্থ বছরের আর্থিক ফলাফলের সার সংক্ষেপ নিম্নরূপ:

স্থায়ী সম্পদ

ধারাবাহিক উন্নয়নের অংশ হিসেবে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসির নিম্নোক্ত অগ্রগতি সাধিত হয়েছে ।

১. ভূমি ক্রয় ও ভূমি উন্নয়ন;

২. নতুন প্রকল্প সমূহের জন্য প্রয়োজনীয় ইমারত নির্মাণ;

৩. উৎপাদন, মান নিয়ন্ত্রণ ও ইউটিলিটির জন্য নতুন মূলধনী মেশিন ক্রয়।

আইপিআই এর কৌশলগত পরিকল্পনার অগ্রাধিকার প্রকল্প হিসেবে ফার্মা ইউনিট-২ (মাওনা প্রজেক্ট) তে Oral Solid Dosage (OSD), Sterile and Oncology ওষুধ উৎপাদিত হবে। ইতোমধ্যে ফার্মা ইউনিট-২ প্রকল্প বাস্তবায়নের কাজ প্রায় সমাপ্তির পথে। চলতি অর্থবছরের মধ্যে বাণিজ্যিক উৎপাদন ও বিপণনের কার্যক্রম শুরু করা সম্ভব হবে, ইনশাআল্লাহ।

অন্যদিকে চকপাড়া, মাওনা, গাজীপুরে অবস্থিত দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর দ্বিতল প্রশাসনিক ভবন, ৪তলা প্রোডাকশন ভবন এবং দ্বিতল জেনারেটর ভবন এর নির্মাণ কাজ সমাপ্ত হয়েছে। প্রয়োজনীয় মেশিনারিজ এলসি

করপূর্ব মুনাফা

২০২৫-২৬	২০২৪-২৫
১,০১৪,৫৮০,৭৩৮	৮৩৯,৯৭৪,৩৫৩

নীট সম্পদ মূল্য

২০২৫-২৬	২০২৪-২৫
৪,৫১৬,৬০৮,২৪৭	৩,৯২৬,৯০১,৬৬৪

আয়কর

২০২৫-২৬	২০২৪-২৫
২২১,৬৫৩,৪৩৬	২০৬,৭১৮,১২৫

শেয়ার প্রতি আয়

২০২৫-২৬	২০২৪-২৫
২৫.৪৩	২০.২৭

কর পরবর্তী মুনাফা

২০২৫-২৬	২০২৪-২৫
৭৯২,৯২৭,৩০১	৬৩৩,২৫৬,২২৮

শেয়ার প্রতি নীট চলতি নগদ প্রবাহ

২০২৫-২৬	২০২৪-২৫
৩৭.৯৫	২৩.১৬


রিটেইন্ড আর্নিংস

২০২৫-২৬	২০২৪-২৫
৪,২২০,২৯১,৫৭৬	৩,৬২৫,৬১৭,৬১৫


শেয়ার প্রতি নীট সম্পদ মূল্য

২০২৫-২৬	২০২৪-২৫
১৪৪.৫৬	১২৫.৬৯


শেয়ার প্রতি আয়



শেয়ার প্রতি নীট চলতি নগদ প্রবাহ



শেয়ার প্রতি নীট সম্পদ মূল্য



করা হয়েছে। আগামী জানুয়ারি ২০২৭ সালের মধ্যে ইন্সটলেশন ও কমিশনিং পূর্বক ট্রায়াল প্রোডাকশন শুরু হবে বলে আশা করছি।

সকল নতুন প্রকল্পের কার্যক্রম এবং মূলধনী যন্ত্রপাতি কোম্পানীর স্থায়ী সম্পদ বৃদ্ধিতে গুরুত্বপূর্ণ অবদান রাখছে। আলোচ্য অর্থ বছরে স্থায়ী সম্পদে যুক্ত হওয়া সম্পদে বিস্তারিত তথ্য বার্ষিক প্রতিবেদনের ২৪৩ পৃষ্ঠায় উপস্থাপিত হয়েছে।

উৎপাদন সক্ষমতা ও প্রযুক্তির ব্যবহার

কোম্পানীর প্লান্টের উৎপাদন ক্ষমতা, কর্মদক্ষতা, উৎপাদনশীলতা ও গুণগত মান বৃদ্ধির লক্ষ্যে উন্নত প্রযুক্তি সংযোজন, গবেষণা পরিচালনা ও প্রশিক্ষণ কার্যক্রম অব্যাহত রেখেছে। আলোচ্য বছরে ফার্মা, সেফা ও ন্যাচারাল মেডিসিন প্লান্টে সর্বাধুনিক ও উন্নত মানের মেশিনারিজ ও যন্ত্রপাতি ক্রয় ও স্থাপন এবং বেশ কিছু নতুন প্রোডাক্ট বাজারজাতকরণের মাধ্যমে সার্বিক বিনিয়োগ বৃদ্ধি পেয়েছে যা কোম্পানীর অভ্যন্তরীণ উৎস ও ব্যাংক বিনিয়োগের মাধ্যমে নির্বাহ করা হয়েছে।

উন্নত কাঁচামাল ও ওষুধের গুণগত মান

মানব কল্যাণের লক্ষ্যে কোম্পানী তার উৎপাদিত ওষুধের গুণগত মান রক্ষায় প্রতিশ্রুতিবদ্ধ। এ লক্ষ্যে মূল উপাদানের সঠিক মান ও উৎসের সন্ধান এবং উন্নত কাঁচামাল সংগ্রহ, সংরক্ষণ ও সঠিক মাত্রার ওষুধ প্রস্তুত করার লক্ষ্যে আইপিআই-এ টোটাল কোয়ালিটি ম্যানেজমেন্ট (TQM) সিস্টেম কার্যকর রয়েছে। বিশ্বমানের যন্ত্রপাতির মাধ্যমে উৎপাদন ও কঠোর মান নিয়ন্ত্রণের মধ্য দিয়ে উৎপাদিত ওষুধ গ্রাহকের দোরগোড়ায় সাশ্রয়ী মূল্যে পৌঁছানোর জন্যে কোম্পানী নিরলস চেষ্টা চালিয়ে যাচ্ছে।

নতুন ওষুধ বাজারজাতকরণ

ফার্মা মেডিসিন

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি প্রচলিত ওষুধের পাশাপাশি নিয়মিত নতুন ওষুধ বাজারজাত করেছে যা কোম্পানীর প্রবৃদ্ধি অর্জনে গুরুত্বপূর্ণ ভূমিকা পালন করেছে। এরই ধারাবাহিকতায় কোম্পানী ২০২৫-২৬ অর্থবছরে ৭টি জেনেরিকের, ৮টি নতুন প্রোডাক্ট বাজারজাত করেছে যার মধ্যে আছে ফিনোট্যাব ১০ ট্যাবলেট, কোলোস্টাট ৪০ ট্যাবলেট, বায়োটন আইভি ইনজেকশন, স্টুভেক ইনজেকশন, সিনাটইড ৫০/৫০০ কোজিক্যাপ ড্রাই পাউডার ইনহেলার (ডিপিআই), ফ্যান্টাজেসিক ইনজেকশন, এগিক্যাল-ডি ট্যাবলেট, এগিক্যাল-ডিএক্স ট্যাবলেট। বায়োটন আইভি ইনজেকশন, এগিক্যাল-ডি ট্যাবলেট এবং এগিক্যাল-ডিএক্স ট্যাবলেট চিকিৎসক মহলে বেশ সমাদৃত হয়েছে।

ন্যাচারাল মেডিসিন

এলোপ্যাথিক ওষুধের পাশাপাশি বিশ্বব্যাপী ন্যাচারাল মেডিসিনের বাজারও সম্প্রসারিত হচ্ছে। দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. ইতোমধ্যে ভোক্তা এবং চিকিৎসকগণের আস্থা অর্জন করতে সমর্থ হয়েছে। আলহামদুলিল্লাহ।

কোম্পানী ধারাবাহিকভাবে প্রচলিত প্রোডাক্টের পাশাপাশি নতুন নতুন প্রোডাক্ট বাজারজাতকরণের মাধ্যমে বিক্রয় বৃদ্ধিতে উল্লেখযোগ্য অবদান রাখছে।

২০২৫-২৬ অর্থবছরে কোম্পানীটি নতুন প্রোডাক্ট বাজারজাত করেছে। সেগুলো হলো: মরিঙ্গা এল এক্স ক্যাপসুল ৫০০ মিগ্রা, সিনাসয় ট্যাবলেট ৫০০ মিগ্রা, কোলাজেন প্লাস ক্যাপসুল ৫০০ মিগ্রা এবং ব্যাসিগাট ৯ ক্যাপসুল ৫০০ মিগ্রা। মরিঙ্গা এলএক্সে ৯০টি পুষ্টি উপাদান, ৪৬টি অ্যামিনো এসিড এবং প্রধান ফাইটোকেমিকেল রয়েছে, যা পুষ্টি, শক্তি এবং রোগপ্রতিরোধ ক্ষমতা বৃদ্ধি করে। এটি আয়রনের ঘাটতি দূর করতে সাহায্য করে, স্তনে দুধ উৎপাদন বাড়ায় এবং ডায়াবেটিসের প্রবণতা হ্রাস করে। সিনাসয় ট্যাবলেট একটি ফার্মেন্টেড নন-জিএমও সয়া সাপ্লিমেন্ট, যা ল্যাকটোব্যাসিলাস ডেলব্রুয়েকি (রোজেল-১৮৭) দ্বারা প্রস্তুত। এটি গ্যাস্ট্রিক ও ডুওডেনাল আলসার, দীর্ঘস্থায়ী গ্যাস্ট্রাইটিস, অতিরিক্ত এসিডিটি, হার্টবার্ন এবং অম্লতা নিয়ন্ত্রণে কার্যকর। কোলাজেন প্লাস একটি কম্বিনেশন সাপ্লিমেন্ট, যা অস্টিওআর্থ্রাইটিস ব্যবস্থাপনায় একাধিক পথকে টার্গেট করে। প্রদাহ ও রোগ প্রতিরোধ প্রক্রিয়াকে নিয়ন্ত্রণের মাধ্যমে এটি রিউম্যাটয়েড আর্থ্রাইটিসে অস্থিসন্ধির উন্নতি সাধন করে। ব্যাসিগাট ৯ একটি প্রোবায়োটিক মিশ্রণ, যা ৯ বিলিয়ন সিএফইউ সম্পন্ন এবং অন্ত্রের মাইক্রোফ্লোরা ভারসাম্য পুনঃপ্রতিষ্ঠা করে, আইবিএস, গ্যাস ও কোষ্ঠকাঠিন্য উপশম করে, হজমশক্তি উন্নত করে এবং রোগ প্রতিরোধ ক্ষমতা বাড়ায়।

বিতরণ

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর বিতরণ বিভাগটি উপযুক্ত ও সুসজ্জিত। এ বিভাগে নিয়োজিত দক্ষ, পরিশ্রমী ও মেধা সম্পন্ন জনশক্তি সম্মিলিতভাবে প্রতিযোগিতা ও যুগোপযোগী বিতরণ কার্যক্রম সম্পাদন করছেন। কোম্পানীর উৎপাদিত ওষুধ সরবরাহের লক্ষ্যে বিতরণ বহরে নিজস্ব প্রায় ১০০টি পরিবহন রয়েছে। তাছাড়া ২১টি সেল্স ডিপোর মাধ্যমে ভোক্তা সাধারণের দোরগোড়ায় জরুরী জীবন রক্ষাকারী ওষুধ যথাসময়ে সরবরাহ নিশ্চিত

করছে। আধুনিক প্রযুক্তি তথা সফটওয়্যার, অটোমেশন নেটওয়ার্কে সুবিধাদি ব্যবহার করে সুফল ভোগের পাশাপাশি কাস্টমার সার্ভিস ত্বরান্বিত করা হচ্ছে। আগামীতে "মডেল ডিপো" ধারণার আলোকে ডিপো ব্যবস্থাপনা পদ্ধতিকে উন্নত করার মাধ্যমে কাঙ্ক্ষিত বিক্রয় লক্ষ্যমাত্রা অর্জনে এ বিভাগ সর্বদা প্রস্তুত ও প্রতিশ্রুতিবদ্ধ।

রপ্তানি কার্যক্রম

স্বাস্থ্যসেবা প্রদানের মাধ্যমে দ্বিপক্ষীয় ব্যবসায়িক বন্ধন আরও জোরদার করার জন্য দি ইবনে সিনা ফার্মা তার কারখানা বৈদেশিক ক্রেতা এবং বিধিবদ্ধ কর্তৃপক্ষের পরিদর্শনের জন্য সর্বদা উন্মুক্ত রেখেছে। এ মুহূর্তে ইবনে সিনা ফার্মা শতাধিক বিভিন্ন মাত্রার প্রোডাক্ট সেন্ট্রাল আমেরিকার গুয়েতেমালা এবং ভেনিজুয়েলা, এশিয়া মহাদেশের ফিলিপাইন, কম্বোডিয়া, মিয়ানমার, শ্রীলঙ্কা এবং মালদ্বীপ, আফ্রিকা মহাদেশের কেনিয়া, মালি, সোমালিয়া ও সিয়েরালিওনে রপ্তানি করছে। ভবিষ্যতে ব্যবসা উন্নয়নের জন্য আরও অনেক দেশের সাথে চুক্তি করার কার্যক্রম চলমান আছে। বিশ্বের জেনেরিক মার্কেটের সুযোগকে কাজে লাগানোর জন্য ইবনে সিনা ফার্মা বর্তমানে আন্তর্জাতিক বিধিবদ্ধ সংস্থা /কর্তৃপক্ষ দ্বারা এই উৎপাদন ইউনিটগুলোর জন্য অনুমোদন গ্রহণের প্রচেষ্টা প্রক্রিয়াধীন আছে।

মানব সম্পদ উন্নয়ন

কোম্পানী তার সুদূরপ্রসারী লক্ষ্য ও উদ্দেশ্যকে বাস্তবায়ন করার জন্য জনশক্তি পরিকল্পনা প্রণয়ন, জনবল নিয়োগ, কর্মী মূল্যায়ন, পদোন্নতি ইত্যাদি কর্মকান্ডের মাধ্যমে হেড অফিস, ফিল্ড ও ফ্যাক্টরির সকল পর্যায়ে একটি সুসমন্বিত অনুকুল কার্যকর কর্মপরিবেশ তৈরীর ইতিবাচক প্রয়াস অব্যাহত রেখে চলেছে।

লিগ্যাল অ্যাফেয়ার্স এন্ড এস্টেট

কোম্পানীর মানব সম্পদ সহ সার্বিক ব্যবস্থাপনার ক্ষেত্রসমূহকে যথাসম্ভব আইনানুগ রাখা, শ্রমিক ও শ্রমিক ইউনিয়ন (সিবিএ) সহ শ্রম বিরোধসমূহের আইনী নিষ্পত্তি সাধন, মামলা- মোকদ্দমাসমূহ লিগ্যাল অ্যাফেয়ার্স বিভাগ সুষ্ঠুভাবে তদারকী ও পরিচালনা করছে। কোম্পানীর সম্পদ এবং জমি-জমা প্রতিনিয়ত একটি আইনী সুরক্ষার মাধ্যমে আহরণ ও রক্ষণাবেক্ষণ করা হচ্ছে।

অন্যদিকে এস্টেট ডিপার্টমেন্ট কোম্পানীর প্রধান কার্যালয়, কারখানা, সেলস ডিপোসমূহ ও ফিল্ড পর্যায়ে অবস্থিত এবং সাবসিডিয়ারি কোম্পানী ও প্রজেক্টসমূহ সহ সকল প্রকারের স্থাবর-অস্থাবর সম্পদের খাতওয়ারি তালিকাভুক্তিকরণ পূর্বক ডাটাবেজ তৈরীর মাধ্যমে পেশাদারিত্বের সাথে আইনী ও দাপ্তরিক কাঠামোয় এসবের সার্বক্ষণিক সুরক্ষা ও সংরক্ষণ কাজ যথারীতি সম্পন্ন করে যাচ্ছে।

ট্রেনিং এন্ড স্কিলস ডেভেলপমেন্ট

কোম্পানীর বিপুল সংখ্যক জনশক্তির দক্ষতা উত্তরোত্তর বৃদ্ধি সহ তাঁদের মেধা ও যোগ্যতার যুগোপযোগী উৎকর্ষ সাধনে নানামুখী প্রশিক্ষণের ব্যবস্থা গ্রহণ করা হয়েছে। উল্লেখ্য, আলোচ্য অর্থ বছরে কোম্পানীর বিভিন্ন স্তর ও বিভাগে কর্মরত প্রায় ৪২০০ জনকে নিজস্ব ব্যবস্থাপনায় প্রশিক্ষণ দেয়া হয়েছে এবং ক্ষেত্র বিশেষে বিভিন্ন পেশাদার দেশী-বিদেশী প্রতিষ্ঠানে প্রশিক্ষণের জন্য প্রেরণ করা হয়েছে। প্রশিক্ষণোত্তর কর্মক্ষেত্রে এর প্রভাব ও কার্যকারিতা মূল্যায়ন (Effective Evaluation) করা হয়। একটি যুঁতসই প্রশিক্ষণ নীতিমালার আলোকে আগামীতে পুরো জনবলকে পর্যায়ক্রমে প্রয়োজন মাফিক প্রশিক্ষণ (Need-Based Training) কর্মসূচির আওতায় আনা হবে, যা ভবিষ্যতে কোম্পানীর উন্নয়নে ইতিবাচক ভূমিকা রাখতে সক্ষম হবে বলে আশা করা যায়।

তথ্য প্রযুক্তি

একটি গতিশীল ফার্মাসিউটিক্যাল কোম্পানী হিসেবে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি মান সম্পন্ন পণ্য উৎপাদন ও বাজারজাত করণের প্রতিটি ধাপে সর্বশেষ তথ্য প্রযুক্তির ব্যবহার নিশ্চিত করেছে। প্রকিউরমেন্ট, ইনভেন্টরী, উৎপাদন, কস্টিং, মানব সম্পদ, প্রশাসন, হিসাব, বিপণন, মার্কেট সার্ভে এবং বিক্রয় ও বিতরণ মড্যুলসে ইআরপি পদ্ধতিতে কার্যক্রম চলছে। এ পদ্ধতি চাহিদা মোতাবেক সময়োচিত সিদ্ধান্ত ও পদক্ষেপ গ্রহণে খুবই সহায়ক। প্রতিদ্বন্দ্বিতা ও প্রতিযোগিতামূলক বাজারের সফলতা অর্জনের জন্য কোম্পানী আধুনিকায়ন ও সময়ের সদ্ব্যবহারের লক্ষ্যে সর্বশেষ তথ্য প্রযুক্তির সর্বোচ্চ ব্যবহার করতে বদ্ধপরিকর।

কর্পোরেট গভর্নেন্স কমপ্লায়ান্স রিপোর্ট

কর্পোরেট গভর্নেন্স কমপ্লায়ান্স অডিটর কোম্পানীর কমপ্লায়ান্স স্ট্যাটাস মূল্যায়ন করে সন্তোষজনক প্রতিবেদন পেশ করেছেন। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন ইস্যুকৃত 'কর্পোরেট গভর্নেন্স কোড' (নোটিফিকেশন নং বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ /এডমিন / ৮০, তারিখ ০৩ জুন, ২০১৮) প্রতিপালনের মাধ্যমে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর কার্যক্রম পরিচালনায় কোম্পানী অঙ্গীকারাবদ্ধ। আলোচ্য অর্থ বছরে কোম্পানীর জন্য প্রযোজ্য "কর্পোরেট গভর্নেন্স কোড" যথাযথভাবে অনুসরণ করা হয়েছে। কমপ্লায়ান্স অডিটর কর্তৃক নিরীক্ষিত রিপোর্ট বার্ষিক প্রতিবেদনের ১৮১ ও ১৮২ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

ব্যবস্থাপনা সংক্রান্ত বিবৃতি ও পর্যালোচনা

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর কর্পোরেট গভর্নেন্স কোড বিধি নং বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ / এডমিন / ৮০, তারিখ ০৩ জুন, ২০১৮ অনুসারে কোম্পানীর চলমান সক্ষমতা, আর্থিক অবস্থা ও অন্যান্য প্রকাশিত বিবৃতিগুলো সম্পর্কে পৃথকভাবে বার্ষিক রিপোর্টের ব্যবস্থাপনা পরিচালকের প্রতিবেদনের ৬৭ পৃষ্ঠায় বিস্তারিত আলোচনা করা হয়েছে।

অতিরিক্ত বিধিবদ্ধ তথ্য

সম্মানিত শেয়ারহোল্ডারগণ ও স্টেকহোল্ডারগণের প্রতি জবাবদিহির দৃষ্টিভঙ্গি নিয়ে সুচারুরূপে কোম্পানী পরিচালনা করা হচ্ছে "কর্পোরেট গুড গভর্নেন্স" এর মূল উদ্দেশ্য। পরিচালকগণ বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর Corporate Governance Code অনুসারে নিম্নে উল্লিখিত বিষয়সমূহের মান নিশ্চিত করেনঃ-

১. কোম্পানীর শিল্প দৃষ্টিভঙ্গি এবং সম্ভাব্য ভবিষ্যৎ উন্নয়ন সম্পর্কিত বিষয় বার্ষিক প্রতিবেদনের ৬৯ পৃষ্ঠায় বর্ণিত হয়েছে;

২. সেগমেন্ট বা পণ্য ভিত্তিক Performance সম্পর্কিত তথ্য বার্ষিক প্রতিবেদনের ৮০ ও ৮১ পৃষ্ঠায় বর্ণিত হয়েছে;

৩. অভ্যন্তরীণ ও বহিঃ ঝুঁকির কারণসহ ঝুঁকি ও অনিশ্চয়তা সম্পর্কিত প্রতিবেদন, স্থায়ীত্বের প্রতি হুমকি ও পরিবেশের ওপর নেতিবাচক প্রভাব সম্পর্কে প্রতিবেদনের ১৭৪ পৃষ্ঠায় বর্ণিত হয়েছে;

৪. Cost of Goods Sold, Gross Profit Margin Ges Net Profit Margin সম্পর্কিত তথ্য বার্ষিক প্রতিবেদনের ৭২ পৃষ্ঠায় বর্ণিত হয়েছে;

৫. অস্বাভাবিক কর্মকান্ড (লাভ ক্ষতি) ও এর প্রভাব সম্পর্কে প্রতিবেদনে আলোচনা করা হয়েছে;

৬. কোম্পানীর ব্যবসা সংশ্লিষ্ট পক্ষের লেনদেন সম্পর্কিত তথ্য প্রতিবেদনের ২৩৯ পৃষ্ঠায় বর্ণিত হয়েছে;

৭. প্রান্তিক হিসাব ও বার্ষিক হিসাবের সাথে উল্লেখযোগ্য পার্থক্য নেই;

৮. স্বতন্ত্র পরিচালকসহ পরিচালনা ভাতা (Remuneration) সম্পর্কিত তথ্য প্রতিবেদনের ২৩২ পৃষ্ঠায় বর্ণিত হয়েছে;

৯. কোম্পানীর ব্যবস্থাপনা কর্তৃপক্ষ কর্তৃক প্রস্তুতকৃত আর্থিক বিবরণী সম্পর্কিত বিভিন্ন কার্যক্রমের চিত্র, ফলাফল, পরিচালনা নীতিমালা, নগদ অর্থ প্রবাহ এবং তারল্যের পরিবর্তন যুক্তিযুক্ত ও দূরদর্শী বিবেচনার ভিত্তিতে উপস্থাপিত হয়েছে;

১০. কোম্পানীর হিসাব বহি সমূহ যথাযথভাবে সংরক্ষিত হয়েছে;

১১. হিসাব নীতিমালা অনুসরণ পূর্বক আর্থিক বিবৃতি সমূহ প্রস্তুত করা হয়েছে এবং হিসাব সম্পর্কিত অনুমানগুলো বিচক্ষণতার সাথে যুক্তিসঙ্গতভাবে তৈরী করা হয়েছে;

১২. আর্থিক বিবরণী সমূহ প্রস্তুতকালে বাংলাদেশে প্রযোজ্য আন্তর্জাতিক হিসাব মান (IAS & IFRS) অনুসরণ করা এবং যথাযথভাবে উপস্থাপিত করা হয়েছে;

১৩. অভ্যন্তরীণ নিয়ন্ত্রণ ব্যবস্থার কার্যকর প্রয়োগ ও তত্ত্বাবধান নিশ্চিত করা হয়েছে;

১৪. ক্ষুদ্র বিনিয়োগকারীদের স্বার্থ সুরক্ষা সম্পর্কিত তথ্য প্রতিবেদনে উল্লেখ করা হয়েছে;

১৫. চলমান প্রতিষ্ঠান হিসেবে কোম্পানীর সক্ষমতা প্রমাণিত;

১৬. কোম্পানীর পরিচালনাগত ব্যাপারে পূর্ববর্তী বছরের তুলনায় উল্লেখযোগ্য কোন বিচ্যুতি নেই;

১৭. পাঁচ বছরের পরিচালনা ও আর্থিক ফলাফল সমূহ ৭২ পৃষ্ঠায় বর্ণিত হয়েছে;

১৮. পরিচালনা পর্ষদের সভায় উপস্থিতির বিবরণ ১৫৫ পৃষ্ঠায় বর্ণিত হয়েছে;

১৯. কোম্পানীর শেয়ারহোল্ডিং প্যাটার্ন ৮৭ ও ২২৩ পৃষ্ঠায় বর্ণিত হয়েছে;

২০. পরিচালনা পর্ষদের নিয়োগ অথবা পূনর্নিয়োগ সম্পর্কিত তথ্য প্রতিবেদনের ৫০ পৃষ্ঠায় বর্ণিত হয়েছে;

২১. কোম্পানীর ব্যবস্থাপনা পরিচালক প্রদত্ত পরিচালনা (Management) সংশ্লিষ্ট পর্যালোচনা ও বিশ্লেষণ সম্পর্কিত তথ্য প্রতিবেদনের ৬৭ পৃষ্ঠায় বর্ণিত হয়েছে;

২২. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর নোটিফিকেশন অনুসারে ব্যবস্থাপনা পরিচালক এবং চিফ ফাইন্যান্সিয়াল অফিসার কর্তৃক আলোচ্য বছরে তাঁদের দায়িত্ব ও কর্তব্য সম্পর্কিত ঘোষণা প্রতিবেদনের ১৬৯ পৃষ্ঠায় বর্ণিত হয়েছে;

২৩. বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের প্রোফর্মা অনুযায়ী কর্পোরেট গভর্নেন্স কমপ্লায়ান্স রিপোর্ট প্রতিবেদনের ১৮১ এবং ১৮২ পৃষ্ঠায় উপস্থাপিত হয়েছে;

IAS, IFRS সহ অন্যান্য আরোপযোগ্য আইন ও নীতি সমূহের যথাযথ বাস্তবায়ন

কোম্পানী আইন, ১৯৯৪ এবং বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন বিধি, ১৯৮৭ এবং বাংলাদেশ ফিন্যান্সিয়াল

রিপোর্টিং অ্যাক্ট ২০১৫ অনুসরণ পূর্বক কোম্পানী যাতে তার যাবতীয় আর্থিক লেনদেনের হিসাব সংরক্ষণ করা সহ সঠিক আর্থিক অবস্থা প্রকাশ করে, তা নিশ্চিত করার দায়িত্ব কোম্পানীর পরিচালনা পর্ষদের। সকল আর্থিক হিসাব প্রণয়নে The International Accounting Standard (IAS) The International Financial Reporting Standard (IFRS) সহ অন্যান্য আরোপযোগ্য নীতি সমূহের পূর্ণ অনুসরণ পূর্বক প্রস্তুত করার প্রক্রিয়া নিশ্চিত করা হয়। আর্থিক হিসাব প্রস্তুত প্রক্রিয়ায় পরিচালকগণের করণীয় সম্পর্কিত পৃথক একটি রিপোর্ট ১৭০ পৃষ্ঠায় দেয়া হয়েছে।

আর্থিক প্রতিবেদন ঃ স্বচ্ছতা ও জবাবদিহি

আলোচ্য অর্থ বছরের প্রথম প্রান্তিক, অর্ধ-বার্ষিক ও তৃতীয় প্রান্তিকের আর্থিক হিসাব প্রস্তুত, আর্থিক বছর শেষে বার্ষিক হিসাব এবং কার্যক্রমের যথাযথ মূল্যায়ন ও প্রকাশের দায়িত্ব পরিচালনা পর্ষদ পালন করে যাচ্ছেন। পরিচালনা পর্ষদ কর্তৃক গঠিত অডিট কমিটি এসব প্রতিবেদনের তথ্যাবলীর সঠিকতা, যথার্থতা, স্বচ্ছতা ও পূর্ণাঙ্গতা নিয়মিত নিরীক্ষা করে থাকেন।

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং এসইসি/ সিএমআরআরসিডি/ ২০০৮ -১৮৩/এডমিন/ ০৩-৩৪, তারিখ ২৭ সেপ্টেম্বর, ২০০৯ এবং ঢাকা স্টক এক্সচেঞ্জ পিএলসি ও চট্টগ্রাম স্টক এক্সচেঞ্জ পিএলসি এর লিষ্টিং রুলস ২০১৫ অনুযায়ী ২০২৫-২৬ অর্থ বছরের প্রথম প্রান্তিক, অর্ধ-বার্ষিক ও তৃতীয় প্রান্তিক এর অনিরীক্ষিত হিসাব কোম্পানীর ওয়েব সাইট, খবরের কাগজ ও অনলাইন নিউজ পোর্টালের মাধ্যমে প্রকাশ করা হয়েছে এবং কোম্পানী যথারীতি ও নিয়মিতভাবে BSEC, DSE, CSE সহ অন্যান্য নিয়ন্ত্রণকারী প্রতিষ্ঠান সমূহে প্রেরণ করেছে।

ব্যবসা সংশ্লিষ্ট পক্ষগণের সাথে লেনদেন

ব্যবসায় সংশ্লিষ্ট পক্ষসমূহের সাথে লেন-দেন International Accounting Standard IAS-২৪ ও ব্যবসায়িক নীতিমালা অনুসরণ করে বাণিজ্যিক ভিত্তিতে করা হয়েছে। আলোচ্য অর্থ বছরে সংশ্লিষ্ট পক্ষসমূহের সাথে লেন-দেনের প্রকৃতি, ধরণ, মান ইত্যাদি বিস্তারিতভাবে আর্থিক প্রতিবেদনের ২৩৯ পৃষ্ঠায় উপস্থাপন করা হয়েছে।

সংখ্যালঘু শেয়ারহোল্ডারগণের স্বার্থ রক্ষা

২০২৫-২৬ অর্থ বছরে সংখ্যালঘু শেয়ারহোল্ডারগণের স্বার্থ সুরক্ষিত। প্রত্যক্ষ বা পরোক্ষ কোন ভাবেই সংখ্যালঘু শেয়ারহোল্ডারগণের স্বার্থহানিকর কোন কার্যক্রম সংগঠিত হয়নি। কোম্পানী আইনের ২৩৩ ধারা "সংখ্যালঘু সদস্য বা শেয়ারহোল্ডাগণের স্বার্থ রক্ষার্থে আদালত কর্তৃক নির্দেশ দান" যথাযথভাবে প্রতিপালন করা হয়েছে।

অস্বাভাবিক লাভ-ক্ষতি

২০২৫-২৬ অর্থ বছরে অস্বাভাবিক লাভ-ক্ষতি পরিলক্ষিত হয়নি।

পরিচালনা পর্ষদের ধারণকৃত শেয়ার

কোম্পানীর পরিচালনা পর্ষদের নাম ও তাঁদের নামের বিপরীতে ধারণকৃত শেয়ার সংক্রান্ত বিবরণী প্রতিবেদনের ৮৭ পৃষ্ঠায় বর্ণিত হয়েছে।

সুবিধাভোগী ব্যবসা নিষিদ্ধ করণ বিধিমালা প্রতিপালন

কোম্পানী তার সকল পরিচালক, সকল কর্মকর্তা-কর্মচারী, শ্রমিক এবং এর সাথে সংশ্লিষ্ট সবার জন্য শেয়ার লেনদেন এর ক্ষেত্রে বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর বিধি অনুসারে সুবিধাভোগী ব্যবসা নিষিদ্ধকরণ বিধিমালা যথাযথভাবে প্রতিপালিত হচ্ছে।

আইনের প্রতি শ্রদ্ধা

রাষ্ট্রীয় আইন ও অন্যান্য প্রযোজ্য বিধি-বিধানের যথাযথ অনুসরণ ও প্রতিপালনে সর্বোচ্চ অগ্রাধিকার প্রদান করা হচ্ছে এবং করণীয় বিষয়সমূহ যথাসময়ে ও যথাযথভাবে নিশ্চিত করা হচ্ছে। কোম্পানী আইন প্রয়োগকারী ও নিয়ন্ত্রণকারী সংস্থা এবং অন্যান্য আইন প্রণয়নকারী কর্তৃপক্ষের বিধি বিধান মেনে চলতে বদ্ধপরিকর।

শ্রম আইনের প্রতিপালন

শ্রমবান্ধব পরিবেশ বজায় রাখার লক্ষ্যে কোম্পানী বাংলাদেশ শ্রম আইন, ২০০৬ (সংশোধিত, ২০২৬) ও শ্রম বিধি, ২০১৫ (সংশোধিত, ২০২২) যথাযথভাবে প্রতিপালন করছে।

দূষণমুক্ত পরিবেশ

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি পরিবেশ আইনের প্রতি শ্রদ্ধাশীল এবং এ লক্ষ্যে সংশ্লিষ্ট সকল কার্যক্রম গ্রহণ করেছে। ক্রমবর্ধমান মানবসৃষ্ট দূষণ ও বিপর্যয়ের কারণে সৃষ্ট পরিবেশ ও জনস্বাস্থ্য ঝুঁকিমুক্ত রাখা এবং উৎপাদনকালীন অভ্যন্তরীণ দূষণ ও বর্জ্য নিঃসরণে রাষ্ট্রীয় সংস্থা পরিবেশ অধিদপ্তর ও ওষুধ প্রশাসন অধিদপ্তরের বিধিমালা অনুসরণ করে ETP ও অন্যান্য দূষণমুক্ত কার্যক্রম পরিচালনা করে যাচ্ছে।

বিধিবদ্ধ পরিশোধ সমূহ

কোম্পানীতে কর্মরত কর্মকর্তা-কর্মচারী-শ্রমিকগণের এবং রাষ্ট্রীয় সকল বিধিবদ্ধ দেনা সমূহ যথাযথভাবে হালনাগাদ পরিশোধিত হয়েছে।

পুঁজি বাজারের বিধি সমূহ প্রতিপালন

কোম্পানী ঢাকা স্টক এক্সচেঞ্জ পিএলসি ও চট্টগ্রাম স্টক এক্সচেঞ্জ পিএলসি এ তালিকাভুক্ত হওয়ার পর থেকে বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন, ঢাকা স্টক এক্সচেঞ্জ পিএলসি ও চট্টগ্রাম স্টক এক্সচেঞ্জ পিএলসি সহ এতদসংশ্লিষ্ট অন্যান্য কর্তৃপক্ষের সময়ে সময়ে ইস্যুকৃত আইন, বিধি ও নির্দেশনা সমূহ যথাযথভাবে প্রতিপালন করে যাচ্ছে।

উল্লেখযোগ্য আর্থিক বিবরণীর তথ্যাদি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর নির্দেশনা অনুযায়ী আলোচ্য বছর সহ গত ৫ বছরের উল্লেখযোগ্য আর্থিক কার্যক্রম ও ফলাফলের সংক্ষিপ্ত বিবরণী প্রতিবেদনের ৭২ পৃষ্ঠায় বর্ণিত হয়েছে।

কোম্পানীর কর্মকর্তা, কর্মচারী ও শ্রমিকগণের জন্য কল্যাণমূলক কার্যক্রম

আলোচ্য অর্থ বছরে কোম্পানীর কর্মকর্তা-কর্মচারী-শ্রমিকগণের জন্য কল্যাণমূলক কার্যক্রমের বিবরণী প্রতিবেদনের ১২৯ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

শ্রমিক মুনাফা অংশীদারিত্ব তহবিল (WPPF) ও কল্যাণ তহবিল (Welfare Fund)

শ্রম আইন, ২০০৬ (সংশোধিত ২০২৬) অনুযায়ী, অর্জিত মুনাফার সর্বমোট অর্থের ৫% অর্থাৎ ৫২,৯৭৯,৯০৪/- (পাঁচ কোটি ঊনত্রিশ লক্ষ ঊনআশি হাজার নয়শত চার) টাকা WPPF-এ স্থানান্তর করা হবে।

উল্লেখ্য বিগত বছরের অনুমোদিত WPPF এর ১০% অর্থাৎ ৪,৩৩৫,৮৩৯/- (তেতাল্লিশ লক্ষ পঁয়ত্রিশ হাজার আটশত ঊনচল্লিশ) ইতোমধ্যে গণপ্রজাতন্ত্রী বাংলাদেশ সরকারের শ্রম ও কর্মসংস্থান মন্ত্রণালয়ের "বাংলাদেশ শ্রমিক কল্যাণ ফাউন্ডেশন" এর হিসাবে বিধিমাফিক স্থানান্তর করা হয়েছে।

চলমান প্রতিষ্ঠান

পরিচালনা পর্ষদ কোম্পানীর ব্যবসায়িক গতি প্রকৃতি বিশ্লেষণের মাধ্যমে মহান আল্লাহর রহমতে নিশ্চিত হয়েছেন যে, আগামী দিনগুলোতে ব্যবসায়িক কার্যক্রম চালিয়ে নেয়ার মত যথেষ্ট সঙ্গতি কোম্পানীর রয়েছে। চলমান নীতিমালার আলোকেই কোম্পানীর আর্থিক বিবরণীসমূহ প্রস্তুত করা হয়েছে। কোম্পানীর ব্যবস্থাপনা কর্তৃপক্ষের বিবেচনায় এরূপ কোন ঘটনা বা পরিস্থিতি সম্পর্কিত বৈষয়িক উদ্বেগ বা অনিশ্চয়তা সৃষ্টি হয়নি, যার দ্বারা কোম্পানী চলমান প্রতিষ্ঠান হিসেবে এর ভবিষ্যৎ কার্যক্রম চালিয়ে যাওয়ার ক্ষেত্রে সক্ষমতার বিষয়ে কোনরূপ সন্দেহ সৃষ্টি করতে পারে।

জাতীয় কোষাগারে অবদান

সামাজিক অঙ্গীকারের অংশ হিসেবে কোম্পানী নিয়মিতভাবে জাতীয় কোষাগারে অবদান রাখছে। কোম্পানী জাতীয় রাজস্ব কোষাগারে কর ও ভ্যাট বাবদ ০১ জুলাই ২০২৫ থেকে ৩০ জুন ২০২৬ পর্যন্ত ২,৪৮৭,৭৫৭,৬৩১ টাকা প্রদান করে জাতীয় অর্থনীতি বিকাশে উল্লেখযোগ্য অবদান রেখেছে।

অভ্যন্তরীণ নিয়ন্ত্রণ ও ঝুঁকি ব্যবস্থাপনা

কোম্পানীর অভ্যন্তরীণ ও বহিঃস্থ ঝুঁকি সম্পর্কিত সম্ভাব্য সবক্ষেত্রে শক্তিশালী অভ্যন্তরীণ নিয়ন্ত্রণ ও ঝুঁকি ব্যবস্থাপনা বিদ্যমান রয়েছে। এর বিবরণী প্রতিবেদনের ১৭৪ পৃষ্ঠায় দেয়া আছে।

মূল্য সংবেদনশীল ও বস্তুগত তথ্য প্রকাশের নীতিমালা ঃ

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি /সিএমআরআরসিডি /২০২১-৩৯৬/৫২/এডমিন /১৪০ তারিখ ২৮.১২.২০২২ মোতাবেক ক্ষুদ্র বিনিয়োগকারী ও অন্যান্য স্টেকহোল্ডারদের স্বার্থ সংরক্ষণার্থে দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি পরিচালনা পর্ষদ মূল্য সংবেদনশীল ও বস্তুগত তথ্য প্রকাশের নীতিমালা প্রণয়ন করেছে। কোম্পানীর ওয়েবসাইট: www.ibnsinapharma.com এটি নির্দেশক কাঠামো হিসাবে প্রকাশ করা হয়েছে এতে শেয়ারহোল্ডারগণ সহ অন্যান্য স্টেকহোল্ডারগণ মূল্য সংবেদনশীল ও বস্তুগত তথ্য যথাসময়ে অনায়াসে অবহিত হতে পারবেন।

মূল্য সংবেদনশীল ও বস্তুগত তথ্য বলতে কোম্পানীর আর্থিক অবস্থার পরিবর্তন, কর্পোরেট ঘোষণা, কর্পোরেট কাঠামো পরিবর্তন, পুঁজি কাঠামো ব্যবসা কার্যক্রম সম্প্রসারণ বা পরিবর্তন, ঋণ ও ফান্ড ব্যবস্থাপনা ইত্যাদির উল্লেখযোগ্য পরিবর্তন বুঝায়। এটি দ্বারা শেয়ারহোল্ডারগণ ও সম্ভাব্য বিনিয়োগকারীগণ বিনিয়োগ করার ক্ষেত্রে প্রভাবিত হন।

পরিচালনা পর্ষদের 'কোড অব কন্ডাক্ট' প্রতিপালন

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এর বিধি প্রতিপালনার্থে কোম্পানীর পরিচালনা পর্ষদ পরিচালকগণের জন্য পৃথক একটি 'কোড অফ কন্ডাক্ট' অনুমোদন করেছে। বার্ষিক প্রতিবেদনের ১৬৫ পৃষ্ঠায় সেটি বর্ণিত হয়েছে। কোড অফ কন্ডাক্টটি কোম্পানীর অফিসিয়াল ওয়েবসাইটে (www.ibnsinapharma.com) যথারীতি আপলোড করা হয়েছে।

নৈতিকতা পরিপালন

কোম্পানী নৈতিকতার ওপর সর্বোচ্চ গুরুত্ব দিয়ে থাকে। যাতে আইন কানুন ও পেশাদারিত্ব বজায় রেখে সংশ্লিষ্ট কর্মকর্তা, কর্মচারী এবং শ্রমিকবৃন্দ সঠিক ও সুচারুভাবে স্ব স্ব দায়িত্ব পালন করতে সক্ষম হন।

পরিচালনা পর্ষদের ভাতা

স্বতন্ত্র পরিচালক সহ পরিচালনা পর্ষদের সদস্যগণের সম্মানী ও ভাতা বাবদ ব্যয়ের পরিমাণ আর্থিক প্রতিবেদনের ২৭.০১ নং নোটে উল্লেখ করা হয়েছে, যা বার্ষিক প্রতিবেদনের ২৩০ পৃষ্ঠায় বর্ণিত হয়েছে।

পারিশ্রমিক নীতি

পারিশ্রমিক বিষয়ে সিদ্ধান্ত নেয়ার ক্ষেত্রে মুদ্রাস্ফীতি, মূল্য তালিকা এবং অপরাপর প্রতিযোগী কোম্পানী সমূহের সাথে সামঞ্জস্য রেখে কর্মকর্তা, কর্মচারীগণের এবং শ্রমিকগণের ক্ষেত্রে সরকারের ন্যূনতম মজুরী বোর্ড এর নির্দেশনার আলোকে বেতন-ভাতা-মজুরী ইত্যাদি নির্ধারণ করা হয়। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের জারিকৃত কর্পোরেট গভর্নেন্স কোড অনুসারে NRC এর সুপারিশ মোতাবেক কার্যনির্বাহী পরিচালকগণের মূল্যায়ন ও সম্মানী বোর্ডের অনুমোদন সাপেক্ষে প্রদানের পদ্ধতি অনুসরণ করা হয়।

আর্থিক বিবরণী প্রস্তুত পরবর্তী ঘটনাবলী

আর্থিক বিবরণীর নোট নং ৪৭ এ বর্ণিত বিষয় ব্যতিত ০১ জুলাই ২০২৫ থেকে ৩০ জুন ২০২৬ পর্যন্ত সময়ের আর্থিক বিবরণী প্রস্তুত পরবর্তী সমন্বয়ের প্রয়োজনীয়তা অথবা আর্থিক বিবরণীতে প্রকাশযোগ্য কোন ঘটনা ঘটেনি। যা বার্ষিক প্রতিবেদনের ২৪২ পৃষ্ঠায় বর্ণিত হয়েছে।

লভ্যাংশ প্রদানের নীতি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি/সিএমআরআরসিডি/২০২১-৩৮৬/০৩ তারিখ জানুয়ারি ১৪, ২০২১ প্রতিপালনার্থে কোম্পানীর পরিচালনা পর্ষদ লভ্যাংশ ঘোষণা, লভ্যাংশ পরিশোধ, লভ্যাংশ বিতরণ এবং এ সম্পর্কিত বিবরণী শেয়ারহোল্ডারগণের জন্য নির্দেশক কাঠামো হিসেবে বার্ষিক প্রতিবেদনে প্রকাশ ও কোম্পানীর অফিসিয়াল ওয়েবসাইটে (www.ibnsinapharma.com) আপলোড করে একটি "লভ্যাংশ প্রদান নীতি" প্রণয়ন করেছে। কোম্পানীর "লভ্যাংশ প্রদান নীতি" বার্ষিক প্রতিবেদনের ১৭১ পৃষ্ঠায় বিবৃত হয়েছে।

রিজার্ভ এন্ড সারপ্লাস

২০২৫-২৬ অর্থ বছরে কোম্পানীর রিজার্ভ এন্ড সারপ্লাস ৪,২২৪,৬৮৩,৬৮৬ টাকায় উন্নীত হয়েছে যা পূর্ববর্তী ২০২৪-২৫ অর্থ বছরে ছিল ৩,৬৩০,০০৯,৭২৫ টাকা।

অভ্যন্তরীণ নিয়ন্ত্রণ ও নিরীক্ষা

কোম্পানীর অভ্যন্তরীণ নিয়ন্ত্রণ ও নিরীক্ষা ব্যবস্থা সুষ্ঠু ভিত্তির ওপর প্রতিষ্ঠিত আছে এবং গৃহীত ব্যবস্থা যথাযথভাবে কাজ করছে। পরিচালনা পর্ষদ সময়ে সময়ে অভ্যন্তরীণ নিয়ন্ত্রণ পদ্ধতি মূল্যায়ন ও উন্নয়নের জন্য প্রয়োজনীয় পরিবর্তন আনয়ন করে থাকেন। পুঁজির সর্বোত্তম ব্যবহার, সর্বোচ্চ উৎপাদনশীলতা এবং স্বচ্ছতা নিশ্চিত করার জন্য একটি সুদৃঢ় অর্থনৈতিক ও অভ্যন্তরীণ নিয়ন্ত্রণ ব্যবস্থা কার্যকর রয়েছে।

পুঁজি বাজারে কোম্পানীর অবস্থান

আলোচ্য সময়ে কোম্পানীর শেয়ার ঢাকা স্টক এক্সচেঞ্জ পিএলসি ও চট্টগ্রাম স্টক এক্সচেঞ্জ পিএলসি এ অতিমাত্রায় বৃদ্ধি বা অবমূল্যায়িত হয়নি। শেয়ারহোল্ডারগণ সর্বদা আইপিআই এর শেয়ারের ওপর আস্থাশীল। উভয় স্টক এক্সচেঞ্জে প্রতি ১০ টাকার অভিহিত মূল্যের শেয়ার সর্বনিম্ন ২৭৩ টাকা থেকে সর্বোচ্চ ৩৭১ টাকায় ট্রেডিং হয়েছে।

হুইসেল ব্লোইং পলিসি

হুইসেল ব্লোইং পলিসির মাধ্যমে কোম্পানী সকল পর্যায়ের স্বচ্ছতা নিশ্চিত করা সহ যেকোন ধরনের জালিয়াতি ও ঝুঁকি ব্যবস্থাপনায় সাহায্য করে থাকে। এ নীতি অনুসরণে কোম্পানীর যেকোন কর্মকর্তা বা কর্মচারী বা শ্রমিক অন্য কর্মকর্তা বা কর্মচারী বা শ্রমিকের অস্বাভাবিক ও অসঙ্গতিপূর্ণ কার্যকলাপ সম্পর্কে কর্তৃপক্ষকে কোম্পানীর স্বার্থে অবহিত করে থাকেন।

ইন্ডিপেনডেন্ট স্ক্রুটিনাইজার

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি/সিএমআরআরসিডি/২০০৯-১৯৩/০৮ মার্চ ১০, ২০২১ প্রতিপালনার্থে ৩০ সেপ্টেম্বর, ২০২৬ তারিখে অনুষ্ঠিত পরিচালনা পর্ষদের ৩৪২তম সভায় ২৩ নভেম্বর, ২০২৬ তারিখে ভার্চুয়াল প্লাটফর্মে অনুষ্ঠিতব্য ৪২তম বার্ষিক সাধারণ সভার রেজুলেশন, শেয়ারহাল্ডারগণের ভোটাধিকার প্রয়োগের সুবিধাদি পর্যবেক্ষণের জন্য এম. মহসিন এন্ড কোং, চার্টার্ড সেক্রেটারীজ ইন প্র্যাকটিস-কে ইন্ডিপেনডেন্ট স্ক্রুটিনাইজার হিসেবে নিয়োগ দান করা হয়।

বার্ষিক সাধারণ সভা সমাপ্তির নির্দিষ্ট সময়সীমার মধ্যে নির্বাচন এবং ভোটের ফলাফলের সঠিকতা বিষয়ে বিস্তারিত তথ্যাদি ইন্ডিপেনডেন্ট স্ক্রুটিনাইজার বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন এ সভা সমাপ্তির ৪৮ ঘন্টার মধ্যে জমা দেবেন।

কর্মকর্তা-কর্মচারী-শ্রমিক সু-সম্পর্ক

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এ কর্মরত সর্বস্তরের কর্মকর্তা-কর্মচারী-শ্রমিকগণের মাঝে কাজের প্রতি একাগ্রতা, নিষ্ঠা, গভীর আন্তরিকতা, অর্থবহ সহযোগিতা ও মর্যাদাপূর্ণ ভ্রাতৃপ্রতিম সুসম্পর্ক বিরাজ করছে যা কোম্পানীর উন্নয়ন ও উৎপাদনের গতিশীলতা বৃদ্ধিতে প্রতিনিয়ত শক্তি যোগাচ্ছে।

অ-দাবীকৃত লভ্যাংশ পুঁজিবাজার স্থিতিশীলকরণ তহবিলে স্থানান্তর

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের বিধি নং-বিএসইসি / সিএমআরআরসিডি / ২০২১-৩৮৬ / ০৩, তারিখ জানুয়ারি ১৪, ২০২১ এবং ক্যাপিটাল মার্কেট স্ট্যাবিলাইজেশন ফান্ড রুলস ২০২১ প্রতিপালনার্থে কোম্পানীর ২০২১-২২ অর্থবছরের অ-দাবীকৃত/ অ-বিতরণকৃত/ অ-মিমাংশীত লভ্যাংশ বাবদ ৯,২০৮,৮১৯.১৪/- (বিরানব্বই লক্ষ আট হাজার আটশত উনিশ টাকা চৌদ্দ পয়সা) টাকা মাত্র ইনভেস্টমেন্ট কর্পোরেশন অব বাংলাদেশ (আইসিবি) এর অধীন "পুঁজি বাজার স্থিতিশীল করণ তহবিল" কমিউনিটি ব্যাংক বাংলাদেশ লি., গুলশান কর্পোরেট শাখায়, হিসাব নং-০০১০৩১১৫২১৩০১ এ জমা দেয়া হয়েছে। বছর ভিত্তিক অ-দাবীকৃত / অ-বিতরণকৃত / অ-মীমাংসিত লভ্যাংশের পরিমাণ বার্ষিক প্রতিবেদনের ১৭৩ পৃষ্ঠায় বর্ণিত হয়েছে।

লভ্যাংশ

পরিচালনা পর্ষদ ২০২৫-২৬ অর্থবছরে ১০ টাকা অভিহিত মূল্যের প্রতিটি শেয়ারের জন্য ৭৭% নগদ লভ্যাংশ প্রদানের সুপারিশ করেছে। পরিচালকবৃন্দ ২০২৫-২৬ অর্থবছরে কোন বোনাস শেয়ার বা স্টক ডিভিডেন্ড ঘোষণা করেননি এবং উক্ত বছরে কোন অন্তর্বর্তীকালীন স্টক ডিভিডেন্ড ঘোষণা করা হবে না।

অডিট কমিটি

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ / এডমিন / ৮০, তারিখ ৩ জুন ২০১৮ এর নির্দেশনা মোতাবেক পরিচালনা পর্ষদ কর্তৃক গঠিত ২ জন স্বতন্ত্র পরিচালকসহ বহুমুখী পেশাগত অভিজ্ঞতা সম্পন্ন ৩ (তিন) সদস্য বিশিষ্ট অডিট কমিটি কাজ করছে। কমিটি তার রিপোর্টে বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন ও বোর্ড কর্তৃক প্রদত্ত দায়িত্ব সম্পাদন, অভ্যন্তরীণ নিরীক্ষা পদ্ধতি, অনিরীক্ষিত প্রান্তিক আর্থিক বিবরণী, বার্ষিক আর্থিক প্রতিবেদন প্রস্তুত এবং বহিঃ নিরীক্ষকগণের পর্যবেক্ষণগুলোর বিশদ আলোচনা ও পর্যালোচনা করেছেন। রিপোর্টিং এর কোন পর্যায়ে ন্যূনতম ত্রুটি, অমিল অথবা সত্য পরিপন্থী তথ্য না থাকায় আর্থিক অবস্থার প্রতিবেদন বাস্তব ও স্বচ্ছ হিসেবে গণ্য হয়েছে। অডিট কমিটির একটি রিপোর্ট ১৫৮ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

নমিনেশন ও রেম্যুনেরেশন কমিটি (NRC)

বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের কর্পোরেট গভর্নেন্স কোড (বিএসইসি / সিএমআরআরসিডি / ২০০৬-১৫৮ / ২০৭ / এডমিন / ৮০, তারিখ ৩ জুন, ২০১৮) এর ৬নং শর্ত অনুসারে পরিচালনা পর্ষদের উপ কমিটি হিসেবে ৩ (তিন) সদস্য বিশিষ্ট একটি Nomination and Remuneration Committee (NRC) কাজ করছে। আলোচ্য অর্থ বছরে NRC এর কার্যক্রমের বিস্তারিত বিবরণ ও NRC নীতি প্রতিবেদনের ১৬৪ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

কর্পোরেট সামাজিক দায়বদ্ধতা (CSR) নীতি

কর্পোরেট সামাজিক দায়বদ্ধতাকে সামনে রেখে কোম্পানীর Good Governance Practice নিয়মিত ও ধারাবাহিক প্রতিপালনের লক্ষ্যে পরিচালনা পর্ষদ অনুমোদিত কর্পোরেট সামাজিক দায়বদ্ধতা (CSR) নীতি অনুযায়ী কাজ করে যাচ্ছে। এ নীতি সুষ্ঠুভাবে কার্যকর করার জন্য বোর্ড তিন সদস্য বিশিষ্ট একটি উপ-কমিটি গঠন করেছে। বোর্ডের সাংবিধানিক উপ-কমিটি হিসাবে CSR কাজ করছে। বোর্ড গঠিত CSR উপ-কমিটি আলোচ্য অর্থ বছরে কোম্পানী কর্তৃক গৃহীত CSR নীতিমালা অনুসারে কর্পোরেট সামাজিক দায়বদ্ধতা কার্যক্রম পর্যবেক্ষণ ও পর্যালোচনা করেছে, যা প্রতিবেদনের ১২৯ পৃষ্ঠায় সন্নিবেশিত হয়েছে।

পরিচালক নির্বাচন

অধ্যাপক এ.এন.এম.এ জাহের এবং অধ্যাপক ড. চৌধুরী মাহমুদ হাসান কোম্পানী আইন, ১৯৯৪ এর ধারা ৯১(২) এবং কোম্পানীর সংঘ বিধির ২৮ ধারা অনুসারে ৪২তম বার্ষিক সাধারণ সভায় অবসর গ্রহণ করবেন। অবসর গ্রহণকারী পরিচালকদ্বয় পুনর্নির্বাচনের যোগ্য। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন প্রদত্ত নির্ধারিত পদ্ধতিতে পরিচালকদ্বয়ের সংক্ষিপ্ত জীবন বৃত্তান্ত প্রতিবেদনে সন্নিবেশিত হয়েছে।

নিরীক্ষক নিয়োগ

কোম্পানীর নিরীক্ষক মালেক সিদ্দিকী ওয়ালী এন্ড কোং, চার্টার্ড একাউন্ট্যান্টস ২০২৫-২৬ অর্থ বছরের নিরীক্ষা কার্য সম্পাদন করেছেন। মালেক সিদ্দিকী ওয়ালী এন্ড কোং, চার্টার্ড একাউন্ট্যান্টস ৪২তম বার্ষিক সাধারণ সভায় অবসর গ্রহন করেছেন। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশনের নোটিফিকেশন নং- বিএসইসি /সিএমআরআরসিডি/২০০৯-১৯৩/১০৪ এডমিন তারিখ ২৭ জুলাই, ২০১১ অনুসারে বর্তমান নিরীক্ষক নিরীক্ষা কার্যক্রম করার যোগ্য। মালেক সিদ্দিকী ওয়ালী এন্ড কোং, চার্টার্ড একাউন্ট্যান্টস পুনঃ নিরীক্ষা কার্যক্রম করার জন্য আগ্রহ (Expression of Interest) প্রকাশ করেছেন।

অডিট কমিটি নিরীক্ষা ফার্ম মালেক সিদ্দিকী ওয়ালী এন্ড কোং, চার্টার্ড একাউন্ট্যান্টস কে ২০২৬-২০২৭ অর্থ বছরের জন্য নিরীক্ষক হিসাবে নিয়োগ দানের সুপারিশ করেছে।

নিরীক্ষা প্রতিষ্ঠান কর্তৃক নিরীক্ষা কার্যক্রম সম্পাদনের পর কোম্পানী আইন-১৯৯৪ মোতাবেক উপযুক্ত বিবেচিত হওয়ায় পরিচালনা পর্ষদ অডিট কমিটির সুপারিশ মোতাবেক ৪,০০,০০০/- (চার লক্ষ) টাকা সম্মানী ধার্য করে ২০২৬-২৭ অর্থ বছরেরে জন্য মালেক সিদ্দিকী ওয়ালী এন্ড কোং, চার্টার্ড একাউন্ট্যান্টস কে নিরীক্ষক হিসাবে ৪২ তম বার্ষিক সাধারণ সভায় শেয়ারহোল্ডারগণের অনুমোদন সাপেক্ষে নিয়োগ দানের সিদ্ধান্ত গ্রহণ করেছে।

কমপ্লায়ান্স অডিটর নিয়োগ

বাংলাদেশ সিকিউরিটিজ এন্ড একচেঞ্জ কমিশনের ইস্যুকৃত কর্পোরেট গভর্নেন্স কোড অনুযায়ী মেসার্স এসএ রশীদ এন্ড এসোসিয়েটস কোম্পানীর ২০২৫-২৬ অর্থ বছরের কমপ্লায়ান্স অডিট সম্পন্ন করেছেন এবং মেসার্স এসএ রশীদ এন্ড এসোসিয়েটস বিধি অনুযায়ী ৪২তম বার্ষিক সাধারণ সভায় অবসর গ্রহণ করবেন।

কোম্পানী কর্তৃক কমপ্লায়ান্স অডিটর হিসেবে কাজ করার জন্য স্বীকৃত দুইটি চার্টার্ড সেক্রেটারিজ ফার্ম এর নিকট থেকে Expression of Interest (EOI) গ্রহণ করা হয়েছে। ফার্ম দুইটির বৃত্তান্ত ও বিবরণ পর্যালোচনার পর কোম্পানীর অডিট কমিটি এম.মহসিন এন্ড কোং চার্টার্ড সেক্রেটারিজ-কে ২০২৬-২৭ অর্থবছরের জন্য কমপ্লায়ান্স অডিটর হিসেবে নিয়োগ দানের সুপারিশ করেছে।

সংশ্লিষ্ট ফার্ম এর বৃত্তান্ত ও বিবরণ পর্যালোচনা এবং বিধি মোতাবেক উপযুক্ত বিবেচিত হওয়ায় পরিচালনা পর্ষদ অডিট কমিটির সুপারিশ গ্রহণ করে আসন্ন ৪২তম বার্ষিক সাধারণ সভার অনুমোদন সাপেক্ষে ২০২৬-২৭ অর্থবছরের জন্য কমপ্লায়ান্স অডিটর হিসেবে এম.মহসিন এন্ড কোং চার্টার্ড সেক্রেটারিজ-কে ৮০,০০০/- (আশি হাজার) টাকা সম্মানী নির্ধারণপূর্বক নিয়োগদানের সিদ্ধান্ত গ্রহণ করেছে।

সাবসিডিয়ারি কোম্পানীর পরিচালনা পর্ষদ এবং গভর্নেন্স

কর্পোরেট গভর্নেন্স কোড এর সাথে সঙ্গতি রেখে সাবসিডিয়ারি কোম্পানীর পরিচালনা পর্ষদে হোল্ডিং কোম্পানীর প্রতিনিধিত্ব রয়েছে। সে হিসেবে প্রত্যেক সাবসিডিয়ারি কোম্পানীর পরিচালনা পর্ষদে একজন করে স্বতন্ত্র পরিচালক প্রতিনিধিত্ব করছেন। সাবসিডিয়ারি কোম্পানী দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি., দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এবং দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর পরিচালনা পর্ষদের সভার কার্যবিবরণী দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি এর পরিচালনা পর্ষদের সভায় উপস্থাপন করা হয়েছে এবং যথাযথভাবে তা পর্যালোচনা ও নথিভুক্ত করা হয়েছে। কোম্পানীর পরিচালনা পর্ষদ সাবসিডিয়ারি কোম্পানীর সাময়িক ও বার্ষিক আর্থিক বিবরণী পর্যালোচনা করেছেন। নিম্নে ধারাবাহিকভাবে সাবসিডিয়ারি কোম্পানীগুলোর প্রকৃত চিত্র তুলে ধরা হল:-

দি ইবনে সিনা ন্যাচারাল মেডিসিন লি.

বিশ্বব্যাপী প্রাকৃতিক ও ঐতিহ্যবাহী ওষুধ (যেমন হারবাল মেডিসিন) ব্যবহারের ক্রমবর্ধমান হার বৃদ্ধি পাবার পরিপ্রেক্ষিতে, কোম্পানী সব ধরণের প্রাকৃতিক ওষুধ-ইউনানী, আয়ুর্বেদিক, হারবাল, পুষ্টি ও ডায়েটরী সাপ্লিমেন্টস্, হেলথ ফুড পণ্য, মেডিকেটেড কনজুমার প্রোডাক্ট, কসমেটিকস ও টয়লেট্রিজ উৎপাদনের ব্যবস্থা করেছে।

দি ইবনে সিনা ন্যাচারাল মেডিসিন লি. এর আলোচ্য বছরের কার্যক্রমের ওপর পরিচালনা পর্ষদের একটি রিপোর্ট বার্ষিক প্রতিবেদনের ২৪৬ পৃষ্ঠায় বিবৃত হয়েছে।

দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি.

দেশের অভ্যন্তরে এবং রপ্তানীর নতুন ক্ষেত্র সমূহে একটিভ ফার্মাসিউটিক্যাল ইনগ্রিডিয়েন্টস পণ্যের ব্যাপক চাহিদা সৃষ্টি এবং TRIPS চুক্তির আওতায় স্বল্প আয়ের দেশগুলোর ফার্মা সেক্টর এটি দ্বারা প্রভাবিত হওয়ার বিষয়টি বিবেচনায় নিয়ে একটিভ ফার্মাসিউটিক্যালের কাঁচামাল উৎপাদনের জন্য কোম্পানী মুন্সিগঞ্জ জেলার গজারিয়ায় সরকারী এপিআই শিল্প পার্কে বরাদ্দ প্রাপ্ত শিল্প প্লটে একটি কারখানা স্থাপন করা হয়েছে।

অভূতপূর্ব সফলতার সাথে এগিয়ে চলা বাংলাদেশের ফার্মাসিউটিক্যাল সেক্টরের প্রধান অত্যাবশ্যকীয় বিষয় হচ্ছে- কাঁচামাল সরবরাহ। এপিআই পার্কে স্থাপিত আমাদের কারখানাটি বাণিজ্যিকভাবে একটিভ ফার্মাসিউটিক্যাল কাঁচামাল উৎপাদনের জন্য সম্পূর্ণভাবে প্রস্তুত। ডিসেম্বর, ২০২৩ থেকে এটিতে পরীক্ষামূলক উৎপাদন শুরু হয়। বর্তমানে বাণিজ্যিক উৎপাদনের জন্য চুড়ান্ত পর্যায়ে রয়েছে।

দি ইবনে সিনা এপিআই ইন্ডাস্ট্রি লি. এর আলোচ্য বছরের কার্যক্রমের ওপর পরিচালনা পর্ষদের একটি রিপোর্ট বার্ষিক প্রতিবেদনের ২৫৭ পৃষ্ঠায় বিবৃত হয়েছে।

দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি.

দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. মূলত পলিমার জাত পণ্য উৎপাদন করে। যার মধ্যে রয়েছে পেট বোতল, আই-ড্রপ ভায়াল, বিভিন্ন কন্টেইনার এবং পিভিসি ফিল্ম, যা

ফার্মাসিউটিক্যাল পণ্য উৎপাদনে প্রাথমিক প্যাকেজিং উপকরণ হিসেবে ব্যবহৃত হয়।

দি ইবনে সিনা পলিমার ইন্ডাস্ট্রি লি. এর পরিচালনা পর্ষদের একটি বিবরণী অত্র প্রতিবেদনের ২৬৭ পৃষ্ঠায় দেয়া হয়েছে।

শেয়ারহোল্ডারগণের সাথে যোগাযোগ ও সম্পর্ক

কোম্পানী আইন মোতাবেক কোম্পানী যথারীতি নিয়মিত বার্ষিক সাধারণ সভা আয়োজন করে আসছে, যার মাধ্যমে শেয়ারহোল্ডারগণকে আর্থিক ফলাফল, অগ্রগতি, গৃহীত গুরুত্বপূর্ণ কার্যক্রম ও উন্নয়ন সম্পর্কে অবহিত করা হয়। ফলে শেয়ারহোল্ডারগণ ও সংশ্লিষ্ট প্রতিষ্ঠান কোম্পানী সম্পর্কে বিভিন্ন প্রয়োজনীয় তথ্য যথাসময়ে অবহিত হচ্ছেন। শেয়ারহোল্ডারগণ কোম্পানীর শেয়ার বিভাগ থেকে টেলিফোন, মোবাইল ফোন, ই-মেইল (shareipi@ibnsinapharma.com) ও ওয়েব সাইট (www.ibnsinapharma.com) সহ সরাসরি যোগাযোগের মাধ্যমে প্রতিনিয়ত প্রয়োজনীয় তথ্যাদি সংগ্রহ ও সেবা নিতে সক্ষম হচ্ছেন।

কৃতজ্ঞতা ও ধন্যবাদ জ্ঞাপন

পরিচালনা পর্ষদ ওষুধ শিল্পের সাথে সংশ্লিষ্ট স্বাস্থ্য মন্ত্রণালয়, ওষুধ প্রশাসন অধিদপ্তর, ওষুধ শিল্প সমিতি, সম্মানিত চিকিৎসক, কেমিস্টসহ জাতীয় রাজস্ব বোর্ড এবং শ্রম মন্ত্রণালয়, শ্রম অধিদপ্তর ও কলকারখানা ও প্রতিষ্ঠান পরিদর্শন অধিদপ্তরের অকুণ্ঠ সমর্থনের জন্য আন্তরিক ধন্যবাদ জানাচ্ছে। বাংলাদেশ সিকিউরিটিজ এন্ড এক্সচেঞ্জ কমিশন, ঢাকা স্টক এক্সচেঞ্জ পিএলসি. ও চট্টগ্রাম স্টক এক্সচেঞ্জ পিএলসি সহ সরকারের বিভিন্ন সংস্থা সমূহের সার্বিক সহযোগিতার কথা পরিচালকমণ্ডলী কৃতজ্ঞচিত্তে স্মরণ করছে।

পরিচালনা পর্ষদ ব্যবসায়িক সফলতায় আন্তরিক অবদান রাখা সহ সব পর্যায়ের ক্রেতা-ভোক্তা, পৃষ্ঠপোষক ও শুভানুধ্যায়ীকে সার্বিক সহযোগিতার জন্য আন্তরিক মোবারকবাদ জানাচ্ছে। পাশাপাশি কর্মকর্তা, কর্মচারী ও শ্রমিকবৃন্দের গভীর আন্তরিকতা, অর্থবহ সহযোগিতা, আনুগত্য ও কর্তব্য নিষ্ঠার জন্য ধন্যবাদ জ্ঞাপন করছে।

সম্মানিত শেয়ারহোল্ডারগণ পরিচালনা পর্ষদের ওপর যে আস্থা ও বিশ্বাস রেখেছেন তা তাঁদেরকে গভীরভাবে উৎসাহিত ও অনুপ্রাণিত করেছে। এটি বজায় রাখতে ব্যবস্থাপনা কর্তৃপক্ষ, কর্মকর্তা, কর্মচারী ও শ্রমিকবৃন্দ দৃঢ় প্রতিজ্ঞ। দেশ ও জাতির অব্যাহত উন্নয়নে আমাদের সব অকৃত্রিম ও নিরলস প্রয়াস আল্লাহ তায়ালা কবুল করুন।

পরিশেষে আমাদের প্রিয় জন্মভূমি গণপ্রজাতন্ত্রী বাংলাদেশ, এ দেশের আপামর জনসাধারণ এবং কোম্পানীর উত্তরোত্তর উন্নতি, সমৃদ্ধি ও সার্বিক অগ্রগতির জন্য মহান আল্লাহ রাব্বুল আলামীনের দরবারে রহমত কামনা করছি।

আল্লাহ হাফিজ।

পরিচালনা পর্ষদের অনুমোদনক্রমে ও পক্ষে,

প্রফেসর ড. এ কে এম সদরুল ইসলাম
ব্যবস্থাপনা পরিচালক

কাজী হারুন অর রশিদ
চেয়ারম্যান



Statement from the Managing Director

Bismillahir Rahmanir Rahim

Dear Honourable Shareholders

Assalamu Alaikum Wa Rahmatullah

By the grace of Almighty Allah (swt), The IBN SINA Pharmaceutical Industry PLC has completed its journey of 42 years of excellence with good track of achievement, growth records in the Pharmaceutical business (Pharma and Natural Medicine).

A warm welcome to our Integrated Annual Report for the year 2025-26. It is a pleasure to provide an update about performance of the Company and outline the path forward. As the salient financial highlights has been elaborated in the Directors' Report and Management Discussion and Analysis, I would limit myself to other important aspects of the business.

A warm welcome to our Integrated Annual Report for the year 2025-26. It is a pleasure to provide an update about performance of the Company and outline the path forward. As the salient financial highlights has been elaborated in the Directors' Report and Management Discussion and Analysis, I would limit myself to other important aspects of the business.

In the FY 2025-26, inflation soared to 10.3%. Taka devaluation to 122.71 per US Dollar increased cost of goods and contributed to the high inflation. Dependency on imported RM, import payment settlement, debt servicing, shortage of power supply like gas and electricity are the major economic challenges. The cost of borrowing increased sharply from 11% to over 15% during the year. Higher interest rate affected profitability across business segments.

However, the year 2025-26, IPI registered a growth of 5% which relied on its resilience and adaptive management system to deliver a durable operational and financial performance.

IPI focused on refining the systems and processes to adapt the evolving market conditions while implementation of strategic changes, optimization of cost structures offered the potential growth and resilience. The sincere efforts of management and all level of employees with integrity led us to attain the expected results in the financial year 2025-26 also similar to the past positive track records.

We acknowledge with gratitude for solid trust and support of our valued shareholders, patrons, physicians, regulatory authorities, and the end users of Company's products.

I would like to take the opportunity to convey some of the facts and figures of our Company with you as follows:

- Net Asset Value (NAV) per share is Tk. 144.56 which was Tk. 125.69 in 2024-25;
- Earnings per share (EPS) stood Tk. 25.43 which was Tk. 20.27 in the year 2024-25;
- Enriching product portfolio by introducing 8 (eight) new products with 7 (seven) generics in Pharma and 4 (four) new products in Natural Medicine;
- Contribution to the National Exchequer in the form of VAT, AIT and Corporate Tax of Tk. 2,487,757,631 which was Tk. 2,180,666,966/= in the year 2024-25.

As per condition no. 1 (5) (xxv) of the Corporate Governance Code 2018 issued by Bangladesh Securities and Exchange Commission, the **"Management's Discussion and Analysis"** representing detailed analysis of the Company's position and operations along with a brief discussion of changes in the financial statements for the year 2025-26, is given below:

Accounting Policies and Estimation for Preparation of Financial Statements

The IBN SINA Pharma follows International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) along with the Laws of Bangladesh applicable for preparation of Financial Statements.

The accounting policies and estimation used for the preparation of financial statements of the Company has been mentioned in details in the page no. 207 of the Annual Report.

Changes in Accounting Policies and Estimation

No changes in accounting policies and estimation which have the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes was observed in the year under review and the description on the issue is stated in the page no. 209 of the Annual Report.

Comparative Analysis of Financial Performance and Operational Performance Company performance

Comparative analysis of the financial performance and financial position of our Company over the last 5 (five) years are as under:

Particulars	2025-26	2024-25	2023-24	2022-23	2021-22	2020-21
Revenue	13,899,792,434	11,883,593,713	11,370,922,344	9,125,331,307	8,479,819,569	7,376,042,094
Gross Profit	5,752,708,574	4,799,853,846	4,531,507,148	3,871,099,631	3,566,070,119	3,100,717,195
Net Profit After Tax	792,927,301	633,256,228	671,350,473	605,808,719	605,674,624	488,971,771
EPS	25.43	20.27	21.46	19.38	19.39	15.66
Dividend Payout Ratio %	30.28%	31.58	29.36	30.96	30.94	30.02
Gross Profit Ratio %	41.39%	40.39	39.85	42.42	42.05	42.04
Current Ratio	0.68	1.15	1.13	1.26	1.50	1.26
Debt Equity Ratio%	0.89	0.52	0.52	0.30	0.38	0.40
Return on Equity %	18.78%	17.06	20.60	21.54	25.50	24.93

Detail comparative analysis of financial performance and operational performance for current financial year with immediate preceding five years has been explained with reasons thereof in the page no. 72 of the Annual Report

Comparison of Financial Performances and Financial Position as well as Cash Flows with Peer Industry Scenario:

Peer Industry Analysis

The Company is diversified business conglomerate having different type of production plants. On the other hand, top leading Pharmaceutical Companies are mostly private or proprietorship Company, therefore, despite the difficulties of making segment-based comparison of financial performance or results and financial position as well as cash flows with some peer industries we have made the followings for ease of understanding.

We have selected three of the listed Companies for comparison and have used ratio analysis as it is one of the best tools for assessing and comparing the financial performance of the Company based on the published Annual Report 2024-25 and 2023-24.

Particulars	2024-25				2023-24			
Financial Ratio	**IBN SINA**	**Orion**	**Square**	**Renata**	**IBN SINA**	**Orion**	**Square**	**Renata**
Current Ratio	1.15	2.07	6.37	1.57	1.13	2.24	12.48	1.44
Return on Equity%	18.76	(1.92)	13.63	6.34	20.60	1.38	15.11	10.67
NAV Per Share	125.69	86.09	124.71	305.49	111.94	92.05	119.35	295.56
NOCPS	23.16	4.72	17.96	41.16	12.48	6.78	17.70	18.16
EPS	20.27	(1.77)	27.04	19.36	21.46	1.36	23.61	31.53

Financial and Economic Scenario of Bangladesh and Global Position:

Bangladesh Perspective

Bangladesh faces a transitional and fragile economic scenario in 2026, characterized by a modest GDP growth recovery to around 4.1%–4.3% as political uncertainty eases post-election in 2026. Inflation remains elevated around 8%–9%, keeping consumer purchasing power under pressure while our strong inflows of remittances have provided a vital cushion for household consumption and foreign exchange reserves.

Financial and Economic Scenario of Bangladesh and Global Position:

Bangladesh Perspective

Bangladesh faces a transitional and fragile economic scenario in 2026, characterized by a modest GDP growth recovery to around 4.1%–4.3% as political uncertainty eases post-election in 2026. Inflation remains elevated around 8%–9%, keeping consumer purchasing power under pressure while our strong inflows of remittances have provided a vital cushion for household consumption and foreign exchange reserves.

As we know well that external debt servicing costs have risen sharply over the recent years, where foreign exchange reserves remain vulnerable. Major structural challenges coming as Bangladesh is set to graduate from the LDC group, leading to the gradual loss of preferential trade access for its applicable export and import-oriented industry.

In financial sector, it persists vulnerabilities, governance challenges, and high non-performing loans continue to constrain private sector credit growth.

However, coming of new investors to the emerging business sectors to be increased and encouraged as we know investment is considered as the main growth engine, imports of capital machinery and raw materials also to be accelerated and vibrant.

Global Perspective

Bangladesh is a rapidly growing, lower-middle-income developing economy and the second-largest in South Asia, transitioning from a frontier to an emerging market. Its economy is driven by strong performance in sectors like textiles, pharmaceuticals, and shipbuilding, with agriculture also playing a vital role.

Diversity of our economy beyond the ready-made garments sector like pharmaceutical industry fostering private sector development is must. Enhancing resilient infrastructure, improving energy security, strengthening financial sector governance, and attracting foreign investment are crucial to accelerating growth, creating jobs, and boosting competitiveness where impact of upcoming Least Developed Country (LDC) graduation to be considered.

Besides, the global energy market volatility, regional geopolitical tensions, and shifting U.S. tariff policies weigh heavily on manufacturing shipments and import costs are also the matter of challenges being addressed.

Risk and Concerns Issues Related to the Financial Statements:

The IBN SINA Pharmaceutical Industry PLC is always subject to analysis of systematic risk factors of the industry and market that may impact organization's operations and strategies.

The Risk Management report, a comprehensive guide for the stakeholders presented on page no 174. detailing of the risks faces and their potential impact on the business to understand, and the management strategies employed for risk-reduction tactics, continuity plans and protective controls.

Future Outlook and Forecast for Company's Operations, Performances and Financial Position:

The Pharmaceutical Industries in Bangladesh have achieved a rare credibility that the only LDC country in the world meets more than 97% of its domestic demand of pharmaceutical and medicinal products and export its products to more than 100 countries including EU & USA. This pivotal achievement has become possible only after confirming advanced technology and meeting the regulatory requirements. In spite of adoring themselves with modern technology the pharmaceutical industries maintain their firm advancement and established themselves as one of the country's most rapid growing and advanced economic sector. The IBN SINA Pharmaceutical Industry PLC is one of the proud member of Bangladesh Pharma Industries to the national development

In addition to all general essential medicines, our company produce lifesaving medicines and medical products, and eventually contributes towards huge foreign currency savings. The initial challenges involved in adherence to the regulatory and compliance requirements are generally met and stands at par with the multinational companies. However, the challenges to The IBN SINA Pharmaceutical Industry PLC are not over, our endeavorance is to step forward at an equal footing with other parallel Pharma Companies in Bangladesh.

In order to cope up with the prevailing Pharma market trends and challenges (both local market & export/international markets), our company have evaluated the overall scenario and taken some pragmatic steps in its development plan with the latest and innovative products as well as new technology and cutting-edge facilities. As ongoing of these activities, implementation of some emerging new projects and development activities are in progress as mentioned below.

The IPI PLC implemented the Extended Production unit included some compliance facilities like OSD

floor, Sterile/Injection production floor, and the MDI/DPI production floor. These are dedicated for the production of high-tech products.

The backward linkage of raw material supply has become a vital issue to the pharma sectors. Because the scanty status of pharma backward linkaged items compelled the pharma Manufactures to become dependent on import of both general raw material and active raw materials (API-Active Pharmaceutical Ingredients). Realizing the importance of the issue, API Industry was established to capitalize the registration of patented drugs prior to expiry of TRIPS and we are working on it.

Polymer products are widely used in Pharma factory as packaging materials, and the products include PET Bottles & Caps, Eye Drops Vials, measuring items like Cups, Spoons, Droppers, Small containers for tablets/Capsules packaging, PVC films, and so on. All these are the key important backward linkage items. Even today, huge ED Vials, containers are imported from outside. The IBN SINA Polymer Industry Ltd. is ready to start trial production of different Pharma grade polymer products hopefully by this year.

As ongoing expansion, IBN SINA Pharma Factory Unit-2 Project, located at Gazipur Bazar Union, Gazipur is completed by the kind grace of the Almighty Allah. We are hopeful that after completion of validation (including OQ & PQ), trial production will be started in December 2026. January 2027 is going to be the milestone of starting commercial production in this plant. It is cutting edge (state-of-the-art) project established as distinct and fully plant. The establishment of next unit, Oncology plant on this premise as scheduled will be started by Feb. 2027.

You all will be happy to know that as part of sustainable expansion strategy, IPI at its Shafipur pharma factory premises is going to introduce a dedicated Veterinary Unit (Animal Health division) considering its rapid growing commercialization of the livestock, poultry, and aquaculture sectors. As we know well that over the last decade, farming has being shifted from a subsistence backyard activity to an organized, high-density commercial industry, and hence the demand for professional veterinary medicines, vaccines, and nutritional supplements are drastically increasing.

The management on strategic outlook of new project planning and development works with a forecast of minimum twenty years sets up project implementation strategies including judicious financial assessment and feasibility study, project completion time line, break-even and margin of safety analysis, etc. Institutional financial supports are being considered as required for uninterrupted fund flow for the projects implementation. As a result, the managements foresight to catch every nuance of a project integrity and financial rate of return projection certainly makes a clear difference in new project implementation.

While, concluding, I appreciate for the leadership offered by the Board of Directors and the Management and also I would like to express my sincere appreciation to our valued customers, shareholders, suppliers, bankers, business partners, the healthcare professionals, Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange PLC (DSE), Chittagong Stock Exchange PLC (CSE), other regulatory authorities and all other stakeholders for their trust and continued support to the Company and to all the employees of the Company for their hard endeavor.

We pray to the Almighty Allah (swt) for His gracious blessings for the Company's bright success in future.



Prof. Dr. A K M Sadrul Islam
Managing Director



Managing Director along with the Senior Officials of the Company visiting IPI Pharma Unit-2, Mawna.



Front View of Pharma Unit-2, Mawna.

Consolidated Financial Highlights

AMOUNT IN TAKA

PARTICULARS	2025-26	2024-25	2023-24	2022-23	2021-22	2020-21
Sales (Net)	13,899,792,434	11,883,593,713	11,370,922,344	9,125,331,307	8,479,819,569	7,376,042,094
Sales Growth (%)	16.97%	4.51%	24.61%	7.61%	14.96%	19.13%
Cost of goods sold (COGS)	8,147,083,860	7,083,739,867	6,839,415,197	5,254,231,676	4,913,749,450	4,275,324,899
COGS Growth (%)	15.01%	3.57%	30.17%	6.93%	14.93%	18.92%
Gross Profit	5,752,708,574	4,799,853,846	4,531,507,148	3,871,099,631	3,566,070,119	3,100,717,195
Gross Profit Ratio (%)	41.39%	40.39%	39.85%	42.42%	42.05%	42.04%
Net Profit before Tax	1,014,580,738	839,974,353	894,698,822	804,731,983	799,862,485	704,448,050
Net Profit after Tax	792,927,301	633,256,228	671,350,473	605,808,719	605,674,624	488,971,771
Net Profit Ratio	5.70%	5.33%	5.90%	6.64%	7.14%	6.63%
Workers P.P. Fund & Welfare Fund	52,979,904	43,358,391	45,486,240	40,551,773	40,341,605	35,733,665
No. of Share holder	12,533	12,500	11,634	10,814	12,085	11,841
Return on Equity	18.78%	18.76%	20.60%	21.54%	25.50%	24.93%
Current Ratio	0.68	1.15	1.13	1.26	1.50	1.26
Equity per Share (Taka)	144.56	125.69	111.94	96.68	83.36	68.69
Earning per Share (orginal)	25.43	20.27	21.46	19.38	19.39	15.66
Price Earning Ratio (Time)	12.57	14.51	11.64	14.79	15.30	15.76
Quoted Price per Share-DSE (Year End)	319.60	294.10	249.80	286.60	296.70	246.70
Dividend per Share	77% Cash	64% Cash	63% Cash	60% Cash	60% Cash	47 % Cash
Reserve & Surplus (Year End)	4,224,683,686	3,630,009,725	3,193,655,224	2,710,594,864	2,292,640,082	1,833,618,116
Dividend Yield	2.41%	2.18%	2.52%	2.09%	2.02%	1.91%
Dividend Payout Ratio	30.28%	31.58%	29.36%	30.96%	30.94%	30.02%
Retained Earning	4,220,291,576	3,625,617,615	3,189,263,114	2,706,202,754	2,288,247,972	1,829,226,006
Retained Earning (Yearly)	552,351,373	433,297,015	474,515,622	418,346,957	418,212,862	342,126,724
Current Assets	3,302,659,427	2,845,250,397	2,620,323,446	1,836,444,762	1,683,200,873	1,457,828,253
Current Liabilities	4,863,761,044	2,476,567,357	2,318,099,470	1,461,481,620	1,124,020,711	1,155,278,552
Fixed Assets (Net)	2,638,512,168	2,655,519,636	2,628,798,080	2,447,741,823	2,342,489,248	2,209,734,247
NAV	4,516,608,247	3,926,901,664	3,497,480,774	3,020,764,783	2,604,390,765	2,146,199,473
NOCFPS	37.95	23.16	12.48	28.08	13.40	17.67
Debt Equity Ratio	0.89	0.52	0.52	0.30	0.38	0.40

Consolidated Horizontal and Vertical Analysis

Horizontal Analysis	2025-26	2024-25	2023-24	2022-23	2021-22
Consolidated Statement of Profit or Loss and Other Comprehensive Income Data					
Net Revenue	16.97%	4.51%	24.61%	7.61%	14.96%
Gross Profit	0.15%	0.04%	0.30%	0.07%	0.15%
Operating Profit	22.70%	-1.51%	11.59%	-0.13%	12.08%
Profit before Tax	20.79%	-6.12%	11.18%	0.61%	13.54%
Profit for the year (after Tax)	25.21%	-5.67%	10.82%	0.02%	23.87%
EPS	25.50%	-5.57%	10.75%	-0.07%	23.87%
Comprehensive Statement of Financial Position Data					
Total non-current assets	59.69%	20.89%	22.71%	18.53%	11.99%
Total current assets	16.08%	8.58%	42.68%	12.22%	12.26%
Total Assets	**43.25%**	**15.94%**	**30.04%**	**16.13%**	**12.09%**
Share capital	0.00%	0.00%	0.00%	0.00%	0.00%
Retained earnings	16.40%	13.68%	17.85%	18.27%	25.09%
Total equity attributable to owners of the Company	**16.46%**	**13.15%**	**15.63%**	**16.41%**	**22.12%**
Total non-current liabilities	20.39%	63.03%	34.70%	-13.00%	3.82%
Total current liabilities	96.39%	6.84%	58.61%	30.02%	-2.71%
Total liabilities	73.43%	19.25%	52.62%	15.69%	-0.63%
Total Equity and Liabilities	**43.25%**	**15.94%**	**30.04%**	**16.13%**	**12.09%**

Vertical Analysis	2025-26	2024-25	2023-24	2022-23	2021-22
Consolidated Statement of Profit or Loss and Other Comprehensive Income Data					
Net Revenue	100.00%	100.00%	100.00%	100.00%	100.00%
Gross Profit	41.39%	40.39%	39.85%	42.42%	42.05%
Operating Profit	8.35%	7.96%	8.44%	9.43%	10.16%
Profit before Tax	7.30%	7.07%	7.87%	8.82%	9.43%
Profit for the year	5.70%	5.33%	5.90%	6.64%	7.14%
Comprehensive Statement of Financial Position Data					
Total non-current assets	69.45%	62.30%	59.74%	63.31%	62.03%
Total current assets	30.55%	37.70%	40.26%	36.69%	39.05%
Total Assets	**100.00%**	**100.00%**	**100.00%**	**100.00%**	**100.00%**
Share capital	4.03%	4.93%	5.29%	6.98%	7.81%
Retained earnings	39.04%	48.04%	49.00%	54.06%	53.09%
Total Equity Attributable to Owners of the Company	**43.07%**	**52.98%**	**54.28%**	**61.05%**	**60.90%**
Total non-current liabilities	11.94%	14.21%	10.10%	9.75%	13.02%
Total current liabilities	44.99%	32.82%	35.61%	29.20%	26.08%
Total liabilities	56.93%	47.02%	45.72%	38.95%	39.10%
Total Equity and Liabilities	**100.00%**	**100.00%**	**100.00%**	**100.00%**	**100.00%**


Value Added Statement

For the year ended 30 June, 2026

Amount in Taka

PARTICULARS	2025-26	Percentage (%)	2024-25	Percentage (%)
VALUE ADDED				
Revenue & other income	13,935,024,676		11,908,799,736	
Less: Material costs & services	6,633,736,159		5,712,980,339	
	7,301,288,517	**100.00**	**6,195,819,397**	**100.00**

APPLICATIONS				
To Employees as salaries, wages & allowances	3,688,940,424	50.52	3,104,093,394	49.72
To Providers of finance as financial charges	127,838,224	1.75	87,403,328	1.40
To National exchequer	2,487,757,631	34.07	2,180,666,966	34.93
For replacement of fixed assets as depreciation	204,065,440	2.79	210,358,629	3.37
Dividend to Shareholders	240,575,928	3.29	199,959,213	3.20
For future growth as retained earning	552,110,870	7.56	460,202,811	7.37
	7,301,288,517	**100.00**	**6,242,684,341**	**100.00**



- To Employees as salaries, wages & allowances
- To Providers of finance as financial charges
- To National exchequer
- For replacement of fixed assets as depreciation
- Dividend to the Shareholders
- For future growth as retained earnings

- To Employees as salaries, wages & allowances
- To Providers of finance as financial charges
- To National exchequer
- For replacement of fixed assets as depreciation
- Dividend to the Shareholders
- For future growth as retained earnings


Market Value Added Statement

Market value added statement reflects the Company's performance evaluated by the market through the share price of the Company. This statement shows the difference between market capitalization and book value of the shares outstanding. In other words, it is the sum of all capital claims held against the Company plus the market value of debt and equity.


The higher MVA is the better indication. A high MVA indicates the Company has created substantial wealth for the shareholders. A negative market value added means the value of management's actions and investments are less than the value of the capital contributed to the Company by the capital market.

The following statement shows how the MVA has been calculated for the year 2025-26 and 2024-25 :-

Particulars	Amount in Million Taka	
	2025-26	**2024-25**
Market Value of Shares Outstanding	9985.46	9163.76
Book Value of Shares Outstanding	312.44	312.44
Market Value Added	**9673.02**	**8851.32**



Market Value of Shares Outstanding



Market Value Added

Economic Value Added Statement

For the year ended 30th June, 2026

Economic value added (EVA) is a measure of a company's financial performance based on the residual wealth calculated by deducting its cost of capital from its operating profit, adjusted for taxes on a cash basis. EVA can also be referred to as economic profit, and it attempts to capture the true economic profit of a company.


(Amount in Taka)

Description	2025-26	2024-25
Operating Profit	1,160,166,625	945,530,049
Provision for Income Tax	(221,653,436)	(206,718,125)
Net Operating Profit After Tax (NOPAT)	**938,513,188**	**738,811,924**
Charges for Capital		
Capital Employed	5,946,617,584	5,070,006,721
WACC	11.79%	12.72%
Capital Charges	700,811,731	644,770,728
Economic Value Added	**237,701,457**	**94,041,195**
Capital Employed		
Total Assets	10,810,378,628	7,546,574,078
Less: Current Liabilities	4,863,761,044	2,476,567,357
Capital Employed	**5,946,617,584**	**5,070,006,721**




Performance Indicators


NET SALES



CURRENT ASSETS




GROSS PROFIT




EARNING PER SHARE (EPS)


EARNING PER SHARE (EPS)




NET PROFIT BEFORE TAX




GROSS PROFIT RATIO (%)




NET PROFIT AFTER TAX




EQUITY PER SHARE (TAKA)




OPERATING PERFORMANCE




FINANCIAL POSITION ANALYSIS





FINANCIAL POSITION ANALYSIS





Segment Wise Reports













Segment Wise Reports


Devision Wise Sales Contribution %




Therapeutic Class Share: 2025-26 % (Pharma)




NET ASSETS VALUE (TK.)




SHARE VALUE (TK.)




RETURN ON SHAREHOLDERS' EQUITY (%)




CURRENT RATIO




NAV PER SHARE



ROCE (%)




MARKET CAPITALIZATION (BDT MIL.)




DIVIDEND YIELD




PRICE EARNING RATIO (TIMES)




DEBT EQUITY RATIO (%)



NOCFPS (TK.)



EBITDA (%)




Shareholders' Information

For the year ended 30 June 2026

STATUS OF SHAREHOLDINGS-2026 (JUNE)

Sponsors	: 13,843,312	(44.31%)
Public	: 9,348,249	(29.92%)
Institutions	: 8,052,066	(25.77%)



As per BSEC Notification no.-SEC/CMRRCD/2008-183/Admin/03-34, dated 27.09.2009
The Quarterly Reports are given below :-

QUARTERLY RESULTS

During the year 2025-26 operational results of the Company were announced on-

First Quarter Report	12 November 2025
Half Yearly Report	27 January 2026
Third Quarter Report	27 April 2026


DIVIDEND : FINANCIAL YEAR 2024-25


Board Meeting for the Year 2024-25	30 September 2025
Record Date for the Year 2024-25	26 October 2025
41th Annual General Meeting for the Year 2024-25	23 November 2025
Commencement of Cash Dividend Warrant Distribution for the Year 2024-25	10 December 2025
Completion of Cash Dividend Warrant Distribution for the Year 2024-25	17 December 2025
Submission of Dividend Distribution Report	29 December 2025

Share Performance

PARTICULARS	DSE	CSE
Stock Symbol	IBNSINA	IBNSINA
Business Segment	Pharmaceuticals and Chemicals	Pharmaceuticals and Chemicals
Company ID	18464	13013
Listing Year	1989	1996
Market Category	A	A
Electronic Share	Y	Y
Total Number of Outstanding	31,243,627	31,243,627

PARTICULARS	JUNE 2026	JUNE 2025
Market Capitalization- DSE (BDT million)	9985.46	9163.76
Market Capitalization- CSE (BDT million)	10060.44	9185.63
EPS (BDT)	25.43	20.27
DPS (BDT)	7.70	6.40
Payout Ratio (%)	31.00%	29.36%
Share Price- DSE (BDT)	319.60	293.30
Share Price- CSE (BDT)	322.00	294.00
Weighted average number of share outstanding	31,243,627	31,243,627





Pattern of Shareholdings

AS AT JUNE 30, 2026

As per condition 1(5)(xxiii) of the Corporate Governance Code issued by BSEC, the shareholding pattern was as follows:

Name of Shareholder	Descripition	No. of shares held	% of holding
Shares held by :			
(a) Parents or Subsidiary or Associated Companies and other related parties :		**N/A**	-
IBN SINA Trust	Sponsor	13,843,312	44.308
(b) i) Shares held by Directors			
Kazi Harun or Rashid	Chairman	103,692	0.3319
Prof. Dr. A K M Sadrul Islam	Managing Director	3,280	0.0105
Prof. ANMA Zaher	Director	Nil	-
Prof. Dr. Choudhury Mahmood Hasan	Director	6,939	0.0222
Dr. Mohammad Ayub Miah	Director	Nil	-
Prof. Col. (Retd.) Dr. Zehad Khan	Director	1210	0.0039
Prof. Dr. Shamsuddin Ahmed	Rep. IBN SINA Trust	Nil	-
Md. Rafiqul Islam Khan, FCA (Independent Director)	self	Nil	-
Parsa Begum (Independent Director)	self	Nil	-
Abdus Sadeque Bhuiyan (Independent Director)	self	Nil	-
(b) ii) Shares held by Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit & Compliance and their spouses		**No. of shares held**	**Percentage**
Company Secretary, his Spouse and minor children	self	544	0.0018
Chief Financial Officer, his Spouse and minor children	self	217	0.0007
Head of Internal Audit and Compliance, his spouse and minor children	self	136	0.0005
(c) Shares held by top five salaried employees other than the Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and their spouses			
Dr. Rafiqul Huq	self	234	0.0008
Md. Abdul Khaleque	self	549	0.0018
Md. Mizanur Rahman	self	Nil	-
Md. Parvez Kabir	self	540	0.0018
Md. Shah Alam	self	Nil	-
(d) Shareholders holding 10% or more voting right :		N/A	-

Note : Total 13,843,312 no. of shares are registered against the name of Seven Trustees nominated by The IBN SINA Trust. None of the individual Director/Shareholder holds more than 10% share.

Our Approach to Sustainability

We are a branded pharmaceutical company, committed to promoting access to medicines and improving the health of patients across the world through our high quality, affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability. Our approach to sustainability focuses on creating and protecting value, driving growth and innovation, and providing societal value through our core business activities, to make a meaningful contribution to the Country. The significant social benefits delivered through our products and services are supported by our CSR activities.

Integrating sustainability into corporate policies is a crucial aspect of our strategy as it helps us create long term value and safeguard our business in the future. With several global issues, such as climate change, increasing inequalities, and economic challenges, our adoption of sustainability practices has enabled us to be a responsible business while pursuing long-term value creation for our shareholders.

We believe that building positive relationships with all our stakeholders, starting with society as a whole, and including the global environment, our customers, shareholders, employees, and business partners, and developing these relationships in a balanced manner, is crucial for the sustainable development of our business, and ultimately enhances our corporate value and stakeholder value.

Our sustainability strategy builds on our purpose and establishes clear priorities to create long-term societal and financial value. We are taking action to integrate sustainability into everything we do and focus on three areas where we can have the most impact:

- Access to innovation: Access to innovation and health equity are core to our business and key to our commitment to improve patient outcomes. We want to maximize access to our innovative medicines and diagnostics solutions and advance health equity for patients.
- Work environment: Our people are at the heart of our business. We are committed to fostering an inclusive work environment where people can thrive and which keeps employees safe and healthy, embraces diversity and reflects the communities we serve.
- Environment: Respect for the environment has always been a priority for IBN SINA, and we have already done a lot to reduce our impact. It is critical that we continue working across our value chain to cut emissions and minimize the impact of our products at every stage of their life cycle. We aim to make a positive contribution to the health of nature, our water systems, our climate and people.

Our governance processes act as an essential foundation for our priorities, ensuring we uphold high standards of business ethics and integrity, diligently manage risks and transparently report on our progress and impacts.

The sustainability issues are broad, deep and complex. We understand that planetary and human health and prosperity are interlinked. We know it will take innovation and collaboration to tackle environmental and social challenges at scale. Through the collective power of our people collaborating with stakeholders beyond our company, we will contribute to the long-term success of IBN SINA and society, and fulfil our purpose of doing now what patients need next.

Our Sustainability Strategy

Six Priorities

Access to Innovation	People	Environment
◆ Access ◆ Health Equity	◆ Work Environment	◆ Climate Change ◆ Sustainable Products ◆ Biodiversity and Water

Governance

Corporate Governance | Risk Management | Business Ethics and Integrity | Sustainability Reporting

Our Sustainable Pillars

We are committed to creating a culture of accountability and strong ethics by integrating sustainability into its daily operations and strategy. The Company recognizes the importance of using natural resources responsibly to meet the needs of patients and customers.



Our Business Segments

We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer channels through our key business segments.

Commercial Pharmaceuticals



We provide high quality, affordable medicines, focusing on niche therapeutic areas.

A widely diverse range of trusted medicines with a strong domestic or global presence.

Total Revenue
13899 Million

Manufacturing

Complex manufacturing expertise Vertical integration advantages Globally competitive, scalable and widely accredited manufacturing facilities.



More than
5500
employees

Our People

Our strength is our diverse and talented team who work together every day, united in our purpose to improve the health and quality of life of patients.

Our Manufacturing Capabilities

Our manufacturing capabilities span a wide variety of product types including Solid dosage forms, Liquid dosage forms, Powder for suspension (dry syrups), Sterile and non-sterile ophthalmic and tropical, Parenteral products (ampoules, vials), Prefilled Syringes, Lyophilized Vials, Small Volume Parenteral (SVP), Biotech, Metered Dose Inhaler (MDI) and Dry Power Inhaler (DPI) (Pipeline) and APIs. Our manufacturing sites hold approvals from some of the most stringent government regulatory authorities (DGDA).

Our Global Presence

We supply medicines to People of Asia Africa, Central America, South America and USA are consuming IPI's best products in different dosage forms within the affordable prices

Credit Rating of the Company

Alpha Credit Rating Limited (Alpha Rating) assigned the following rating to The IBN SINA Pharmaceutical Industry PLC, which is based on audited financial statements as on June 30, 2025 and relevant qualitative information till December 2, 2025. This Rating indicates the Company's sound Credit worthiness of Long-Term and Short-Term as well.

Year	Rating Action	Long-Term Rating	Short-Term Rating	Outlook
2025	Surveillance	AA+	ST-1	Stable
2024	Surveillance	AA+	ST-1	Stable

Our Commitment To Sustainability

Delivered through four sustainability pillars our commitment is to create value for our stakeholders in a manner that is responsible, transparent and respects the rights of all.

Patients

- Improving health and quality of life for patients that use our medicines
- Provision of quality and affordable treatment options and medicines to patients and healthcare professionals
- 8 (Pharma), 4 (Natural Medicine) products launched

Our People

- Tk. 72,97,952 invested in training and skill development for our employees
- Zero occupational fatalities

Society

- Tk. 3,902,256.00 has been transferred to the Director General, Bangladesh Sromik Kallyan Foundation, Labour and Employment Ministry, Government of Bangladesh.
- Silver Award at the 15th ICSB National Award for 'Corporate Governance Excellence-2025.
- Free health care complex to underprivileged people in 5 days a week
- Supported socio-economic development projects
- Medical student's scholarship program
- Winter Cloth Support

  Continuous health bulletin awareness
- Emergency food support to flood affected people

Environment

- Water consumption: Underground water, Potable 1,84,800 cubic meter. Purified water (PW) 9,60.00 cubic meter, Water for injection (WFI) 2,01,600 cubic meter, Mineral Water Packed 10.5 cubic meter
- 42,00,000 kWh
- Non Renewable Electricity Consumption 1,16,40,000 kWh
- Waste management- Reduce, Reuse and Recycle
- Renewable Energy Consumption 84000 kwh




SUSTAINABLE DEVELOPMENT GOALS

As a trusted name in Bangladesh's pharmaceutical sector, The IBN SINA Pharmaceutical Industry PLC remains dedicated to advancing the United Nations Sustainable Development Goals (SDGs). The Company integrates sustainability into our core business strategy ensuring healthy life, sustainable employment, environmental responsibility, and collaborative growth for a better future.

Our SDG Commitments



- **Delivered safe, effective, and affordable medicines to millions of patients across domestic and global markets.**
- **Expanded production of life-saving drugs for critical and chronic illnesses.**
- **Strengthened employee wellness programs covering physical, mental, and preventive healthcare.**
- **Conducted nationwide health awareness campaigns, focusing on preventive care and responsible medicine use.**



- Created fair employment for over 350 people, ensuring diversity and equal opportunity.
- Enforced world-class occupational health and safety practices across facilities.
- Invested continuously in training and capacity building to future-proof our workforce.
- Supported the national economy through Tax contributions, exports, and sustainable business growth.



- Built state-of-the-art manufacturing plants with modern R&D facilities.
- Introduced automation and advanced technologies to improve quality and productivity.
- Strengthened local supply chains, reducing dependency on imports and enhancing resilience.
- Partnered with academia to promote pharmaceutical innovation and research excellence.



- Reduced production waste through lean manufacturing practices.
- Adopted eco-friendly packaging and recycling initiatives.
- Maintained strict adherence to Good Manufacturing Practices (cGMP) and global quality standards.
- Promoted responsible medicine use through public awareness and educational outreach.



- Reduced carbon emissions through energy efficiency and process optimization.
- Transitioned towards renewable and cleaner energy sources in production sites.
- Conducted regular environmental audits and compliance reporting.
- Launched green awareness campaigns for employees and local communities.



- Collaborated with Government Regulatory Authorities and global organizations to expand healthcare service availability.
- Established academic collaborations to advance pharmaceutical research and talent.
- Actively engaged in multi-stakeholder platforms to advance sustainable healthcare solutions.

The Company will continue to integrate sustainability into every aspect of its operations by aligning with its commitment to affordable, best quality healthcare, expanding green energy adoption, and enhancing the well-being of employees and the wider community.

Integrated Report


This Integrated Report provides a multidimensional view of The IBN SINA Pharmaceutical Industry PLC's performance over the year 2025-26. It has been prepared in accordance with the guiding principles and content elements outlined by the International Integrated Reporting Council (IIRC).

About This Report

This Integrated Report of The IBN SINA Pharmaceutical Industry PLC is designed to present a fair, comprehensive, and transparent view of our strategy, performance, opportunities, and future outlook, particularly in relation to material financial, economic, social, and governance matters. The primary purpose of this report is to support long-term value creation for investors, while also ensuring that all key stakeholders are appropriately informed with relevant and meaningful insights. Our objective is to protect, generate, and sustain long-term value for all stakeholders through an integrated reporting approach, guided by the six-capitals framework.

Our Integrated Thinking

We embrace integrated thinking to identify and evaluate the diverse factors that could influence our ability to create long-term, sustainable value. These insights are embedded into our strategic framework, guiding us to proactively manage risks while also leveraging new and emerging opportunities for continued growth and resilience.



REGULATIONS WE FOLLOW

Companies Act, 1994;
Labour Laws, 2006 (as amended 2026)
The Regulations, 2015 of DSE and CSE
Laws and Policies issued by the Directorate General of Drug Administration (DGDA)
Financial Reporting Act., 2015
Financial Institutions Act 1993;
Securities and Exchange Rules 1987;
Corporate Governance Code issued by BSEC in 2018;
Relevant Rules and Regulations of Bangladesh Bank and
Other applicable laws and regulations of the land.

REPORTING FRAMEWORKS AND GUIDELINES

International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS);
Global Reporting Initiative (GRI)-GR4 Framework;
International Integrated Reporting Framework by Financial Reporting Council;
SAFA Integrated Reporting Checklist;
ICAB Corporate Governance Checklist and
ICSB Secretarial Standards.

SCOPE AND BOUNDARIES OF THIS REPORT

This report covers the period from July 01, 2025 to June 30, 2026, which encompasses the activities that have been carried out within the geographical areas of Bangladesh and global operation of IBN SINA and its subsidiaries.

We have referred to the guidelines of Integrated Report, issued by the Institute of Chartered Accountants of Bangladesh (ICAB) in the form of 'Integrated Reporting Checklist', which is in congruence with the integrated reporting framework prototype issued by the International Integrated Reporting Council (IIRC).

In clarifying the Company's operations and financial performance, we have extracted the financial information from the Audited Financial Statements for the financial year ended June 30, 2025 with relevant comparative information. The financial statements consistently comply with the mandated requirements of the laws of the land and of the industry that includes Companies Act 1994, Securities and Exchange Rules 1987, BSEC's Corporate Governance Code, 2018, International Financial Reporting Standards and other relevant acts and rules applicable for the Company.

Our Values

We blend integrity, creativity, and intelligent innovation to generate sustainable, long-term value for our shareholders, customers, local communities, and society as a whole. Through this commitment, we responsibly bridge essential resources from their origin to the people who need and value them most, ensuring meaningful and ethical impact at every step.



Our Vision

To deliver value to our stakeholders as a responsible corporate citizen that provides high quality, affordable medicines globally.

Our Values

Defining the foundation on which IBN SINA Pharma has been built. These are the values we share as we work together toward achieving the vision of the Company.

Our Purpose

To improve the health and quality of life of patients.

Integrated Approach to Value Creation

The IBN SINA Pharmaceutical Industry PLC is committed to delivering long-term sustainable value for all stakeholders through the application of the Six Capitals Model, which enables a more balanced, comprehensive, and decision-useful reporting framework.

The Company recognizes that identifying and prioritizing the most effective pathways for sustainable development presents ongoing challenges. Through integrated reporting based on these six forms of capital, the Company combines both qualitative and quantitative information to clearly and demonstrably illustrate how The IBN SINA Pharmaceutical Industry PLC creates value over time in a structured and holistic manner.



Financial Capital

Financial capital is secured through various sources, including equity financing, grants, as well as internally generated funds from operations and investments. The Financial Capital of The IBN SINA Pharmaceutical Industry PLC is deployed in a prudent, effective, and efficient manner in accordance with the strategic directives and governance framework established by the Board of Directors.

Human Capital

Human capital, also referred to as human resources, plays a pivotal role across diverse areas ranging from strategic planning and corporate reputation to customer satisfaction and regulatory compliance. Accordingly, the significance of Human Capital in attaining the Company's strategic goals cannot be overstated. The Company is supported by a workforce of more than 5,500 employees possessing relevant experience, skills, qualifications, and competencies to ensure smooth day-to-day operations. Regular training and development programs are conducted periodically to further strengthen employee capabilities and enhance professional skills.

Manufactured Capital

Manufactured capital encompasses the tangible physical assets owned and utilized by the organization in delivering its products and services. The Company's physical assets are broadly categorized as land, buildings, furniture and fixtures, motor vehicles, machinery and equipment, and computer systems and related equipment. All such assets are utilized efficiently for business operations and are adequately safeguarded against potential risks through appropriate insurance coverage. In addition, modern technologies are applied to ensure effective management, maintenance, and optimal use of these resources.

Intellectual Capital

Intellectual Capital represents the organization's knowledge-driven intangible assets, encompassing 'Intellectual Property' such as patents, copyrights, software, rights, and licenses, as well as 'Organizational Capital' including expertise, systems, procedures, and operational protocols.

The Company, drawing on over 42 years of operational experience, has systematically developed, standardized, and documented its business procedures. These procedures remain flexible and adaptable, enabling the incorporation of innovations required to respond effectively to evolving market dynamics. The comprehensive repository of these procedures is efficiently and effectively utilized to launch new and alternative products, broaden the customer base, and ultimately enhance profitability.

Social and Relationship Capital

Social and Relationship Capital comprises shared norms, collective values and behaviors, key stakeholder relationships, intangible associations with the organization's brand, and its reputation and social license to operate.

Social and relationship capital is recognized as one of the organization's most valuable assets. It reflects the company's image and reputation carried by all stakeholders and plays a vital role in achieving strategic objectives and ensuring sustainable future growth acknowledging customer satisfaction at the highest priority. It has consistently maintained strong and positive relationships with customers, agents, surveyors, reinsurers, reinsurance brokers, vendors, banks, and all other stakeholders.

Natural Capital

Natural Capital encompasses all renewable and non-renewable environmental assets and ecological processes that deliver essential services supporting the past, present, and future prosperity of an organization. It includes key natural resources such as air, water, land, minerals, forests, and other elements of the natural environment. Natural capital forms the foundation of ecosystems that sustain human life. It is therefore of paramount importance that an organization manages natural capital responsibly and efficiently, ensuring long-term protection of ecosystems and preventing environmental degradation.

The Company remains committed to contributing to environmental sustainability by progressively transitioning toward paperless operations, implementing energy-efficient and conservation-focused technologies, promoting tree plantation across all its premises, and encouraging the prudent use of water to minimize wastage. Our continued efforts to foster a green office environment reflect our strong commitment and passion for environmental stewardship.

Strategic Focus and Future Outlook

Our business strategy and future outlook defines our short, medium and long-term strategic objectives. and the resource allocation mechanism in place to implement those strategic objectives. Referring page no. 69 for details on corporate strategy where the strategic objectives have also been defined in respective capitals. Our forward-looking statement Page no. 14 addresses our expected condition and performance, status of projects disclosed last year also explaining about the sources of information and assumptions used for projections.

Risk and Opportunities

Principles of materiality are applied in assessing the information required to be included in our report and the materiality assessment is also discussed in our Report. This report focuses on risks, opportunities and challenges that have a material impact on our capitals. Company's risk management and internal control processes are discussed in detail on page 174 Directors' report, financial statements and sustainability report represents our integrated thinking and the way we make decisions.

Assurance On	Assurance Providers
Financial Statement and Audit Report	Malek Siddiqui Wali Chartered Accountants
Corporate Governance Certification	S.A. Rashid & Associates Chartered Secretaries
Provident Fund Audit	Masih Muhith Haque & Co. Chartered Accountants
Gratuity Fund Audit	R.A. Khan & Co. Chartered Accountants
Superannuation Fund Audit	Masih Muhith Haque & Co. Chartered Accountants
Entity Credit Rating	Alpha Credit Rating Limited

Management Responsibility

All material and significant disclosures reported are aligned with the applicable disclosure requirements as per Companies Act 1994, Bangladesh Securities and Exchange Commission guidelines and notification issued time to time and other applicable rules and regulations. To enhance governance inaccuracy, risk management and controls, the contents of this Report have been reviewed by a team of directors headed by the Managing Director of the Company.

Disclaimer

It is noted that the integrated annual report includes forward-looking statements which relates to the company's operations. These are not statements of fact but rather statements by the management based on current estimates and expectations of future performance. No assurance can be provided on these forward-looking statements, and shareholders are advised to exercise caution in this regard.

Availability of the Annual Report

The Annual Report of the Company is sent to all shareholders through email in due course of time whose email address is available with us as per CDBL record on record date and copy of the same is also made available on the website of the Company: www.ibnsinapharma.com. In case of non-receipt of the Annual Report sent through email, shareholders are welcome to collect the same from the Registered Office of the Company.

Business Model

The IBN SINA Pharmaceutical Industry PLC pursues the creation of new business and the enhancement of existing business based on company business philosophy and the company's Corporate Mission Statement that had been passed down over the years. We accomplish it by anticipating changes in the times and quickly assessing the challenges of global environment and society while combining the management base comprised of six types capital with the diverse business functions of the business. The Company contributes to realizing a sustainable society by creating social, environmental and economic value through its business activities. The mechanism for this entire process of value creation is illustrated in the Value Creation Model process.

Focus Areas

- Enhance share of specialty products in overall business.
- Develop and commercialize differentiated and difficult to manufacture products.
- Maintain market leadership and high brand equity in Bangladesh leverage strengths for in-licensing latest generation innovative products for the domestic market.
- Gain critical mass across key international markets.
- Focus on improving return ratios.
- Ensure high level of corporate governance and focus on improving access to healthcare for all, community upliftment and reducing carbon footprint.


We create value mostly in two ways:

Creating Positive Impact

We contribute to economic advancement and employment generation by supporting businesses through financial assistance and fostering growth opportunities. At the same time, we are committed to empowering our employees by offering career development opportunities within a safe, diverse, and inclusive workplace environment.

Reducing Negative Impact

We recognize that, like any responsible organization, certain business activities may create indirect environmental or social challenges. Our financing activities, if not carefully managed, could unintentionally support practices that affect environmental sustainability or labour rights. To mitigate such risks, we implement rigorous policies, responsible lending standards, and strict investment guidelines to ensure ethical and sustainable business practices.



Our Value Creation Model

The following section presents an overview of the value creation framework of The IBN SINA Pharmaceutical Industry PLC, which is structured around four integrated stages:

Inputs : These are the essential resources that enable us to conduct our operations effectively. They include the expertise, dedication, skills, and experience of our employees, along with the financial capital and trust invested by our valued shareholders.

Business Activities : This represents the operational foundation of our organization — where value is generated through continuous research and development, advanced manufacturing practices, stringent quality assurance, strategic marketing initiatives, and efficient distribution of safe, effective, and affordable healthcare products.

Outputs : These are the direct results derived from our business operations, including the delivery of high-quality and accessible medicines to patients, the provision of competitive compensation, employee benefits, and professional development opportunities for our workforce, as well as sustainable financial returns for shareholders.

Outcomes : These reflect the broader and long-term impact of our activities — enhancing public health and well-being, strengthening the national healthcare infrastructure, generating employment opportunities, advancing sustainable business practices, and making meaningful contributions to society and the economy.

A significant portion of the value created by The IBN SINA Pharmaceutical Industry PLC is financial in nature; however, our contributions also extend across social, human, intellectual, and environmental dimensions. To illustrate this comprehensive approach, our value creation model is aligned with the Integrated Reporting Framework and is built upon six forms of capital: manufactured capital, financial capital, intellectual capital, human capital, social capital, and natural capital.

Stakeholder Engagement

Stakeholder Group	How we engage	Key issues in 2025-26
Clients Individual customers, Hospital, and larger corporates	■ Regular customer surveys ■ Doctor Visit	■ New product launching ■ Arranged Seminar ■ Prepared Booklet ■ Transition to more sustainable business practic
Employees Full-time and contractual employees	■ Employee engagement survey ■ Meetings with unions and other employee representative groups	■ Training & Development ■ Improving Customer Focus ■ Personal Recognitation
Investors Shareholders and Stakeholders	■ Annual General Meeting (AGM) ■ Public Retation Booth ■ Through "Grivance Redressal"	■ Financial performance and Strategy execution ■ Changes in business market environment
Society Suppliers and other business partners, local communities, governments and regulatory bodies	■ Regular meetings with regulatory bodies ■ Industry roundtables and conferences In-person ■ meetings with suppliers and business partners	■ Cost of financial inclusion ■ Pharmaceutical sector regulation

RESOURCES

Financial

- Strong financial foundation supporting sustained business growth
- Strong balance sheet and high liquidity buffer
- Investment in growth opportunities

Manufacturing

- Globally competitive, scalable, and widely accredited manufacturing facilities
- Regulatory approval by major agencies such as DGDA.

Intellectual

- Enhanced research and development capabilities
- Goal-driven product development

Human

- Ensure equality and fairness
- Championing diversity
- Promoting inclusivity

Social and relationships

- Improving quality of lives
- Enhancing choices and capabilities

Natural

- Striving towards a net-zero future
- Establishing a robust and resilient value chain

INPUTS

Financial

- Strong balance sheet;
- A disciplined capital expenditure investment approach;
- Planned prioritization of capital allocation;
- Strong operating cash flow generation.

Manufacturing

- A production system specialized in ophthalmology that manufactures high-quality products;
- Stable supply through a global product supply network;
- Expanding production capacity through construction of new plants and conversion of plants to smart factories;
- Globally competitive, scalable and widely accredited manufacturing facilities.

Intellectual

- Trusted IBN SINA brand;
- Excellent technologies and Institutionalized knowledge;
- Data utilization;
- Targeted and efficient product portfolio renewal;
- Trained employees;
- Strong presence in emerging markets.

Human

- Experienced leadership team;
- High performance and innovative culture;
- Committed and loyal employees;
- Healthy workforce;
- Equal opportunities;
- Industry-specific specialist skills.

Social and relationships

- Partnerships with medical professionals and suppliers;
- Strong stakeholder relationships and corporate reputation;
- Robust corporate governance framework;
- Support of local communities;
- Contribution to the WPPF.

Natural

- Focus on environmental protection;
- Use of environmentally friendly water resources;
- Initiatives to reduce consumption of scarce natural resources;
- Social and Environmental Management System.

OUTPUT

Financial

Increase in capital efficiency and improvement in profitability.

Manufacturing

Develop, popularize and conduct an overseas rollout of products and services that leverage the strengths of IBN SINA and its partner companies and organizations.

Intellectual

Develop and provide products and services that utilize digital and other technologies to meet the needs of people.

Human

Provide employees with career realization opportunities, growth opportunities and a digital workplace provide training for medical professionals.

Social and relationships

Engaging the shareholders and investors towards the realization of a sustainable society and corporate growth.

Natural

Use sustainable technologies and efficiently utilize water resources.

OUTCOMES

Financial

Sustainable financial return to shareholders prudent growth and financial stability.

Manufacturing

Productivity increase employee loyalty and improved capabilities and competencies.

Intellectual

Launched new products implementing robotic processing technology integrated risk management framework that safeguard the business from externalities.

Human

Expansion of geographical footprint upgraded working environment and better customer reach.

Social and relationships

Customer satisfaction growth in customer base engagement with community and CSR activities.

Natural

Involve in environment protection, recycling of waste.

The values we create

As a pharmaceutical company, we play an important role in contributing to the health and wellbeing of people. Our sustainable business model creates long-term values for our key stakeholders.



Patients, healthcare professionals and customers

- Improving health and quality of life for patients that use our medicines
- Provision of quality and affordable treatment options and medicines to patients, healthcare professionals and healthcare system



Our employees

- Providing employment and opportunities for growth and development in the geographic regions in which we operate
- Diverse and inclusive working environment free of discrimination and harassment



Communities in which we operate

- Contribution to society through engagement with civil society and investment in socio-economic development
- Responsible management of our impact on the environment



Our investors and sponsors

- Sustainable returns to shareholders
- Servicing and timely repayment of debt



Our suppliers and business partners

- Economic stimulus through procurement of goods and services
- Collaboration and partnering opportunities



Governments and pharmaceutical regulatory authorities

- Contribution to national exchequer
- Contribute to effective healthcare systems through pharmaceutical
- Regulatory compliance in the countries in which we operate

Financial Capital

Financial capital


Our aim to create value for all of our shareholders by managing our financial capital in a commercially astute and diligent manner, thereby harnessing opportunities for long-term sustainable economic growth.

FINANCIAL CAPITAL

The IBN SINA Pharmaceutical Industry PLC, decisions regarding capital allocation are fully embedded within our strategic direction and annual budgeting framework, with a clear focus on the sustainable enhancement of shareholder value over the long term. Our capital deployment approach is guided by several key priorities. These include ensuring a balanced allocation of resources between the maintenance and strengthening of our intellectual property and manufacturing infrastructure, thereby safeguarding operational efficiency and returns. We place strong emphasis on maintaining a robust balance sheet, which provides financial stability and operational flexibility across different phases of the business cycle. In addition, we actively invest in both organic expansion and strategic inorganic opportunities that create long-term value, while also ensuring appropriate returns to our shareholders through consistent dividend distribution. The Board of Directors maintains comprehensive oversight of all capital and budgetary decisions, ensuring that financial resources are allocated in the most efficient and value-generating manner in alignment with the company's strategic objectives.

SOURCES OF FINANCIAL CAPITAL

Our financial capital includes the monetary resources contributed by our investors are being enhanced through our business activities, which is embedded in our business model. The main sources of financial capital are:



Approaches to maintenance of financial capital

The followings are some of the approaches to maintaining our financial capital:

- Maintenance of strict financial discipline and controls Deciding on deployment of available capital;
- Measurement of financial performance, value creation and cash generation;
- Active engagement with providers of capital and debt funding;
- Seeking out investment opportunities to increase revenue generation, profitability and shareholder returns
- Focus on organic growth;
- Generation of synergistic benefits from acquired businesses;
- Focus on working capital management;
- Focus on increased tax reporting requirements and tax transparency

Maintenance of Financial Health

To ensure the sustainability of our business model and deliver enhanced value for investors, we hold a fiduciary responsibility to our stakeholders to prudently manage our financial capital. We maintain strong financial control frameworks along with effective treasury management systems to minimize exposure to currency fluctuations, interest rate movements, and credit risks to the greatest extent reasonably practicable. The Audit & Risk Management Committee supports the Board in fulfilling its responsibilities relating to the safeguarding of assets, the integrity of accounting systems and practices, the effectiveness of internal control mechanisms, and the preparation of both the Subsidiary and Company Annual Financial Statements.

The overall financial performance of the Company for the reporting financial year 2025-26 is stated in the page no. 72.

Human Capital

Empowering People Through Digital Transformation

In 2026, the Human Resource Department of The IBN SINA Pharmaceutical Industry PLC continued its commitment to building a future-ready workforce by strengthening digital HR practices, enhancing employee development, and fostering a culture of performance, collaboration, and continuous improvement. Throughout the year, our initiatives remained focused on aligning people strategies with organizational goals while ensuring compliance, operational excellence, and employee well-being.

Digital HR and Process Excellence

Throughout 2026, the Human Resource Department continued the development of SINA ERP, the Company's integrated Human Resource Information System. The project progressed through the enhancement of core HR modules, workflow optimization, and system testing to ensure a reliable, user-friendly, and scalable platform. Once fully implemented, SINA ERP is expected to streamline employee data management, payroll, attendance, leave administration, recruitment, performance evaluation, and training records while improving data accuracy, operational efficiency, and decision-making. During the year, the HR Department also continued to improve existing processes through standardization, digital documentation, and automation initiatives, laying a strong foundation for a smooth transition to the new system.

Talent Acquisition and Workforce Development

Recognizing that organizational success depends on exceptional talent, we continued to strengthen our recruitment strategy by attracting skilled professionals through campus recruitment, digital hiring platforms, and structured selection processes. Our onboarding program was further refined to help new employees integrate quickly into the organization's culture, values, and operational standards.

Learning and development remained a strategic priority throughout the year. Employees participated in technical, regulatory, leadership, and behavioral training programs designed to enhance professional competencies and prepare future leaders. Specialized development initiatives were also conducted for sales and marketing teams, focusing on performance improvement, customer engagement, and productivity enhancement.

Performance, Recognition, and Employee Experience

Our performance management framework continued to evolve through regular performance reviews, continuous feedback, and objective-based evaluation. Employee achievements were recognized through promotions, salary increments, performance incentives, and appreciation programs, reinforcing a culture where excellence, accountability, and innovation are valued.

Employee well-being remained central to our people strategy. We promoted a healthy and supportive work environment through wellness initiatives, employee engagement activities, team-building programs, and open communication channels. Feedback collected through employee surveys and regular interactions enabled us to identify opportunities for continuous improvement and strengthen workplace satisfaction.




JOURNEY FROM
GOOD TO
GREAT
AWARD GIVING
SESSION
NATIONAL
CONFERENCE
2025
IBN SINA
NATIONAL CONFERENCE 2025


JOURNEY FROM
GOOD TO
GREAT
National Conference 2025
IBN SINA
AWARD GIVING
SESSION

Compliance and Operational Excellence

The HR Department maintained its commitment to ensuring full compliance with the Bangladesh Labour Act, Bangladesh Labour Rules, and the Company's Service Rules. All employee lifecycle activities—including recruitment, transfers, promotions, disciplinary procedures, separation management, and final settlements—were administered with transparency, fairness, and professionalism. Continuous process improvements helped deliver HR services more efficiently while maintaining high standards of governance and confidentiality.


Looking Ahead

As we move into 2027, our focus will be on leveraging HR analytics to support strategic decision-making, expanding digital learning opportunities, strengthening succession planning, and further enhancing employee engagement through technology-driven HR solutions. We also aim to foster a more agile, inclusive, and high-performing workplace capable of meeting the evolving demands of the pharmaceutical industry.

The Human Resource Department remains committed to empowering our people, nurturing talent, and building an organization where employees can grow, innovate, and contribute to sustainable business success. Together, we will continue strengthening the foundation of The IBN SINA Pharmaceutical Industry PLC and creating lasting value for our employees, customers, and stakeholders.

Training and Skill Development

At The IBN SINA Pharmaceutical Industry PLC, we believe that our people are our greatest competitive advantage. By blending cutting-edge Training and Skill Development with an employee-first culture, we actively transform individual talent into corporate excellence. We are completely redefining the modern workplace by leveraging advanced technology and fostering strong, cross-functional collaboration. This strategic report highlights our ongoing commitment to driving measurable productivity, recognizing outstanding performance, and building an agile workforce. Together, these unified HR pillars lay the strong foundation required to accelerate our journey toward becoming a top-ten industry leader.



Training and Skill Development Process





Employee Engagement, Achieving Productivity and Well-being

Every great organization thrives on the strength of its people. At The IBN SINA Pharmaceutical Industry PLC, we transform individual potential into collective excellence by giving our team the cutting-edge competencies they need to succeed through robust Training and Skill Development initiatives. Our HR strategy bridges human talent with modern technology, ensuring our workforce discards outdated habits, adopts smarter tools, and drives peak operational efficiency.

Communication, Collaboration and Teamwork: Driving Success Together

Great ideas shouldn't live in silos. We believe that the best solutions come from vibrant, collective effort where cross-departmental teams share knowledge freely and tackle challenges together. To make this happen, our HR department has actively broken-down corporate barriers and introduced modern platforms that encourage employees to step outside their comfort zones. This unified approach speeds up problem-solving, builds deep organizational trust, and creates a highly supportive culture where everyone wins together.

Performance Management, Talent Actuation and Rewards

We build motivation through transparency and fairness. This year, we completely overhauled our performance management system to replace rigid yearly reviews with a dynamic, real-time feedback loop aligned directly with our corporate goals. We don't just reward the final numbers; we celebrate the creativity, effort, and teamwork behind them. By tying recognition directly to both individual milestones and team victories, we inspire a shared passion for excellence across the entire company.

Future Outlook and Achieving in Top Ten

As we march forward, the Human Resource Department is building an agile, unstoppable workforce ready to lead through any industry shift. We are deploying advanced HR data analytics to make smarter, employee-first decisions that elevate our entire corporate performance. By embedding a culture of continuous Training and Skill Development, we ensure every employee can grow their career and directly accelerate our journey.

Conclusion

The past year has been a transformative period of growth, learning, and innovation for the Human Resource Department at The IBN SINA Pharmaceutical Industry PLC. Through targeted Training and Skill Development programs and enhanced employee well-being initiatives, we have successfully boosted workplace productivity and morale. Our strategic focus on collaborative frameworks and a transparent rewards system has built a highly cohesive, goal-driven corporate culture. Ultimately, these robust HR strategies are precisely designed to drive our long-term vision of firmly establishing the company as an industry leader achieving in the top ten.



Manufactured Capital

Manufactured Capital is the collection of physical, material and technological objects that are available to an organization for use in the provision of services and therefore in fulfilling its purpose. Investment in manufactured capital is vital in order to produce high quality medicines that would contribute to sustainable advantage. Significant investment in our manufactured capital is an ongoing phenomenon that aims to safeguard our ability to deliver the quality products for sustainable growth and continual improvement.

OUR SOURCES OF MANUFACTURED CAPITAL

Current Good Manufacturing Practices (cGMP)
ISO 9001:2018
Plant Infrastructure
Manufacturing Facilities, Technology and Equipment
Manufacturing Process
Environment, Health and Safety Provision
Distribution Network


Our Pharma Plant

The IBN SINA PharmaceuticalIndustry PLC (IPI) was founded in the year 1983 on a campus of about 14 acres of land, about 56 km away from Dhaka city. Its commercial production was started in May 1986 since its journey with a few products. Now the Manufacturing Plant has been established with modern state of the art technology and equipped with, high standard machineries and for the production and quality checking of various dosage forms of several therapeutic classes by the 'Current Good Manufacturing Practices' standards of various international regulatory authorities like WHO cGMP, ISO etc.

This Plant contains General Production Building, Injection Building and Cephalosporin Building. The site houses other supplementary infrastructures including Admin Building, Warehouse, Engineering Building, Officers Quarter etc. Our Utility Infrastructure has been designed including Water Treatment Facility (DM, RO& WFI Plant), Boiler, and Compressor, Generator etc. to ensure adequate supply of water, electricity, steam and gas. Besides, we have a central ETP for waste management. There is Specialized Compliance Formulation Plant at Mawna (Sreepur, Gazipur), API project at Munshiganj and Central warehouse at Kaliakoir.

IPI is now producing more than 400 pharmaceutical products with various types of dosage forms including solid dosage forms (tablets and capsules), parenteral products (ampoules, vials), liquid dosage forms including syrup, solutions, suspensions & powder for suspension (dry syrups); sterile ophthalmic products, cream, ointments, gel, eye drops and sachet, etc. covering almost all therapeutic classes where a lot of products are in the launching pipeline.

The production site follows the best practices for fire, water and air management system, employee health and safety issues. In totality, this plant does not only result in increased production capacity, but also has resulted compliance with more regulatory requirements, safeguarding the environment, safety and health protection of employees in the workplace and environment.



Managing Director along with Sr. Officials in Fluid Bed Dryer (FBD) Section of Pharma Unit-2

IBN SINA Pharma Plant at a glance

Location	Area	Production Facilities
Shafipur, Kaliakoir Gazipur, Bangladesh	14 acres	General Pharma Plant Natural Medicine Plant Cephalosporin Plant

Production lines

- Solid dosage forms (tablets capsules and Sachet)
- Liquid dosage forms including syrup, solutions, suspensions
- Powder for suspension (dry syrups)
- Sterile and non-sterile ophthalmic and tropical products (cream, ointments, gel eye & nasal drops)
- Parenteral products (ampoules, vials)
- Prefilled Syringes, Lyophilized Vials Small Volume Parenteral (SVP), Biotech Metered Dose Inhaler (MDI) and Dry Power Inhaler (DPI) (Pipeline).

Manufacturing Facilities, Technologies and Equipments

Tablets

Tablets are the major product ranges in OSD (Oral Solid Dosage) production facilities comprising about 45% of the total pharma production. To fulfill the market demand a new compliance area has been developed where many sophisticated machines like Auto-granulation line, Fette Tablet Compression machine from Germany, Sejong Tablet Compression machine from South Korea, Romaco Compactor for potent and sensitive drug have been incorporated in this area.

Moreover, we have another two dedicated granulation unit (one is Auto-granulation), six sophisticated tablet compression machine, six tablet coating machine including IMA tablet coating (from Italy) which is highly sophisticated and faster, eight blister machine including Heino-Ilsemann blister machine (from Germany) with auto-cartoning, Romaco blister machine (from Germany) with auto-cartoning and 21CFR part11. Besides we have two Auto tablet counting machines.

Capsule

Two sophisticated automatic capsule filling machines Pam from India and NJP from China are now in operation. These machines have versatile capacity of filling pellets and liquid in hard gelatin shell. Two existing automatic Zanasi Capsule filling Machines are used for non-antibiotic & miscellaneous antibiotic production. In view of the increased demand of existing powder fill capsule products & considering the upcoming new products to our product range, the IPI management has installed a high capacity powder capsule filling machine recently. This machine can also be used for pellet filling. Now we are fulfilling present demand by blistering with Hoonga blister machine from Korea and newly installed high capacity Tien Tuan blister machine from Viatname.

Ophthalmic (Sinavision)

Ophthalmic Products are marketed under the division named "Sinavision". The se include ophthalmic drops, ointment and gels. All the ophthalmic products are manufactured in class A under HVAC system in a background class B. We have installed a fully automatic ophthalmic eye drops production line including automatic washing, drying, autoclaving, filling and sealing. A fully automatic eye drops filling machine I-dositechno from Spain (under installation) and an automatic lamitube filling machine from China has been installed.

Injectable (Parenteral) Products and Inhaler

The injection production facilities comprise Class A (ISO Class 5) production area and the adjacent areas are of different classification and there is a change room facilities as per compliance. The sterile products are manufactured in high tech machine like Tofflon (China), Fedegari autoclave (Italy) ,water treatment plant with looping, Flexicon (Denmark) etc.

IPI is launching Prefilled Syringes, Lyophilized Vials, Small Volume Parenteral (SVP), Biotech, Metered Dose Inhaler (MDI) and Dry Power Inhaler (DPI)



Pharma Unit-2

preparations to its product portfolio by dedicated sophisticated machines like Lyophilizer (Freeze Dryer) (Tofflon, China), Solution Preparation Vessel and CIP & SIP Skid (Tofflon, China), Automatic Prefilled Syringe Filling & Sealing Machine (i-DOSETECHNO, Spain), Flexicon Dry Powder Filling Machine (Denmark), Freeze Drying Microscope (FDM) (McCRONE, USA), Fedegari Autoclave (Italy) ,nitrogen generator plant and Vaporized Hydrogen Peroxide (VHP) Sterilizer (China). Some Injectable productions including Esolok 40mg Injection, Prolok 40mg Injection, Pantolok 40mg Injection, Clovir 500 & 250 IV Infusion, Metsina IV Infusion, Bactin IV Infusion and Oxyfer 500mg Injection already in the market.

Semisolid Products

Some popular brands of topical ointments, creams and gels are produced in IBN SINA factory. These products are manufactured with automatic Italian AxomaticLamitube Filling Machine that's on line with emulsifier. Products are Fungicort cream, Fungin cream, Fungin-B cream & Neocort ointment etc. In every year new products are adding with existing products.

Liquid Products

IBN SINA is one of the leading manufacturers of liquid pharma products in Bangladesh. It has five production lines including (1) Auto- Glass Bottle Line for Syrups, (2) Auto-Antanil Production Line, (3) High Capacity PET Line for Syrup and Suspension Products, (4) the Pediatric Drops & Suspension Line, and (5) High Capacity PET Bottle (Vitalgin) filling line.

Auto PET Bottle and other Liquid Production Line are most sophisticated liquid production lines. There have bottle feeding unit, rotary bottle washing unit, light checking unit, multi head linear liquid filling unit, capping & sealing unit, auto sticker labeling unit and packing line with auto carton strapping unit. It has a production capacity of 120-150 bottles per minute.

A dedicated& compliance online Gavisol Suspension process & filling line is under construction.


Powder for Oral Suspension Products

Powder for suspensions are mainly antibiotic products intended for children and young patients. We have two separate areas for production of power for suspensions. The major powder for suspension brands are Bactin, Nitasol, Erymex, Romycin, Buticef, Iluca etc.

Sachet

Unisaline is a popular brand of IBN SINA for ORS. We have a self-contained separate production facility for sachets, lined with three-sophisticated sachet filling machines. The IBN SINA Pharma has already started marketing of Unisaline with different flavor like Fruity Lemon, Fruity Orange & Fruity Mango. Many new products including Tasty & Rise ORS are in pipeline. Other non ORS sachet brand is Sinalax, which was introduced in Bangladesh by IBN SINA for the first time.

Manufacturing Process



Fire, Water & Air Management System

Fire Management System

IPI uses intelligent addressable fire detection system. Fire drills are done at least two in every year and training is provided to the personal who are the member of the fire team.

Our actions in this context are:

We have adequate training facilities against fire, earthquake and other disasters. Almost all employees were trained against fire defense by Bangladesh Fire Service and Civil Defense.

All the areas including Production, QA, QC, PD, Microbiology, Warehouse and other utility areas are covered by smoke detectors and modern fire alarm system.

The whole facility is equipped with adequate number of fire extinguishers and fire hoses with fire hydrant.

We also have proper evacuation system, assembly point with dedicated rescue and first aid team.

High pressure fire pumps along with standby pump and jokey pumps are installed to fight against fire.

Water management system

Pure water is very essential and inevitable element for every Pharmaceutical Industry. IPI is committed and constantly working on improving the water management of the company and plant as conserving water will contribute to more sustainable water availability.

Our actions in this context are:

We have the most modern RO (Reverse Osmosis) Plant with 3000 Ltr/hr capacity for fulfilling our present water demand.

We have another most modern DM (Demineralization) Plant with 3000 Ltr/hr capacity for fulfilling our present water demand.

Air management system

IPI has the right air management technology installed in all buildings as pharmaceutical manufacturing facilities require high quality of air because the products are ingested of placed in humans and animals.

Our actions in this context are:

- Individual Air Handing Unit (AHU) with HEPA filter.
- Temperature control system.
- Humidity control system.
- Precise pressure difference control system by software.

Environment, Health and Safety Consideration

The inherent safety risks relating to the pharmaceutical and chemical industry is always be a key focus as standardized health, safety and environment (HSE) process that are embedded across all of our operations. The IBN SINA Pharmaceutical Industry PLC is committed to pursue excellence in Health, Safety and Environment conducts its activities safety and in an environmentally responsible manner. Safety is our first priority. It is integral to our culture.

In order to ensure reliable and safe operations, we continue to focus on day to day management of operational risks, including risks related to Health, Safety and Environment. To promote safety throughout the business operations, execute management meets regularly to review environment and safety performance.

It is the nature of our industry that our people face many stressful situations in the workplace. We continue to offer comprehensive health and wellness service to our employees. Our employee's Physical and emotional wellbeing appears to be in line with the industry norms related to Health, Safety and Environment.

Environment Consideration

IPI gives utmost importance to environment protection and strictly avoid the activities which may have any adverse impact on the environment. We believe that environment protection should be implemented due to climate changes and natural calamities which affect our country every year. We have therefore designed the production process in the most resource and energy –efficient way as possible.

Our actions in this contexts are:

We have established an Effluent Treatment Plant (ETP) of capacity 500 liters/hr. to treat effluent from plant.

We are conducting incineration by Prism Bangladesh Foundation.

Health & Safety Consideration

Our Plant has been designed following the modern concept of safety guidelines. We make regular safety assessments and ensure compliance with all existing laws in the field of environmental protection, hygiene and safety at work. A special care and training is planned for the safe handling of Hazardous chemical. A Standard Operating Procedure (SOP) on safety guidelines is followed by each and every person in our Plant.

Our Steps to Health, Safety and Environment

- We have a specialized medical team in our plant premises for employee's health related issues.
- The entire areas of plant are well equipped with modern fire alarm system, adequate number of fire extinguishers, fire hoses with fire hydrant and others fire safety equipments.
- We have well trained fire fighter team and adequate training management system.
- We have a central Effluent Treatment Plant (ETP) with capacity of 500 liters/hr. to treat effluent from plant.
- We have a collboration management for disposal of hazardous pharmaceutical products to Prism Bangladesh Foundation for incineration by double chamber incinerator maintaining 1100 temperature at Medical Waste Management Plant



Natural Medicine

Nature is divine; the motto of the 21st century is "Back to the Nature"

The IBN SINA Natural Medicine Ltd., a Subsidiary of The IBN SINA Pharmaceutical Industry PLC is dedicated to serve humanity by manufacturing and providing quality natural medicines and services to its customers with marching onward for sustainable growth and continual improvement.

Back to Nature

Our approach is to using natural resources in a conservative way and taking initiative to reduce any adverse impact not only on human being but also on nature to make a greener environment.

About natural Medicine


IBN SINA Natural Medicine plant is equipped with the latest technological support with a view to facilitate the best natural therapeutic service to the people .within a very short time our natural medicine has achieved a goodwill and credibility of medical professionals and consumers for its efficacy and quality .Following this trend most of the leading pharmaceutical companies have also started marketing of the natural medicine production. The growth is increasing day by day after starting its journey .it has undergone potential expansion in multiple sectors due to its responsible business practices. The ranking of the natural medicine division is among the most important multidisciplinary groups and advocates for the principle of the care for the future, high professionalism, employee friendly approach, financial stability transparency, safety and leadership. It is striving to strengthen its market access in locally and globally. Formulating its competitive strategies and putting emphasis on productivity enhancement, thus playing a pivotal role in the country's commerce and trade sectors.

Manufactured Capital

Investment in manufactured capital is vital in order to produce high-quality medicines that contribute to sustainable competitive advantage .Significant investment in our finished products, manufacturing facilities, operations, technologies, capacities and distribution is an ongoing phenomenon that aims to safeguard our resources,satisfy the customer needs and achieve the strategic intent of the business.

Manufacturing Process

Production is ongoing with separate manufacturing division, these are Unani division and Herbal division very soon we are going to open Auyabadic medicine division and also medicated consumer products, medicated cosmetics and toiletries .



Unani Division

Facilitates are decorated with sophisticated production machnaries for tablet, capsule, powder (Sufoof) and syrup products with enlarged area. Here is top selling products like Vinsina Herbisal syrup, Hazmi syrup, Alkof, Basok syrup, sinar syrup and Myrosin etc syrup. Among the topical products Vigogel and dermaris.

Herbal Division

This area is furnished with art of state machinaries for tablet, capsule, powder, sachet products. There is a new sensitive product probiotic manufacturing area has built and production ongoing. Lyophilized papaya products is first time in Bangladesh for the treatment of the dengue fever has launched. The major products in the herbal division are Rebio capsule, Isbulgul plus sachet, Ginsin capsule, Dirolina capsule, silicap capsule, etc.

Input

1. API, excipient, various types herbs and packing materials are received and inspected as per standard operating procedure SOP and kept in quarantine area.
2. Sample analysis is done by Quality Control whereby QC performs identification, potency determination and necessary test of materials.
3. Following QC approval, pass levels are fixed on container and materials are shifted from quarantine to a specific approved area for preservation .
4. Material requisition is placed by production department along with batch manufacturing procedure of the product.
5. Materials are collected as for bill of materials and sent to Production for dispensing.
6. Purity, temperature, humidity and other condition of the materials are checked by the production and quality assurance and
7. Materials are weighted and dispensed to production as per requisition.

Process

1. The IBN SINA Natural medicine have several dosage forms like capsule, tablet, oral liquid, ointment-cream, probiotic, Halawa, sachet and powder dosage form. Manufacturing procedure of these dosage forms are different and has separate SOP.
2. Rooms and machines are fully cleaned and prepared for production having HVAC system.
3. Medicine and product is processed according to validated SOP. The production operator and officer follow the written SOP and keep record of all the activities along with sufficient retention sample.
4. The in process quality is checked by QA at every step of manufacturing and quality is ensured in every steps.
5. After completion of every sub process, sample analysis is performed by the QA and sent to QC for evaluation.
6. Upon approval by QC, QA fix the label on the container and gives approval for next step and
7. The prerequisites environment and the regulatory condition of the products are maintained and ensured by the QA and Production at every level.

Output

a) After packaging of products, all documents are reviewed by the QA and approved for distribution and sales.

b) Representative sample form every batch is kept by the QA up to the shelf life of the product for monitoring real life.

c) Real time instability study up to the shelf life is performed by the QA for further development and

d) When launching new products, product development and accelerated and real-time stability is performed by R&D.



Production

The IBN SINA Natural Medicine has update modern production facilities with modern sophisticlied production machineries which complies GMP and cGMP requirements. We have extraction and distillation facilities with cutting-edge technology to guarantee the quality of our products.

For production of different dosage form our production area is totally separated for Unani products and Herbal products.

To meet marketing demand we have complete separate liquid, sound, semi-solid cream and ointment powder and oil product processing area.

Moreover we have being preparing our new production building dedicated for herbal products production. where tablet, capsule, liquid, powder product will be manufactured in dedicated and separated area. Our present probiotic product productions area. is dedicated class area.This area will be increased in our new herbal production building. We have plan to include soft gelation capsule production area in our new herbal production building.

Ensuring Quality (QA & QC)

Our journey for maintaining better quality begins from Raw Materials selection process. We have the standard vendor selection procedure to select the right party for our intended quality products. Quality Control and Quality Assurance Departments are well furnished and equipped with the valuable machineries in light of the latest technology such as AASP, HPLC, FTIR, TLC, UV Visible Spectrophotometer, Digital Polarimeter, Refractometer, Viscometer, Karl Fischer auto-titrator, Sieve shaker, Tapped density tester, Disintegration tester, Melting point apparatus, PH meter, Moisture balance, Centrifuzer etc. We assure the quality of raw materials and finished products equally. The Quality Assurance Department ensures and monitors quality of products in every step of manufacturing operations. As a result it becomes possible to deliver the quality products to the customers.

A modern and well equipped QC laboratory and dedicated QA department is being developed in the new GMP compliance manufacturing building. About 7000 sq-ft area has been sanctioned for new QC and QA department.

Product Development Department

The Product Development Department (PDD) at The IBN SINA Natural Medicine Ltd. plays a pivotal role in driving innovation and upholding ethical standards within Bangladesh's healthcare sector. Our steadfast commitment to the highest scientific and ethical principles ensures the safety, efficacy, and pioneering nature of our natural medicine-based health solutions.

In the past fiscal year, we achieved a significant milestone in product commercialization with the successful launch of four new offerings: Moringa LX, Tablet Sinasoy, Isubgul NE, and Isubgul N. These introductions demonstrate our agility and responsiveness to market demands.

Our innovation pipeline remains robust, with 9 additional products currently under active development. Furthermore, 21 Unani formulations are in their final stages, awaiting regulatory clearance and imminent market release. The future also holds promise for several new herbal products, which are currently undergoing regulatory consideration for subsequent launch.

The Product Development Department has significantly bolstered its capabilities through the integration of modern laboratory equipment, which has enhanced our research and product quality testing processes. A new six-story building is currently under construction to establish a dedicated research zone, further augmenting our capabilities to meet expanding regulatory and operational demands. Looking ahead, we are strategically planning to establish advanced softgel manufacturing capabilities. This initiative will enable us to diversify our dosage form offerings and cater to a broader range of consumer preferences.

The PDD team comprises a highly qualified and diverse group of professionals, including PhD researchers, renowned natural medicine experts, meticulously trained formulation scientists, pharmacists, chemists, and esteemed natural medicine advisors. Their collective knowledge and experience continuously drive our engagement in evidence-based research and consumer-focused innovation, thereby strengthening the future of natural and Unani medicines across Bangladesh.

Herbarium and Standard Sample

There is a standard and well furnished herbarium and plant profiles in the natural medicine factory. Here, a team of efficient manpower including qualified taxonomist for identification of different Raw Materials and also preserved them accordingly.

Engineering Department

This department is equipped with all essential machineries tools and utensils to run the factories smoothly. A balanced technical team with electrical, mechanical, HVAC, utilites expert in this line in sufficient quantities for routine and preventive maintenance. The utilities sector is well furnished with own power generating generator, boiler, oil free air compressor and HVAC system. We have canteen and prayer facilities in self contained facilities.

Technical Team


The company is enriched with technically qualified both in academically and professionally. These are pharmacist, chemist, and botanist, BUMS, taxonomist, microbiologist and supply chain specialist. They all are under schedule training with evaluation programs. The training is conducted with items expert both from local and aboard. These programs assist us to keep up- to-date both in technically and professionally.



Natural Medicine Factory, Shafipur

Intellectual Capital

Our intellectual capital supports our commitment to increase the number of lives that benefit our focused therapeutic class of high quality, affordable medicines. As a pharmacutical Company in an intensely competitive market space, our ability to understand changing consumer preferences and sustain our competitive position is dependent on intangible factors such as brand value, research and development capabilities, innovation capacity, our tacit knowledge, operating processes and strategic partnerships. These elements form our Intellectual Capital and play a vital role in sharpening our competitive edge.



Our Products Portfolio

We strongly focus on to develop topper product portfolio in Bangladesh. As a consequence, we analyze the customer demand, competitor activity, international market and so on to strengthen the existing portfolio by launching new and innovative product and technology as well as introducing new molecule in Bangladesh.

Our product portfolio is:

Therapeutic Class	Description	IPI's Strength
Antibiotic	"Antibiotics, also known as antibacterials, are medications that destroy or slow down the growth of bacteria.They include a range of powerful drugs and are used to treat diseases caused by bacteria. When used properly, Antibiotics fight against infections and can save live . The first antibiotic was Penicillin. Penicillin-based antibiotics, such as Ampicillin, Amoxicillin, and Penicillin G, are still available to treat a variety of infections and have been around for a long time. There are different types of antibiotics, but most of them can be classified into 6 groups: 1. Penicillins (such as Penicillin, Amoxicillin etc), 2. Cephalosporins (such as Cephradine, Cefixime etc), 3. Aminoglycosides (such as Gentamicin, Tobramycin etc), 4. Tetracycline (such as Tetracycline, Doxycycline etc), 5. Macrolides (such as Azithromycin, Erythromycin etc), 6. Fluoroquinolones (such as Ciprofloxacin, Levofloxacin etc). Other antibiotics include Chloramphenicol, Fusidic acid, Nitrofurantoin etc. "	We are enriched in Penicillins with brands Sinamox, Sinaclox, Sinaflox etc, Oral Cephalosporins with brands like Cefixim, Merocef, Meroclav etc, Macrolides with brands like Romycin, Clarith etc, Floroquinolones with Bactin, Floromox, Gemitab etc. We strongly cover institutions and hospitals by Cephalosporin and Carbapenem injectables like Axosin, Gen4, Taxceph, Merotrax, Zoline etc. We produce antibiotics by maintaining all the cGMP guidelines, with world class raw materials from different renowned sources and are committed to serve the people with highest quality products.
Anti-ulcerant	"This class of drugs is used to treat ulcers in the stomach and the upper part of the small intestine. There are several types of anti-ulcerant drugs like the proton pump inhibitors which workby blocking the secretion of gastric acid of parietal cells of stomach; H2 receptor blockers stop the action of histamine on the gastric parietal cells which ultimately inhibits thesecretion of gastric acid; non systemic antacids provide local acid neutralizing effect and anti-foaming agents are used to reduce bloating, discomfort or pain caused by formation of excessive gas in stomach."	The Company is very strong in anti-ulcerant portfolio having pioneer brands like Dexlan and Gavisol. We have introduced Dexlan First time in Bangladesh. We also have introduced Gavisol first time in Bangladesh among the local manufacturer. Dexlan and Esolok are the first bioequivalent Dexlansoprazole and Esomeprazole Capsule respectively in Bangladesh. We also have some potential brands in this portfolio including Xorel, Pantolok, Gavisol suspension 10 ml sachet, Famas 20 mg & 40 mg tablet, Xorel MUPS, Esolok MUPS, Sucrasol 200 ml syrup, Xevon 20 tablet, Gavisol Kids sachet, Sinasoy tablet etc.
Antiasthmatic	Antiasthmatic drugs are used to treat asthma, bronchitis, emphysema or bronchiectasis. Asthma is a major no communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children. Inflammation and narrowing of the small airways in the lungs cause asthma symptoms, which can be any combination of cough, wheeze, shortness of breath and chest tightness.	Enriched with different classes of antiasthmatic drugs including Ventisal, Ventisal-L, Xofyl, Montex etc. IPI has launched dry powder inhaler (DPI) which is a new dosage form. In this new dosage form the first product is Sinatide cozycap.

Therapeutic Class	Description	IPI's Strength
Antihistamine	Antihistamines are drugs that can relieve allergy symptoms such as runny nose, sneezing, and congestion. These drugs help treat conditions caused by too much histamine, a chemical created by body's immune system. Antihistamines are most commonly used by people who have allergic reactions to pollen and other allergens. They are also used to treat a variety of other conditions such as stomach colds, anxiety and more.	A number of potential antihistamine brands including Bilamin, Fexomin, Rupamin, Ebamin, Sinamin, Nosemin, Silora etc. Among them Bilamin is completely nonsedative. So, Bilamin tablet and Bilamin Kids are very much suitable for active people involved in driving, learning etc.
Cough Medicines	Cough medicines are used to relieve from cough. There are 2 types of OTC cough medicines: Cough expectorants and antitussives. Expectorants are a type of cough medicine that thins mucus in the respiratory tract, making it easier to expel. Antitussives are cough suppressants.	Cough medicines are enriched with a number of popular brands like Lytex, Abexol, Abex plus, Bromotex and Sinakof.
Antidiabetic	"Antidiabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetes is a disease in which the blood glucose, blood sugar, levels are too high. Diabetes can lead to several life-threatening complications, including stroke, heart attack, chronic kidney diseases, neuropathy, visual impairment etc. Diabetes patients are tremendously increasing in Bangladesh."	"Having different class of antidiabetic drugs including Linax, Linax plus, Taglimet, Glipatab, Dapatab, Glipatab-M, Linax-E etc. that are confidently prescribed by renowned diabetologists and other doctors. As these products are needed to take for long time, we are giving special price offer for most of the CVS products as a patient benefit."
Antispasmodic	Antispasmodic drugs reduce muscle spasms of the intestine, biliary system, urinary bladder & uterus. These drugs are used for the treatment of pain in gastrointestinal, biliary, urinary and gynecological diseases such as gastroenteritis, diarrhoea, dysentery, biliary colic, enterocolitis, cholecystitis, colonopathies, mild cystitis & spasmodic dysmenorrhoea.	Potential brands in this portfolio like Visceral, Alverate, Buscon etc.
Antineuropathic	Antineuropathic drugs are used to treat neuropathic pain. Neuropathic pain can be defined as a process occurring after a primary lesion or disease of the somatosensory nervous system. The pathophysiological states that determine the onset of neuropathic pain mostly involved are metabolic disorders (e.g. peripheral diabetic neuropathy (PDN), neuropathies associated with viral infections (e.g. post-herpetic neuralgia, HIV, leprosy), autoimmune disorders affecting the central nervous system (e.g. multiple sclerosis and Guillain–Barre syndrome), chemotherapy-induced peripheral neuropathies, damage to the nervous system of traumatic origin (e.g. spinal cord injury (SCI) and amputation), inflammatory disorders, hereditary neuropathies, and channelopathies.	Potential antineuropathic brands like Neurega, Neuralgin, Remylin etc.

Therapeutic Class	Description	IPI's Strength
CVS drugs	Cardiovascular drugs are used to treat high blood pressure, heart failure, angina and heart attacks etc. Cardiovascular diseases (CVDs) are the leading cause of death globally. Cardiovascular disease occur as a result of heredity or behavioral risk factors like unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. Cardiovascular diseases are considered as life threatening as it may lead to stroke, myocardial infarction and ischemia, if not appropriately treated.	Our CVS portfolio includes a number of products like Olmedip, Orabis, Cilmedip, Colostat, Restat, Diplor, Diplor Plus, Zivent MR Tablet, Tildex 90 Tablet, Teltab 40 & 80 Tablet, Olmetab 20 & 40 Tablet, Orneb, Ranovent etc. As these products are needed to take for long time, we are giving special price offer for most of the CVS products as a patient benefit.
CNS drugs	The central nervous system consists of the brain and spinal cord. It is referred to as "central" because it combines information from the entire body and coordinates activity across the whole organism. Different classes of drugs are used to treat CNS diseases.	Different types of CNS related drugs imparting strong image among Neurologists, Psychiatrists and other doctors community. The brands include Moodnor, Myotril, Remood, Rivacap, Citinex Tablet, Tripsina etc.
Gastroprokinetic agent	Gastroprokinetic agent is a type of drug which enhances gastrointestinal motility by increasing the frequency or strength of contractions, but without disrupting their rhythm. They are used to treat certain gastrointestinal symptoms, including abdominal discomfort, bloating, constipation, heart burn, nausea, and vomiting; and certain gastrointestinal disorders, including irritable bowel syndrome, gastritis, gastroparesis, and functional dyspepsia.	Gastroprokinetic drug includes Dopadon.
NSAIDs	NSAIDs (nonsteroidal anti-inflammatory drugs) are some of the most commonly used pain medicines in adults. They are also a common treatment for chronic (long-term) health problems, such as arthritis (rheumatoid arthritis, osteoarthritis, and others). NSAIDs also can decrease inflammation, such as fever, swelling and redness.	Enriched with wide ranges of NSAIDs brands including Nupralgin, Nupralgin Plus, Etolac, Preservin, Preservin SR, Anodyne, Anodyne SR, Longpara, Sinapol, PAC, Oxiflam, Algirex, Volicool, Peratrum, Paroxib, Fantagesic etc.
Laxative	Laxatives, purgatives or aperients are substances that loosen stools and increase bowel movements. They are used to treat and prevent constipation. Constipation is a condition which occurs when the movements of bowel become less frequent and stools become difficult to pass. It happens most often due to changes in diet or routine, or due to inadequate intake of fiber.	Laxative drugs to treat and prevent constipation like Sinalac, Isabgul-N and Isabgul-NE, Sinapride-1 & Sinapride-2 Tablet, Ezygo Tablet & 100 ml Solution .


Therapeutic Class	Description	IPI's Strength
"Vitamin Minerals and Hematinics"	Vitamins and minerals are used as a supplement to relieve from the symptoms of Vitamins and mineral deficiency in the body. Vitamins and minerals are organic compounds that our bodies use in very small amounts for a variety of metabolic processes. Basically, they keep us healthy and help our bodies to function. They support healthy development of body, strong immune function and emotional and mental vitality. Also, they convert food into energy and repairs cellular damage. We get vitamins and minerals from the foods we eat especially from fruits and vegetables. But daily food habit of many people fails to maintain the daily requirement of Vitamin-Minerals for the body and is causing an ultimate need of Vitamin-Mineral supplemental medicines. Haematinics are substances required in the formation of blood & are used for treatment of anaemia.	Vitamins-Minerals and Heamatinics portfolio is enriched with a number of popular brands. These brands are used to relieve from deficiency of vitamins and minerals of children and adults. The brands include Vitalgin, Sinagold, Sinasilver, Lyovit, Coraltab, Coraltab DX, D, Junivit, Biozinc, Biozinc-B, Ipical, Ipical-D, Eggikal-D, Eggikal-DX, Zepiron, Zepiron Plus, Oxyfer, Bioton etc.
Topical Dermatological agents	Topical Dermatological agents are the medicines used to treat skin conditions include topical and oral drugs for the treatment of a wide variety of diseases of the skin, hair and nails. These agents are applied directly on the skin to treat skin conditions. Topical dermatological agents include anti-inflammatory agents, anti-infective agents, antifungal, antiviral, agents for psoriasis such as topical corticosteroids, emollients, astringents, agents to treat acne, local anesthetics, cleansing agents and so on.	Reputed topical dermatological brands including Terbinox, Dermacom, Luly, Dermacort, Dermastin, Sinacort, Fungin, Fungin-B, Neocort, Fungicort etc.
ORS	Oral rehydration solutions (ORS) are used to treat dehydration caused by diarrhea, a common illness for all age groups. Unlike other fluids, the ratio of the ingredients in an ORS matches what the body needs to recover from a diarrheal illness. This simple mixture saves millions of lives with very low cost.	Very popular ORS brands like Unisaline, Unisaline Fruity (Mango), Unisaline Fruity (Orange), Unisaline Fruity (Lemon).
Antiviral	Antiviral drugs are one class of antimicrobials used for treating viral infections. The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. Most of the antiviral drugs now available are designed to help deal with COVID-19, SARS, Influenza, Dengue fever, Zika, HIV, Hepatitis, Polio, Ebola, Influenza, etc.	Potential antiviral products like Favitab. It is a tablet preparation of Favipiravir 200 mg. Favipiravir was approved in 2014, in Japan to treat influenza that were unresponsive to conventional treatment. Favipravir shows its efficacy at targeting several strains of influenza. It is indicated for the treatment of novel viruses including Ebola and most recently, Covid-19. We also have Clovir exerts its antiviral effect on herpes simplex virus (HSV) and varicella-zoster virus by interfering with DNA synthesis and inhibiting viral replication. We have Clovir 200 & 400 Tablet, Clovir 250 & 500 infusion.

Therapeutic Class	Description	IPI's Strength
Antiprotozoal	Antiprotozoal agents are a class of drugs used to treat infections caused by protozoa, which are single-cell organisms, belonging to a group of parasites. Protozoan typically are microscopic and similar to plants and animals as they are eukaryotes, thus having a clearly defined cell nucleus. Many of the most prevalent and deadly human diseases are caused by a protozoan infection, including African sleeping sickness, amoebic dysentery, and malaria. Diarrhea continues to be a major cause of childhood mortality and morbidity in developing countries. Southeast Asian region including Bangladesh, experienced the highest mortality rate among children with diarrhea.	"Enriched with drugs to fight against protozoan infections. Our antiprotozoal portfolio includes several brands like Metsina, Nitasol. Metsina, a popular brand is available as suspension, tablet and IV dosage form. Metsina is very much effective in amoebic dysentery and some other protozoal infection."
Antiemetic	An antiemetic is a drug that is effective against vomiting and nausea. Antiemetic are typically used to treat motion sickness, pregnancy and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer.	Enriched in antiemetics with brands like Emiston & Palostat. They are effectively used to treat nausea and vomiting due to motion sickness, pregnancy and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer.
Antifungal	"Antifungal medicines treat fungal infections. Fungus in the soil, air and on your skin can cause yeast infections, ringworm, and nail and skin infections. Breathing in fungal spores can lead to respiratory illnesses. People who have weak immune systems are more prone to fungal infections that require antifungal medicine. Over one billion people in Bangladesh are believed to suffer from a fungal infection annually. These increasing number of fungal infected patients contributing a distinguishable progression on antifungal drug market in Bangladesh."	We have wide range of both topical and oral products like Terbinox, Sporagin, Votab, Luly, Sertagin, Ketotab, Fungin, Fungin-B, Illuca etc. We have introduced Sporagin oral solution first time in Bangladesh.
Anti-fibrinolytic	"Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. Antifibrinolytics are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the breakdown of blood clots. Antifibrinolytic agents may be used to help prevent or treat serious bleeding in patients who have certain conditions, such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors."	Potential drug Nexyl to treat haemorrhage or risk of haemorrhage in increased fibrinolysis that may occur in conditions like Prostatectomy and bladder surgery, Menorrhagia, Epistaxis, Conization of the cervix, Management of dental extraction in patients with coagulopathies, Ulcerative colitis, Haematuria, Gastrointestinal haemorrhage.

Therapeutic Class	Description	IPI's Strength
Ophthalmic drugs	Ophthalmic drugs are used to treat a large number of diseased states of the eye. These states may include bacterial infections, viral infections, Fungal infections, eye inflammation, eye allergy, eye injury, glaucoma, cataract and dry eye.	Very strong image in ophthalmic market. We are producing a variety of popular ophthalmic products from different therapeutic classes including Antibiotic (Floromox, Levosina, Bactin, Cloram, Romycin, Tomycin etc), Steroid (Loterex, Isolon, Eylon, Dexon, Loterex eye gel, Flupred etc), Antibiotic plus Steroid combination (Loterex-G, Loterex-T, Dexon-G, Bactin-D etc), NSAIDs (Bromofen, Nep-TS, Etolac etc), Antiallergic (Patalon, Patalon-DS, Ketof etc), Antifungal (Fungin, Natoph), Drugs for Dry Eye Syndrome (Sinafresh, Glamor, Polygel, Optear, Hydromer ophthalmic gel etc), Anti glucoma (Avost, Avost Plus, Azopress, Rsudil Plus etc), Ophthalmic Vitamin and Mineral (Optagold), Anticataract (Ractovit).
Contrast agent	Diagnostic products are used for clear imaging or diagnosis for different part of body examination MRI, CT Scan.	For the first time The IPI PLC has launched diagnostic contrast agent. For the use in examiniation e.g. MRI & CT Scan IPI has launched Visican, Lopitrast, Gadosol. Among the contrast agents Gadosol has been launched first time in Bangladesh.
Others	There are many other classes of drugs IPI owns.	We have many other brands from different therapeutic classes like Glucocorticoids (Cordef), Muscle relaxant (Bacofen, Myoson), Drugs for BPH (Urocap, Urocap-D), Antiarthritis supplement (Articulex, Ostorin), Drugs for vertigo (Cinarzin, Cinarzin Plus), Drug for overactive bladder (Migron 25 ER Tablet), Mouthwash (Lister Plus 250 ml), Hemocal, Hemocal LD, Audicom ear drops, Drugs for CKD (Aprodust, Finotab). We have also many other drugs from different classes.

Management Approach

IPI PLC's Intellectual Capital consisting of tacit knowledge, trusted brand, systems and processes, and innovative products as the building blocks of new growth line.



INPUTS

- Tacit Knowledge
- Reputed Brand
- Organizational Capital
- Relational Capital
- Technology

MANAGEMENT FOCUS

- Develop skills and expertise of employees
- Staff retention
- Continuous investment in IT infrastructure
- Technology innovations
- Investment in brand building initiatives
- Utilize our relationships for sustainable value creation

OUTPUTS

- Brand equity growth
- Market share increase
- Improved skills of employees
- Most innovative pharmaceutical Company

Quality Control (Q.C)

The Company has separate Quality Control Department for each Manufacturing division. Each Quality Control Laboratory has the following wings-

- Physical Lab
- Chemical Lab
- Instrument Lab
- Microbiological Lab
- Packaging Materials Section
- On-going stability study Section
- Method Validation Section

For Conforming to the Quality of-

- Raw Materials
- Packaging Materials
- Intermediate Products
- Bulk and Finished Products

All laboratories are equipped with modern facilities and sufficient sophisticated equipment.

The IBN SINA Pharmaceutical Industry PLC has dedicated international regulatory affairs section under Quality Control Department to register the products in overseas market such as United States of America, Guatemala, Myanmar, Sri Lanka, Cambodia, Vietnam, Laos, Kenya, Somalia, Afghanistan, Yemen, Mali, Bhutan, Georgia, Ghana, Mauritius, Senegal, Uganda and Zimbabwe.

Quality Assurance

Another important department is Quality Assurance (QA) whose prime responsibilities are to ensure the quality of products at every step of production operation and release/rejection of finished products. To carry out the QA activities effectively, it has the following sections:

- Separate in process QA Laboratory for each section of production department for proper monitoring of production operation, supervision of production environments, recording and documentation.
- Compliance
- Validation and Calibration
- Documents preparation, distribution and archiving
- Training

To supervise the effectiveness and applicability of the quality assurance system, QA perform the following activities:

- Implementation of cGMP and training;
- Change control management;
- Deviation management;
- Risk assessment & management;
- CAPA management;
- Conduct Internal audit;
- Annual product quality review;
- Market complain handling;
- Process validation IPQA instrument calibration;
- Documents like SOP, BMR, BPR, master list etc preparation, distribution and archiving;
- Packing materials checking, approval and controlling and
- Retention sample management.

For proper co-ordination among the different departments, we developed Quality Operation Management System. Quality is our commitment and we are marching on ward to achieve this goal. Quality management System (QMS) and international standard cGMP are in practice now. We are trying to achieve the recognition of TGA, Australia first and then we shall proceed for other international compliance certification one by one.


Product Development (PD)

Product Development is an important wing of The IBN SINA Pharmaceutical Industry PLC We have two separate PD Departments for Pharma and Natural Medicine. Both are enriched with a number of highly qualified and experienced personnel.

The goal of PD Department is to develop innovative, high quality pharmaceutical products in a cost-effective way maintaining its highly ethical issues regarding human health.

Our experienced PD team is dedicated to develop & introduce quality products according to ICH guidelines and continuous improvement of new and existing product for customer satisfaction, environmental change, technology change and other competitors. The inter department liaison of PD with Strategic Marketing Department, QA, QC, Purchase & Production helps a successful introduction of a new product to the valued customers.

PD Department is equipped with highly sophisticated machineries and equipments of cGMP standard for development of new products in an efficient manner.



PD team ensures following activity

- Preformulation Study
- Pharmaceutical Formulation
- Stability Study
- Process Development and Validation
- Pharmaceutical Analysis
- Reformulation
- Preparation of Samples for DGDA and Documents
- Comparative Dissolution Study with Innovator Products
- Technology Transfer to Production, QC & QA

We have developed central PD laboratory and Scale-up area for Process Validation for The IBN SINA Pharmaceutical Industry PLC having required space with all modern equipments facility.

PD yields around 30 new products in health sector every year. This active participation of The IBN SINA Pharmaceutical Industry PLC in pharmaceutical sector stands as one of the leading pharmaceutical industries in Bangladesh.

Microbiology

Microbiology department plays a vital role to maintain quality of the pharmaceutical products. Having understood the significance of the works the IPI PLC Microbiology department has been decorated by setting many sophisticated instruments & device likes double door autoclave, vertical autoclave, LAF working bench, a number's of bacterial incubators, cold incubators, World class brand inter science 4000 zone reader, colony counter, Kinetic LAL analyzer, Bio-safety cabinet, Air borne particle counter, Air sampler, Air velocity meter (Anemometer) etc.

Well trained a group of microbiologists are working in this department having splitted the department into two sections e.g. laboratory microbiology section & environmental monitoring, validation section. In the laboratory section, different microbiological tests are conducted e.g. test for sterility, microbiological limit test, detection of pathogenic organisms, microbiological assay, bacterial pyrogen test & test method validation works etc. On the other hand Microbiology environment section monitors different class standard clean area, sterile products process validation, sterilizer likes autoclave, dry heat sterilizer, dry heat tunnel etc routine monitoring & performance validation etc.

All the microbiological quality related test, validation & environmental monitoring works, specially the sterile products e.g. ophthalmic, injection and antibiotic quality analysis & clean area routine monitoring, validation are done by the Microbiology department. To perform the mentioned works accurately & precisely, thare follow BP, USP and WHO GMP, GLP guideline strictly.

Our IT System

Being an ever expanding, Leading Pharmaceutical company, The IBN SINA Pharmaceutical Industry PLC is producing quality products and is making accuracy in every arena applying its up-to-date Information Technology. The company already introduced Cloud Infrastructure to run it's business through an ERP System where Procurement, Inventory, Production, Costing, HR, Admin, Accounts, Marketing, Sales, Survey and Distribution modules are being incorporated. As a result, the management could provide all sorts of budget and could implement their plan accordingly. The company is now able to find out any type of costing, even to produce a single product or a labour hour. Our Sales and Distribution people are now using mobile apps to execute customer order and receiving payments which in turn is helping distribution people for preparing invoice and doing payments acknowledgement. The Procurement department is procuring materials in advance and production department is producing quality goods timely since the marketing department provides sales forecast quarterly, half yearly and annually through ERP. The Accounts and Finance department could implement their Capital and Financial budget, allocate Finance and prepare their Financial Statement based on costing and other related factors comes out from ERP. HR department is using ERP for recruitment, promotion, increment, leave, attendance, training and development purposes. Finally, the Company Affairs and Admin department is implementing policies, rules and regulation in the ERP. The management is now able to view any type of report through ERP by a single click only. IT Department is ensuring all sorts of security for deploying Firewall, Anti-Virus and up to date network device. The department is more concerned about strong backup system for data recovery at any type of digesters. The systems have been deployed in the Cloud Infrastructure installed as data center (DC). The company has already deployed disaster recovery (DR) center in another location of the Cloud to ensure smooth and continuous operation in any disaster.

IT department is working for more modernization and time benefiting of this system to cope up the growing demand of the competitive challenging markets with the help of expert management of the company.


Social and Relationship Capital

Engagement with the corporate responsibility and sustainability initiatives supports our key stakeholders and sharing values with them as fundamental to sustainable growth. We, as a responsible corporate citizen, carry out the business activities with transparency, integrity that enables us to invest in various socio-economic development activities for the well-being of our country.

Social and Relationship Capital (SRC) includes shared norms, common values and behavior, key stakeholder relationships, intangible association with organization's brand and reputation and organization's social license for business operation.

We think social and relationship capital as one of the key assets of the Company. It acts as the image and reputation of the organization. Viewing this perspective, due importance of social and relationship capital is given maintaining healthy relationship to the stakeholders, the beneficiary concerned like customers, suppliers, surveyors, reinsurers, vendors, banks and all other stakeholders.

Sources of Social & Relationship Capital



CSR in Operational Activities

To foster a strong culture of corporate governance, The IBN SINA Pharmaceutical Industry PLC has adopted a comprehensive Corporate Social Responsibility (CSR) Policy. The CSR Committee, constituted by the Board of Directors, oversees and implements the Company's CSR initiatives in accordance with the established Corporate Social Responsibility Policy.

The Company is committed to:

Conducting its business operations in a socially responsible and ethical manner;

Safeguarding the environment while ensuring the health and safety of people;

Upholding human rights and maintaining harmonious relationships with stakeholders and employees; and

Engaging with, learning from, respecting, and supporting the communities and cultures in which it operates.

These objectives are realized through the Company's products, values, and corporate spirit, all of which contribute to enhancing the quality of human life and promoting well-being. The effective implementation of CSR strategies serves as a vital driver of sustainable business success. The key dimensions of CSR practices adopted by the Company are outlined below:

CSR for the Employees

Considering the overall welfare, safety and security for the officers and workers, Company has formed a Provident Fund (PF), Gratuity and Superannuation Fund. Separate Trustee Board is entrusted to govern these funds. Besides of these, group insurance for workers of factory and full-time health services for the workers employed in the factory are also available. Expenditure of the treatment for partial or total physical damage for accidental causes during and out of normal course of service is being endeavored from the Company and also a special amount as donation is given to the successor of deceased personnel causing accidental death during and out of normal course of action.

Group Insurance

As per Section- 99 of Bangladesh Labour Laws 2006 (as amended upto 2026), the Company has established Group Insurance for its employees with the recognized Insurance Company.

Officer Workers Benevolent Fund

Employees are being facilitated from Officers-Workers Benevolent Fund where financial assistance is needed. It recognizes our employees with respect, dignity, caring each other that ensure good atmosphere of the employment.

Superannuation Fund

This is a structural pension program approved by the Board for the wellbeing of its employees in order to mitigate the various specified problems like accidental death, disablement, serious chronic illness, etc. during the period under job. During the year under review, total 08 officers and workers were facilitated paying Tk. 1,400,000/- (Forty Lac) to the successors of the deceased members of this Fund.

Medical Expense Provided to Insolvent Employees

The employees who are not capable of paying the expenditure incurred for their medical treatment for various diseases/accidental causes happened either during in course of service or in any other way are being taken under special consideration for payment of such medical expense. In the year 2025-26 total medical expense supported by the Company is about more than Tk. 4,395,425/- (Forty Three Lac Ninety Five Thousand Four Hundard Twenty Five).

Donation on Death

When a regular employee of IPI dies during working hours or later, the family members of deceased employee are provided some financial assistance as instant support. In many cases, the Company also takes up the responsibility of education of the children of the deceased employee as an acknowledgement of their contribution and dedication to the Company.

Sponsoring Holy Umrah

Sponsoring to perform holy Umrah is another CSR scheme for the employees of IPI. Every year certain number of good performers from respective departments of the Company are selected. Employees are very enthusiastic and spirited availing such opportunity from the Company.



Work with Recreation

The IBN SINA Pharmaceutical Industry PLC organizes Annual Picnics, Cultural Programs, Sports Events, and Excursions for its employees to foster a pleasant working atmosphere, strengthen mutual relationships among colleagues, and enhance overall productivity.

Community Development

The IBN SINA Pharmaceutical Industry PLC believes that community development can be advanced through mutual care and collaborative support between the Company and its employees. Such participatory initiatives promote team spirit and encourage active involvement in social welfare and community betterment activities.









Gift for New Born Baby

Children are a precious blessing of the Almighty and symbolize the beauty of life. Around 5,000 officers and employees are engaged in this organization. To celebrate the joy of parenthood, the Company provides gift boxes to employees on the occasion of the birth of their newborn babies, sharing happiness with their families.

Setting up Medicine & Doctor's Corner

A medicine corner has been established so that employees can purchase medicine instantly from medicine corner for themselves and their family members at considerate price.

Human Rights

We are committed to upholding the Universal Declaration of Human Rights by the UN and the labor standards set out by the International Labour Organization and Bangladesh Labour Laws 2006 (As amended upto 2026).

Employee Training and Development Program

The IBN SINA Pharmaceutical Industry PLC considers education and training as fundamental drivers for enhancing employees' capabilities and unlocking future potential. The Company emphasizes the principles of "Right-to-Know" and "Partners-in-Leadership" to ensure the continuous professional development of its workforce, contributing to both organizational excellence and national progress.

Details of the in-house and overseas training programs conducted for employees during the year 2025–26 are presented on page no. 45 of the Annual Report.



Workers' Profit Participation Fund and the Welfare Fund

The Company handed over the Cheque of Welfare Fund of WPPF amounting to Tk. 52,979,904 and Tk. 3,902,256 (Taka Thirty Nine Lac Two Thousand Two Hundard Fifty Six) to the Director General, Bangladesh Sromik Kallyan Foundation, Labour and Employment Ministry, Government of Bangladesh.

Free Healthcare Complex

A complimentary medical center operates five days a week at Shafipur, Gazipur, serving underprivileged communities, particularly mothers and children residing around the IPI factory area. Factory employees are also provided with free medical treatment on the campus by qualified doctors and Hakims (Natural Medicine Practitioners).

Medicine Donation

As part of the CSR activities, Company had donated good volume of medicine to different recognized charity events/organizations.





Scholarship for Medical Students

One of the notable CSR initiatives of IPI is dedicated to supporting medical students in their educational journey. The Company continuously endeavors to encourage future healthcare professionals through financial assistance and motivational support. Up to the reporting date, a total of 70 students have been receiving scholarships.



Distribution of Warm Clothing

During the winter season, The IBN SINA Pharmaceutical Industry PLC distributed warm clothes among cold-affected people in Rangpur, Kurigram, Dinajpur, Rajshahi, and Thakurgaon and other areas of greater north bengal.

Emergency Food Support

The Company provides emergency food assistance to thousands of vulnerable floods affected people of the Country.

Afforestation Program

As part of its continuous commitment to social and environmental responsibility and environmental preservation policies, the Company has undertaken annual tree plantation programs to enhance greenery and improve the ecological landscape of the country. The afforestation activities were carried out within factory premises, project sites, and surrounding depot areas nationwide.




IBN SINA
রোপণ কর্মসূচি ২০২৬


IBN SINA
গাছের চারা বিতরণ


WORLD
Environment
DAY 2026


WORLD
Environment
DAY 2026



During Visiting in Central Warehouse



Sr. Officials seen in Central Warehouse



On Visiting Pharma Unit-2

Paperless-Operations

The corporate world is progressively embracing paperless practices. Reducing paper consumption helps conserve the environment, prevent deforestation, and preserve the natural supply of fresh oxygen. IPI PLC is steadily transforming its traditional paperwork into a modern, technology-driven digital system for operations and communication with customers and employees.

Virtual Office Activity

The IBN SINA Pharmaceutical Industry PLC operates within a modern digital workplace ecosystem that enables employees to participate in virtual office functions seamlessly. This includes online meetings, training sessions, digital libraries, correspondence, and other remote collaboration tools that enhance efficiency and connectivity.

Use of Natural Lighting

The Company encourages an energy-conscious workplace culture by maximizing the utilization of natural daylight during working hours. Dependence on artificial lighting is minimized whenever possible. In addition, all lights are switched off during lunch and prayer breaks to promote energy conservation.

Reduction in Business Travel

To reduce its carbon footprint and energy conservation initiatives, the company has minimized its travelling. Most operations requiring in-person interaction have been digitalized using online communication mediums.

Waste Minimization

Water conservation is an integral part of the Company's environmental stewardship efforts. Employees are encouraged to use water responsibly and avoid unnecessary wastage. To ensure proper waste management, cleanliness is regularly monitored, and waste is segregated into paper, plastic, metal, and organic categories to facilitate recycling and proper disposal. The Company also operates a well-maintained Effluent Treatment Plant (ETP), duly licensed by the Department of Environment (DoE), to ensure compliant and responsible waste treatment.

Relationship Capital: Connecting Our Stakeholders

The Company is committed to creating value across different time horizons by engaging stakeholders based on key principles such as influence, accountability, proximity, dependency, willingness to engage, and representation. Regular consultations are conducted through relevant departments to maintain meaningful stakeholder dialogue and collaboration.

Stakeholder Engagement Policy

The Company is committed to maintaining transparent, effective, and continuous communication with its stakeholders through timely dissemination of financial results and disclosure of significant developments. The key objectives of this policy are:

- Identification prioritization and understanding of all stakeholders.
- Maintain healthy and sustained relationship with the stakeholders.
- Provide access of the relevant information to enhance public image of the Company.
- Provision of sharing feedback and resolving the complaints as early as possible.

Response to Shareholders Queries

The Company has established several communication platforms to ensure strong and transparent engagement with shareholders, including the Annual General Meeting (AGM)/Extraordinary General Meeting (EGM), Shareholders' Corner at the Share Department, Public Relations Office, official website, Annual Report, and mandatory regulatory disclosures. These channels are maintained to foster an effective and responsive relationship with the Company's shareholders.

The Company Secretariat is responsible for addressing inquiries from shareholders, investors, and other stakeholders. Quarterly financial performance results are regularly published on the Company's official website. The Share Department remains highly attentive and committed to delivering services to shareholders in line with their expectations and requirements.

Customer Complaint Form

Customers' complaints are being dealt with as per SOP. Our customers can provide their feedback or complaints, if any, by filling up a "Customer Complaint Form" available to each depot. In response to their complaint, feedback is given ensuring necessary corrective measures as required so that repetition of such problem could be avoided in future.

Publication of IBN SINA Health Magazine

The IBN SINA Health Magazine, published monthly and sponsored by The IBN SINA Pharmaceutical Industry PLC, is distributed among physicians, valued customers, and the general public to enhance awareness of various health-related issues. The magazine features up-to-date and significant medical topics contributed by renowned specialist physicians.





Management Coordination and Business Review Meeting

IPI PLC conducts management coordination meeting on a monthly basis and business review meeting on a quarterly basis comprising of Mid-Level and Top-Level Management with a view to developing future leaders of the company where change management, team building, HR development, overall business performance and topics on current socio-economic condition is highly and extensively emphasized.

Activities for Medical Professionals

IPI PLC's aims at sharing with medical professionals' useful information on various subjects of medical interest, organizing and sponsoring clinical workshop and meeting from time to time, arranging video shows on acute medical emergencies. The Strategic Marketing Department carries out programs like scientific seminars, round table meetings, rural promotional campaigns, intern doctor's reception programs and many more.

Scientific seminar is a continuous medical education program, where individual department or host institutions present a particular research-based case study with medical professionals and learners of medical college. Rural promotional campaigns are conducted among Diploma in medical faculty doctors, who work as a community-based health service provider. Such campaigns help to increase the engagement of rural level medical professionals with the company.





Pharma Unit-1, Shafipur

Natural Capital

According to the International Institute for Sustainable Development, "Natural capital is the land, air, water, living organisms and all formations of the Earth's biosphere that provide us with ecosystem goods and services imperative for survival and well-being. Furthermore, it is the basis for all human economic activity."

Natural capital is continually providing us with something of value, whether it is the air that we breathe, the water that we drink, or the raw materials that we use in our products.

The problem is that we have not traditionally placed a financial value on these natural resources. By not placing a financial value on them, it became easy to destroy forests, pollute rivers, endanger species and habitats, and otherwise plunder our natural resources.

Now, however, we are starting to recognize the value of natural capital.

Embracing Natural Capital for a Sustainable Future

We see natural capital not just as a resource but as a responsibility, a call to act, innovate, and transform. Every step we take towards sustainability is a step towards a greener tomorrow, where progress and preservation go hand in hand.



Ways to Manage our Natural Capital

Although methodologies for assigning financial value to natural capital are still evolving, several practical initiatives can help integrate natural capital considerations into business operations:

- Initiatives aimed at minimizing waste, conserving water, and enhancing energy efficiency contribute significantly toward sustainable resource management. Simple yet effective measures include using recycled paper, encouraging double-sided printing, maximizing natural lighting, and reducing disposable items within workplace operations.
- Businesses can further advance sustainability by improving operational efficiency and reducing waste throughout production processes. Such initiatives not only conserve valuable natural resources but may also create long-term financial benefits through cost optimization and improved productivity.
- Organizations may also adopt globally recognized frameworks such as the Natural Capital Protocol to better assess, manage, and integrate environmental considerations into business decision-making processes.

One of the most significant advantages of incorporating natural capital into business strategy that supports both environmental sustainability and economic efficiency. Efficient resource utilization, waste reduction, and responsible environmental practices contribute directly to operational savings and long-term business value creation.

Our Priorities



Waste Management

Our key initiatives towards waste management is Reduce, Reuse and Recycle.

Reduction of Paper Usage

As paper remains one of the primary materials used in our daily operations, The IBN SINA Pharmaceutical Industry PLC has undertaken various initiatives to minimize paper consumption. These initiatives include enabling double-sided printing, encouraging printing only when necessary, and promoting draft printing practices. The Company is also fostering a paperless working environment through the implementation of e-QMS, e-logbook, e-learning systems, STEPS ERP, leave management, and KPI systems.

Use Reusable Items

Eliminating the use of all disposable items such as paper plates, paper napkins, paper mug or cup in the office kitchen. In that place we use, reusable ceramic plates, glass mug/ cap & reusable towel. Continued to outsource all the photocopy machines to a third party and get refill the print cartridge and use to maximum possible duration indirectly.

Recycling of Waste

We continue to validate partner for paper, polybag, plastic, and glass bottle, foils collection to shred our waste in an environmentally friendly manner and achieve reduction of our total waste.


Water Consumption

We focus our efforts on reducing our water consumption for the long term; working on recycling and reuse of effluents. As a result, we installed sensor taps, created awareness on water conservation aiming water management.

Ground Water No Use	**Underground Water 2,42,850 m3**
Potable Water/PW/WFI 77,724 m3	**Mineral Water (Packed) 6.72 m3**

Energy Consumption

Our key energy consumptions are electricity used for office premises and fuel used for business travelling. We continue to focus on enhancing energy efficiency in all aspects of our operations.





Key Initiatives to Reduce Energy Consumption

- Installation of timer switches for air conditioners (A/Cs) in office premises to ensure operation only during working hours.
- Conducting online staff training programs to reduce commuting-related energy consumption and associated costs.
- Encouraging employees to use electricity and fuel responsibly in their daily activities.
- Installation of master key switches on office floors to enhance overall energy efficiency.
- **Utilization of Natural Daylight :** To promote sustainable energy efficiency, The IBN SINA Pharmaceutical Industry PLC has adopted building designs that maximize the use of natural daylight. By allowing greater access to sunlight within the workplace, the Company benefits from reduced dependence on artificial lighting. Optimizing natural daylight is considered one of the most practical and cost-effective approaches to minimizing overall energy consumption.
- **Solar PV Panels :** The IBN SINA Pharmaceutical Industry PLC has installed solar PV panels to support electricity generation through renewable energy sources. The primary objective of this initiative is to reduce reliance on the national grid and generators for power supply. The Company remains committed to contributing toward a cleaner, pollution-free environment and a more sustainable future for the country.

Conserve Eco-System

Ecological Plan

Landscaping has been carefully designed to prevent water accumulation during heavy rainfall. In addition, a wide range of trees, plants, and grass have been cultivated in open spaces to avoid dust generation from exposed soil. The drainage infrastructure has been engineered to effectively control dust dispersion. A well-planned green initiative has been implemented to ensure a balanced ecological environment through systematic plantation and greenery development.

Effluent Treatment Plant (ETP)

We operate an Effluent Treatment Plant (ETP) equipped with the capacity to neutralize all wastewater generated from the manufacturing facility. Liquid waste and effluents are systematically collected through an integrated industrial drainage network installed beneath each production floor. Production areas and the central washing zone are fitted with industrial hygiene floor traps, and all wastewater is conveyed via UPVC piping to an underground collection pit located outside the production building. From there, it is directly transferred to the ETP through a dedicated pipeline for treatment, ensuring environmental safety.

Incinerator

An incinerator is a high-temperature furnace designed for the controlled combustion of solid waste, reducing waste volume by eliminating combustible materials. It is used for the safe disposal of rejected pharmaceutical products such as tablets, capsules, powders, blisters, ampoules, and vials generated during daily manufacturing activities.

During formulation processes, an unavoidable process loss of approximately 2–3% occurs, which is not recoverable. Such waste is also safely disposed of through incineration. The Company maintains an annual contract with PRISM Bangladesh Foundation for the monthly incineration of solid waste in a controlled and compliant manner.

Upgraded Lighting System

To enhance energy efficiency and reduce carbon emissions, energy-saving LED lighting systems have been installed across both the administrative offices and manufacturing facilities. Through this initiative, we have adopted an energy-efficient lighting solution that significantly reduces electricity consumption while ensuring optimal illumination throughout the premises.

Looking Ahead

Moving forward, we remain committed to strengthening best practices in energy management, water conservation, emission control, and comprehensive waste and effluent management across our entire value chain. As a responsible corporate citizen, continuation to expand green initiatives and contribute further to environmental protection through increased plantation and sustainability-driven projects have been ensured.




Pharma Unit-1 Guarden

Human Resource Accounting

Human Resource Accounting (HRA) for Training and Skill Development involves the systematic measurement and reporting of investments made by an organization to enhance the knowledge, skills, and capabilities of its workforce. It recognizes employees as valuable assets whose worth can increase through effective training and development initiatives.

In a broad sense, Human resources accounting is involved in identifying, measuring, capturing, tracking and analyzing the potential of a Company's Human assets and communicating the resultant information to the company's stakeholders. Human resource accounting is an attempt to identify, quantity and report Investments made in the human resources, that are not presently accounted for under conventional accounting practice.

It monitors effectively the use of human resources by the management of continuous training and evaluation. It is a new concept of training accounting aids in the development of Management principles and proper decision making what the future, by classifying the financial consequence of various practice.



Advantage of Human Resources Accounting

Better Decision-Making

1. Improved Decision-Making

- Supplies management with reliable data for making informed decisions regarding recruitment, training, promotion, and compensation.
- Helps assess the return on investment (ROI) in human capital development.

2. Stronger Human Resource Planning

- Supports forecasting of future workforce requirements and succession planning.
- Assists in identifying skill gaps and training needs.

3. Enhanced Performance Evaluation

- Enables evaluation of employee contributions to organizational success.
- Links individual performance with overall financial outcomes.

4. Greater Transparency

- Provides a clear view of the organization's most valuable asset—its people.
- Strengthens trust among investors, stakeholders, and employees through disclosure of HR-related investments.

5. Higher Motivation and Employee Morale

- Recognizing employees as valuable assets increases motivation and job satisfaction.
- Leads to stronger employee engagement and improved retention.

6. Cost Control and Operational Efficiency

- Facilitates analysis of cost-effectiveness of training, recruitment, and retention initiatives.
- Promotes more efficient allocation of HR budgets.

7. Support in Mergers and Acquisitions

- Enhances company valuation by incorporating human capital considerations.
- Plays a vital role in due diligence and organizational assessment.

8. Strategic Alignment

- Aligns HR strategies with overall organizational objectives and financial planning.
- Encourages long-term workforce development planning.

Training and Skill Development human resources a team performance and increases profitability. Developing HR accounting in a company increases the utilization up money and time. Improve steam work increase specific skill, and leadership quality and prevent uncertainty in a company.

To develop skill as well as efficiency and competency of all level's employees, the training and skill development activities of various professional training but the early training calendar. The training and skill development department task a deliberate plan to ensure that an employee gets at least three training in a year as per departmental training needs assessment



Types	Description	Amount
Welfare Issues	Education/Treatment Family Problem/flooding superannuation facilities Gift for New Born Baby Donation on family crisis moment etc.	Tk. 1,000,000

Health, Safety and Environment

Health, Safety and Environment (HSE) remain the fundamental values of The IBN SINA Pharmaceutical Industry PLC (IPI), where a comprehensive set of policies and procedures is developed and implemented to ensure practical protection of the environment, as well as the health and safety of all stakeholders within the Company. The inherent risks associated with the pharmaceutical and chemical industry are always treated as a top priority, with standardized HSE systems firmly embedded across all operational activities. The Company is fully committed to achieving excellence in Health, Safety, and Environment performance and carries out all operations in a safe, responsible, and environmentally conscious manner.

Safety is regarded as the highest priority and an essential part of our organizational culture. We strongly believe that zero harm is achievable through focused commitment, disciplined execution, and effective teamwork. Guided by this belief, IPI ensures that all business activities are conducted in a way that prevents harm to people, assets, and the environment.

To ensure safe, reliable, and efficient operations, we consistently emphasize the daily management of operational risks, particularly those related to Health, Safety, and Environment. In order to strengthen safety culture across the organization, the executive management team holds regular meetings to review HSE performance and environmental safety outcomes.

We are also committed to providing comprehensive health and wellness support for our employees. The physical and emotional wellbeing of our workforce is maintained in alignment with industry best practices and recognized standards relating to Health, Safety, and Environment.

During 2025–26, we further strengthened the three core pillars of our Health, Safety & Environment operating model: Critical Risk Management, Workforce Engagement, and Continuous Improvement, reinforcing our long-term commitment to sustainable and safe operations.



Corporate Governance

The corporate governance framework of The IBN SINA Pharmaceutical Industry PLC is founded on the four core principles of governance—fairness, transparency, accountability, and independence—ensuring responsibility toward both shareholders and society as a whole. The Company conducts its operations in accordance with a Board-approved Code of Conduct, developed in line with the guidelines and directives issued by the relevant regulatory authorities, with the objective of reinforcing sound governance practices and meeting the rightful expectations of all stakeholders.

All stakeholders associated with the Company remain dedicated to preserving the principles embedded in the organization's core values and ethical standards, a commitment that the Company proudly upholds. A strong and effective corporate governance structure promotes sustainable value creation while maintaining accountability across every level of the organization.






Key Elements of Corporate Governance

The Board of Directors

The Board consists of one Chairman, two Functional Directors, three Non-Executive Directors, and three Independent Directors (IDs), including one female Independent Director with distinguished professional expertise, knowledge, and competence. The Board acts as the highest governing body of the Company, while the Executive Committee, Audit Committee, Nomination and Remuneration Committee (NRC), and Corporate Social Responsibility (CSR) Committee serve as its four key supporting pillars, collectively contributing to the efficient administration and sustainable advancement of the Company.



- Non-executive Director
- Independent Non-functional Director
- Functional Director

Policy on Appointment of Directors


The appointment of Directors is carried out in full compliance with the Companies Act and all applicable notifications issued by BSEC. In accordance with the Companies Act, 1994, Directors retire by rotation at every Annual General Meeting (AGM). The term of an Independent Director is three years, which may be renewed for an additional three-year period. All appointments, nominations, removals, and appointments against casual vacancies are executed in conformity with the applicable laws, rules, and regulatory requirements.The Directors of the Company are:

Nominated Directors

Nominated by the Sponsor Shareholders

Non-Executive Independent Directors

Being appointed/recommended to be appointed as per the prescribed qualifications of Independent Directors pursuant to the Corporate Governance Code of BSEC, 2018.



Practice of the Board

The Board is entrusted with determining the strategic vision, policy framework, and operational direction of the Company, while also ensuring their proper execution in achieving organizational objectives. Ultimately, the Board remains accountable to the shareholders.

A comprehensive Code of Conduct has been formulated for the Chairman, Board Members, and the Managing Director/Chief Executive Officer. Compliance with the Code is reviewed annually based on the recommendations of the Nomination and Remuneration Committee (NRC), appropriately documented, and disclosed on the Company's official website.

In performing its duties and responsibilities, the Board adheres to the Bangladesh Securities and Exchange Commission (BSEC) Corporate Governance Code, the Companies Act 1994, the Bangladesh Labour Act 2006 (amended up to 2026), the Memorandum and Articles of Association, the Company's Service Rules, and all other applicable laws and regulations. The Board also ensures the effective implementation of strategies and policies adopted by the Company from time to time.




Composition of Non-Executive Directors

In line with sound corporate governance standards, The IBN SINA Pharmaceutical Industry PLC maintains a Board comprising six (6) Non-Executive Directors, including three (3) Independent Directors, within a total Board strength of nine (9) members.

Independent Directors and Their Independence

In compliance with the Corporate Governance Code issued by the Bangladesh Securities and Exchange Commission (BSEC), one-third of the total Board members are Independent Directors (IDs). Accordingly, out of the total nine (9) Directors, three (3) are Independent Directors, including one female Independent Director, all of whom are free from any vested interest in the Company. The independence of the respective Independent Directors is duly verified during their nomination and appointment process, and they remain committed to upholding such independence throughout their tenure of office.



Role of Independent Directors

Chairman of the Board

The Chairman of the Company is elected by the Board of Directors. The Board recognizes the Chairman as an independent and Non-Executive Director.

Role of the Chairman


The principal responsibility of the Chairman is to ensure that the Board functions effectively in determining and executing the Company's strategic direction and objectives. Upon the recommendation of the NRC, the Board approved the roles and responsibilities of the Chairman. The key responsibilities of the Chairman include the following:

- Providing leadership to the Board;
- Assuming responsibility for the Board's composition and development;
- Ensuring the availability of adequate and timely information for the Board;
- Planning and conducting Board meetings efficiently and effectively;
- Encouraging active participation of all Directors in Board activities;
- Ensuring the Board remains focused on its core responsibilities;
- Leading the Board in evaluating and enhancing its performance;
- Supervising the induction, orientation, and development of Directors; and
- Extending guidance and support to the Managing Director.

Annual Assessment of the Board's Performance and Disclosure

Evaluating the performance of the Board helps define the individual and collective duties and responsibilities of the Directors, while enhancing their understanding of the expectations associated with their roles. Such evaluations contribute to strengthening the effectiveness of the Board and fostering a more productive relationship between the Board and the Management of The IBN SINA Pharmaceutical Industry PLC.

The Board formulates policies, establishes implementation guidelines, reviews the effectiveness of adopted policies, and provides recommendations for corrective measures whenever deemed necessary. Through this process, the Board assesses whether the intended objectives are being achieved efficiently within the expected timeframe and through the optimum utilization of resources. The Directors have consistently exercised prudent and constructive judgment in the best interests of the Company, and their contributions and performance have been duly evaluated and acknowledged.



Process for Improving the Effectiveness of the Board of Directors

Annual Evaluation of the Managing Director by the Board

The Board of Directors conducts an annual evaluation of the Managing Director based on performance assessment criteria recommended by the Nomination and Remuneration Committee and subsequently approved by the Board. The evaluation is carried out against the goals and objectives established at the beginning of each year in alignment with the Company's vision and mission. During the appraisal process, the Board considers both financial and non-financial performance indicators.



The criteria are considered for the evaluation

Training and Development of the Board

The Board recognizes the importance of continuous professional development to strengthen the knowledge, expertise, and competencies required for the effective discharge of Directors' responsibilities. All newly appointed Directors participate in a structured orientation programme designed to familiarize them with the Company's strategic objectives and aspirations, business operations, corporate functions, key financial highlights, audit processes, compliance requirements, and risk management framework.

Financial and Accounting Knowledge and Expertise of the Directors

The Board of Directors of The IBN SINA Pharmaceutical Industry PLC comprises individuals with extensive expertise and diverse professional backgrounds in finance, economics, management, business administration, marketing, law, and other critical business disciplines. This collective experience enables the Board to formulate sound strategic policies for sustainable business growth, while ensuring balanced oversight of Management through independent judgment and broad-based perspectives.



Bangladesh Secretarial Standard (BSS)

The Company conducts its Board meetings, records meeting minutes, and maintains all statutory books and records in compliance with the provisions of the Bangladesh Secretarial Standards (BSS) adopted by The Institute of Chartered Secretaries of Bangladesh and notified by Bangladesh Securities and Exchange Commission.

Whistle Blowing Policy

The Whistle Blowing Policy of The IBN SINA Pharmaceutical Industry PLC is designed to uphold transparency and accountability across all operational activities, while strengthening risk management practices and facilitating the detection and prevention of fraud, forgery, embezzlement, or any unethical conduct.

Board and Committee Meetings

The composition of the Board and its sub-committees as of 30 June 2026, together with the attendance record of the Directors at the Board and sub-committee meetings conducted during the year 2025-26, is disclosed below.

Attendance At Board Meeting

Name of Directors	Position	Number of Meeting	
		Eligible to Attended	Attended
Kazi Harun or Rashid	Chairman	9	9
Prof. ANMA Zaher	Director	9	9
Prof. Dr. A K M Sadrul Islam	Managing Director	9	8
Prof. Dr. Choudhury Mahmood Hasan	Director	9	9
Dr. Mohammad Ayub Miah	Director	9	8
Prof. Col. (Retd.) Dr. Zehad Khan	Director	9	7
Abdus Sadeque Bhuiyan	Independent Director	9	9
Md. Rafiqul Islam Khan, FCA	Independent Director	9	9
Ms. Parsa Begum	Independent Director	9	9

In Attendance

Md. Kabir Hossain	Company Secretary	9	9
Md. Jasim Uddin, FCA	Chief Financial Officer	9	9
Sayed Amimul Ihsan, FCS	Head of Corporate Affairs	9	9
Md. Abdur Rakib	Head of Internal Audit and Compliance	9	9

Audit Committee

The Board has constituted an Audit Committee comprising three (3) members possessing diversified professional expertise and sound financial knowledge in accordance with the directives of the Bangladesh Securities and Exchange Commission (BSEC), duly approved by the Board. The Committee is entrusted, among other responsibilities, with reviewing matters related to the financial affairs of the Company, overseeing audit activities, internal control and inspection mechanisms, internal policies, and ensuring compliance with applicable regulatory requirements. During the year 2025-26, the Committee held seven (7) meetings.

Comprehensive information regarding the Audit Committee, including its background, composition, responsibilities, meetings, reporting framework, and activities performed during the year, is presented under the section titled "Report of the Audit Committee" on page no. 158 of the Annual Report.



Nomination and Remuneration Committee

To strengthen and uphold sound corporate governance practices within the Company, the Nomination and Remuneration Committee (NRC) was established as a sub-committee of the Board in compliance with the Corporate Governance Code issued by the Bangladesh Securities and Exchange Commission (BSEC). The Committee consists of three Directors, including two Independent Directors. The required number of meetings was duly held during the year 2025-26.

The NRC supports the Board in developing nomination criteria and policies relating to the qualifications, competencies, positive attributes, and relevant experience required for the Company. The Committee also assists the Board in formulating policies concerning the structured and continuous determination of remuneration and honorarium for Directors, Executive Directors, and senior management personnel.

The Report of the Nomination and Remuneration Committee is presented on page no. 164 of the Annual Report.

Remuneration of Chairman and the Directors

The Chairman of the Company serves in a non-executive capacity and therefore does not receive any remuneration from the Company. Executive Directors, including the Managing Director, are remunerated in accordance with the recommendations of the NRC and subsequent approval of the Board.



Executive Committee

The Executive Committee (EC) comprises three (3) Directors nominated by the Board to exercise such authority and perform such functions as delegated by the Board in accordance with the Service Rules of the Company. The Company Secretary acts as the Secretary to the Executive Committee. During the year 2025-26, a total of ten (10) Executive Committee meetings were held.

Other Operational Committees

The Managing Director carries out his duties and responsibilities with the support of a dynamic and competent management team, along with a number of operational committees comprising skilled and experienced senior officials. These committees' function under the direct supervision and guidance of the Chief Executive and Managing Director of The IBN SINA Pharmaceutical Industry PLC. The company's performance evaluation process is closely aligned with a strategic action plan designed to achieve the annual targets set by the Board of Directors.

The operational committees are as follows:

1. Development Planning and Monitoring Committee;
2. Quality Assurance Committee;
3. Marketing Coordination Committee;
4. Construction Committee;
5. Budget Monitoring Committee;
6. New Product Monitoring Committee;
7. Disciplinary Committee;
8. Factory Technical Committee;
9. Extended Purchase Committee;
10. Factory Tender and Quality Evaluation Committee;
11. Inventory Management Committee;
12. Risk Management and Control Committee;
13. CBA Dealing Committee.

Company Secretary

Md. Kabir Hossain serves as the Company Secretary of the Company. He possesses extensive and diversified professional experience spanning over 40 years in various fields. He holds a BSc (Hons) and MSc in Chemistry from the University of Dhaka. The Board of Directors has clearly defined his roles, responsibilities, and duties as Company Secretary.

Chief Financial Officer

Md. Jasim Uddin FCA, serves as the Chief Financial Officer (CFO) of The IBN SINA Pharmaceutical Industry PLC. He is a Fellow Member of the Institute of Chartered Accountants of Bangladesh (ICAB). He is responsible for overseeing the Accounts and Financial Management functions of the Company. The Board of Directors has clearly defined his roles, responsibilities, and duties.

Head of Internal Audit and Compliance

Md. Abdur Rakib, the Head of Internal Audit and Compliance (HIAC), has completed the Professional Level of the Institute of Chartered Accountants of Bangladesh (ICAB). The Board of Directors has clearly outlined his roles and responsibilities in accordance with the recommendations of the Audit Committee.

Internal Audit and Compliance

The Company recognizes Internal Audit and Compliance as a key and ongoing functional pillar of its governance framework. An independent Internal Audit and Compliance Department operates within the organization under the administrative supervision of the Managing Director. The Audit Committee of the Board provides oversight and guidance over the activities and performance of this department.

Maintaining a Website

The Company maintains an official corporate website (www.ibnsinapharma.com), which is also integrated with the websites of the stock exchanges—Dhaka Stock Exchange PLC (DSE) and Chittagong Stock Exchange PLC (CSE). In compliance with the requirements of the Bangladesh Securities and Exchange Commission (BSEC), the Listing Regulations, 2015 of DSE PLC and CSE PLC, the Company ensures that all material disclosures and required information are duly published and updated on its website.

Corporate Social Responsibility (CSR) Policy

With a view to strengthening good governance practices, the Board of Directors has approved a comprehensive Corporate Social Responsibility (CSR) Policy, aligned with globally accepted best practices. For effective implementation of CSR activities, a dedicated CSR Committee has been constituted by the Board, which carries out its responsibilities in accordance with the approved CSR Policy.

The Company is committed to conducting its business in a socially responsible and ethically sound manner by:

- Upholding environmental protection and ensuring the safety and well-being of people;
- Engaging with, learning from, respecting, and supporting the communities and cultures in which it operates;
- Promoting and safeguarding human rights while maintaining strong relationships with stakeholders and employees.

Through its products and corporate values, the Company strives to enhance the quality of human life and contribute to overall well-being, making people feel satisfied and happy in line with its CSR strategy, which serves as an effective instrument for sustainable business success. The principal components of CSR practices adopted by the Company are detailed on page no. 129 of the Annual Report.

Report of the Audit Committee

For the year ended 30 June 2026

The IBN SINA Pharmaceutical Industry PLC has established an independent Audit Committee in accordance with the Corporate Governance Code of the Bangladesh Securities and Exchange Commission (BSEC) dated June 03, 2018. The scope of the Committee is determined by its Terms of Reference (ToR), which, in turn, are shaped by the BSEC Code of Corporate Governance. These include, but are not limited to, exercising surveillance over: Internal control system of the Company, Financial reporting and risk management, Internal Control and Compliance department, and Compliance with regulatory requirements. The Committee is one of the Company's foremost committees. The Audit Committee assists the Board in ensuring that the financial statements present a true and fair view of the Company's affairs and maintains a robust financial monitoring and surveillance system. The Committee's responsibilities are documented clearly and reported to shareholders and stakeholders through this report. The Chairman of the Audit Committee attends all General Meetings to address queries regarding its activities.



Feature and Composition

The Audit Committee Acts as a statutory committee of the Board. All members of the Audit Committee are suitably qualified and expert knowledgeable of finance and accounting including pharmaceutical activities. The Audit Committee functions with the specific guidelines issued by the Regulatory bodies: BSEC, FRC, RJSC, DSE and the CSE including internal policy and procedures. Its formation and functions are aligned with these guidelines. During the financial year 2025-26, Seven (7) meetings of the Audit Committee were held. The composition of the Audit Committee and the Attended of the Members are given below:

Name of Members	Designation	Position	Number of meetings held while a member	Number of meetings attended
Md. Rafiqul Islam Khan FCA	Independent Director	Member & Chairman	7	7
Abdus Sadeque Bhuiyan	Independent Director	Member	7	7
Dr. Mohammad Ayub Miah	Director	Member	7	5

Chief Financial Officer (CFO) and the Head of Internal Audit and Compliance (HIAC) always attended the meeting on invitation to meet instant queries of the Audit Committee. In addition, Heads of different Departments whose audit reports were placed to the Audit Committee were also present in the meetings to respond to the issues derived from the reports of Internal Audit and Compliance Department.

Terms of Reference of the Audit Committe

1) The Board shall appoint Non-Executive Directors of the IPI, excluding the Chairman of the Board, as members of the Audit Committee;

2) Members of the committee may be elected for a term of 03 (three) years;

3) The Chairman of the Audit Committee shall be elected from among the independent directors;

4) Md. Rafiqul Islam Khan FCA, serving as the Independent Director, shall assume the role of Chairman of the Audit Committee;

5) The term of office of the Chairman of the Audit Committee shall be 03 (three) years. No independent director shall serve as Chairman of the Audit Committee for two consecutive terms;

6) A quorum for the Audit Committee meeting shall be formed in presence of 02 (two) members;

7) The quorum for the Audit Committee meeting necessitates the presence of at least one Independent Director;

8) The tenure of office for the Audit Committee members shall be 03 (three) years;

9) The Company Secretary shall serve as the Secretary to the Audit Committee; and

10) The Chairman of the Audit Committee is required to be present at the Annual General Meeting (AGM).

Charter of the Audit Committee

The Audit Committee is constituted by the Board of Directors for the primary purpose of assisting the Board in: Overseeing the integrity of the company's financial statements. Overseeing the improvement of corporate governance standard of the company. Overseeing the Company's system of disclosure, internal controls and procedures. Overseeing IPI's internal control over financial reporting. Overseeing IPI's compliance with ethical standards adopted by IPI. Making reports and recommendations to the Board.

Roles and Responsibilities

The role of the Audit Committee is to assist the Board in discharging its duties and responsibilities for financial reporting, effective monitoring, corporate governance, internal control. The added roles of the Audit Committee include, but not limited to the following:

i) Internal Control

a)Reviewing statements of significant party transactions submitted by the management.

b) Reviewing Management Letters/ Letter of Internal Control Weakness issued by Statutory Auditors.

c) Monitoring internal control process.

ii) Financial Reporting

a) Overseeing the financial reporting process.

b) Monitoring choice of accounting policies and principles.

c) Reviewing the Annual Financial Statements before submission to the Board for approval or adoption.

d) Reviewing the quarterly and half-yearly Financial Statements before submission to the Board for approval.

e) Reviewing the Financial Statements, in particular the investments made by the subsidiary company.

f) Reviewing the Management's Discussion and Analysis before disclosing in the Annual Report.

iii) Internal Audit

a) Reviewing the adequacy of internal audit functions;

b) Monitoring Internal Audit and Compliance process including approval of Internal Audit plan; and

c) Reviewing the Internal Audit Report and Compliance thereof.

iv) Compliance with existing laws and regulations

a) Maintaining oversight on regulatory compliance, ethics and whistle-blower hotlines;

b) Reviewing the compliance status of the Minutes of the Audit Committee Meeting;

c) Reviewing Audit Committee's own terms of reference; and

d) Reviewing fund raising through Repeat Public Offering/ Rights Issue and its use and application.

Coordination with the External Auditor

a) Overseeing hiring and performance of external auditors;

b) Overseeing the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;

c) Meeting with the representatives of the External Auditors to review of the Annual Financial Statements before submission to the Board for perusal and recommendation; and

d) Reviewing the findings and recommendations raised by the external auditors for remedy of recurrence of irregularities.

The role of internal audit and compliance

The role of the internal auditor has expanded in recent years as internal auditors seek to monitor all aspects (not just accounting) of organizations and add value to their employers.

Examination of financial and operating information

a) Reviewing of the means used to identify, measure, classify and report such information and specific enquiry into individual items including detailed testing of transactions, balances and procedures.

b) Reviewing of the economy, efficiency and effectiveness of operational activities;

c) Reviewing of compliance with laws, regulations and other external obligations and with internal policies and directives and other requirements including appropriate authorization of transactions;

d) Reviewing of the implementation of corporate objectives. This includes review of the effectiveness of planning, the relevance of standards and policies, the organization's corporate governance compliance procedures and the business operation of specific procedures, etc.

e) Identification of significant business and financial risks, monitoring the organization's overall risk management policy to ensure effective operation, and monitoring the risk management strategies to ensure continuity of business operation effectively.

Activites of the Audit Committee during 2025-26

During the year 2025-26, the Audit Committee carried out its regular functions on the areas pertaining to its responsibilities. Some of the issues that are performed during the year under review for improvement of operational performance of the Company are listed below:

Reviewing related party transactions

The Committee examined all related party transactions for compliance with the Company's policies and regulatory requirements. It ensured that all transactions were conducted at arm's length and properly disclosed in the financial statements. No material irregularities or unapproved transactions were identified.

Reviewing and ensuring internal control and risk management

The Committee evaluated the adequacy and effectiveness of internal controls, risk management, and governance processes. Focus areas during the year included:

- The Committee reviewed the Company's risk management and corporate governance framework, ensuring effective identification, analysis, assessment, and communication of risks in a regular and timely manner.
- Compliance with internal policies, standards and procedures was evaluated.
- Assurance was obtained that proper controls were in place before major changes within the Company.

Reviewing Management's Discussion & Analysis (MDA)

The Committee reviewed MDA and operational performance, key business drivers, financial ratios and future outlook as presented in the quarterly and annual management discussion papers. It noted management's continued focus on improving operational efficiency, cost management, and cash flow stabilization.

Reviewing Financial Statements and Financial Position

a) The Audit Committee reviewed the Consolidated Financial Statements of The IBN SINA Pharmaceutical Industry PLC for the year 2025-26, which include Statement of Financial Position, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows and Notes to the Financial Statements;

b) The Audit Committee also reviewed the Financial Statements of the Subsidiary Companies: The IBN SINA Natural Medicine Ltd., The IBN SINA API Industry Ltd. and The IBN SINA Polymer Industry Ltd. for the year 2025-26;

c) The quarterly, half-yearly and annual financial results of The IBN SINA Pharmaceutical Industry PLC reviewed and the relevant announcements made to the regulatory authorities, like BSEC and Stock Exchanges by the Board of Directors;

d) The quarterly, half-yearly and annual financial statements of the subsidiary Company's- The IBN SINA Natural Medicine Ltd., The IBN SINA API Industry Ltd. and The IBN SINA Polymer Industry Ltd. were duly reviewed by the Committee prior to submission to the Board of Directors for approval;

e) Audit Committee reviewed the quarterly and annual financial statements of the Company with the Finance Director and the Managing Director before recommending them to the Board of Directors for approval. The Committee also concluded that the financial statements presented a true and fair view of the Company's financial position as well as the performance as a whole;

f) The Committee recommended for approval of the Annual Financial Statements of the Company to the Board;

The Audit Committee held meeting with External Auditor for Review of Financial Statements

a) The Committee recommended for appointment as External Auditors of Malek Siddiqui Wali & Co, Chartered Accountants for the Statutory Audit of The IBN SINA Pharmaceutical Industry PLC and its subsidiaries;

b) The activities were persuaded as approved Annual Audit Calendar of the Company for the year 2026-27;

c) The Audit Committee reviewed the Company's yearly budget before submission to the Board for final review and approval;

d) The Audit Committee reviewed the yearly internal audit activities (Audit Report), audit process and effectiveness of internal audit and compliance;

e) The Audit Committee reviewed the Auditor's Certification on Corporate Governance Compliance for the year ended 30 June 2026;

f) The Audit Committee reviewed and ascertained that the internal control system including financial and operational controls, accounting system, and reporting structure are adequate and effective;

g) The Audit Committee reviewed the periodical reports submitted by the internal auditors and recommended to the management regarding proper and prompt resolution of the irregularities/issues stated therein;

h) The Audit Committee reviewed the actions taken by the management for implementation of Audit Committee observations on the issues deliberated in the Audit Committee reports;

i) The Committee placed its reports regularly to the Board for review and monitoring the activities recommended on internal control system, compliance with rules and regulations of the regulatory bodies;

j) Discussed and opined on the status of the Risk Management Process (RMP) and the Company's business Continuation as a going concern;

k) Audit Committee reviewed reports of related party transactions and possible conflicts of interest;

l) Reviewed the findings of internal audit team and suggest its corrective actions;

m) Assessed the findings of external auditors and compliance of IAS and IFRS for preparation of Financial Statements;

n) Based on the above review and discussion, the Audit Committee is of the view that the internal control and compliance procedures are adequate to present a true and fair view of the activities and financial status of the Company;

o) Reviewed that the adequate internal control system of the company is in place; and

p) Reviewed the compliance requirements of Bangladesh Securities and Exchange Commission (BSEC) guidelines, RJSC, DSE, CSE notifications and other regulatory laws applicable for the company. Audit Committee expressed their sincere thanks to all members of the Board, team of Internal Audit and Compliance, team of Accounts & Finance and the Management of the Company for their active supports.

Reporting to Shareholders and General Investors

It reports to the shareholders and other interested parties on annual basis by means of presenting a summary of its activities in the form of 'Audit Committee Report'. During the year under review, the committee met seven (7) times to discharge its duties and responsibilities and accordingly, forwarded their reports to the Board. The Board's view is that no other issues had a significant material impact on the company's Financial Statements, which needed to be disclosed to the Board or the regulatory authorities.

Appreciation

The Audit Committee wishes to express its deep appreciation to the Board members, management, statutory auditors and internal auditors for their steadfast support and collaboration, which have been crucial in facilitating the effective fulfilment of its duties and responsibilities and recommendations made during the financial year to improve the system of internal control derived from the findings of the internal and external auditors, and from the consultations of the Audit Committee itself.

On behalf of the Audit Committee



Md. Rafiqul Islam Khan FCA
Chairman, Audit Committee
Wednesday, September 30, 2026

Nomination and Remuneration Policy and Evaluation Criteria

[As per condition no. 6 (5) (c) of the Corporate Governance Code]

As per condition no. 6(5) (b) of the Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) vide its Notification No. BSEC/CMRRCD/2006-158/207/Admin/80: 3 June 2018, the Nomination and Remuneration Policy (duly approved by the Board as recommended by NRC) regarding nomination and remuneration of the directors, top level executives in formulating the criteria for :-

- Determining qualifications, positive attributes and independence of the Directors.
- Evaluation of performance of independent directors and the Board.

Overview of the Nomination and Remuneration Policies:

The Company inevitably will follow the nomination and remuneration policies and the benchmark of which pursuing the business code of conduct and standards perceptible in the market context and appropriate to meet the present and future needs of the Company. The broad criteria in this respect for the Directors and Top-Level Executives of the Company are as follows:

a) Nomination Criteria

i. The Company policies as well as guidelines and applicable laws/regulations for the Company;

ii. A prescribed selection process that is transparent in all respects;

iii. Following a process which is compatible to the recognized standards and the best practices;

iv. Distinguishing the core competencies of the respective personnel for the different level of management and employees of the Company;

v. Follow diversity in age, maturity, qualification, expertise and gender disciplines.

b) Recruitment and Selection Standards

The outline of the Company needs for the employees at different levels, as determined by the management. The recruitment and selection of Directors, Top-level Executives and other Employees of the Company are made according to the following core guiding principles: Top Level Executives/Executive Directors: The candidate(s) for Executive Director(s), based on the set criterions of BSEC and Service Rules of the Company. The Board of Directors appoints the top Level Executives, Executive Director(s) upon nomination and recommendation of the NRC.

Independent Director: The Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws that can make meaningful contribution to the businesses. The Independent Director should have competence of the relevant sector in which Company operates, and necessarily should have the qualifications as required by the Code of BSEC. The Board of Directors appoints Independent Directors upon nomination and recommendation of the NRC, which is then approved by shareholders at the Annual General Meeting of the Company.

c) Remuneration Criteria

The key features of the Remuneration Criteria recommended by the NRC are as follows:-

i. The structure, scale and composition of remuneration/ honorarium are reasonably considered based on the Company's Policies and Guidelines set by the Board of Directors to attract, retain and motivate the top level executives/executive directors to run the Company efficiently and successfully;

ii. The context of packages, including remuneration/ benefits is categorically laid down which meets the appropriate performance benchmarks as per the Company Policies and Guidelines ratified by the Board as and when required;

iii. The NRC will recommend the Board meeting attendance fees, honorarium, including incidental expenses, if any; and

iv. No member of the NRC will be allowed to receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Board meetings and Board's sub-committee meetings attendance fees from the Company.

d). Evaluation Criteria

Directors/Executive Directors/Top Level Executives: The respective line authority of the Directors/Executive Directors/Top Level Executives sets the performance measurement criteria based on the respective role profile and responsibilities through the Company's annual appraisal policy/process at a certain time of each calendar year.

Independent Director and the Board: The evaluation of performance of the Independent Directors (IDs) is to be carried out according to the criteria of attendance and participation at the Board meetings and committee meetings; participation in the Board meetings and committee meetings and contribution to the improvement of the corporate governance practices of the Company.

Nomination and Remuneration Committee (NRC) Report

(For the year ended 30 June 2026)

Nomination and Remuneration Committee (NRC) is working as per the requirements of the Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) issued on 03 June 2018. In compliance with the Corporate Governance Code, 2018, the Board constituted the Nomination and Remuneration Committee (NRC). NRC as a Sub-Committee of the Board formed to assist the Board in formulating the nomination criteria or policy for determining qualifications, positive attributes, experiences, independence of Directors, Executive Directors and Functional Directors. The NRC also assists the Board to formulate policy for formal and continued process of considering remuneration of Executive Directors and Directors.

Composition of the Committee

Nomination and Remuneration Committee is constituted comprising of the following members:

Abdus Sadeque Bhuiyan Independent Director	Chairman
Prof. Col. Dr. Zehad Khan (Retd.) Non-Executive Director	Member
Ms. Parsa Begum Independent Director	Member
Md. Kabir Hossain Company Secretary	Secretary

The Nomination and Remuneration Committees' jurisdiction, responsibilities and the duties are guided by the Terms of References (ToR) as specified by the Board of Directors as per Corporate Governance Code of BSEC.

Meeting and Attendance

Three NRC meetings were held during the year 2025-26. The attendance of the meeting has duly been recorded and the members who could not attend the meeting were granted leave of absence.

Overview of the Nomination and Remuneration Policies

Nomination and Remuneration Committee recommended in formulation of Nomination and Remuneration Policy which was duly approved by the Board. The Company follow the nomination and remuneration policies and the benchmark pursuing the business code of conduct and standards perceptible in the market context and appropriate to meet the present and long term strategic management needs of the Company. This Policy also covers the Nomination Criteria, Recruitment and Selection Standards, Remuneration Criteria and Evaluation Criteria.

Key Responsibilities of NRC

a. Nomination and Remuneration Committee is an independent Sub-Committee of the Board and hence discharging its activities being responsible and accountable to the Board and to the Shareholders;

b. NRC discharges its responsibilities and oversees the functions specified in the Terms of Reference approved by the Board in line with the BSEC's Code of Governance, 2018.

Activities of the NRC performed during the year, 2025-26

The NRC carried out the following activities during the reporting period:

i. Considered the Terms of Reference (ToR) of NRC, approved by the Board of Directors;

ii. Reviewed the matter of appointment and reappointment of Executive Directors of the Company.

iii. Reviewed the matter of contractual tenure and services of functional and Executive Directors and revision of their remuneration.

iv. Reviewed and recommended the requirement of a Succession Planning for the key Position of the Company for proper acceleration and smooth operation in the future days.



Abdus Sadeque Bhuiyan
Chairman, NRC
Wednesday, September 30, 2026



Code of Conduct for the Board

Code of Conduct for Board Members (Chairman, other Board Members and Managing Director) of The IBN SINA Pharmaceutical Industry PLC on the Duties and Responsibilities, Conflict of Interest and Confidentiality, Compliance with the Laws, Rules and Regulations.

As per Condition no. 1(7)(b)of BSEC Notification no-BSEC/CMRRCD/2006-158/207/Admin/80 dated June 03, 2018 on Corporate Governance Code, based on the recommendation of the Nomination and Remuneration Committee (NRC), the Board of Directors of the Company has laid down a code of conduct for the Chairman, Board Members and Managing Director of the Company including among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.

I. Introduction

The Board of Directors hereby establishes its Code of Conduct to provide guidance to its members regarding prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.

Compliance with the provisions of this Code will allow the Board to fully implement its Governance Manual; to enhance relationships and foster teamwork among the Board members and also with staff; and to build respect, confidence, and credibility with the stakeholders and shareholders at large.

II. Standards of Conduct and Code of Ethics

Each Board Member shall adhere to the following Code of Conduct and Ethics:

1. The Directors shall maintain high ethical and moral character, both professionally and personally, so that their behavior will reflect positively upon the Board of The IBN SINA Pharmaceutical Industry PLC.

2. Members of the Board shall use proper care and exercise independent professional judgment and competence in the performance of their duties.

3. The Board shall maintain confidentiality about all matters that are considered in the meetings.

4. It is required to be familiar and comply with the provisions of the Companies Act., 1994. In addition to such compliance, Board members to be aware of the "Conflict of Interest" contained in the Companies Act, 1994.

5. None of the Directors will have private contracts or business dealings with any Department of the Company.

6. The Board shall exercise due diligence to avoid breaches of duty and/or obligations.

7. Board's decisions and actions are to be based on integrity, competence, and independent judgment on the merits and benefits to the stakeholders/shareholders of the Company.

8. Board Member will play full and active role in the work of the Company to fulfill their duties and responsibilities responsibly and at all times, act in good faith and in the best interests of the Company.

9. The dealings of the Board with the public and their affairs should be to the best of their ability.

10. Board Members will strive to cultivate and maintain good relations with the Shareholders, Customers and Employees as set forth in the Code.

11. It has the duty to ensure the safeguarding of funds and the assets of the Company.

12. The Directors must carry out their fiduciary obligations responsibly that is, take appropriate measures to ensure that the Company uses resources efficiently, economically and effectively, avoiding waste and extravagance.

13. Board Member who misuse information gained by virtue of their position may be liable for breach of contract under the Companies Act, 1994 (Amendment 2020) and/or insider dealing legislation.

14. The Directors must comply with the Service Rules of the Company and relevant rules and regulations applicable for the Company.

III. Duties and Responsibilities of Directors

A Director is responsible to:

1. Carry out his/her fiduciary duties with a sense of objective judgment and independence in the best interests of the Company and Stakeholders as a whole.

2. Perform his duties in an independent and objective manner and avoid activities that may impair, or may appear to impair, their independence or objectivity or official responsibilities.

3. Be informed of the Memorandum and Articles of Association of the Company, its mission, vision, values, policies and codes of conduct as they pertain to the duties of a Director;

4. Attend Board meetings regularly, serve on committees of the Board as appointed and contribute from personal, professional and life experience to the deliberations of the Board;

5. Exercise due care and diligence in the performance of his / her duty and employ his/her skills pursuant to applicable laws and objectives of the Company;

6. Be independent and impartial in giving advice and in expressing views on any issue which comes up for consideration and/or decision of the Board.

7. Not be influenced by self-interest, outside pressure, expectation of reward or fear of criticism;

8. Act with honesty and integrity and conduct himself / herself in a manner consistent with the nature of the responsibilities and the maintenance of public confidence in the conduct of the Board's business;

9. Voice clearly and explicitly, at the time taking a decision any contrary view to a decision being considered by the Board;

10. Maintain solidarity with fellow Directors in support of a decision that has been made in good faith in a legally constituted meeting, by Directors in reasonably full possession of the facts;

11. Request review of a decision, if she/he has reasonable grounds to believe that the Board has acted without full information or in a manner inconsistent with its fiduciary obligations;

12. Allow the executives of the Company to independently discharge their functions in conformity with the underlying governance practices;

13. Comply with all other codes and policies approved by the Board from time to time.

14. The Directors shall unless otherwise required by law, maintain confidentiality and shall not divulge/disclose any information obtained in discharging their duties.

15. For not to use any confidential information for his/her personal gain, directly or indirectly, received or obtained by him in his/her capacity as a member of the Board.

IV. Conflict of Interest

The fundamental relationship between each director and the Company is absolutely based on fiduciary. Essential to trust is a commitment to honesty and integrity. These narrations are intended to ensure the maintenance of the highest standard and integrity of the Board.

The Directors shall put the interests of the Company ahead of any personal interest or the interest of any other person, group or entity. It also means performing his / her duties and transacting the affairs of the Company in such a manner that promotes public confidence and trust in the integrity, objectivity, impartiality and high standard of ethics of the Board.

(1) Definition

(a) A conflict of interest refers to situations in which personal, occupational or financial considerations may affect, or appear to affect, a Director's objectivity, judgment or ability to act in the best interest of the Company.

(b) A conflict of interest may be real, potential or perceived in nature.

(c) A real conflict of interest arises where a Director has a private or personal interest.

(d) A potential conflict of interest may arise when a Director has a private or personal interest such as an identified future commitment.

(e) A perceived or apparent conflict of interest situation in one where a person of ordinary prudence has reason to doubt or believe that a Director has a conflict of interest.

(f) Full disclosure, in itself, does not remove a conflict of interest unless the Board, having analyzed the disclosed facts, considers the conflict neither material nor of any significance.

(2) Pecuniary Advantage

(a) No Director shall directly or indirectly receive any profit from his / her position as such, provided that the Directors may receive reasonable payments for their services and reimbursement for reasonable expenses incurred by them in the performance of their duties.

(b) The pecuniary interests of immediate family members (including the immediate family members of a Director's spouse) or close personal or business associates of a Director are also considered to be the pecuniary interests of the Director.

(3) Principles for Dealing with Conflict of Interest

(a) Both prior to serving on the Board and during the term of office, each Director must openly disclose a potential, real or perceived conflict of interest sooner the any matter of conflict arises and/or come into the knowledge.

(b) If a Director is not assured whether she/he is in a conflict of interest situation, the matter may be brought to the attention of the Chairman of the Board for advice and guidance empathetically.

(c) If there is any question or doubt about the existence of a real or perceived conflict, the Board will determine by majority vote if a conflict exists. The concerned Director potentially in conflict of interest shall withdraw from the meeting when the Board discusses the issue.

(d) The disclosure and decision as to whether a conflict exists shall be duly recorded in the minutes of the meeting.

V. Confidentiality

It is the responsibility of Directors to know what information is confidential and to obtain clarification when in doubt. Except as he/she may be compelled by applicable legal process, a Director must, both while having and after ceasing to have that status, treat as confidential all information regarding the policies, internal operations, systems, business or affairs of the Company obtained by reason of his / her status as a Director and not generally disclosed to the public. A Director shall not use information obtained in his/her capacity as a Director for personal benefit. Each Director shall avoid activities which may create appearances of availing benefit from confidential information received as a Director.

VI. General Provisions

1. Board of Directors shall govern the Company within the purview of the Memorandum of Association (MOA) and Articles of Association (AOA) of the Company.

2. The Board must operate the Company in accordance with the rules set forth in the Service Rules of the Company and the decision taken by the Board and the Shareholders in General Meeting time to time.

3. The Board must comply with the Companies Act, Corporate Governance Code of BSEC, the Rules and regulations, Directives and Notifications given / issued / promulgated by the concerned regulatory bodies of the Country.

4. The provisions of this policy/code do not excuse any Board member from other restrictions of state or company law regarding conflicts of interest.

5. Any breach of this Code of Conduct and Ethics shall be reported to the Audit Committee. The Committee will investigate as appropriate and report its findings and recommendations to the Board and if feels expedient may place the same to the Shareholders in General Meeting.



The IBN SINA Pharmaceutical Industry PLC

Declaration by Managing Director and Chief Financial Officer

September 30, 2026

The Board of Directors
The IBN SINA Pharmaceutical Industry PLC
Tanin Center, 3 Asad Gate, Mirpur Road
Mohammadpur, Dhaka-1207.

Subject: Declaration on the Financial Statements of the Company for the year ended June 30, 2026

Dear Sirs,

Pursuant to the condition No. I(5) (xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006-I58I207IAdmin/80, Dated: 3 June 2018 under Section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

1. The Financial Statements of The IBN SINA Pharmaceutical Industry PLC for the year ended on 30th June 2026 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;

2. The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;

3. The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;

4. To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;

5. Our internal-auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and

6. The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that: -

(i) We have reviewed the financial statements for the year ended on 30th June, 2026 and that to the best of our knowledge and belief:

a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

b) These statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws,

ii) There are, to the best of knowledge and belief no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

Prof. Dr. A K M Sadrul Islam
Managing Director

Md. Jasim Uddin FCA
Chief Financial Officer

Statement of Directors' Responsibilities for Financial Report

The Directors are responsible for ensuring that the Company keeps proper books of accounts of all the transactions and the financial statements for the period from July 01, 2025 to June 30, 2026 and gives a true and fair view of the state of affairs and profit for the year.

The Directors also ensure that the financial statements have been prepared and presented in accordance with the International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS) as adopted by Financial Reporting Council, Bangladesh and provide the information as required by the Companies Act 1994 (Amended in 2020), Bangladesh Securities and Exchange Ordinance 1969, Bangladesh Securities and Exchange Commission Rules 1987 and The Regulations, 2015 of the Dhaka Stock Exchange PLC and Chittagong Stock Exchange PLC.

It ensures that the estimates and judgments relating to the financial statements were made on a prudent and reasonable basis, so that they reflect in a true and fair manner and reasonably present the Company's true state of affairs.

The Company has taken proper and sufficient care in installing a system of internal control, which is reviewed, evaluated and updated on regular basis. To augment those objectives, the Board of Directors has formed an Audit Committee as per code of Governance of Bangladesh Securities and Exchange Commission (BSEC). They have performed their responsibilities without any undue interference from any of the Directors.

Internal Audit and Compliance Department of the Company conducts periodic audits to provide reasonable assurance that the established policies and procedures of the Company are consistently followed.

The Company has adequate resources to continue operational existence for the foreseeable future and therefore, has continued to adopt the going concern basis in preparing the Accounts.

The Board of Directors confirms that International Accounting Standards, as adopted in Bangladesh by the Institute of Chartered Accountants of Bangladesh, have been adhered to, subject to any material departure being disclosed and explained in the notes to the accounts.

The Directors also confirm that the annual reports together with the Directors' Report and the Financial Statements Consolidated and solo have been prepared in compliance with the law, rules and regulatory guidance applicable for the Company.

The Auditors of the Company, Malek Siddiqui Wali Chartered Accountants, had carried out the Annual Audit to review on the system of internal controls, as they consider appropriate and necessary, for expressing their opinion on the financial statements. They have also examined the financial statements made available by the management together with all the financial records, related data and Minutes of the Board, relevant policies and expressed opinion thereon.



Prof. Dr. A K M Sadrul Islam
Managing Director



Md. Kabir Hossain
Company Secretary

Dividend Distribution Policy

In compliance with the Directive No. BSEC / CMRRCD / 2021-386 / 03 dated 14 January, 2021 of the Bangladesh Securities and Exchange Commission (BSEC), the Board of Directors of The IBN SINA Pharmaceutical Industry PLC ("IBN SINA Pharma" or the "Company") has formulated The Dividend Distribution Policy about dividend declaration, pay off, disbursement and compliance and disclosed the same publishing this statement as a guiding framework for the shareholders in the company's annual report and official website.

This statement provides a brief outline of the legal and regulatory provisions relating to dividend, key issues in dividend considerations and the procedure for the declaration, approval and payment of dividend.

Definitions

"The Act" means The Companies Act, 1994.

"The Company" means The IBN SINA Pharmaceutical Industry PLC.

"AGM" means Annual General Meeting.

"Board" means Board of Directors of The IBN SINA Pharmaceutical Industry PLC.

"Shareholders" means Members whose name is registered in the Member Register (BO holder and Folio holder) of the Company.

"Shares" means Ordinary Equity Shares.

Concept of Dividend

Dividend is the share of the profit payable to the Shareholders of a Company as recommended by the Board of Directors and subsequently approved by the Company in General Meeting to distribute the same among its Shareholders in proportion to the amount paid-up on shares held by the respective Shareholders in the form of Cash and/or Stock (Bonus). No dividend shall be paid otherwise than out of profit of the Company.

Kinds of Dividend

The Act deals with two types of dividend - Interim and Final.

Interim dividend is the dividend declared by the Board being authorized by the Act between two AGMs during any financial year out of the profits/the surplus shown in the Financial Statements.

Final dividend is the dividend derived out of the profits/the surplus shown in the particular year's Financial Statements of the Company which is recommended by the Board and thereafter be approved by the Shareholders at the AGM of the Company. Dividend once recommended by the Board of Directors cannot be changed ahead of the scheduled AGM.

Declaration of Dividend

It is the Company's practice to declare dividend on annual basis based on annual financial performance. However, the Board may also declare interim dividend based on periodic financial results. Historically the Company declared dividend in either cash or stock or in prudent combination of cash and stock.

Key Factors in Dividend Decisions

The circumstances for dividend pay-out decision depends on various external and internal factors while recommending/declaring dividend, the Board of Directors shall consider among others:

External Factors:

- Endeavoring to retain a certain portion of profits to build upthe reserves for future requirements as per norms;
- Evaluating the market trends in terms of technological changes which may require the Company to conserve the resources;
- Considering the restrictions, if any, imposed by the Act and other applicable laws;
- Legal and regulatory compulsion and tax implication of retention and payout;
- Dividend distribution tax or any tax deduction at source as required by tax regulations;

- Any debt/loan covenants restricting dividend announcements; and
- The other factors beyond control of the Management like biographical (caused by pandemic/catastrophic, etc.) matters, natural calamities, etc. materially effecting operations of the Company may also impact the decision about dividend declaration.

Internal Factors

- Company's current net earnings i.e. Profitability of the Company;
- Liquidity of the Funds i.e. accumulated distributable reserves/surplus and availability of free cash flow;
- Capital expenditure requirements for the existing businesses;
- BMRE status (Expansion/Modernization) of the Company;
- Investments in subsidiaries/associate(s) of the Company;
- Cost of raising funds from the alternate sources;
- Cost of servicing outstanding debts;
- Funds for meeting contingent liabilities;
- Mergers and acquisitions;
- Consistency of the dividend over reasonable and foreseeable coming years and also shareholders' perceptions; and
- Any other factors reasonably considered proper by the Board of Directors.

Eligibility of Shareholders for Dividend

Dividend is declared on the face value of each Equity Share. Unless otherwise stated, all the holders of Equity Shares whose names appear on the register of the Company on the Record Date declared by the Company for entitlement of dividend are eligible to get the dividend.

Timing of Dividend Announcement and Payment

The Board of Directors of the Company in its meeting duly held within 120 days from the date of closing of the financial year takes the decision of Annual dividend to be distributed to the entitled Shareholders. Such decisions are based on the results of the audited financial statements. The dividend recommended by the Directors is notified to the Shareholders through stock exchanges, website and public media (printing and digital).

Dividend recommended by the Board is transferred to the dedicated Bank Account approved for the purpose before AGM date.

Directors' recommendations of the dividend are to be placed in the Annual General Meeting of the Company for the Shareholders' approval. Dividend are transferred to the respective Shareholders' account within 30 days from the date of its approval. Interim Dividend if any declared by the Company, are paid within 30 days from the Record Date fixed by the Company for the entitlement of such dividend.

Dividend Compliance Report

Dividend Compliance Report is submitted to the Bangladesh Securities and Exchange Commission (BSEC), Dhaka Stock Exchange PLC (DSE) and Chittagong Stock Exchange PLC within 7 (Seven) days of payment of dividend.

Disclaimer

The above Policy Statement neither gives a guarantee of dividend to be declared by the Company nor does it constitute a commitment for any future dividend and thus be read as a general guidance on different dividend related issues. The policy upholds the Board's absolute/complete liberty to recommend any dividend in deviation of the policy.

Policy Approval and Effective Date

This Policy approved by the Board of Directors of the Company at its meeting held on September 21, 2021 is effective and applicable for dividend, if any, to be declared for the particular Financial Year.

Disclosure

This "Dividend Distribution Policy" and annual "Dividend Distribution Compliance Report" shall be disclosed in the Annual Report of the Company and on the Company's website: www.ibnsinapharma.com.

Review and Amendment

As necessitated by the legal and regulatory requirements and for any other obvious reasons deemed to be pertinent in this regard, the Board may amend, abrogate, modify or revise any or all provisions of this Policy. However, amendments already made and/or to be made in this behalf in the Act or in the Listing Regulations shall be binding even if not incorporated in this Policy.

Unclaimed Dividend information

Cash Dividend	
Particulars	**Amount in Taka**
Dividend for 1993-2022 & 2024-25	64,856,684.58

NB: Unclaimed Cash Dividend from 1992-93 to 2021-22 & 2024-25 Tk. 64,856,684.58 transferred to the Capital Market Stabilization Fund (CMSF).

Cash Dividend	
Particulars	**Amount in Taka**
Dividend for 2022-23	10,966,874.07
Dividend for 2023-24	9,905,202.28
Dividend for 2024-25	7,168,414.03
Total	**28,040,490.00**

Stock Dividend	
Particulars	**Number of Share**
Dividend for 2008-09	173,840
Dividend for 2009-10	187,290
Dividend for 2010-11	297,118
Dividend for 2011-12	297,255
Dividend for 2012-13	177,184
Dividend for 2013-14	98,206
Dividend for 2014-15	205,107
Dividend for 2015-16	102,350
Dividend for 2016-17	233,625
Dividend for 2017-18	258,686
Total	**2,030,661**
Distributed to shareholders from CMSF	**356,143**
Grand Total	**1,674,518**

NB: 2,030,661 number of Bonus Shares as Unclaimed Stock Dividend from 2008-09 to 2017-18 transferred to the Capital Market Stabilization Fund (CMSF).



Internal Control and Risk Management

Risks and Concerns

The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries operate in a dynamic and highly regulated business environment and are exposed to various strategic, operational, financial, regulatory, and compliance risks. The Company manages these risks through an effective risk management framework under the oversight of the Board of Directors and the Audit Committee. Senior Management regularly identifies, assesses, monitors, and mitigates key risks through appropriate policies and internal controls. This approach helps protect the Company's assets, ensures regulatory compliance, supports business continuity, safeguards shareholders' interests, and contributes to sustainable growth.

Risk Culture

The Company believes that a strong risk culture is the foundation of effective Enterprise Risk Management. Risk culture reflects the collective values, attitudes, and behaviors that guide how employees identify, assess, communicate, and respond to risks across the organization.

The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries are committed to fostering a transparent, ethical, and accountable working environment where risk awareness is embedded in everyday business activities. Employees at all levels are encouraged to openly report emerging risks, operational concerns, and compliance issues without hesitation. This culture of openness, supported by strong leadership and continuous awareness initiatives, enables the Company to respond proactively to changing risk conditions and reinforces its commitment to sustainable business performance.

Risk Management at Board Level

The IBN SINA Pharmaceutical Industry PLC and its subsidiaries' risk management framework is robust, and its risk management network is spread throughout the Company. Its top-to-bottom risk management framework helps to maintain good financial health and keep the risk level to a minimum. There are three separate committees of the Board, namely: Executive Committee, Audit Committee, Nomination and Remuneration Committee, Budget Monitoring Committee, Credit

Control Committee, Under Rate Monitoring Committee, and New Product Selection Committee, which are responsible for risk management and operations of the Company.

Internal Audit and Compliance

The Internal Audit function provides independent and objective assurance to enhance the effectiveness of the Company's governance, risk management, and internal control processes. The Company adopts a risk-based internal audit approach, focusing on key business risks and evaluating the adequacy of internal controls, operational efficiency, and compliance with applicable laws, regulations, and internal policies. Audit findings and recommendations are regularly reported to Management and the Audit Committee, and follow-up actions are monitored to ensure timely implementation and continuous improvement.

Compliance Unit

The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries have established the best compliance culture throughout the organization by encouraging employees to comply with policies, procedures, and regulations. To establish and uphold the momentum of compliance culture, the Company and its Subsidiaries have a strong Compliance Department under the Internal Audit & Compliance Department, which is dedicated to ensuring compliance of guidelines/ observations/ recommendations of Regulatory and Internal Audit/Investigation. In line with that, 3 (three) separate units are formed under the Compliance Unit, namely: Regulatory Compliance Unit, Internal Compliance Unit and Audit Committee recommendation. Compliance Department also ensures required reporting to the Management, Audit Committee and the Regulators accordingly.

Financial reporting control

In order to ensure the reliability of the financial statements, the company has implemented different policies, practices, and control mechanisms that are designed to identify and solve key financial reporting problems, including the risks of changes in accounting standards. The Managing Director (MD) and Chief Financial Officer (CFO) are required to provide their certification on the true and fair view of the financial statements. In addition, the Chief Financial Officer attends the quarterly Board meetings held for the quarterly and half-yearly accounts of the company. Further to that, the integrity of the financial statements is supported by the Audit Committee's review and recommendation, and is approved by the Board of Directors.

Credit risk

Risk of financial loss arising from counterparty default on trade receivables, advances, and prepayments, including settlement timing differences.

Credit risk is managed through close supervision by field management and coordinated oversight by credit and finance teams. Regular credit monitoring reports enable early risk identification and timely management action.

Liquidity risk

Insufficient liquidity can disrupt day-to-day operations, affecting the company's ability to meet short-term obligations. Delays in cash flow can hinder planned investments, including strategic initiatives. Liquidity stress may weaken financial flexibility and increase borrowing costs.

The company maintains prudent cash flow management practices with regular monitoring of inflows and outflows to ensure operational stability. The company is diversifying funding sources and strengthening banking relationships to secure access to credit lines and short-term financing. Building adequate liquidity buffers and adopting efficient working capital management to enhance financial resilience.

Compliance And Governance Risk

Compliance risk refers to the potential for legal, regulatory, or financial consequences arising from failure to comply with applicable laws, regulations, and standards. Governance risk relates to weaknesses in the Company's governance framework that may affect effective oversight, decision-making, accountability, and transparency.

The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries address these risks through clearly defined policies, procedures and ethical standards that guide employee conduct and regulatory compliance. These frameworks are regularly reviewed and updated to reflect changes in the regulatory environment. The Company is supported by a competent and independent Board that provides effective oversight, while fostering a culture of accountability, integrity and transparency across the organization.

Technology Related Risk

The pharmaceutical industry is dynamic and heavily driven by technology. Hence, technology always plays a vital role here. Adopting better technology can help to gain remarkable core competencies that certainly create competitive advantages like increased productivity, reduced costs, and better perception of customers. Firms are exposed to technology risks

when there are better technologies available in the market than the ones used by the Company, which may cause operational inefficiency. As one of the leading pharmaceutical companies in the country, there is clear intent regarding the adaptation of the latest technology in the Company here, and the management is aware of technological changes and is always trying to adopt new technology according to its needs. Furthermore, routine and proper preventive maintenance of the equipment carried out by the Company ensures a longer service life for the existing equipment and facilities.

Environment, Health and Safety and Sustainability

The risk level has increased due to greater emphasis on environmental controls from regulators, activists and stakeholders across our direct operations and supply chain. An emerging area of focus is post-consumption waste associated with medicines. There are ever-more stringent regulations and standards in developed as well as developing countries. The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries' risk exposure remains unchanged as we continue to focus on more appropriate control over our supply chain, particularly of our Active Pharmaceutical Ingredient (API), The IBN SINA Natural Medicine Ltd. (INM) and The IBN SINA Polymer Industry Ltd.

Product Liability Risk

Pharmaceutical products are usually exposed to high quality control risk. Each product is required to be marketed through a stringent compliance procedure. Manufacturing of products requires the flexibility to accommodate the changing local and global regulatory needs. Any deviation from the standard may result in serious market reputational damages and might also create a regulatory barrier. Over the years, IBN SINA Pharmaceutical Industry PLC and its subsidiaries have been recognized locally and globally for quality standards and manufacturing excellence. Our manufacturing facilities are certified by leading global regulatory agencies. As such, IBN SINA Pharma is exposed to lower quality control risk. Additionally, the Company has taken adequate insurance cover to minimize the product liability risk.

Input Prices and Supply Chain Risk

As with other pharmaceutical companies of the country, the IBN SINA Pharmaceutical Industry PLC and its Subsidiaries are largely dependent on imported APIs. Any substantial increase in prices in the international market may affect future profitability of the company. To mitigate the risk, the Company and its subsidiaries import raw materials from multiple sources, both local and international, at competitive prices. The Company is not reliant on any single supplier for its materials, and this therefore reduces the individual supplier's influence on procurement prices. Most of the suppliers have their local agent and the Company maintains close relationships with them. Moreover, the Company and its subsidiaries manufacture a few of the APIs and have plans to expand the API manufacturing facilities to further strengthen its backward linkage.

Changing Economic Conditions

Economic advancement and consequent increase in the purchasing power of the people has direct implications on the demand for pharmaceutical products. Any decline in economic growth could, as for any other industry, impact the future demand for pharmaceutical products. Bangladesh, however, has maintained steady economic progress over the years with substantial uplift in all socio-economic indexes and it is anticipated that the trend will continue in the immediate future.

Foreign Exchange risk

Exchange rate risk relates to the core business of The IBN SINA Pharmaceutical Industry PLC and its Subsidiaries since it mostly imports materials from abroad in foreign currency. The Company imports raw materials against the payment of foreign currency, and the price of raw materials in the international market is relatively volatile. Unfavorable volatility or currency fluctuation may affect the profitability of the Company. The volatility of Taka against the Dollar and the recent trend of local currency devaluation may expose foreign currency risk. However, the Company and its subsidiaries can significantly reduce the foreign currency risk and price escalation risk through forwarding bookings if it is justifiable in terms of cost-benefit analysis. The Company also maintains Economic Order Quantity (EOQ) for its material imports, which provides a considerable cushion against an adverse movement of the exchange rate and price in the international market.

Conclusion

The Company remains committed to strengthening its risk management framework to effectively address existing and emerging risks. Through strong governance, effective internal controls, and continuous monitoring, the Company aims to enhance operational resilience, ensure regulatory compliance, and support sustainable growth. The Board believes that the existing risk management practices provide reasonable assurance for achieving the Company's strategic objectives while protecting the interests of shareholders and other stakeholders.

Our Stakeholders' Relation Policy

Communication with Shareholders

The Company has implemented multiple methods of communication to maintain an effective relationship with the shareholders of the Company. The Company encourages communication with shareholders on an ongoing basis throughout the year and welcomes their participation in the Annual General Meeting (AGM). At the AGM, the Company's management receives shareholders' valuable opinions and makes every effort to implement these for the betterment of the Company. The Company discloses the quarterly, half yearly and yearly financial performance and other reports in due course for meeting the best interests of shareholders.

+880-2-41022148, 41022150-58
+88-01709-645081
shareipi@ibnsinapharma.com
Tanin Center, 3 Asad Gate
Mirpur Road, Mohammadpur
Dhaka-1207
www.ibnsinapharma.com



Way of Communication with the Shareholders

Relations with Shareholders

The Board of Directors acknowledges their responsibility to represent the interests of all shareholders and to maximize shareholders' value of the Company. Shareholders expect from the Board and Senior Management to:



Investor Relations Section on Company's Website

Information is comprehensively disseminated to Company's investors, shareholders and other stakeholders through multiple platforms including the Company's Website. In compliance with the requirements of applicable regulatory framework, the website is maintained. The website is regularly updated to provide comprehensive information including but not limited to business strategy, governance, products & services, financial highlights, investor relations and dividend history, etc.

The Company's website www.ibnsinapharma.com displays management portfolio, vision and mission, investor relations, products, promotions and events. All information regarding financial statements, pattern of shareholding, corporate governance, notices, price sensitive information, code of conduct for the board, dividend distribution policy, nomination and remuneration policy, principles of disclosure of material information and price sensitive information, Unclaimed dividend, etc. are duly uploaded.

All disclosures required by the Bangladesh Securities and Exchange Commission, Listing Regulations-2015 of The Dhaka Stock Exchange PLC. and The Chittagong Stock Exchange PLC in the form of Price Sensitive Information are made adequately and promptly. In addition to ensuring timely compliance, this also enables dissemination of information to all stakeholders and the public through print and online media.

Grievance Redressal


The IBN SINA Pharmaceutical Industry PLC strongly believes in maintaining smooth and cooperative relationships with all stakeholders. We pursue a proactive and high quality shareholder's redressal policy to handle all grievances and complaints in an effective and fair manner. Any query received from investors is treated fairly and with the overall objective of dealing with it in a timely and transparent manner.

Investors Complaint Redressal

- Any investor may lodge their complaint relating to their investment in the Company through a formal letter sent to the official's email of Share and Public Relation Department or by phone call to the Share Department;
- The Share and Public Relation Department officials review the investors complaint on a weekly basis and take necessary steps accordingly;
- A designated person of the Company addresses investor grievances on a daily basis;
- Managing requests for updating of e-TIN number in the BO account if cash dividend is declared;
- Handling requests for updating of bank account details in the BO account while sending dividend through the BEFTN system;
- Folio holders are being handled in due course to meet their requirements;
- Review the instances of non-receipt of Annual Report and the declared dividend; and
- Consider all matters related to shareholders of the Company efficiently and with due importance.


The process of communication with the Shareholders, how particular relationships are managed, frequency of requisite engagements during the year, elaboration on how these relationships are likely to affect the performance and values of the entity, are cited as 'shareholders' engagement'.

Below Summarised Process has been Established to Manage Shareholder Interest within our Organization



IBN SINA

The IBN SINA Pharmaceutical Industry PLC



Organizational Chart

SARashid & Associates
(Chartered Secretaries)
Noakhali Tower (12th Floor, 13-D)
55/B Purana Paltan, Dhaka-1000, Bangladesh
Phone : +88 02 22 33 83 847, +88 01 755 944 966
E-mail : sarashid12000@yahoo.com, sarashidnasso@gmail.com

S. Abdur Rashid FCS
MBS, MBA (Finance), PGDHRM, LLB, **FIPM**
Chartered Secretary in Practice
Private Practice Certificate No.: 003

Report to the Shareholders of The Ibn Sina Pharmaceutical Industry PLC. on Compliance on the Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by The Ibn Sina Pharmaceutical Industry PLC. for the year ended on 30 June 2026. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

(a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above-mentioned Corporate Governance Code issued by the Commission except as stated in the remarks column of the Statement on Status of Compliance prepared by the Directors of the Company;

(b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;

(c) Proper books and records have been kept by the company as required under the Companies Act 1994, the securities laws and other relevant laws;

and

(d) The Governance of the Company is satisfactory.

For
SARashid & Associates

S. Abdur Rashid FCS
Chartered Secretary in Practice

Place : Dhaka
Dated : 17 October 2026

Compliance Report on Corporate Governance Code (CGC) issued by BSEC

[As per Condition No. 1(5)(xxvii) & Condition No. 9 and Annexure-C of CGC]

Status of compliance with the conditions imposed by the Commission's Notification No. SEC/CMRRCD/2006-158/207/Admin/80, dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969.

(Report under Condition No. 9)

Condition No.	Title	Compliance Status (Put √ in the appropriate column)		Remarks (if any)
		Complied	Not-Complied	
1	**Board of Directors**			
1(1)	**Size of the Board of Directors:** The number of Board members shall not be less than 5 (five) and more than 20 (twenty);	✓		
1(2)	**Independent Directors (ID)**			
1(2)(a)	At least 2 (two) directors or one-fifth (1/5) of the total number of directors in the company's Board, whichever is higher, shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of Independent Director(s); Provided that the Board shall appoint at least 1 (one) female independent director in the Board of Directors of the company;	✓		
1(2)(b)	**Criteria of "Independent Director"**			
1(2)(b) (i)	Who either does not hold share in the company or holds less than one (1%) shares of the total paid up shares of the company;	✓		
1(2)(b) (ii)	Who is not a sponsor of the company or is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company;	✓		
1(2)(b) (iii)	Who has not been an executive of the company in immediately preceding 2 (two) financial years;	✓		
1(2)(b) (iv)	Who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary/associated companies;	✓		
1(2)(b) (v)	Who is not a member or TREC holder, director or officer of any stock exchange;	✓		
1(2)(b) (vi)	Who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	✓		
1(2)(b) (vii)	Who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm;	✓		
1(2)(b) (viii)	Who shall not be an independent director in more than 5 (five) listed companies;	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
1(2)(b) (ix)	Who has not been reported as a defaulter in the latest Credit Information Bureau (CIB) report of Bangladesh Bank for nonpayment of any loan or advance or obligation to a Bank or a Financial Institution;	✓		
1(2)(b) (x)	Who has not been convicted for a criminal offence involving moral turpitude;	✓		
1(2)(c)	The Independent Director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM): "Provided that the Board shall appoint the independent director, subject to prior consent of the Commission, after due consideration of recommendation of the Nomination and Remuneration Committee (NRC) of the company;"	✓		
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90 (ninety) days;	✓		
1(2)(e)	The tenure of office of an Independent Director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only;	✓		
1(3)	**Qualification of Independent Director (ID)**			
1(3)(a)	Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial, regulatory and corporate laws and can make meaningful contribution to business;	✓		
1(3)(b)(i)	Business Leader who is or was a Promoter or Director of an unlisted company having minimum paid-up capital of Tk.100.00 million or any listed company or a member of any national or international chamber of commerce or registered business association;	✓		
1(3)(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	✓		
1(3)(b)(iii)	Former or existing official of Government or Statutory or Autonomous or Regulatory body in the position not below 5th Grade of the National Pay Scale, who has at least educational background of Bachelor degree in Economics or Commerce or Business or Law: Provided that in case of appointment of Existing Official as Independent Director, it requires clearance from the organization where he or she is in service;	✓		
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law;			Not Applicable
1(3)(b)(v)	Professional who is or was an advocate practicing at	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
	least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;			
1(3)(c)	The independent director must have at least 10 (ten) years of in any field mentioned in clause (b);	✓		
1(3)(d)	In special cases the above qualifications may be relaxed subject to prior approval of the Commission.			Not Applicable
1(4)	**Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer**			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and/or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	✓		
1(4)(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	✓		
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	✓		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/or Chief Executive Officer;	✓		
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.			Not Applicable
1(5)	**The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the Companies Act, 1994 (Act No. XVIII of 1994):**			
1(5)(i)	An Industry outlook and possible future developments in the industry;	✓		
1(5)(ii)	The Segment-wise or product-wise performance;	✓		
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	✓		
1(5)(iv)	Discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	✓		
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	✓		Not Applicable
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	✓		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;			Not Applicable
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Offer, Direct Listing, etc.			Not Applicable

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
1(5)(ix)	If significant variance occurs between Quarterly Financial performance and Annual Financial Statements the management shall explain about the variance on their Annual Report;	✓		
1(5)(x)	A statement of remuneration paid to the directors including independent directors;	✓		
1(5)(xi)	A statement that the financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	✓		
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	✓		
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	✓		
1(5)(xiv)	A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	✓		
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	✓		
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	✓		
1(5)(xvii)	A statement that there is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	✓		
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	✓		
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	✓		
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;			Not Applicable
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	✓		
1(5)(xxii)	The number of Board meetings held during the year and attendance by each director shall be disclosed.	✓		
1(5)(xxiii)	**The pattern of shareholding shall be reported to disclose the aggregate number of shares (along with name wise details where stated below) held by:-**			
1(5)(xxiii)(a)	Parent/Subsidiary/Associated Companies and other related parties (name wise details);	✓		
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
	Secretary, Chief Financial Officer, Head of Internal Audit and their spouses and minor children (name wise details);			
1(5)(xxiii)(c)	Executives; and	✓		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name wise details).	✓		
1(5)(xxiv)	**In case of the appointment/re-appointment of a Director the company shall disclose the following information to the shareholders**			
1(5)(xxiv) (a)	A brief resume of the director;	✓		
1(5)(xxiv) (b)	Nature of his/her expertise in specific functional areas; and	✓		
1(5)(xxiv) (c)	Names of companies in which the person also holds the directorship and the membership of committees of the board.	✓		
1(5)(xxv)	**Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on:**			
1(5)(xxv) (a)	Accounting policies and estimation for preparation of financial statements;	✓		
1(5)(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	✓		
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	✓		
1(5)(xxv) (d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	✓		
1(5)(xxv) (e)	Briefly explain the financial and economic scenario of the country and the globe;	✓		
1(5)(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company;	✓		
1(5)(xxv)(g)	Future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	✓		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A;	✓		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C;	✓		
1(5)(xxviii)	The Directors' report to the shareholders does not require to include the business strategy or technical specification related to products or services, which have business confidentiality.	✓		
1(6)	**Meetings of the Board of Directors**			
	Conducting Board meetings and recording the minutes of the meetings and keeping required books	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
	and records in line Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB), in so far as those standards are not inconsistent with any condition of this Code.			
1(7)	**Code of Conduct for the Chairperson, other Board members and Chief Executive Officer**			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	✓		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	✓		Code of Conduct has been posted on the website of the company
2	**Governance of Board of Directors of Subsidiary Company**			
2(a)	Provisions relating to the composition of the Board of Directors of the holding company shall be made applicable to the composition of the Board of Directors of the subsidiary company;	✓		As on 30 June 2026, each Board of 3 Subsidiaries included one ID; However, the Board of one subsidiary consists of 6 members including ID.
2(b)	At least 1 (one) Independent Director on the Board of Directors of the holding company shall be a director on the Board of Directors of the subsidiary company;	✓		
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company;	✓		
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	✓		
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	✓		
3	**Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS):**			
3(1)	**Appointment**			
3(1)(a)	The Board shall appoint a MD or CEO, CS, CFO and HIAC;	✓		
3(1)(b)	The positions of the MD or CEO, CS, CFO and HIAC shall be filled by different individuals;	✓		
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time: Provided that CFO or CS of any listed company may	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
	be appointed for the same position in any other listed or non-listed company under the same group for reduction of cost or for technical expertise, with prior approval of the Commission: Provided further that the remuneration and perquisites of the said CFO or CS shall be shared by appointing companies proportionately;			
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	✓		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	✓		
3(2)	**Requirement to attend Board of Directors' Meetings:**			
	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	✓		
3(3)	**Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)**			
3(3)(a)	They have reviewed financial statements for the year and that to the best of their knowledge and belief:	✓		
3(3)(a)(i)	These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;	✓		
3(3)(a)(ii)	These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	✓		
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members;	✓		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in this Annual Report.	✓		
4	**Board of Directors' Committee**			
4(i)	Audit Committee;	✓		
4(ii)	Nomination and Remuneration Committee	✓		
5	**AUDIT COMMITTEE:**			
5(1)	**Responsibility to the Board of Directors**			
5(1)(a)	The company shall have an Audit Committee as a subcommittee of the Board of Directors;	✓		
5(1)(b)	The Audit Committee shall assist the Board of Directors in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	✓		
5(1)(c)	The Audit Committee shall be responsible to the Board of Directors. The duties of the Audit Committee shall be clearly set forth in writing.	✓		
5(2)	**Constitution of the Audit Committee**			

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	✓		
5(2)(b)	The Board shall appoint members of the Audit Committee who shall be directors of the company and shall include at least 1 (one) Independent Director;	✓		
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	✓		
5(2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 60 (sixty) days from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	✓		
5(2)(e)	The company secretary shall act as the secretary of the Committee;	✓		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without Independent Director;	✓		
5(3)	**Chairman of the Audit Committee**			
5(3)(a)	The Board of Directors shall select 1 (one) member of the Audit Committee to be Chairman of the Audit Committee, who shall be an Independent Director;	✓		
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	✓		
5(3)(c)	Chairman of the audit committee shall remain present in the Annual General Meeting (AGM).	✓		
5(4)	**Meeting of the Audit Committee**			
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year;	✓		
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	✓		
5(5)	**Role of Audit Committee:**			
5(5)(a)	Oversee the financial reporting process;	✓		
5(5)(b)	Monitor choice of accounting policies and principles;	✓		
5(5)(c)	Monitor Internal Control Risk management process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
5(5)(d)	Oversee hiring and performance of external auditors;	✓		
5(5)(e)	Hold the meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	✓		
5(5)(f)	Review along with the management, the annual financial statements before submission to the board for approval;	✓		
5(5)(g)	Review along with the management, the quarterly and half yearly financial statements before submission to the board for approval;	✓		
5(5)(h)	Review the adequacy of internal audit function;	✓		
5(5)(i)	Review the Management's Discussion and Analysis before disclosing in this Annual Report;	✓		
5(5)(j)	Review statement of significant related party transactions submitted by the management;	✓		
5(5)(k)	Review Management Letters/ Letter of Internal Control weakness issued by statutory auditors;			Not Applicable
5(5)(l)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; and	✓		
5(5)(m)	Oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission:			Not Applicable
5(6)	**Reporting of the Audit Committee:**			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board of Directors.	✓		
5(6)(a)(ii)	**The Audit Committee shall immediately report to the Board of Directors on the following findings, if any:-**			
5(6)(a)(ii)(a)	Report on conflicts of interests;			Not Applicable
5(6)(a)(ii)(b)	Suspected or presumed fraud or irregularity or material defect in the internal control system;			Not Applicable
5(6)(a)(ii)(c)	Suspected infringement of laws, including securities related laws, rules and regulations;			Not Applicable
5(6)(a)(ii)(d)	Any other matter which shall be disclosed to the Board of Directors immediately.			Not Applicable
5(6)(b)	**Reporting to the Authorities –** If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.			Not Applicable
5(7)	**Reporting to the Shareholders and General Investors** Report on activities carried out by the Audit	✓		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
	Committee, including any report made to the Board under condition No. 5(6) (a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer Company			
6	**Nomination and Remuneration Committee (NRC)**			
6(1)	**Responsibility to the Board of Directors**			
6(1)(a)	Nomination and Remuneration Committee (NRC) as a subcommittee of the Board;	✓		
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	✓		
6(1)(c)	ToR of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b);	✓		
6(2)	**Constitution of the NRC**			
6(2)(a)	The Committee shall comprise of at least three members including an Independent Director;	✓		
6(2)(b)	At least 02 (two) members of the Committee shall be non-executive Directors;	✓		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	✓		
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	✓		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;			Not Applicable
6(2)(f)	The Chairperson of the Committee may appoint or coopt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;			Not Applicable
6(2)(g)	The company secretary shall act as the secretary of the Committee;	✓		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	✓		
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	✓		
6(3)	**Chairperson of the NRC**			
6(3)(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	✓		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly	✓		Not Applicable

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
	recorded in the minutes;			
6(3)(c)	The Chairperson of the NRC shall attend the Annual General Meeting (AGM) to answer the queries of the shareholders.	✓		
6(4)	**Meeting of the NRC**			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year	✓		
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;			Not Applicable
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	✓		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	✓		
6(5)	**Role of the NRC**			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	✓		
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board:			
6(5)(b)(i)	Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:			
6(5)(b)(i)(a)	The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the Company successfully;	✓		ToR of NRC includes this Role
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	✓		ToR of NRC includes this Role
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	✓		ToR of NRC includes this Role
6(5)(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	✓		ToR of NRC includes this Role
6(5)(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	✓		ToR of NRC includes this Role
6(5)(b)(iv)	Formulating the criteria for evaluation of performance of independent directors and the Board;	✓		ToR of NRC includes this Role
6(5)(b)(v)	Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; and	✓		ToR of NRC includes this Role
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies;	✓		ToR of NRC includes this Role

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Non-Complied	
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	✓		
7	**External or Statutory Auditors**			
7(1)	The issuer Company shall not engage its external or statutory auditors to perform the following services of the company, namely:-			
7(1)(i)	appraisal or valuation services or fairness opinions;	✓		
7(1)(ii)	financial information systems design and implementation;	✓		
7(1)(iii)	book-keeping or other services related to the accounting records or financial statements;	✓		
7(1)(iv)	Broker-dealer services;	✓		
7(1)(v)	Actuarial services;	✓		
7(1)(vi)	Internal audit services or special audit services;	✓		
7(1)(vii)	Any service that the Audit Committee determines;	✓		
7(1)(viii)	Audit or certification services on compliance of corporate governance as required under condition No. 9(1); and	✓		
7(1)(ix)	Any other service that creates conflict of interest.	✓		
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company:	✓		
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General Meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	✓		
8	**Maintaining a website by the Company**			
8(1)	The company shall have an official website linked with the website of the stock exchange;	✓		
8(2)	The company shall keep the website functional from the date of listing;	✓		
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	✓		
9	**Reporting and Compliance of Corporate Governance**			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in this Annual Report.	✓		
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting.	✓		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	✓		



Auditors' Report and Financial Statements

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Independent Auditor's Report to the Shareholders of

To the Shareholders of THE IBN SINA Pharmaceutical Industry PLC.

Report on the Audit of the Consolidated and Separate Financial Statements

Opinion

We have audited the consolidated financial statements of THE IBN SINA Pharmaceutical Industry PLC. and its subsidiaries (the "Group") as well as the separate financial statements of THE IBN SINA Pharmaceutical Industry PLC. (the "Company"), which comprise the consolidated and separate statements of financial position as at June 30, 2026, the consolidated and separate statements of profit or loss and other comprehensive income, consolidated and separate statements of changes in equity and consolidated and separate statements of cash flows for the year then ended, and notes to the consolidated and separate financial statements, including material accounting policy information and other explanatory information.

In our opinion, the accompanying consolidated and separate financial statements give a true and fair view of the consolidated financial position of the Group and the separate financial position of the Company as at June 30, 2026, and of their consolidated and separate financial performance and consolidated and separate cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the Financial Reporting Council (FRC) of Bangladesh.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated and Separate Financial Statements section of our report. We are independent of the Group and the Company in accordance with the ethical requirements of the Financial Reporting Council together with the ethical requirements of the Institute of Chartered Accountants of Bangladesh (ICAB) Bye-Laws that are relevant to audits of the financial statements of public interest entities in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated and separate financial statements of the current period. These matters were addressed in the context of our audit of the consolidated and separate financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Risk	Our response
Revenue Recognition	
At the year ended, the company's reported total revenue of Tk. 13,899,792,434. Revenue is measured net of trade discount and VAT. Time of revenue recognition is matter. The revenue may overstated for the early recognition of revenue to achieve the desire result.	We have tested the design and operating effectiveness of key controls focusing on the following: • Policy of revenue recognition: • Issuance of VAT challan; • Segregation of duties in invoice creation and modification; and • Timing of revenue recognition. Our substantive procedures in relation to the revenue recognition comprises the following: • Obtaining supporting documentation for sales transactions recorded either side of year end as well as credit notes issued after the year end date to determine whether revenue was recognized in the correct period;

International Affiliation :
Reddy Siddiqui LLP, UK, Chartered Accountatnts
Website: www.reddysiddiqui.com

Branch Office :
Rupayan Shopping Square (9th Floor)
Plot # C-2, Block # G, Bashundhara, Dhaka-1229, Bangladesh

Risk	Our response
	• VAT is correctly dealt with; • Critically assessing manual journals posted to revenue to identify unusual or irregular items; and • Finally assessed the appropriateness and presentation of disclosures against relevant accounting Standards.
Please see the note 24.A in this financial statements.	
Valuation of inventory	
The balance of inventory of the Company at the year-end was Tk. 1,972,382,955 held in the company's warehouse. Inventories should carried at the lower of cost and net realizable value. As a result, the managements apply judgment in determining the appropriate values of inventory.	We challenged the appropriateness of management's assumptions applied in calculating the value of the inventory and related provisions by: • evaluating the design and implementation of key inventory controls operating across the Company in respect of inventory management; • to attend the physical inventory counts and reconciling the count results to the inventory listings to test the completeness of data; • to review the inventory costing procedures and methodology. • comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories and comparison to the associated provision to assess whether inventory provisions are complete; • reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year; and • Challenging the completeness of inventory provisions through assessing actual and forecast sales of inventory lines to assess whether provisions for slow- moving/obsolete stock are valid and complete.
Please see the note 8 B in this financial statements.	
Measurement and recognition of deferred tax	
The balance of reported deferred tax liability of the company was Tk. 93,028,338 as on June 30, 2026. The risk for the financial statements is that these provisions may not properly measured for all types of temporary difference as per IAs 12: Income Tax.	We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax. We have assessed the appropriateness of the carrying amounts of net asset value as per tax base and accounting base. We have also assessed the rate of deferred for each temporary difference. Also, we examined the accounting treatment of deferred tax.
Please see the note 19 in this financial statements.	

Other Matter

The statutory auditor of the company for the year ended June 30, 2025 (comparative financial statements for 2025) was S. F. Ahmed & Co., Chartered Accountants, who issued an unmodified audit opinion on the financial statements. As S. F. Ahmed & Co., Chartered Accountants also audited the preceding financial year, we have not expressed a separate opinion on the opening balances of the current year's financial statements.

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Consolidated and Separate Financial Statements

Management is responsible for the preparation of the consolidated and separate financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the IASB and adopted by FRC, and for such internal control as management determines is necessary to enable the preparation of consolidated and separate financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated and separate financial statements, management is responsible for assessing the Group's and the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's and the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated and Separate Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated and separate financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated and separate financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Company's internal control.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's or the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated and separate financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group or the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the consolidated and separate financial statements, including the disclosures, and whether the consolidated and separate financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

• Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the consolidated financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated and separate financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and Financial Reporting Act 2015, we also report the following:

a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) in our opinion, proper books of account as required by law have been kept by the Group and the Company so far as it appeared from our examination of these books;

c) the consolidated and separate statements of financial position and the consolidated and separate statements of comprehensive income dealt with by the report are in agreement with the books of account and returns; and

d) the consolidated and separate financial statements have been prepared in accordance with standards, framework, compliance and guidelines adopted and promulgated by the Financial Reporting Council.

Md. Waliullah, FCA, Enrolment No: 0247
Malek Siddiqui Wali, Chartered Accountants
FRC Firm Enlistment No.: CAF - 001 –091
RJSC Firm Registration No: P-50041/2022
Dhaka/ September 30, 2026
DVC: 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Consolidated Statement of Financial Position

As at 30 June 2026

	Notes	AMOUNT IN TAKA	
		30 June 2026	30 June 2025
ASSETS:			
Non-Current Assets		**7,507,719,201**	**4,701,323,681**
Property, Plant and Equipment	04.A	2,638,512,168	2,655,519,636
Capital Work-In-Progress	05.A	4,785,835,577	1,932,358,746
Right-of-Use Assets	05.B	8,268,178	33,072,711
Advances, Deposits & Prepayments	10.A.1	33,965,070	33,715,070
Financial Assets	06.A	41,138,209	46,657,518
Current Assets		**3,302,659,427**	**2,845,250,397**
Financial Assets	08.A	22,500,000	22,500,000
Inventories	08.B	1,972,382,955	1,808,087,123
Trade and Other Receivables	09.A	189,774,389	196,052,607
Advances, Deposits & Prepayments	10.A.1	820,696,923	503,707,520
Cash & Cash Equivalents	11.A	297,305,160	314,903,147
TOTAL ASSETS		**10,810,378,628**	**7,546,574,078**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
EQUITY:		**4,655,848,970**	**3,997,848,260**
Equity attributable to the Owners of the Company		4,516,608,247	3,926,901,664
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
Fair Value Reserve	14	(20,511,709)	(15,544,331)
Retained Earnings	15.A	4,220,291,576	3,625,617,615
Non Controlling Interest	15.B	139,240,723	70,946,596
LIABILITIES:			
Non-Current Liabilities		**1,290,768,614**	**1,072,158,461**
Long Term Finance	16.A	1,197,232,556	974,705,376
Employee Benefit Obligations	17.A	507,721	990,546
Lease Liabilities	17.B	-	-
Deferred Tax Liabilities	19	93,028,338	96,462,538
Current Liabilities		**4,863,761,044**	**2,476,567,357**
Short Term Finance	20.A	2,636,364,359	953,683,239
Current Portion Of Long Term Finance	21	172,534,991	119,445,855
Lease Liabilities	17.B	-	23,798,698
Trade And Other Payable	22.A	1,307,039,568	842,289,127
Unclaimed Dividend	22.A.1	28,040,490	42,104,508
Provision For Corporate Tax	23.A	719,781,636	495,245,930
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**10,810,378,628**	**7,546,574,078**
Net Assets Value (NAV) Per Share	33.01.B	**144.56**	**125.69**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer | **Company Secretary** | **Director** | **Managing Director** | **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2026

	Notes	AMOUNT IN TAKA 01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
REVENUE	24.A	13,899,792,434	11,883,593,713
Cost of goods sold	25.A	(8,147,083,860)	(7,083,739,867)
GROSS PROFIT		**5,752,708,574**	**4,799,853,846**
OPERATING EXPENSES		**(4,592,541,950)**	**(3,854,323,797)**
Administrative expenses	27.01	(318,137,538)	(267,068,903)
Selling & Distribution expenses	28.01	(4,274,404,411)	(3,587,254,894)
OPERATING PROFIT		**1,160,166,625**	**945,530,049**
Financial charges	33.04	(127,838,224)	(87,403,328)
Other income	29.01	35,232,241	25,206,023
Profit before WPPF and Welfare Fund		**1,067,560,642**	**883,332,744**
Workers' P.P. fund & welfare fund	30.01	(52,979,904)	(43,358,391)
PROFIT BEFORE TAX		**1,014,580,738**	**839,974,353**
Income Tax Expenses:	31.02	(221,653,436)	(206,718,125)
NET PROFIT AFTER TAX		**792,927,301**	**633,256,228**
Profit/(Loss) Attributable to:			
Owner of the Company		**794,633,174**	**633,189,350**
Non-controlling interest	33.05	(1,705,873)	66,877
		792,927,301	**633,256,228**
Other Comprehensive Income:			
Change in fair value of marketable securities	32	(5,519,309)	(7,704,012)
Deferred tax		551,931	770,401
Total other comprehensive income for the year (net of tax)		(4,967,378)	(6,933,611)
Total Comprehensive Income for the year		**787,959,923**	**626,322,617**
Total Comprehensive income Attributable to:			
Owners of the Company		789,665,796	626,255,739
Non-controlling interest	33.05	(1,705,873)	66,877
		787,959,923	**626,322,617**
Earnings Per Share (EPS)	33.01.A	**25.43**	**20.27**
Number of Shares used to Compute EPS		**31,243,627**	**31,243,627**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Consolidated Statement of Changes In Equity

For the year ended 30 June 2026

AMOUNT IN TAKA

Particulars	Paid up Capital	Tax Holiday Reserve	Fair Value Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 30 June 2024	**312,436,270**	**4,392,110**	**(8,610,721)**	**3,189,263,114**	**35,879,718**	**3,533,360,493**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2025			(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Issued during the year					35,000,000	35,000,000
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,625,617,615**	**70,946,596**	**3,997,848,260**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2026			(4,967,378)	794,633,174	(1,705,873)	787,959,923
Dividend for the year 30 June 2025 (Cash-64%)				(199,959,213)		(199,959,213)
Issued during the year					70,000,000	70,000,000
Balance as at 30 June 2026	**312,436,270**	**4,392,110**	**(20,511,710)**	**4,220,291,576**	**139,240,723**	**4,655,848,970**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Consolidated Statement of Cash Flows

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Cash Flows From Operating Activities		
Received from revenue and others	13,915,712,595	11,898,203,387
Payment for operation, expenses & others	(12,406,765,776)	(10,913,617,736)
Miscellaneous income	10,501,552	3,470,820
Cash generated from operations	**1,519,448,370**	**988,056,471**
Cash payment for income tax paid	(205,988,714)	(180,666,966)
Payment for financial charges	(127,838,224)	(83,710,869)
Net cash generated from operating activities	**1,185,621,432**	**723,678,635**
Cash Flows From Investing Activities		
Acquisition of property, plant and equipment	(3,033,192,371)	(976,264,540)
Proceeds from sales of motor vehicles	-	(5,232,246)
Profit received from MTDR	(1,574,907)	-
Acquisition of financial assets	-	142,986,813
Profit from MTDR	2,599,404	-
Dividend received/ IBBL-MPB	507,239	1,972,684
Bank profit received	5,132,598	7,696,969
Net cash used in investing activities	**(3,026,528,036)**	**(828,840,320)**
Cash Flows From Financing Activities		
Payment of dividend	(214,023,231)	(193,870,939)
Long term finance received/(paid) from bank (Net)	222,527,180	444,214,854
Transactions Non Controlling Interest	70,000,000	35,000,000
Short term finance received/(paid) from bank (Net)	1,735,770,256	(231,726,594)
Net Cash used in financing activities	**1,814,274,204**	**53,617,321**
Increase/(decrease) in cash and cash equivalents	(26,632,400)	(51,544,364)
Cash and cash equivalents at the opening	314,903,147	365,229,893
Foreign exchange fluctuation gain/(loss) on FCAD ERQ accounts	9,034,412	1,217,618
Cash and cash equivalents at the closing	**297,305,159**	**314,903,147**
NOCFPS (Note 33.02.01)	**37.95**	**23.16**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Statement of Financial Position

As at 30 June 2026

	Notes	AMOUNT IN TAKA	
		30 June 2026	30 June 2025
ASSETS:			
Non-Current Assets		**7,461,742,876**	**4,710,090,479**
Property, Plant And Equipment	04	2,389,616,834	2,431,653,536
Capital Work-In-Progress	05	3,779,835,116	1,155,822,174
Right of Use Assets	05.B	8,268,178	33,072,711
Financial Assets	06	12,138,209	17,657,518
Advances, Deposits & Prepayments	10.1	33,715,070	33,715,070
Investment In Subsidiary	07	1,238,169,470	1,038,169,470
Current Assets		**2,851,217,065**	**2,424,153,681**
Financial Assets	08	22,500,000	22,500,000
Inventories	08.01	1,738,794,887	1,603,775,310
Trade And Other Receivables	09	180,245,053	187,596,187
Advances, Deposits & Prepayments	10.1	749,291,153	429,600,396
Cash And Cash Equivalents	11	160,385,971	180,681,788
TOTAL ASSETS		**10,312,959,941**	**7,134,244,160**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Equity:		**4,520,143,263**	**3,932,383,056**
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
Fair Value Reserve	14	(20,511,709)	(15,544,331)
Retained Earnings	15	4,223,826,592	3,631,099,007
LIABILITIES:			
Non-Current Liabilities		**1,081,580,746**	**848,925,369**
Long Term Finance	16	990,125,690	753,223,072
Employee Benefit Obligations	17	507,721	990,546
Lease Liabilities	17.B	-	-
Deferred Tax Liabilities	18	90,947,336	94,711,750
Current Liabilities		**4,711,235,932**	**2,352,935,735**
Short Term Finance	20	2,607,058,173	933,771,898
Current Portion of Long Term Finance	21	172,534,991	119,445,855
Lease Liabilities	17.B	-	23,798,698
Trade and Other Payable	22	1,238,363,259	775,229,847
Unclamied Dividend	22.A.1	28,040,490	42,104,508
Provision for Corporate Tax	23	665,239,020	458,584,929
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**10,312,959,941**	**7,134,244,160**
Net Assets Value (NAV) Per Share	33.01 A	**144.67**	**125.86**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer | **Company Secretary** | **Director** | **Managing Director** | **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2026

	Notes	AMOUNT IN TAKA 01 July 2025 to 30 June 2026	AMOUNT IN TAKA 01 July 2024 to 30 June 2025
REVENUE	24	12,418,880,056	10,725,957,022
Cost of goods sold	25	(7,331,664,071)	(6,429,003,064)
GROSS PROFIT		**5,087,215,985**	**4,296,953,958**
OPERATING EXPENSES		**(3,948,680,634)**	**(3,329,259,450)**
Administrative expenses	27	(253,832,840)	(225,676,621)
Selling & Distribution expenses	28	(3,694,847,793)	(3,103,582,828)
OPERATING PROFIT		**1,138,535,351**	**967,694,508**
Financial charges	33.04	(127,838,224)	(87,403,328)
Other income	29	35,237,698	21,739,663
Profit before WPPF and Welfare Fund		**1,045,934,826**	**902,030,843**
Workers' P.P. fund and welfare fund	30	(49,806,420)	(42,953,850)
PROFIT BEFORE TAX		**996,128,405**	**859,076,993**
Income tax expenses	31	(203,441,607)	(198,914,969)
NET PROFIT AFTER TAX		**792,686,798**	**660,162,024**
Other Comprehensive Income			
Change in fair value of Marketable Securities	32	(5,519,309)	(7,704,012)
Deferred tax		551,931	770,401
Total other comprehensive income for the year (net of tax)		(4,967,378)	(6,933,611)
Total Comprehensive Income for the period		**787,719,420**	**653,228,413**
Earnings Per Share (EPS)	33	**25.37**	**21.13**
Number of Shares Used to compute EPS		**31,243,627**	**31,243,627**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Statement of Changes In Equity

For the year ended 30 June 2026

AMOUNT IN TAKA

Particulars	Paid up Capital	Tax Holiday Reserve	Fair Value Reserve	Retained Earnings	Total
Balance as at 30 June 2024	**312,436,270**	**4,392,110**	**(8,610,721)**	**3,167,771,833**	**3,475,989,492**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2025	-	-	(6,933,611)	660,162,024	653,228,413
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,631,099,007**	**3,932,383,056**
Statement of profit or loss and other Comprehensive Income for the year ended 30 June 2026			(4,967,378)	792,686,798	787,719,420
Dividend for the year 30 June 2024 (Cash-64%)			-	(199,959,213)	(199,959,213)
Balance as at 30 June 2026	**312,436,270**	**4,392,110**	**(20,511,710)**	**4,223,826,592**	**4,520,143,263**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Statement of Cash Flows

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Cash Flows From Operating Activities:		
Received from revenue and others	12,435,873,133	10,713,817,824
Payment for operation, expenses & others	(10,951,333,716)	(9,747,244,054)
Miscellaneous income	10,501,552	3,470,820
Cash generated from operations	**1,495,040,968**	**970,044,590**
Cash Payment for income tax paid	(190,610,415)	(174,510,320)
Payment for Financial charges	(127,838,224)	(83,710,869)
Net cash generated from operating activities	**1,176,592,329**	**711,823,401**
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(2,761,237,146)	(744,981,021)
Proceeds from sales of motor vehicles	-	(5,232,246)
Profit received from MTDR	(1,574,907)	-
Acquisition of financial assets	-	66,809,029
Profit from MTDR	2,599,404	-
Investment in subsidiary	(200,000,000)	(185,000,000)
Dividend Received/ IBBL-MPB	507,239	1,972,684
Bank profit received	4,528,055	2,506,832
Net cash used in investing activities	**(2,955,177,355)**	**(863,924,722)**
Cash Flows From Financing Activities:		
Payment of dividend	(214,023,231)	(193,870,939)
Long term finance received/(paid) from bank (Net)	236,902,617	344,215,077
Short term finance received/(paid) from bank (Net)	1,726,375,411	(131,254,491)
Net cash used in financing activities	**1,749,254,797**	**19,089,647**
Increase/(decrease) in cash and cash equivalents	(29,330,229)	(133,011,675)
Cash and cash equivalents at the opening	180,681,788	312,475,845
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	9,034,412	1,217,618
Cash and cash equivalents at the closing	**160,385,971**	**180,681,788**
NOCFPS (Note 33.02)	**37.66**	**22.78**

The annexed notes form an integral part of these financial statements.

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

Signed in terms of our report of even date annexed

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 30, 2026
Document verification code(DVC) No : 2610070247AS453150

The IBN SINA Pharmaceutical Industry PLC

Notes to the Consolidated Financial Statements

for the year ended on 30 June 2026

1. Reporting entity

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd. The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and selling them in both local and international market.

1.3 Subsidiary companies

The IBN SINA API Industry Ltd.

The IBN SINA API Industry Ltd. was incorporated in Bangladesh on 16 September 2019 under the Company Act, 1994. The Company involves in manufacturing, trading and other related activities of Active Pharmaceutical Ingredients and other related products.

The IBN SINA Natural Medicine Ltd.

The IBN SINA Natural Medicine Ltd. was incorporated in Bangladesh on 02 December 2020 under the Company Act, 1994. The Company involves in importing, manufacturing, trading and other related activities of natural medicine and other related products.

The IBN SINA Polymer Industry Ltd.

The IBN SINA Polymer Industry Ltd. was incorporated in Bangladesh on 25 March 2021 under the Company Act, 1994. The Company involves in manufacturing, trading and other related activities of Polymer Plastic Bottles, Plastic Tubes, Laminated tubes and other related products.

2. Basis of preparation of financial statements

2.1 Statement on compliance

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and International Accounting Standard (IAS) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by Financial Reporting Council, Bangladesh, the Companies Act, 1994, Securities and Exchange Rules, 1987 and other relevant laws as applicable.

2.2 Basis of Consolidation

The group has prepared separate financial statements and consolidated financial statements for the group separately. The accounts of all the subsidiaries of the Company have been fully consolidated as the Company controls these entities. The Company holds majority of voting right in all of the subsidiaries.

The name of subsidiaries, country of incorporation and proportion of ownership interest are as follows:

Name of Subsidiary	Country of Incorporation	% of Ownership
The IBN SINA API Industry Ltd.	Bangladesh	99.99%
The IBN SINA Natural Medicine Ltd	Bangladesh	99.99%
The IBN SINA Polymer Industry Ltd.	Bangladesh	65%

i) Subsidiaries

Subsidiaries are entities controlled by the Company. The Company 'controls' an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

ii) Non-controlling interests (NCI)

NCI are measured initially at their proportionate share of the acquiree's identifiable net assets at the date of acquisition. Changes in the Company's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

iii) Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses arising from

intra-group transactions, are eliminated. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

2.3 Other regulatory compliances

The Group is also required to comply with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- The Income Tax Act 2023
- Financial Reporting Act 2015 and FRC Notifications
- The Value Added Tax Act 2012
- The Value Added Tax Rules 2016
- The Drugs Act 1940 and the Drug Rules 1946
- The Drugs (Control) Ordinance 1982
- The Customs Act 1969
- The Stamp Act 1899
- The Bangladesh Securities and Exchange Commission Act 1993
- The Bangladesh Securities and Exchange Commission Rules 1987
- DSE/CSE Rules
- Listing Regulations, 2015
- Bangladesh Labor Act, 2006(as amended to 2018)

2.4 Authorization for issue

The financial statements were authorized for issue by the Board of Directors in its meeting held on 30 September 2026 for publication.

2.5 Basis of measurement

The financial statements have been prepared on going concern basis under the historical cost convention except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

2.6 Accrual basis of accounting

The Group prepares its financial statements, except for cash flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the group recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the IFRS conceptual Framework.

2.7 Functional and presentation currency

Functional and presentation currency items included in these financial statements are measured using the currency of the primary economic environment in which the group operates ('the functional currency'). These financial statements are presented in Bangladesh Taka ("BDT") which is also the functional currency of the group. The amounts in these financial statements have been rounded off to the nearest BDT except otherwise indicated.

2.8 Use of estimates and judgments

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values for financial assets and liabilities.

The Company has established solid internal control with respect to the measurement of fair values. Significant valuation issues are reported to Audit Committee.

When measuring the fair values of an asset or a liability, the Company uses market observable data as far as possible. When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as 'active' if transactions for the assets or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

2.9 Materiality, aggregation and off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the Group has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of assets or liabilities as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

2.10 Going concern assumption

The financial statements are prepared on the basis of going concern assumption. As per management assessment there is no material uncertainties related to events or conditions which may cast significant doubt upon the Group's ability to continue as a going concern.

2.11 Reporting period

The reporting period of the group covers 12 (twelve) months from 01st July 2025 to 30th June 2026.

2.12 Comparative information

Comparative information has been disclosed in respect of 2025-2026 in accordance with IAS-1 "Presentation of Financial Statements" for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current periods of financial statements. Prior year figure has been re arranged wherever considered necessary to ensure comparability with the current period.

2.13 Consistency

Unless otherwise stated, the accounting policies and methods of computation used in preparation of the financial statements as at and for the year ended 30 June 2026 are consistent with those policies and methods adopted in preparing the financial statements as at and for the year ended 30 June 2026.

3. Significant accounting policies

3.1 Property, plant and equipment

Recognition and measurement

An item shall be recognized as property, plant and equipment's if, and only it is probable that future economic benefits associated with the item will flow to the entity, and the cost of the item can be measured reliably.

Items of property, plant and equipment's are measured at cost less accumulated depreciation as per IAS 16: Property, Plant and Equipment.

The cost of an item of property, plant and equipment comprises its purchase price, import duties and non-refundable taxes, after deducting trade discount and rebates, and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the intended manner. The cost also includes the cost of replacing part of the property, plant and equipment and borrowing costs for term debt availed for the construction/ Implementation of the PPE, if the recognition criteria are met.

The cost of self-constructed assets includes the cost of material and direct labor and other costs directly attributable to bringing the assets to a working condition inclusive of inward freight, duties and non-refundable taxes for their intended use.

Subsequent costs

The subsequent expenditure is only capitalized as part of assets when the useful life or economic benefit or both of that asset is increased provided that it is probable that the future economic benefits embodied within the part will flow to the group and its cost can be measured reliably. The costs of day to day servicing of property, plant and equipment are recognized in the Statement of Profit or loss and other comprehensive income as 'Repair and Maintenance' when it is incurred.

Depreciation on non-current assets

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provision of IAS 16 "Property, Plant and Equipment". Depreciation is charged on additions made during the year from the month in which those assets are put into ready to use. Depreciation is charged on all the fixed assets except land and land development on reducing balance method at the following rates.

Particular of Assets	Rate of Depreciation
Building	2.5%
Plant & Machinery	10%
Internal Road	10%
Installations	10%
Equipment	10%
Computers	30%
Furniture & Fixtures	10%
Motor vehicles	10%
Motorcycle	20%
Spare & Loose Tools	30%
Library Books	30%
Temporary Construction	30%

Depreciation methods, useful lives and residual values are reviewed after each reporting period. No estimate of Property, Plant and equipment was revised during the year.

Impairment

The carrying amounts of property, plant and equipment are reviewed at each reporting date to determine whether there is any indication of

impairment loss. If any such indication exists, recoverable amount is estimated to determine the extent of the impairment loss, if any. Impairment loss is recorded on judgmental basis, for which provision may differ in the future years based on the actual experience.

Disposal of property, plant and equipment

An item of Property, Plant and Equipment is removed from the statement of financial position when it is disposed of or when no future economic benefits are expected from its use or disposal. The gain or loss on the disposal of an item of Property, Plant and Equipment is included in the statement of income of the period in which the de-recognition occurs.

Capital work in progress

Property, plant and equipment under construction/ acquisition have been accounted for as capital work-in-progress until construction/acquisition is completed and measured at cost.

3.2 Intangible assets and research and development expenditures

Intangible assets are stated at cost less provisions for amortization and impairments, if any. License, patents, know-how and marketing rights acquired are amortized over their estimated useful lives, using the straight line basis, from the time they are available for use. The cost of acquiring and developing computer software for internal use and internet sites for external use are capitalized as intangible assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset.

In compliance with the requirements of IAS 38 "Intangible Assets", research, development and experimental costs are usually absorbed as revenue charges as and when incurred. However, the research and development expenditures that is definite to yield benefit to the Group and is material in the Group's and/ local context, are capitalized as per IAS-38.

3.3 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds as per IAS 23: Borrowing Costs.

3.4 Revenue

The Group recognises as revenue the amount that reflects the consideration to which the Group expects to be entitled in exchange for goods or services when (or as) it transfers control to the customer. To achieve that core principle, this standard establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations in the contract; and
- Recognise revenue when (or as) the entity satisfies a performance obligation.

Considering the five steps model, the Group recognises revenue when (or as) the Group satisfies a performance obligation by transferring promised goods to a customer. Goods are considered as transferred when (or as) the customer obtains control of those goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

Sale of goods

Revenue from the sale of goods is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods. The Group has generally concluded that it is the principal in its revenue arrangements because it typically controls the goods or services before transferring them to the customer.

Profit on bank deposits

Profit on bank deposits have been accounted on accrual basis.

Dividends

Revenue is recognised when the group's right to receive the payment is established, which is generally the date when shareholders of investee company approve the dividend.

3.5 Financial instruments

IFRS 9 sets out requirements for recognising and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items.

The details of new significant accounting policies and the nature and effect of the changes to previous accounting policies are set out below.

Classification and measurement of financial assets and financial liabilities

IFRS 9 largely retains the existing requirements in IAS 39 for the classification and measurement of financial liabilities. However, it eliminates the

previous IAS 39 categories for financial assets of held to maturity, loans and receivables and available for sale.

The adoption of IFRS 9 has not had a significant effect on the group's accounting policies related to financial liabilities. The impact of IFRS 9 on the classification and measurement of financial assets is set out below.

Under IFRS 9, on initial recognition, a financial asset is classified as measured at: amortised cost; Fair Value through Other Comprehensive Income (FVOCI) – debt investment; Fair Value through Other Comprehensive Income (FVOCI) – equity investment; or Fair Value Through Profit or Loss (FVTPL). The classification of financial assets under IFRS 9 is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. Derivatives embedded in contracts where the host is a financial asset in the scope of the standard are never separated. Instead, the hybrid financial instrument as a whole is assessed for classification.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

a. it is held within a business model whose objective is to hold assets to collect contractual cash flows; and

b. its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

a. it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and

b. its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the group may irrevocably elect to present subsequent changes in the investment's fair value in OCI. This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL.

A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition.

The following accounting policies apply to the subsequent measurement of financial assets.

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on de-recognition is recognized in profit or loss. Trade receivables are classified as financial assets measured at amortised cost.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On de-recognition, gains and losses accumulated in OCI are reclassified to profit or loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are never reclassified to profit or loss.

Impairment of financial assets

IFRS 9 replaces the 'incurred loss' model in IAS 39 with an 'expected credit loss' (ECL) model. The new impairment model applies to financial assets measured at amortised cost, contract assets and debt investments at FVOCI, but not to investments in equity instruments.

The financial assets at amortised cost consist of trade receivables, cash and cash equivalents, and corporate debt securities. The group measures loss allowances at an amount equal to ECL from trade receivables.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative

and qualitative information and analysis, based on The group's historical experience and informed credit assessment and including forward-looking information.

The group considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the group in full, without recourse by The group to actions such as realizing security (if any is held).

Measurement of Expected Credit Losses (ECL)

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the group expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

Presentation of impairment

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is recognised in OCI, instead of reducing the carrying amount of the asset.

Impairment losses related to trade receivables and others, including contract assets, are presented separately in the notes to the financial statement.

3.6 Impairment of Non-financial assets

The carrying amounts of the Group's non-financial assets (other than inventories) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated in order to determine the extent of impairment loss (if any). Where it is not possible to determine the recoverable amount of an individual asset, the Group estimates the recoverable amount of the Cash Generating Unit (CGU) to which the asset belongs. An impairment loss is recognised if the carrying amount of an asset or its CGU exceeds its recoverable amount.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre- tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

Impairment losses are recognised in profit or loss. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation, if no impairment loss had been recognised.

3.7 Inventories

Inventories consisting of raw materials, work in progress, finished goods are valued at lower of cost and net realizable value. Cost of inventories include expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Cost of inventories is determined by using the weighted average cost formula. Where necessary, allowance is provided for damaged, obsolete and slow-moving items to adjust the carrying amount of inventories to the lower of cost and net realizable value. Net realizable value is based on estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

3.8 Cash and cash equivalents

Cash and cash equivalents consists of cash on hand and with banks on current accounts, deposit accounts and short term investments which are held and available for use by the group without any restriction. There is insignificant risk of change in value of the same.

3.9 Earnings per Share (EPS)

Earnings per Share (EPS) are calculated in accordance with the International Accounting Standard IAS- 33 "Earnings Per Share".

Basic earnings per share

Basic earnings per share is calculated by dividing the profit or loss attributable to ordinary equity holders of the entity by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share

For the purpose of calculating diluted earnings per shares, an entity adjusts profit or loss attributable to each ordinary equity holders of the entity, and weighted average number of shares outstanding, for the effects of all dilutive potential ordinary shares. Diluted EPS is only calculated where the group has commitment to issue ordinary share in future at reporting date. No such commitment is hold by group at reporting date.

3.10 Foreign currency transactions

Foreign currency transactions are recorded, on initial recognition in the functional currency at the spot exchange rate ruling at the transaction date.

At the end of each reporting period in compliance with the provision of IAS 21: The Effects of Changes in Foreign Exchange Rates.

a) Foreign currency monetary items are translated using the closing rate.

b) Non-monetary items that are measured in terms of historical costs in a foreign currency are translated using the exchange rate at the date of the transaction.

c) Non-monetary items that are measured at fair value in a foreign currency is translated using the exchange rate at the date when the fair value is determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rate different from those at which they were translated on initial recognition during the period or in previous financial statements is recognized in profit or loss in the period in which they arise.

Amount in FCAD ERQ Account and any other foreign currency balance have been translated into taka at the reporting date at the exchange rate prevailing on that date and gain/(loss) have been accounted for as other income/(loss) in statement of profit or loss and comprehensive income.

3.11 Employee benefits

The Company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective trust deeds and rules. Both of the plans are funded and are recognised/approved under Income Tax Ordinance 1984 from National Board of Revenue (NBR).

(a) Defined contribution plan (provident fund)

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contribution to defined contribution plans are recognised as an employee benefit expense in profit or loss in the period during which related services are rendered by employees. Advance contributions are recognised as an asset to the extent that a cash refund or a reduction in future payment is available.

The Company has a separate recognised provident fund scheme. All permanent employees of The Company contribute 10% of their basic salary to the provident fund and the group makes matching contributions.

The group recognises contribution to defined contribution plan as an expense when an employee has rendered related services in exchange for such contribution. The legal and constructive obligation is limited to the amount The Company agrees to contribute to the fund.

(b) Defined benefit plan (gratuity)

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The employee gratuity plan is considered as defined benefit plan as it meets the recognition criteria. The group's obligation is to provide the agreed benefits to current and former employees. The net defined benefit liability/(asset) in respect of a defined benefit plan is recognised in the statement of financial position.

Current service cost, past service cost and gain/loss on settlement and net interest on the net defined benefit liability/(asset) are recognized in profit or loss. Service cost and gain/loss on settlement are classified as personnel expense.

The gratuity is calculated for all the employees prescribed by the rates as per Labor Act 2006 (as amended to 2018) for their service with the group. The gratuity fund is administered by the Board of Trustees.

Superannuation Fund:

The Company has established a Superannuation Fund in the year 2013 to extend financial help to the employees and their family members as per rules in case of severe diseases, physical disability, death and retirement. Every year the Company contributed to the Fund and will continue its support in the coming days.

Workers' Profit Participation Fund (WPPF)

The Company provides 5% of its profit before Tax after charging contribution to WPPF in accordance with Bangladesh Labor Act, 2006 (as amended to 2018)

(c) Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

3.12 Accruals, provisions and contingencies

(a) Accruals

Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees. Accruals are reported as part of trade and other payables.

(b) Provisions

A provision is recognised in the statement of financial position when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliableestimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the reporting date. Where the group expects some or all of a provision to be reimbursed, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the income statement net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. During the reporting year the group has made sufficient provisions where applicable.

(c) Contingencies

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the group; or a present obligation that arises from past events but is not recognised because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the group. At the reporting date the group does not have any contingent asset.

Contingent liabilities and assets are not recognised in the statement of financial position of the group.

3.13 Operating Segments

No geographical segment reporting is applicable for the Group as required by IFRS 08: Operating Segments, as the Group operates in a single geographical area and has a single business line of product i.e. manufacturing and selling of medicine.

3.14 Statement of cash flows

The Statement of Cash Flows has been prepared in accordance with the requirements of IAS 7: Statement of Cash Flows. The cash generating from operating activities has been reported using the Direct Method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS 7 whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

3.15 Related party disclosures

As per International Accounting Standards IAS-24: 'Related Party Disclosures', parties are considered to be related if one of the parties has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. The Group carried out transactions in the ordinary course of business on an arm's length basis at commercial rates with its related parties. Related party disclosures have been given in Note 36.

3.16 Income tax

Income tax expense comprises current and deferred taxes. Income tax expense is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity in accordance with IAS 12: Income Tax.

3.17 (a) Current tax

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous periods. The tax rate used for the reporting period was 20% as a publicly traded company.

3.17 (b) Deferred tax

Deferred tax is recognized as income or an expense amount within the tax charge, and included in the net profit or loss for the period. Deferred tax relating to items dealt with other comprehensive income is recognized as tax relating to other comprehensive income within the statement of profit or loss and other comprehensive income.

Taxable Temporary difference

A deferred tax liability is recognised for all taxable differences, except to the extent that the deferred tax liability arises from the initial recognition of goodwill; or the initial recognition of an asset or liability in a transaction which is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

Deductible temporary difference

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against

which the deductible temporary difference can be utilized, unless the deferred tax asset arises from the initial recognition of an asset or liability in a transaction that is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

3.18 Events after the reporting period

Events after the reporting period that provide additional information about the group's position at the statement of financial position date are reflected in the financial statements as per International Accounting Standards IAS-10: 'Events after the Reporting Period'.

All material events occurring after the balance sheet date have been considered and where necessary, adjusted for or disclosed.

3.19 Compliance with financial reporting standards as applicable in Bangladesh

The Group as per Para-12 of Securities & Exchange Rule-1987, with the following International Accounting Standards (IASs) and International Financial Reporting Standards (IFRS) as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council, Bangladesh in preparing the financial statements.

Sl. No.	IAS No.	IAS Title	Compliance Status
1	1	Presentation of Financial Statements	Complied
2	2	Inventories	Complied
3	7	Statement of Cash Flows	Complied
4	8	Accounting Policies, Changes in Accounting Estimates and Errors	Complied
5	10	Events after the Reporting Period	Complied
6	12	Income Taxes	Complied
7	16	Property, Plant & Equipment	Complied
8	19	Employee Benefits	Complied
9	20	Accounting for Government Grants and Disclosure of Government Assistance	Not Applicable
10	21	The Effects of Changes in Foreign Exchange Rates	Complied
11	23	Borrowing Cost	Complied
12	24	Related Party Disclosures	Complied
13	26	Accounting and Reporting by Retirement Benefit Plans	Not Applicable
14	27	Separate Financial Statements	Complied
15	28	Investments in Associates and joint ventures	Not Applicable
16	29	Financial Reporting in Hyperinflationary Economics	Not Applicable
17	31	Interest in Joint Ventures	Not Applicable
18	32	Financial Instruments: Presentation	Complied
19	33	Earnings per Share	Complied
20	34	Interim Financial Reporting	Complied
21	36	Impairment of Assets	Complied
22	37	Provisions, Contingent Liabilities and Contingent Assets	Complied
23	38	Intangible Assets	Complied
24	40	Investment Property	Not Applicable
25	41	Agriculture	Not Applicable

Sl. No.	IFRS No.	IFRS Title	Compliance Status
1	1	First-time adoption of International Financial Reporting Standards	Not Applicable
2	2	Share-based Payment	Not Applicable
3	3	Business Combinations	Not Applicable
4	4	Insurance Contracts	Not Applicable
5	5	Non-current Assets Held for Sale and Discontinued Operations	Not Applicable
6	6	Exploration for and Evaluation of Mineral Resources	Not Applicable
7	7	Financial Instruments: Disclosures	Complied
8	8	Operating Segments	Complied
9	9	Financial Instrument	Complied
10	10	Consolidated Financial Statements	Complied
11	11	Joint Arrangements	Not Applicable
12	12	Disclosure of Interests in other Entities	Complied
13	13	Fair Value Measurement	Complied
14	14	Regulatory Deferral Accounts	Not Applicable
15	15	Revenue from Contracts with Customers	Complied
16	16	Lease	Complied

3.20 Leases

Right-of-use Assets and Lease Liabilities as Leasee

The Company assesses whether a contract is or contains a lease, at inception of the contract. As a Leasee, the Company recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less). For these leases, the Company recognizes the lease payments as an expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The Company recognizes a right-of-use asset at the lease commencement date. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received, and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in the statement of financial position.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate.

The lease liability is presented as a separate line in the statement of financial position.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

Finance Lease or operating lease as Lessor

The company as a lessor classify its leases as either an operating lease or a finance lease.

3.21 Investment in Subsidiary

The group's investment in subsidiaries is accounted for in the separate financial statements as per IAS 27: "Separate Financial Statements" using the cost method. Dividends from the subsidiaries are recognized in the separate financial statements of the Company when the Company's right to receive the dividend is established. The dividend is recognized in profit or loss unless the Company elects to use the equity method, in which case the dividend is recognized as a reduction from the carrying amount of the investment.

3.22 Dividend Distribution

Final dividend distributions to the Company's shareholders are recognized as a liability in the financial statements in the period in which the dividends are approved by the Company's shareholders at the Annual General Meeting, while interim dividend distributions are recognized in the period in which the dividends are declared and paid.

3.23 Adoption of new and amended International Financial Reporting Standards

The new and amended standards are not expected to have a material impact on the Company's financial statements.

04. PROPERTY, PLANT AND EQUIPMENT:

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
Cost		
Opening balance	4,169,069,419	3,956,915,644
Addition during the year	137,224,204	215,232,652
Disposal/Adjustment during the year	-	(3,078,877)
Closing balance	**4,306,293,623**	**4,169,069,419**
Accumulated Depreciation		
Opening balance	1,737,415,883	1,554,782,910
Charged during the year	179,260,907	185,554,095
Disposal/Adjustment during the year	-	(2,921,123)
Closing balance	**1,916,676,789**	**1,737,415,883**
Closing balance of Written Down Value (WDV)	**2,389,616,834**	**2,431,653,536**

i. The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company. Please see the annexure -A.
ii. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:

The IBN SINA Pharmaceutical Industry PLC	2,389,616,834	2,431,653,536
The IBN SINA API Industry Ltd.	164,672,352	142,245,156
The IBN SINA Polymer Industry Ltd.	2,380,977	2,288,106
The IBN SINA Natural Medicine Ltd.	81,842,005	79,332,838
	2,638,512,168	**2,655,519,636**

05. CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	711,323,283	366,379,612
Add: Addition during the year	201,319,709	344,943,671
Less: Transferred to property, plant and equipment	-	-
Closing balance	**912,642,992**	**711,323,283**
B) Machinery in transit and installation		
Opening balance	398,469,652	213,664,954
Add: Addition during the year	2,710,341,137	310,149,835
Less: Transit closed during year	(269,073,756)	(125,345,137)
	2,839,737,033	**398,469,652**
Other Goods-In-Transit	27,455,091	46,029,239
	3,779,835,116	**1,155,822,174**

i) A new Factory is being constructed to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. That is why construction working progress and machinery in transit and installation increased significantly.
ii) The amount of machinery in transit represents the amount for opening the LC for the procurement of machineries for newly constructed factory building and increasing production capacity of existing factory which have not received yet .
iii) Amount of borrowing cost capitalised during the year is Tk. 5,133,563
iv) Capitalisation rate used is 7.50% for machinery upas.
v. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:

A) Construction work-in-progress (Building)		
Opening balance	939,492,119	465,469,776
Addition during the year	341,426,379	474,022,343
Less: Transferred to property, plant and equipment	-	-
Closing balance	**1,280,918,499**	**939,492,119**
B) Machinery in transit and installation		
Opening balance	946,837,388	673,427,435
Add: Addition during the year	2,799,698,356	398,755,090
Less: Transit closed during the year	(269,073,756)	(125,345,137)
	3,477,461,987	**946,837,388**
Other Goods-In-Transit	27,455,091	46,029,239
	4,785,835,577	**1,932,358,746**

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
05.B RIGHT OF USE ASSETS (ROU):		
Cost:		
Opening balance	130,252,602	130,252,602
Addition during the year	-	-
Disposal/Adjustment during the year	-	-
Closing balance	**130,252,602**	**130,252,602**
Accumulated Depreciation:		
Opening balance	97,179,891	72,375,357
Charged during the year	24,804,533	24,804,533
Disposal/Adjustment during the year	-	-
Closing balance	**121,984,424**	**97,179,891**
Closing balance of Written Down Value (WDV)	**8,268,178**	**33,072,711**
06. FINANCIAL ASSESTS (NON-CURRENT PORTION):		
Exim Bank PLC	1,140,000	2,090,000
First Security Islami Bank PLC	3,896,900	7,793,800
Shahjalal Islami Bank PLC	1,854,000	1,699,500
Al-Arafah Islami Bank PLC	1,676,325	1,849,365
Social Islami Bank PLC	520,929	1,284,958
Islami Bank Bangladesh PLC in MPB	3,050,055	2,939,895
	12,138,209	**17,657,518**

The above investment in marketable securities are designated as Fair Value thought other comprehensive income by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. Please see the annexure B.

06.A CONSOLIDATED FINANCIAL ASSESTS (NON-CURRENT PORTION):		
Exim Bank PLC	1,140,000	2,090,000
First Security Islami Bank PLC	3,896,900	7,793,800
Shahjalal Islami Bank PLC	1,854,000	1,699,500
Al-Arafah Islami Bank PLC	1,676,325	1,849,365
Social Islami Bank PLC	520,929	1,284,958
Islami Bank Bangladesh PLC in MPB	3,050,055	2,939,895
Investment in API Industrial Park Services Ltd.	29,000,000	29,000,000
	41,138,209	**46,657,518**
07. INVESTMENT IN SUBSIDIARY		
The IBN SINA API Industry Ltd.	799,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.	200,000,000	130,000,000
	1,238,169,470	**1,038,169,470**

i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk. 12.00 crore has been paid as a part of share capital.

ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.

iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company.

iv) Investment in subsidiary increased due to fulfilling subsidiary companies investment need.

08. FINANCIAL ASSESTS (CURRENT PORTION):		
Opening Balance	22,500,000	89,500,000
Closed-during the year	-	(67,000,000)
Investment in MTD	**22,500,000**	**22,500,000**
08.A CONSOLIDATED FINANCIAL ASSESTS (CURRENT PORTION):		
Investment in MTD	**22,500,000**	**22,500,000**

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025

08.1 INVENTORIES

Raw materials	713,243,317	661,133,854
Packing materials	269,533,870	230,992,875
Work-in-process	105,219,105	97,983,312
Finished goods	344,256,222	357,701,249
Physicians' samples	6,578,305	5,836,177
Pad & literature	4,719,383	4,127,335
Spares & stores	429,379	360,234
Indirect materials	515,942	463,694
Printing & stationery	448,072	393,698
Laboratory chemicals	261,565	236,318
Material in transit	293,589,728	244,546,564
	1,738,794,887	**1,603,775,310**

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces, some are in box and some are in kg, gram, milligram and ton as such quantity can not be inserted.
ii) There is no damage goods or slow moving item in the inventory list.
iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.
iv) Inventory for Raw materials , Packing materials, Work In Process, Finished goods and pad & literature changed during the period for ensuring smooth supply of products.

08.B CONSOLIDATED INVENTORIES

Raw materials	799,860,851	768,094,729
Packing materials	295,680,022	245,848,438
Work-in-process	126,653,151	111,124,876
Finished goods	440,506,971	424,409,351
Physicians' samples	9,717,892	8,481,886
Pad & literature	4,719,383	4,127,335
Spares & stores	429,379	360,234
Indirect materials	515,942	463,694
Printing & stationery	448,072	393,698
Laboratory chemicals	261,565	236,318
Material in transit	293,589,728	244,546,564
	1,972,382,955	**1,808,087,123**

09. TRADE AND OTHER RECEIVABLES

Trade receivable (net off bad debt provision)	170,988,026	181,402,168
Receivable from provident fund (PF)	602,059	304,966
Dividend receivable	341,496	-
Profit receivable from MTD	4,966,878	3,391,971
Other receivable-toll charge	3,346,594	2,497,081
	180,245,053	**187,596,187**

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due from the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.
ii) Other receivable increased during the year as few months toll charge bill remain receivable.

The lifetime expected credit loss provision for trade receivables is as follows:

30-Jun-26	Current	1-30 days past due	31-90 days past due	91-120 days past due	120-180 days past due	Above 180 days past due	Total
ECL rate	0%	0.20%	0.50%	5.00%	10.00%	20.00%	
Gross carrying amount	3,597,055	113,642,996	43,485,156	2,846,581	1,501,163	8,315,290	173,388,241
Loss Provision	-	227,286	217,426	142,329	150,116	1,663,058	2,400,215

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:		
Trade receivable (net off bad debt provision)	180,517,362	189,858,588
Receivable from provident fund (PF)	602,059	304,966
Dividend receivable	341,496	-
Profit receivable from MTD	4,966,878	3,391,971
Other receivable-toll charge	3,346,594	2,497,081
	189,774,389	**196,052,607**
10. ADVANCES, DEPOSITS & PREPAYMENTS		
a. Advances against		
Salary	6,102,581	5,482,341
Expenses/works/others	12,433,414	12,433,414
Dep ot rent	6,816,187	6,727,985
Motor cycles-to employees	66,216,715	42,143,838
Building (Flat) - Concord Lily Height'S	105,000,000	-
Others	706,533	706,533
	197,275,431	**67,494,111**
b. Income tax		
Opening balance	374,539,128	200,028,807
Addition	190,610,415	174,510,320
Adjusted during the year	-	-
	565,149,543	**374,539,128**
c. Deposits		
Security money	**20,580,535**	**21,275,544**
d. Pre payments		
Value Added Tax	**715**	**6,683**
	783,006,223	**463,315,466**
10.1 MATURITY ANALYSIS		
Realisable/adjustable within one year.	749,291,153	429,600,396
Realisable/adjustable after one year.	33,715,070	33,715,070
	783,006,223	**463,315,466**

i) The company did not give any advance, deposit and prepayment to the director's of the company, subsidiary, associates and other connected party and employees advances are realised in normal course of business.
ii) Advance against works, salary and motor cycle increased during this year to meet up business needs.
iii) Advance income tax increased during this period to meet up regulatory requirement.
iv) Security money increased during this year as security money was paid to various parties for business purpose.

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
10.A CONSOLIDATED ADVANCES, DEPOSITS & PREPAYMENTS		
a. Advances against		
Salary	16,459,616	9,555,942
Expenses/works/others	13,573,966	31,119,648
Depot rent	6,816,187	6,727,985
Motor cycles-to employees	78,047,148	61,431,738
Building (Flat) - Concord Lily Height'S	105,000,000	-
Others	2,991,698	2,101,636
	222,888,615	**110,936,949**
b. Income tax		
Opening balance	404,148,716	223,481,751
Addition	205,988,714	180,666,965
	610,137,431	**404,148,716**
c. Deposits		
Security money	**21,635,232**	**22,330,241**
d. Pre payments		
Value Added Tax	**715**	**6,683**
	854,661,993	**537,422,590**
10.A.1 MATURITY ANALYSIS		
Realisable/adjustable within one year.	820,696,923	503,707,520
Realisable/adjustable after one year.	33,965,070	33,715,070
	854,661,993	**537,422,590**
11. CASH & CASH EQUIVALENTS		
a. Cash in hand	7,077,597	6,613,494
b. Cash at banks	149,773,374	170,528,294
c. Imprest cash	3,535,000	3,540,000
	160,385,971	**180,681,788**
CASH AT BANKS		
a. Islami Bank Bangladesh PLC		
In SND Accounts	58,932,119	107,552,199
In MSA Accounts	850,241	831,753
In FCAD ERQ Accounts	1,117,739	1,316,416
Cash with IBBL Securities Ltd.	374	524
b. Al-Arafah Islami Bank PLC in SND Accounts	56,874,197	43,945,485
c. Prime Bank PLC in Current Account (Islamic banking branch)	29,396	29,396
d. Shimanto Bank PLC in SND Account	16,435	16,435
e. First Security Islami Bank PLC in SND Accounts	1,488,227	1,411,967
f. Sonali Bank PLC in ERQ Account	360,537	360,390
g. Sonali Bank PLC in STD Account	1,068,682	1,052,377
h. City Bank PLC	24,228,574	359,518
i. Pubali Bank PLC	1,626,666	4,490,038
j. Standard Chartard Bank PLC	360,419	-
h. Standard Bank PLC	2,819,768	9,161,796
	149,773,374	**170,528,294**

i) The bank reconciliation was performed at the year end and found in order.
ii) Physical cash counting was taken place at the year end and no surplus or deficit was found.
iii) Cash and cash equivalent decreased due to settlement of shorter loan.

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
11.A CONSOLIDATED CASH & CASH EQUIVALENTS		
a. Cash in hand	8,616,897	7,137,453
b. Cash at banks	285,023,263	304,095,694
c. Imprest cash	3,665,000	3,670,000
	297,305,160	**314,903,147**
12. SHARE CAPITAL		
Authorized		
50,000,000 Ordinary Shares of Tk. 10 each	**500,000,000**	**500,000,000**
Issued, Subscribed & Paid-Up :		
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash	**312,436,270**	**312,436,270**

The Shareholdings consist of :

Holders	No. of Holders	Total Holdings	Percentage
Sponsor	1	13,843,312	44.31%
Institutions	218	8,052,066	25.77%
General Public	12,314	9,348,249	29.92%
	12,533	**31,243,627**	**100.00%**

The distribution schedule showing the number of share holders and their share holdings as on 30.06.2026 are as follows:

Range of holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,977	1,727,958	5.53%
500 to 5,000 shares	2,188	3,299,599	10.56%
5,001 to 10,000 shares	188	1,341,142	4.29%
10,001 to 20,000 shares	85	1,145,793	3.67%
20,001 to 30,000 shares	24	550,758	1.76%
30,001 to 40,000 shares	15	525,794	1.68%
40,001 to 50,000 shares	8	360,545	1.15%
Above 50,000 shares	48	22,292,038	71.35%
	12,533	**31,243,627**	**100.00%**

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quotedat Tk. 319.60 in the Dhaka Stock Exchange Limited as at 30.06.2026 and at Tk. 335.00 in the Chittagong Stock Exchange Limited as at 30.06.2026 respectively.

13. TAX HOLIDAY RESERVE	**4,392,110**	**4,392,110**

This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.

14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:		
Closing market value of marketable securities	12,138,209	17,657,518
Less: Cost of marketable securities	34,928,997	34,928,997
Unrealised gain before adjustment of deferred tax	**(22,790,788)**	**(17,271,479)**
Less: Deferred tax on unrealised gain (loss)	2,279,079	1,727,148
Net unrealised gain/(loss) on marketable securities	**(20,511,709)**	**(15,544,331)**

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
15. RETAINED EARNINGS		
Opening Balance	3,631,099,007	3,167,771,833
Dividend paid	(199,959,213)	(196,834,850)
Add: Net profit during the year	792,686,798	660,162,024
	4,223,826,592	**3,631,099,007**
15.A CONSOLIDATED RETAINED EARNINGS		
Opening Balance	3,625,617,615	3,189,263,114
Dividend paid	(199,959,213)	(196,834,850)
Add: Net profit during the year	794,633,174	633,189,350
	4,220,291,576	**3,625,617,615**
15.B NON CONTROLLING INTEREST		
The IBN SINA API Industry Ltd.	200	200
The IBN SINA Natural Medicine Ltd.	3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by The IBN SINA Trust)	140,000,000	70,000,000
Add: Share of Profit/(Loss)	(762,477)	943,396
	139,240,723	**70,946,596**
16. LONG TERM FINANCE		
i) From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shirkatul Melk-HPSM)	838,907,795	565,545,640
ii) From Pubali Bank PLC (Long Term -H.P.S.M) Pharma	323,752,886	307,123,287
Current maturity transferred to current liability		
ii) From Al-Arafah Islami Bank Ltd. Secured (Under Hire Purchase Shirkatul Melk) Note-21	(172,534,991)	(119,445,855)
LONG TERM FINANCE - net off current maturity	**990,125,690**	**753,223,072**

i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial position @ 13%, 12.50% & 11 % of profit.

ii) The loan was taken from Al-Arafah Islami Bank PLC and Pubali Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.

iii) HPSM is repayable in 84 monthly equal installment.

iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.

v) The company achieved AA+ rating in long term and ST-1 for short term from Alpha credit rating Ltd.

vi) For construction purpose company has taken loan from Pubali Bank PLC that is why long lerm loan increased significantly.

vii) Information regarding loan fall due after five years.

Loan fall due from 2 to 5 years	559,271,863	377,030,427
Loan fall due from 6 to more years	430,853,827	376,192,645
	990,125,690	**753,223,073**
16.A CONSOLIDATED LONG TERM FINANCE :		
The IBN SINA Pharmaceutical Industry PLC	990,125,689	753,223,072
The IBN SINA API Industry Ltd.	207,106,867	221,482,304
	1,197,232,556	**974,705,376**
17. EMPLOYEE BENEFIT OBLIGATIONS:		
Opening balance	990,546	1,185,180
Provision during the year	117,017,617	97,491,986
Less: Paid during the year	(117,500,442)	(97,686,620)
	507,721	**990,546**
17.A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:		
Opening balance	990,546	1,185,180
Provision during the year	156,776,143	137,250,512
Less: Paid during the year	(157,258,968)	(137,445,146)
	507,721	**990,546**

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
17.B LEASE LIABILITIES		
Opening Balance	23,798,698	50,336,979
Finance charge	1,282,480	3,692,459
Paid during the year	(25,081,178)	(30,230,740)
Closing balance	**-**	**23,798,698**
Less : Transferred to current maturity	-	(23,798,698)
	-	**-**

i) The company has lease against its Head Office and its Depot at Mirpur, Dhaka respectively.
ii) Lease period is upto 31.10.2026
iii) Advance amount paid Tk. 11,661,000
iv) Monthly adjustment Tk. 50,000

18. DEFERRED TAX LIABILITIES/(ASSETS)

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductable) temporary difference	Applicable tax rate	Deferred tax liability/(assets)
Property, plant and equipment	2,389,616,834	1,921,535,868	468,080,965	20.00%	93,616,193
Gratuity	118,008,163	117,500,442	(507,721)	20.00%	(101,544)
Lease	8,268,178	7,309,133	959,044	20.00%	191,809
Unrealized gain on marketable securities	(22,790,788)	-	(22,790,788)	10.00%	(2,279,079)
Bad Debt provision	2,400,215	-	(2,400,215)	20.00%	(480,043)
As at 30 June 2026	**2,495,502,602**	**2,046,345,444**	**443,341,286**		**90,947,336**
Property, plant and equipment	2,431,653,536	1,943,389,552	488,263,984	20.00%	97,652,797
Gratuity	98,677,167	97,686,620	(990,547)	20.00%	(198,109)
Lease	9,274,013	12,994,333	(3,720,320)	20.00%	(744,064)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626		(1,358,626)	20.00%	(271,725)
As at 30 June 2025	**2,523,691,863**	**2,054,070,505**	**464,923,012**		**94,711,750**

DEFERRED TAX (EXPENSES)/INCOME		
Closing balance of deferred tax liabilities	90,947,336	94,711,750
Opening balance of deferred tax liabilities	94,711,750	99,285,702
Total deferred tax expenses	**(3,764,414)**	**(4,573,952)**
Less/Add: Deferred tax expenses related to other comprehensive income	551,931	770,401
	(3,212,483)	**(3,803,551)**

19. CONSOLIDATED DEFERRED TAX LIABILITIES/(ASSETS):

Particulars	Carrying amount	Tax base value	Taxable (deductable) temporary difference	Applicable tax rate	Deferred tax liability/(assets)
Property, plant and equipment	2,638,512,168	2,161,780,901	476,731,266	20% To 27.50%	95,857,055
Gratuity	161,527,536	161,019,815	(507,721)		(101,544)
Accrued profit on mtdr	-	-	-	27.50%	-
Lease	8,011,893	7,309,133	702,759		102,427
Unrealized gain on marketable securities	(22,790,788)	-	(22,790,788)	10%	(2,349,557)
Bad Debt provision	2,400,215	-	(2,400,215)		(480,043)
As at 30 June 2026	**2,787,661,024**	**2,330,109,850**	**451,735,302**		**93,028,338**
Property, plant and equipment	2,653,231,530	2,157,701,612	495,529,918	20% To 27.50%	99,530,336
Gratuity	148,665,292	147,674,745	(990,547)		(198,109)
Accrued profit on mtdr	-	-	-	27.50%	-
Lease	8,813,099	12,994,333	(4,181,234)		(870,815)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)		(271,725)
As at 30 June 2025	**2,794,797,068**	**2,318,370,690**	**471,728,033**		**96,462,538**

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
DEFERRED TAX (EXPENSES)/INCOME		
Closing balance of deferred tax liability	93,028,338	96,462,538
Opening balance of deferred tax liabilities	96,462,538	101,180,185
Total deferred tax expenses	(3,434,200)	(4,717,647)
Less/Add: Deferred tax expenses related to other comprehensive income	551,931	770,401
	(2,882,270)	**(3,947,246)**

20. SHORT TERM FINANCE

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC-(MPI/UPAS)	2,607,058,173	933,771,898
	2,607,058,173	**933,771,898**

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of statement of financial position @ 15% of profit and 0.20% commission per quarter to be paid.

ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite investment facilities LC/MPI/MIB/ TR/UPAS/ Baimuajjal agreement.

iii) Short term loan is repayable within twelve months.

iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.

v) Short term finance decreased significantly due to settlement of short term LCs.

20.A CONSOLIDATED SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/UPAS)	2,607,058,173	933,771,898
B. The IBN SINA API Industry Ltd.	29,306,186	19,911,341
	2,636,364,359	**953,683,239**

21. CURRENT PORTION OF LONG TERM FINANCE

i) From Al-Arafah Islami Bank PLC -Secured (Note-16) (Under Hire Purchase Shirkatul Melk)	**172,534,991**	**119,445,855**

The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank PLC which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.

22. TRADE AND OTHER PAYABLE

Payable to suppliers		705,359,343	354,248,263
Provisions	Note-22.1	166,819,427	187,977,710
Accrued expenses		303,940,483	178,532,052
Security money received from employees and others		12,437,585	11,517,972
Workers' profit participation fund & welfare fund		49,806,420	42,953,850
		1,238,363,259	**775,229,847**

i) Payable to suppliers and accrued expenses increased this year to meetup business need.

ii) Accrued expenses decreased du to payment made same bill after reporting period.

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
22.1 PROVISIONS:		
Opeining balance	187,977,710	144,607,133
Provisions made during the year	166,819,427	187,977,710
Provisions used during the year	(187,977,710)	(144,607,133)
Closing balance	**166,819,427**	**187,977,710**
22.A CONSOLIDATED TRADE AND OTHER PAYABLE		
Payable to suppliers	760,786,943	396,181,410
Provisions	166,819,427	187,977,710
Accrued expenses	314,015,709	203,253,644
Security money received from employees and others	12,437,585	11,517,972
Workers' profit participation fund & welfare fund	52,979,904	43,358,391
	1,307,039,568	**842,289,127**
22.A.1 UNCLAIMED DIVIDEND		
Opening	42,104,508	39,140,597
Addition	199,959,213	196,834,850
Paid to share holders	(214,023,231)	(186,963,608)
Paid to Capital Market Stabilisation Fund	-	(6,907,331)
	28,040,490	**42,104,508**
22.A.2 UNCLAIMED DIVIDEND		
Year-wise break-up is as follows :		
2021-22	-	12,953,290
2022-23	10,966,874	15,606,678
2023-24	9,905,202	13,544,540
2025-26	7,168,414	-
	28,040,490	**42,104,508**
23. PROVISION FOR CORPORATE TAX		
Opening balance	458,584,929	255,866,409
Current tax provision	206,654,091	202,718,520
	665,239,020	**458,584,929**
Adjusted during the year	-	-
	665,239,020	**458,584,929**
23.A CONSOLIDATED PROVISION FOR CORPORATE TAX		
Opening balance	495,245,930	284,580,559
Current tax provision	224,535,706	210,665,371
	719,781,636	**495,245,930**
Adjusted during the year	-	-
	719,781,636	**495,245,930**

i) Income tax liability increased during this year as current tax provision went up with highier profit.
ii) Tax rate is applicable as finance act 2025 and 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
24. REVENUE		
Local revenue	12,234,822,515	10,537,719,504
Export revenue	184,057,541	188,237,518
	12,418,880,056	**10,725,957,022**

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
24.A CONSOLIDATED REVENUE:		
The IBN SINA Pharmaceutical Industry PLC	12,418,880,056	10,725,957,022
The IBN SINA Natural Medicine Ltd.	1,480,912,378	1,157,636,691
	13,899,792,434	**11,883,593,713**

The above revenue represent the following

Product Group	Unit	2025-2026		2024-2025	
		Quantity	Amount	Quantity	Amount
Tablet	Pcs	1,229,237,911	5,151,525,918	1,094,808,761	4,198,049,398
Capsule	Pcs	415,679,238	2,853,025,236	371,632,360	2,439,756,300
Dry Syrup / ORS	Bottle	26,002,805	581,367,128	27,924,900	544,913,682
Liquid Bottles	Bottle	32,329,710	2,811,158,084	27,797,817	2,295,027,321
Drops	Pcs	7,359,975	585,600,313	5,723,391	507,238,083
Ointment	Pcs	8,995,541	571,991,775	7,834,010	419,163,600
Injection	Pcs	10,305,718	1,353,213,524	8,190,285	1,479,445,329
Total Value			**13,907,881,978**		**11,883,593,713**

24.B Timing of revenue recognition			
Products transferred at a point in time		12,418,880,056	10,725,957,022
Products and services transferred over time		-	-
		12,418,880,056	**10,725,957,022**
25. COST OF GOODS SOLD			
This is arrived at as follows:			
Raw materials consumed	Note-25.1	3,883,201,045	3,406,401,899
Packing materials consumed	Note-25.2	1,989,363,352	1,733,049,756
		5,872,564,397	**5,139,451,655**
Opening work-in-process		97,983,312	103,450,764
Closing work-in-process		(105,219,105)	(97,983,312)
Total Consumption		**5,865,328,604**	**5,144,919,107**
Manufacturing expenses	Note-26	1,556,365,257	1,330,536,247
Cost of Production		**7,421,693,861**	**6,475,455,354**
Opening finished goods		357,701,249	356,044,770
Closing finished goods		(344,256,222)	(357,701,249)
		7,435,138,888	**6,473,798,875**
Cost of physicians' sample		(103,474,816)	(44,795,810)
		7,331,664,071	**6,429,003,064**
25.1 RAW MATERIALS CONSUMED			
This is arrived at as follows :			
Opening stock		661,133,854	447,551,352
Purchases		3,935,310,508	3,619,984,401
Closing stock		(713,243,317)	(661,133,854)
		3,883,201,045	**3,406,401,899**
25.2 PACKING MATERIALS CONSUMED			
This is arrived at as follows:			
Opening stock		230,992,875	149,636,336
Purchases		2,027,904,347	1,814,406,295
Closing stock		(269,533,870)	(230,992,875)
		1,989,363,352	**1,733,049,756**

		AMOUNT IN TAKA	
		01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
25.A CONSOLIDATED COST OF GOODS SOLD :			
This is arrived at as follows:			
Raw materials consumed	Note-25.A.1	4,298,249,495	3,706,324,109
Packing materials consumed	Note-25.A.2	2,183,647,200	1,912,037,354
		6,481,896,695	**5,618,361,463**
Opening work-in-process		111,124,876	114,219,828
Closing work-in-process		(126,653,151)	(111,124,876)
Total Consumption		**6,466,368,420**	**5,621,456,415**
Consolidated manufacturing expenses		1,816,597,001	1,541,797,757
Cost of Production		**8,282,965,421**	**7,163,254,172**
Opening finished goods		424,409,351	398,534,726
Closing finished goods		(440,506,971)	(424,409,351)
		8,266,867,801	**7,137,379,547**
Cost of physicians' sample		(119,783,940)	(53,639,679)
		8,147,083,860	**7,083,739,867**
25.A.1 RAW MATERIALS CONSUMED			
This is arrived at as follows :			
Opening stock		768,094,729	593,235,375
Purchases		4,330,015,617	3,881,183,463
Closing stock		(799,860,851)	(768,094,729)
		4,298,249,495	**3,706,324,109**
25.A.2 PACKING MATERIALS CONSUMED			
This is arrived at as follows :			
Opening stock		245,848,438	194,418,191
Purchases		2,233,478,784	1,963,467,601
Closing stock		(295,680,022)	(245,848,438)
		2,183,647,200	**1,912,037,354**

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
26. MANUFACTURING EXPENSES		
Salary, wages & allowances	956,042,739	789,665,283
Travelling & Conveyance	6,020,390	2,650,339
Printing & stationery	6,436,141	5,130,886
Repairs & Maintenance-Building	19,796,061	18,487,690
Repairs & Maintenance- Machinery & Equipment	117,609,352	68,989,386
Vehicle fuel & maintenance	12,004,779	11,993,591
Medical expenses	628,727	595,837
Power & Fuel	162,414,467	173,783,005
Training expenses	181,284	414,630
Insurance Premium	9,706,760	9,327,445
Entertainment	2,978,854	3,510,562
Staff Welfare	72,739,639	63,584,087
Telephone, Fax, etc.	2,472,868	2,185,968
Fees & charges	5,185,133	3,322,720
News paper & periodicals	451,349	223,460
Staff Uniform	11,726,477	9,225,004
Laboratory chemicals & stores	24,249,762	18,960,842
Indirect materials	9,596,234	7,151,795
Depreciation	136,007,372	141,189,496
Sundry expenses	116,870	139,120
	1,556,365,257	**1,330,536,247**

(a) The number of employees employed in the factory throughout the year who received aggregate remuneration less than Tk. 36,000 was nil.

(b) The number of employees employed in the factory for part of the year who received aggregate remuneration less than Tk.3,000 per month was nil.

(c) Salary, wages & allowances include P.F. contribution of Tk. 19,605,631 and Gratuity of Tk. 16,338,026.

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
27. ADMINISTRATIVE EXPENSES		
Salary, wages & allowances	142,020,704	124,211,809
Directors' remuneration	12,000,000	11,900,000
Directors' meeting fee	1,811,789	2,423,894
Travelling & conveyance	6,979,792	4,941,025
Repairs & maintenance-building & equipment	15,768,203	15,867,751
Vehicle fuel & maintenance	4,059,224	4,345,861
Audit fees	485,250	350,000
Medical expenses	67,492	53,937
Postage & stamp	182,275	209,859
Training expenses	147,775	241,102
Insurance premium	313,587	465,675
Entertainment	5,830,054	5,642,797
Staff uniform	516,895	251,117
Staff welfare	5,310,085	4,596,166
Telephone, fax, etc.	1,714,559	1,443,247
Fees & charges	6,234,137	4,848,028
Bank Charge	1,283,045	1,794,713
Donation & subscription	34,000	421,000
Advertisement	6,136,577	6,396,030
News paper & periodicals	205,898	236,935
Printing & stationery	2,218,362	2,116,188
Water, electricity & gas	3,994,677	4,173,231
Annual general meeting expenses	2,331,213	1,899,390
Expenses relating to dividend	198,722	78,268
Depreciation	26,910,272	25,635,097
Sundry expenses	10,000	133,500
Expenses relating to CSR	7,068,254	1,000,000
	253,832,840	**225,676,621**

(a) The number of employees employed in the administration department throughout the year who received aggregate remuneration less than Tk. 36,000 was nil.

(b) Salary, wages & allowances include P.F. contribution of Tk. 4,687,500 and Gratuity of Tk. 5,859,450.

(c) The number of employees employed in the administration department for part of the year who received aggregate remuneration less than Tk. 3,000 per month was nil.

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
27.01 CONSOLIDATED ADMINISTRATIVE EXPENSES		
Salary, wages & allowances	166,941,612	140,429,307
Directors' remuneration	18,370,000	14,250,000
Directors' meeting fee	2,699,825	3,246,619
Travelling & conveyance	11,856,719	5,176,320
Repairs & maintenance-building & equipment	15,956,428	18,795,281
Vehicle fuel & maintenance	4,622,535	4,810,518
Audit fees	738,250	585,750
Medical expenses	67,492	53,937
Postage & stamp	184,974	209,859
Training expenses	255,968	241,102
Insurance premium	3,152,775	2,669,767
Entertainment	5,854,479	5,655,867
Staff uniform	798,330	345,621
Staff welfare	6,809,956	5,358,955
Telephone, fax, etc.	1,918,319	1,452,447
Research & development	2,296,705	940,388
Fees & charges	7,366,961	5,279,943
Bank charge	1,439,776	1,960,027
Donation & subscription	34,000	421,000
Advertisement	6,374,807	6,563,470
News paper & periodicals	205,898	236,935
Printing & stationery	2,496,855	2,375,796
Water, electricity & gas	10,986,917	8,050,069
Annual general meeting expenses	2,331,213	1,899,390
Expenses relating to dividend	198,722	78,268
Depreciation	37,099,769	34,794,768
Sundry expenses	10,000	187,500
Expenses relating to CSR	7,068,254	1,000,000
	318,137,538	**267,068,903**

28. SELLING & DISTRIBUTION EXPENSES

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Salary, wages & allowances	2,193,592,990	1,855,966,434
Travelling & conveyance	8,727,247	11,081,320
Head office & sales centers rent	31,175,344	31,290,466
Printing & stationery	12,030,431	10,706,931
Repairs & maintenance-building & equipment	10,417,276	9,006,187
Vehicle fuel & maintenance	28,092,887	26,204,151
Medical expenses	2,884,606	1,958,414
Water, electricity & gas	2,186,163	1,049,113
Postage & stamp	741,790	705,040
Field forces conference expenses	25,985,682	22,325,814
Insurance premium	1,889,665	1,299,039
Entertainment	3,362,087	2,468,472
Training expenses	6,968,893	10,309,093
Staff welfare	2,240,517	-
Telephone, fax, etc.	12,291,587	12,538,522
Fees & charges	810,165	677,675
Advertisement	423,558	97,313
Incentive	133,262,041	117,239,028
Sales representatives conference	6,537,061	-
Detailing bag & brief case	1,382,620	924,850
Field personnel expenses	501,114,181	455,264,397
Product development expenses	677,552	521,018
Product pad & literature	89,922,817	76,210,169
Promotional expenses	121,188,801	53,096,827
Physicians' samples	126,188,801	54,629,037
Market survey & research	8,587,992	7,517,266
Export expenses	18,726,598	10,142,821
Delivery expenses	358,983,316	331,123,726
Depreciation	41,147,797	43,534,036
Sundry expenses	5,600	17,560
Staff uniform	121,310	124,953
Bad debts	2,400,215	1,358,626
	3,754,084,388	**3,149,888,296**
Less: Expenses for INM	(59,236,595)	(46,305,468)
	3,694,847,793	**3,103,582,828**

(a) The number of employees employed in the selling & distribution department throughout the year who received aggregate remuneration less than Tk. 36,000 was nil.

(b) Salary, wages & allowances include P.F. contribution of Tk. 69,090,936 and Gratuity of Tk. 68,860,522.

(c) The number of employees employed in the selling & distribution department for part of the year who received aggregate remuneration less than Tk. 3,000 per month was nil.

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
28.01 CONSOLIDATED SELLING & DISTRIBUTION EXPENSES		
Salary, wages & allowances	2,565,956,073	2,173,998,804
Travelling & conveyance	10,270,624	11,830,353
Head office & sales centers rent	32,354,896	32,432,213
Printing & stationery	12,036,281	10,706,931
Repairs & maintenance-building & equipment	10,418,376	9,012,960
Repairs & maintenance-vehicle & others	28,621,361	26,982,820
Medical expenses	3,699,206	1,969,314
Water, electricity & gas	2,201,909	1,049,113
Postage & stamp	741,790	705,040
Field forces conference expenses	32,340,521	28,062,599
Insurance premium	1,889,665	1,309,558
Entertainment	3,590,360	2,636,665
Training expenses	8,578,132	10,761,670
Staff welfare	2,590,729	285,596
Telephone, fax, etc.	13,082,199	13,552,152
Fees & charges	811,890	689,675
Donation & subscription	19,500	500,000
Advertisement	513,558	159,713
Incentive	141,239,688	124,637,429
Sales representatives conference	6,537,061	-
Detailing bag & brief case	1,666,880	1,171,450
Field personnel expenses	586,468,231	536,035,130
Product development expenses	733,233	753,877
Product pad & literature	91,151,678	77,090,473
Promotional expenses	134,769,064	59,104,961
Physicians' samples	142,497,925	60,579,290
Market survey & research	8,587,992	7,517,266
Export expenses	18,726,598	10,142,821
Delivery expenses	367,868,598	338,069,546
Depreciation	41,905,240	44,004,101
Sundry expenses	13,630	19,797
Staff uniform	121,310	124,953
Bad debts	2,400,215	1,358,626
	4,274,404,411	**3,587,254,894**

(a) Field personnel expense increase due to increase of field personnel movement in order to increase sales.

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
29. OTHER INCOME		
Dividend income/ IBBL-MPB	848,735	103,000
Profit on bank deposits	4,528,055	2,506,832
Foreign exchange fluctuation gain/(Loss) on FCAD ERQ accounts	9,034,412	1,217,618
Toll charge-Income	7,428,448	10,485,573
Export cash incentive	8,171,125	-
Rental income from INM and Polymer	610,000	610,000
Received from PF	602,059	304,966
Profit from MTD	2,599,404	4,050,606
Miscellaneous income	1,415,461	2,461,068
	35,237,698	**21,739,663**

i) Toll charge income increased during the year due to work order increased from tall customers.
ii) The amount of provident fund forfeiture has been returned during third period from The IBN SINA Pharmaceutical Industry PLC. Employees provident fund and also recognized as other income as per circular of Financial Reporting Council, Bangladesh no:179/FRC/FRM/Circular/2020/2 dated July 07, 2020.

29.1 CONSOLIDATED OTHER INCOME		
Dividend income/ IBBL-MPB	848,735	103,000
Profit on bank deposits	4,608,549	2,972,217
Foreign exchange fluctuation gain/(Loss) on FCAD ERQ accounts	9,034,412	1,217,618
Toll charge-Income	7,428,448	10,485,573
Export Cash Incentive	8,171,125	-
Received from PF	602,059	304,966
Profit from MTD	2,599,404	7,661,581
Miscellaneous income	1,939,510	2,461,068
	35,232,241	**25,206,023**
	49,806,420	**42,953,850**

30. WORKERS' P.P FUND & WELFARE FUND

This represents 5% of net profit before tax after charging the contribution as per provision of the Bangladesh Labour Act, 2006 and is payable to workers as defined in the said Act.

30.1 CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND		
The IBN SINA Pharmaceutical Industry PLC	49,806,420	42,953,850
The IBN SINA Natural Medicine Ltd.	3,173,484	404,541
	52,979,904	**43,358,391**
31. INCOME TAX EXPENSES		
Current Tax	206,654,091	202,718,520
Deferred Tax (income)/expense (Note-19)	(3,212,483)	(3,803,551)
Prior year tax assessment adjustment	-	-
	203,441,607	**198,914,969**
Tax expenses in relation to Continuing operation	203,441,607	198,914,969
Tax expenses in relation to discontinuing operation	-	-
	203,441,607	**198,914,969**

31.1 Reconciliation of Effective Tax Rate

Types of income	2025-2026			2024-2025	
	Income	Effective Tax Rate	Tax expenses	Tax expenses	Rate
Capital gain	-	20.00%	-	-	15.00%
Dividend income	848,735	20.00%	169,747	20,600	20.00%
Income from associates	-	0.00%		-	0.00%
Business Income	995,279,670	20.00%	199,055,934	171,794,799	20.00%
	996,128,405	**20.00%**	**199,225,681**	**171,815,399**	**20.03%**
Non deductible expenses		0.43%	4,254,241	6,827,610	1.96%
changes of effective tax rate on opening temporary difference		0.03%	271,726	271,961	-1.14%
Prudency adjustment			-	20,000,000	-
Under estimation in prior year		0.00%	-	-	3.71%
		20.45%	**203,751,648**	**198,914,970**	**24.07%**

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
31.02 CONSOLIDATED INCOME TAX EXPENSES		
Current Tax	224,524,099	210,665,371
Deferred Tax income/(expense)	(2,870,662)	(3,947,246)
Prior year tax assessment adjustment	-	-
	221,653,436	**206,718,125**
32. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES		
Closing value of marketable securities	(22,790,788)	(17,271,479)
Opening value of marketable securities	(17,271,479)	(9,567,467)
	(5,519,309)	**(7,704,012)**

	2025-2026	2024-2025
33. EARNINGS PER SHARE (EPS)		
Basic earnings per share has been calculated as follows :		
Earnings attributable to the Ordinary Shareholders (Net profit after tax)	792,686,798	660,162,024
Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
EARNINGS PER SHARE (EPS)	**25.37**	**21.13**

Earning Per Share (EPS) increased during the year 2025-2026 due to increase in sales and maintaining stable

33.01.A CONSOLIDATED EARNINGS PER SHARE (EPS)		
Basic earnings per share has been calculated as follows :		
Earnings attributable to the owners of the company	794,633,174	633,189,350
Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
EARNINGS PER SHARE (EPS)	**25.43**	**20.27**
33.01. NET ASSETS VALUE PER SHARE (NAV)		
Net Assets Value	4,520,143,263	3,932,383,056
Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
Net Assets Value Per Share	**144.67**	**125.86**

Net Assets Value Per Share (NAV) increased during the year 2025-2026 due to increase in sales, maintaining stable expenses growth and increase in retained earning.

		AMOUNT IN TAKA	
		2025-2026	2024-2025
33.01.B	**CONSOLIDATED NET ASSETS VALUE PER SHARE (NAV)**		
	Net Assets Value	4,655,848,970	3,997,848,260
	Less: Non-Controlling Interest	(139,240,723)	(70,946,596)
	Equity Attributable to the owners of the company	4,516,608,247	3,926,901,664
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
	Net Assets Value Per Share	**144.56**	**125.69**
33.02	**NET OPERATING CASH FLOWS PER SHARE (NOCFPS)**		
	Net cash provided by operating activities	1,176,592,329	711,823,400
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
		37.66	**22.78**

Increase in NOCFPS arise due to decrease of supplier payment and others and changes in current assets and liabilities.

33.02.01	**CONSOLIDATED NET OPERATING CASH FLOWS PER SHARE (NOCFPS)**		
	Net cash provided by operating activities	1,185,621,432	723,678,635
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
		37.95	**23.16**

33.03	**RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES**		
	Profit before tax (PBT)	**996,128,405**	**859,076,993**
	Adjustment		210,358,629
	Depreciation	204,065,440	(4,573,952)
	Deferred Tax	(3,764,414)	1,217,618
	Unrealized foreign exchange loss	9,034,412	-
	Dividend received	(848,735)	(103,000)
	Interest Income	(4,528,055)	(2,506,832)
	Change In operating assets		
	Increase in inventory	(135,019,577)	(264,997,476)
	Increase in accounts receivables	7,351,133	(20,287,478)
	Decrease in advances, deposits and prepayments	(129,086,310)	(37,775,097)
	Increase/(decrease) in trade and other payable	552,191,495	229,829,819
	Increase/(decrease) in retirement benefit obligation	(482,826)	(194,634)
	Tax paid during the year	(190,610,415)	(174,510,320)
	Interest expense	(127,838,224)	(83,710,869)
	Net Cash generated operating activities	**1,176,592,329**	**711,823,401**

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025

33.03A CONSOLIDATED RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES

Profit before tax (PBT)	**1,014,580,738**	**839,974,353**
Adjustment		
Depreciation	**204,065,**440	210,358,629
Deferred Tax	(3,764,414)	(4,573,952)
Unrealized foreign exchange loss	9,034,412	1,217,618
Gain on sale of motor vehicles	(848,735)	-
Dividend received	(4,528,055)	(103,000)
Interest Income		(2,506,832)
Change In operating assets		
Increase in inventory	(164,295,832)	(222,736,169)
Increase in accounts receivables	7,351,133	(20,287,478)
Decrease in advances, deposits and prepayments	(111,250,689)	(47,270,578)
Increase/(decrease) in trade and other payable	569,587,199	234,178,513
Increase/(decrease) in retirement benefit obligation	(482,826)	(194,634)
Tax paid during the year	(205,988,714)	(180,666,965)
Interest expense	(127,838,224)	(83,710,869)
Net Cash generated operating activities	**1,185,621,432**	**723,678,635**

33.04 FINANCE CHARGE

Finance charge for long term finance.	126,555,744	83,710,869
Finance charge for lease	1,282,480	3,692,459
	127,838,224	**87,403,328**

Finance charge increased due to increased in long term loan.

33.04.01 CONSOLIDATED FINANCE CHARGE:

Finance charge for long term finance.	126,555,744	83,710,869
Finance charge for lease	1,282,480	3,692,459
	127,838,224	**87,403,328**

33.05 NON-CONTROLLING INTEREST

	Profit Amount	(%)	Net Amount
The IBN SINA API Industry Ltd.	(40,087,406)	0.000067	(27)
The IBN SINA Natural Medicine Ltd.	45,976,099	0.001260	579
The IBN SINA Polymer Industry Ltd.	(4,875,501)	35.000000	(1,706,425)
	1,013,192		**(1,705,873)**

34. VALUE OF IMPORTS ON CIF BASIS

Materials (raw & packing)	3,148,198	2,998,284
Components & spare parts	10,297	9,807
Capital goods	131,612	125,345
	3,290,108	**3,133,436**

34.01 VALUE OF IMPORT AND LOCAL PURCHASE

Value of import and local purchase Raw materials consist of 9805 items which 95.69% are imported.
Value of import and local purchase Packing materials consist of 3,290 items which 4.31% are imported.

35. INSTALLED CAPACITY, ACTUAL PRODUCTION ON SINGLE SHIFT BASIS AND REASONS FOR SHORT-FALL DURING THE YEAR ENDED 30th June, 2026 :

Quantity in Thousand

Product Group	Unit	2025-2026		2024-2025	
		Installed	Actual production	Installed	Actual production
Tablet	Pcs	1,223,000	1,319,116	1,223,000	1,304,926
Capsule	Pcs	410,000	480,801	410,000	418,324
Dry Syrup / ORS	Bottle	57,773	28,218	57,773	31,377
Liquid	Bottle	37,000	36,022	37,000	32,077
Drops	Pcs	6,124	7,607	6,124	7,745
Ointment	Pcs	16,555	10,578	16,555	9,042
Injection	Pcs	19,154	10,745	18,798	8,733

Production was made keeping in view market demand.

36. RELATED PARTY TRANSACTIONS

During the year, the company carried out transactions with related parties in the normal course of business and on an arm's length basis. The name of related parties, relationship, types of transaction and their total value have been set out in accordance with the provisions of IAS 24 "Related Party Disclosures". Transaction with related parties are executed on the same terms as those of other customers of similar credentials and do not involve more than a normal risk.

Name of Party	Relationship	Nature of transaction	Transaction		30-Jun-26	
			Dr.	Cr.	Receivable/(Payable)	
1.The IBN SINA Trust	Sponsor Shareholder	Dividend Payment	88,597,197	-	-	-
2. The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital	-	130,000,000	799,999,800	-
		Receivable	-	-	-	-
3. The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Capital	-	-	238,169,670	-
		Lease rental	-	250,000	-	-
		Distibution commission	-	59,236,595	-	-
		Receivable Payable	-	-	-	-
4. The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share capital	-	70,000,000	-	-
		Lease rental		270,000		

i) The company has been allotted a pieces of land (1.52 Akor) by BSCIC in API Park,(Gozaria, Munshigonj). The company has transferred the right of said land to its 99.99% owned Subsidiary named: The IBN SINA API Industry Ltd. at cost.

ii) Related party transactions between the company and its subsidiaries have been eliminated in the consolidation.

36.1 Key management benefit disclosure personnel and their compensation :

Particulars		2025-2026	2024-2025
Short term employee benefits	No. of Director-4	12,000,000	11,900,000
Post-employment benefits		-	-
Other long term benefits		-	-

Key management personnel compensation includes benefits for employees of the rank of director and above. No remuneration is given to the board of director's apart from attendance fees in connection with board and sub committee meeting during the year 2025-2026. Attendance fees in connection with board and sub board committee meeting are Tk. 1,811,789 (2025-2026 Tk.2,423,894).

DEBTS DUE FROM AND DUE TO KEY MANAGEMENT PERSONNEL.

There is no debts due from and due to key management personnel of the company.

37. Commitment and contingency. There was no contract for Capital Expenditure remaining to be executed and not provided for at 30 June 2026.

38. There was no general nature of credit facilities available to the company under any contract other than trade credit available in the ordinary course of business and not availed of as on 30.06.2026.

39. No brokerage or discount other than usual trade discount against sales was paid during the year.

40. As there was no sales agent, commission therefore was not paid.

41. There is no regular employees who received remuneration less than 36,000.00 in aggregate throughout the financial year.

42. As there was no non-resident shareholder, no dividend was remitted abroad.

43. At the end of this year closing balance of FCAD ERQ account was USD $11,95,199.54 out of which USD $90,498.49 in IBBL, USD $11,01,766.28 in AIBL and USD $ 2,934.77 in Sonali Bank PLC.

44. There were aggregating income tax claims of Tk. 11,047,567 in respect of assessment years 2012-2013, 2013-2014 and 2014-2015 respectively against the Company for Income Tax in different years but no asset or liability was recognized for the claims. The Company filed Income Tax Reference case with High Court Division of the Supreme Court & Appeals remained pending for adjustment for these cases.

45. There was no contingent liability other than letters of credit outstanding for importation of raw & packing materials, capital goods as on 30.06.2026.

46. FINANCIAL RISK MANAGEMENT:

The company management has overall responsibility for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risks from its use of financial instruments.

(a) Credit Risk
(b) Liquidity Risk
(c) Market Risk

46.1 Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the company's receivables. Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. As at 30th June 2026, substantial part of the receivables are as follows and subject to insignificant credit risk. Risk exposures from other financial assets, i.e. Cash at bank and other external receivables are also nominal.

(i) Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting data was:

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
Accounts receivable		
Advance to employees	6,102,581	5,482,341
Advance to suppliers	12,433,414	12,433,414
Trade receivable (net of bad debt provision)	170,988,026	181,402,168
Other receivables	77,086,030	52,075,437
Security deposit	20,580,535	21,275,544
Imprest cash	3,535,000	3,540,000
Cash at bank	149,773,374	170,528,294
	440,498,960	**446,737,199**

The aging of trade receivables at the reporting date is as follows:

Trade receivables (gross)		
Below 30 days	117,240,051	124,764,508
With in 61-90 days	43,485,156	45,591,093
With in 91-120 days	2,846,581	7,011,122
Above 180 days	9,816,453	5,394,071
	173,388,241	**182,760,794**

i) To mitigate the credit risk against trade receivables, the company has a system of specific credit line period to the customers. This outstanding period and amount are regularly monitored. The company endeavors to cover the credit risks on all other receivables, where possible, by restricting credit facility and stringent monitoring.

ii) All of the company's advance, trade receivable are considered good. All of the receivable are considered collectable and hence no doubtful or bad receivable included under trade receivable.

iii) The company did not make any advance, deposit, prepayment to the director, subsidiary, associates or other connected party and advance employees are realized in normal course of business.

iv) Security deposit include advance Tk. 11,661,000 given for head office rent which is adjustable at end of rent agreement .

Consolidated Accounts receivable:		
Advance to employees	16,459,616	9,555,942
Advance to suppliers	13,573,966	31,119,648
Trade receivable (net of bad dept provision)	170,988,026	181,402,168
Other receivables	91,201,628	72,758,441
Security deposit	21,635,232	22,330,241
Imprest cash	3,665,000	3,670,000
Cash at bank	285,023,263	304,095,694
	602,546,730	**624,932,134**

The aging of trade receivables at the reporting date is as follows:

Trade receivables (gross)		
Below 30 days	117,240,051	124,764,508
With in 61-90 days	43,485,156	45,591,093
With in 91-120 days	2,846,581	7,011,122
Above 180 days	9,816,453	5,394,071
	173,388,241	**182,760,794**

46.2 Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalents to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. The carrying amount of financial liabilities represent the maximum exposure to liquidity risk. The maximum exposure to liquidity risk as at 30th June was:

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
Trade and other payables	705,359,343	354,248,263
Security money received from employees	12,437,585	11,517,972
Other current liabilities	49,806,420	42,953,850
	767,603,349	**408,720,085**

46.3 Market Risk

Market risk is the risk that any change in market prices, such as foreign exchange rates and interest rates will affect the company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(i) Interest Rate Risk

Interest rate risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate. Exposure to fair value movement relates to fixed rate instrument subject to fair value accounting and exposure to cash flow fluctuation relates to variable rate instruments. The Company is primarily exposed to cash flow fluctuation arising from variable rate borrowings. The objective of interest rate management for The IBN SINA Pharmaceutical Industry PLC is to reduce financial cost and ensure predictability.

(ii) Currency Risk

The company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw material, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD and related to procurement of raw materials, machineries and equipment from abroad

47. Events after the reporting period :

The Board of Directors of the company approved the financial statements as on 30/09/2026 and recommended 77% cash dividend for the financial year ended June 30, 2026.

PROPERTY, PLANT AND EQUIPMENT (PPE)
AS AT 30 JUNE, 2026

Annexure-A
Amount in Taka

Particulars	Cost/Revaluation					Depreciation				Written down value on 30.06.2026
	On 01.07.2025	Addition during the year	Disposal / Adjustment	Total on 30.06.2026	Rate	On 01.07.2025	For the Year	Disposal / Adjustment	Total on 30.06.2026	
Land & Land Development	599,267,406	-	-	599,267,406	-	-	-		-	599,267,406
Building	380,819,686	-		380,819,686	2.50%	69,022,448	7,794,931		76,817,379	304,002,307
Plant & Machinery	1,779,206,037	42,161,490		1,821,367,526	10.00%	983,734,122	80,386,613		1,064,120,735	757,246,791
Internal Road	4,842,880	-	-	4,842,880	10.00%	3,738,858	110,402		3,849,260	993,620
Installations	93,924,272	-	-	93,924,272	10.00%	45,283,773	4,864,050		50,147,823	43,776,449
Equipment	812,151,720	59,510,819		871,662,540	10.00%	300,953,051	52,210,424		353,163,474	518,499,065
Computers	72,371,404	6,546,079		78,917,483	30.00%	56,060,961	5,797,728		61,858,690	17,058,793
Furniture & Fixtures	91,965,922	15,107,560		107,073,482	10.00%	48,518,324	5,015,788		53,534,112	53,539,370
Motor Vehicles	253,209,246	7,765,831	-	260,975,077	20.00%	186,083,689	14,183,031	-	200,266,720	60,708,358
Motorcycle	43,945,025	6,132,425		50,077,450	20.00%	8,789,005.00	8,257,689		17,046,694	33,030,756
Spares & Loose Tools	28,009,108	-		28,009,108	30.00%	26,189,868	545,772		26,735,640	1,273,468
Library Books	867,659	-		867,659	30.00%	848,906	5,626		854,532	13,127
Temporary Construction	8,489,054	-		8,489,054	30.00%	8,192,876	88,853		8,281,730	207,324
TOTAL-30th June, 2026	**4,169,069,419**	**137,224,204**	-	**4,306,293,623**		**1,737,415,883**	**179,260,907**	-	**1,916,676,789**	**2,389,616,834**
TOTAL-30th June, 2025	**3,956,915,644**	**215,232,652**	**(3,078,877)**	**4,169,069,419**		**1,554,782,910**	**185,554,095**	**(2,921,123)**	**1,737,415,882**	**2,431,653,537**

ALLOCATION OF DEPRECIATION

Allocation to	Note no.	Allocated Depreciation 2024-2025			Allocated Depreciation 2024-2025		
		PPE	ROU	Total	PPE	ROU	Total
Manufacturing Expenses	Note-26	136,007,372	-	136,007,372	141,189,496	-	141,189,496
Administrative Expenses	Note-27	17,102,518	9,807,753	26,910,272	16,442,173	9,192,925	25,635,097
Selling & Distribution Expenses	Note-28	26,151,017	14,996,780	41,147,797	27,922,427	15,611,609	43,534,036
Total		**179,260,907**	**24,804,533**	**204,065,440**	**185,554,095**	**24,804,533**	**210,358,629**

The company has been allotted a pieces of land (152 Decimel) by BSCIC in API Park, (Gozaria, Munshigonj). The company is transferred the right of said land to its 99.99% owned subsidiary named: IBN SINA API Ltd. at cost.

Investment of Marketable Securities (Fair Value): 2025-2026

Annexure-B
Amount in Taka

Sl. No.	Name of Company Mutual Fund/Bond	No. of Shares Held	Face Value per Share	Cost Holding	Average Cost	Quoted Rate per Share as on 30-06-2026	Total Market Value of Shares as on 30-06-2026	Unrealised Gain/(Loss)
1	Exim Bank PLC	380,000	10.00	4,461,895	11.74	3.00	1,140,000	(3,321,895)
2	First Security Islami Bank PLC	2,051,000	10.00	19,129,655	9.33	1.90	3,896,900	(15,232,755)
3	Shahjalal Islami Bank PLC	103,000	10.00	2,096,388	20.35	18.00	1,854,500	(242,388)
4	Al-Arafa Islami Bank PLC	108,150	10.00	2,633,035	24.35	15.50	1,676,325	(956,710)
5	Social Islami Bank PLC	173,643	10.00	2,159,166	12.43	3.00	520,929	(1,638,237)
6	Islami Bank Bangladesh PLC (IBBL)-in Mddaraba Perpetual Bond (MPB)	4,590	1,000.00	4,448,858	969.25	664.50	3,050,055	(1,398,803)
Total (2025-2026)		**2,820,383**		**34,928,997**			**12,138,209**	**(22,790,788)**
Total (2024-2025)		**2,820,383**		**34,928,997**			**17,657,518**	**(17,271,479)**

The above Investment in Marketable Securities that are designated as available for sale by the management. These are measured at fair value and presented as non-current asset and unrealized gain/(loss) from the above investment are recognized as other comprehensive income.

	AMOUNT IN TAKA	
	01 July 2025to 30 June 2026	01 July 2024to 30 June 2025
Gain/(Loss) On Marketable Securities (Unrealised):		
Unrealised Gain/(Loss) Position (Closing)	(22,790,788)	(17,271,479)
Unrealised Gain/(Loss) Position (Opening)	(17,271,479)	17,657,518
Gain on Marketable Securities during the year	(5,519,309)	(34,928,997)

IBN SINA

Reports of the Subsidiary Companies

IBN SINA

The IBN SINA Natural Medicine Ltd.



Directors' Report

Directors' Report to the Shareholders for the year ended June 30, 2026

Dear Shareholders,

The Board of Directors of The IBN SINA Natural Medicine Ltd. is pleased to present the Directors' Report together with the audited financial statements of the Company for the year ended June 30, 2026. The report includes the Statement of Financial Position, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows, and the Statutory Auditors' Report thereon, in compliance with Section 184 of the Companies Act 1994, applicable IAS/IFRS, and the guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC).

The IBN SINA Natural Medicine Ltd. continued to strengthen its position in the natural medicine and healthcare products segment during the year. The Company maintained its focus on product innovation and portfolio expansion, responding to evolving consumer needs and market opportunities. During the fiscal year 2025-2026, the Company introduced four new products, further broadening its portfolio of natural, nutritional and healthcare products. These initiatives, together with the trust and credibility established among consumers and healthcare professionals, contributed to the Company's continued business growth.

Operational Results

A summary of the operational performance for FY 2025–26 is as follows:

Particulars	July 01, 2025 to June 30, 2026 (Amount in Taka)	July 01, 2024 to June 30, 2025 (Amount in Taka)
Turnover	1,480,912,378	1,157,636,691
Gross Profit	665,406,697	502,814,274
Profit from Operation	66,788,191	8,684,815
Profit Before Tax	63,469,607	8,090,813
NET PROFIT AFTER TAX	**45,550,465**	**975,039**
Gross Profit Ratio (%)	44.93%	43.42%
Net Profit Ratio (%)	3.07	0.08%
Net Asset Value (NAV)	**351,271,002**	**305,720,537**

For the year ended June 30, 2026, the Company achieved a total revenue of Tk. 1480.9 million. Effective cost control and sound working capital management enabled the Company to register an operating profit of Tk. 66.7 million, with net profit before tax of Tk. 63.4 million and net profit after tax of Tk. 45.5 million.

Shareholding

The shareholding structure of the Company:

Name of the Shareholders	Shareholding (Shares)	% of Shareholding
The IBN SINA Pharmaceutical Industry PLC	23,816,967	99.9988%
Prof. Dr. A K M Sadrul Islam	100	0.0004%
Mr. Kazi Harun or Rashid	100	0.0004%
Prof. Dr. Choudhury Mahmood Hasan	100	0.0004%
Total	**23,817,267**	**100%**

The IBN SINA Natural Medicine Ltd. continues to hold the status of a subsidiary of The IBN SINA Pharmaceutical Industry PLC.

Board of Directors

The Members of the Board of Directors:

Name	Designation
Dr. Mohammad Ayub Miah (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Chairman
Mr. Kazi Harun or Rashid	Managing Director
Prof. ANMA Zaher (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Director Finance
Prof. Dr. A K M Sadrul Islam	Director
Prof. Dr. Choudhury Mahmood Hasan	Director
Prof. Colonel Dr. Zehad Khan (Retd.) (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Director
Mr. Abdus Sadeque Bhuiyan (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Independent Director

During the year ended June 30, 2026, the Board of Directors held 6 (six) meetings to discharge its responsibilities of business affairs and ensure effective governance of the Company.

Induction of a Director

During the year, at its 341st Meeting held on 30 June 2026, the Board of Directors of The IBN SINA Pharmaceutical Industry PLC, the holding company of The IBN SINA Natural Medicine Ltd., nominated Dr. Mohammad Ayub Miah for appointment as a Director on the Board of The IBN SINA Natural Medicine Ltd.

Subsequently, in the 35th Meeting held on 30 June 2026, the Board of Directors of The IBN SINA Natural Medicine Ltd., upon due consideration and review, appointed Dr. Mohammad Ayub Miah as a Director of the Company, subject to approval by the shareholders at its Annual General Meeting in accordance with the applicable provisions.

Also that, pursuant to the decision of the Board, Dr. Mohammad Ayub Miah was appointed as Chairman of the Board of Directors of the Company for a term of 5 (five) years effect from 1 July 2026 for a term extending from 1 July 2026 to 30 June 2031.

Financial Position

The Statement of Financial Position as on June 30, 2026, along with other related financial statements, is annexed to this report as shown in the page no. 253

Dividend Declaration

As per the audited accounts for FY 2025–26, the Company recorded a net profit after tax of Tk. 45.5 million. Considering future expansion requirements, the Board has recommended not to declare any dividend for the year under review.

With retained earnings and prudent reinvestment of profit, the Board is confident in maintaining a sustainable dividend policy in the coming years.

Compliance with BSEC's Corporate Governance Code

In accordance with Condition No. 2 of BSEC's Corporate Governance Code (Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated June 3, 2018), the Board duly complied with the required conditions, including:

(a) Provisions relating to the composition of the Board of the holding company, The IBN SINA Pharmaceutical Industry PLC was made applicable to the composition of the Board of the subsidiary company, The IBN SINA Natural Medicine Ltd.;

(b) Mr. Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU Independent Director of the holding company has been performing the duties as Independent Director of the Company with dedication and sincerity since January 2022 on the Board of The IBN SINA Natural Medicine Ltd.;

(c) The minutes of the Board meeting of The IBN SINA Natural Medicine Ltd. were placed for review at the following Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC;

(d) The minutes of the respective Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC (IPI) duly stated that they (The Board of IPI) have reviewed the affairs of The IBN SINA Natural Medicine Ltd.;

(e) The Audit Committee of the holding company reviewed the financial statements, in particular the investments made by the subsidiary company, The IBN SINA Natural Medicine Ltd.;

Appointment of Auditors

Malek Siddiqui Wali, Chartered Accountants performed as Statutory Auditors of the Company for the financial year as at June 30, 2026. Malek Siddiqui Wali, Chartered Accountants has given their expression of interest (EOI) to be re-appointed as Auditors for the next financial year.

The profile of the audit firms and their audit works performed in the last year was reviewed by the Audit Committee and suggested to reappoint Malek Siddiqui Wali, Chartered Accountants as Statutory Auditors of the Company for the year, 2026-27.

The Board of Directors of The IBN SINA Natural Medicine Ltd. has concurred with the opinion of Audit Committee and hence recommended in favor of Malek Siddiqui Wali, Chartered Accountants to reappoint as Statutory Auditors of the Company for the year 2026-27 with a remuneration of Tk. 85,000/= (Taka Eighty Five Thousand).

Acknowledgement

The Board of Directors expresses its sincere appreciation to all employees of the Company for their hard work, dedication, and contribution to the Company's progress. The Board also gratefully acknowledges the support, cooperation, and encouragement received from shareholders, stakeholders, and well-wishers.

Signed on behalf of the Board of Directors.

Kazi Harun or Rashid
Managing Director

Dr. Mohammad Ayub Miah
Chairman

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Independent Auditor's Report to the Shareholders of

To the Shareholders of The IBN SINA Natural Medicine Ltd.

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of The IBN SINA Natural Medicine Ltd. (the Company), which comprise the statement of financial position as at June 30, 2026, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at June 30, 2026, and of its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the Financial Reporting Council (FRC) of Bangladesh.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements of the Financial Reporting Council together with the ethical requirements of the Institute of Chartered Accountants of Bangladesh (ICAB) Bye-Laws that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matter

The statutory auditor of the Company for the year ended June 30, 2025 (comparative financial statements for 2025) was S. F. Ahmed & Co., Chartered Accountants, who issued an unmodified audit opinion on the financial statements. As S. F. Ahmed & Co., Chartered Accountants also audited the preceding financial year, we have not expressed a separate opinion on the opening balances of the current year's financial statements.

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the IASB and adopted by the Financial Reporting Council (FRC) of Bangladesh, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

International Affiliation :
Reddy Siddiqui LLP, UK, Chartered Accountatnts
Website: www.reddysiddiqui.com

Branch Office :
Rupayan Shopping Square (9th Floor)
Plot # C-2, Block # G, Bashundhara, Dhaka-1229, Bangladesh

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Report on other Legal and Regulatory Requirements:

In accordance with the Companies Act 1994 and Financial Reporting Act 2015, we also report the following:

a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of these books;

c) The statement of financial position and the statement of comprehensive income dealt with by the report are in agreement with the books of account and returns; and

d) The financial statements have been prepared in accordance with standards, framework, compliance and guidelines adopted and promulgated by the Financial Reporting Council;

Md. Waliullah, FCA, Enrolment No: 0247
Malek Siddiqui Wali, Chartered Accountants
FRC Firm Enlistment No.: CAF - 001 –091
RJSC Firm Registration No: P-50041/2022
Dhaka/ September 27, 2026
DVC: 2610070247AS929730

The IBN SINA Natural Medicine Ltd.

Statement of Financial Position

As at 30 June 2026

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
ASSETS		
Non-Current Assets	**84,317,895**	**81,894,410**
Property, Plant and Equipment	81,841,937	79,332,838
Advances, Deposits and Prepayments	250,000	250,000
Right-of-Use Assets	2,225,958	2,311,572
Current Assets	**388,841,666**	**326,977,949**
Inventories	233,588,068	204,311,813
Trade Receivables	9,529,336	8,456,420
Advances, Deposits and Prepayments	58,801,236	50,697,215
Cash and Cash Equivalents	86,923,026	63,512,501
TOTAL ASSETS	**473,159,561**	**408,872,359**
SHAREHOLDERS' EQUITY AND LIABILITIES		
Shareholders' Equity	**351,271,002**	**305,720,537**
Share Capital	238,172,670	238,172,670
Retained Earnings	113,098,332	67,547,867
LIABILITIES		
Non-Current Liabilities:	**3,246,295**	**3,100,219**
Employee Benefit Obligations	-	-
Lease Liabilities	2,455,645	2,482,243
Deferred Tax Liabilities	790,651	617,976
Current Liabilities	**118,642,262**	**100,051,603**
Lease Liabilities	26,598	24,402
Trade and Other Payables	68,001,813	67,159,816
Current Tax Liabilities	50,613,851	32,867,384
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	**473,159,561**	**408,872,359**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS929730

The IBN SINA Natural Medicine Ltd.

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
REVENUE	1,480,912,378	1,157,636,691
Cost of goods sold	(815,505,681)	(654,822,417)
GROSS PROFIT	**665,406,697**	**502,814,274**
OPERATING EXPENSES	**(598,618,505)**	**(494,129,458)**
Administrative expenses	(19,062,068)	(10,457,392)
Selling and Distribution expenses	(579,556,437)	(483,672,066)
PROFIT FROM OPERATION	**66,788,191**	**8,684,816**
Finance cost on lease	(225,598)	(227,613)
Other income	80,494	38,151
Profit before WPPF & Welfare Fund	**66,643,087**	**8,495,354**
Workers' P.P. fund & welfare fund	(3,173,480)	(404,541)
PROFIT BEFORE TAX	**63,469,607**	**8,090,813**
Income tax expenses	(17,919,142)	(7,115,775)
PROFIT FOR THE YEAR	**45,550,465**	**975,039**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS929730

The IBN SINA Natural Medicine Ltd.

Statement of Changes In Equity

For the year ended 30 June 2026

AMOUNT IN TAKA

Particulars	Share Capital	Share Premium	Retained Earnings/ (Accumulated Losses)	Total
Balance as at 30 June 2025	**238,172,670**	-	**67,547,867**	**305,720,537**
Issue during the year		-	-	-
Net profit/(Loss) for the year	-	-	45,550,465	45,550,465
Balance as at 30 June 2026	**238,172,670**	**-**	**113,098,332**	**351,271,002**
Balance as at 30 June 2024	**238,172,670**	-	**66,572,828**	**304,745,498**
Issue during the year		-	-	-
Net profit/(Loss) for the year		-	975,039	975,039
Balance as at 30 June 2025	**238,172,670**	-	**67,547,867**	**305,720,537**

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS929730

The IBN SINA Natural Medicine Ltd.

Statement of Cash Flows

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
Cash Flows From Operating Activities:		
Received from revenue from customers	1,479,839,462	1,184,385,563
Payment for operation, expenses & others	(1,430,430,469)	(1,128,209,482)
Cash generated from operations	**49,408,993**	**56,176,081**
Income tax paid	(15,024,176)	(4,794,250)
Net cash inflow /(outflow) from operating activities	**34,384,817**	**51,381,831**
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(10,804,787)	(6,989,157)
Received from bank deposits	80,494	38,151
Net cash inflow /(outflow) from investing activities	**(10,724,293)**	**(6,951,006)**
Cash Flows From Financing Activities:		
Payment of lease liabilities	(250,000)	(250,000)
Net cash inflow /(outflow) from Financing activities	**(250,000)**	**(250,000)**
Increase/(decrease) in cash and cash equivalents	23,410,525	44,180,826
Cash and cash equivalents at beginning of period	63,512,501	19,331,675
Cash and cash equivalents at end of year	**86,923,026**	**63,512,501**

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS929730

IBN SINA

The IBN SINA API Industry Ltd.



Directors' Report

Directors' Report to the Shareholders for the year ended June 30, 2026

Dear Shareholders,

The IBN SINA API Industry Ltd. is located at the API Industrial Park, a project under BSCIC, Government of Bangladesh, Gazaria, Munshiganj. The growth of pharmaceutical sector in Bangladesh is remarkable, backward linkage facility like raw material supply, particularly Active Pharmaceutical Ingredients (API), has become imperative.

During the year the Company continued to advance its API and intermediates development, technology transfer and process development activities. Significant progress was achieved across various development and technology transfer initiatives, alongside continued efforts to strengthen in-house R&D and process development capabilities. These initiatives are aimed at enhancing the Company's self-reliance in critical pharmaceutical inputs, strengthening its product pipeline and supporting future commercial production, of API, pharmaceutical raw materials at their intermediates developments.

Operational Results

The brief summary of operational progress during the year 2025-26:

Particulars	July 01, 2025 to June 30, 2026 (Amount in Taka)	July 01, 2024 to June 30, 2025 (Amount in Taka)
Turnover	NIL	NIL
Gross Profit	NIL	NIL
NET PROFIT AFTER TAX	**(40,587,406)**	**(28,154,929)**
Gross Profit Ratio (%)	NIL	NIL
Net Profit Ratio (%)	NIL	NIL
Net Asset Value (NAV)	**684,506,624**	**595,094,030**

The above expenditures mainly relate to construction, salaries, and research & development activities. The reported loss is expected to be recovered upon commencement full-swing commercial operations of the Company.

Shareholding

The Shareholding pattern of the Company as of June 30, 2026:

Name of the Shareholders	Shareholding (Shares)	% of Shareholding
The IBN SINA Pharmaceutical Industry PLC	66,999,980	99.99996%
Prof. Dr. A K M Sadrul Islam	10	0.000002%
Prof. Dr. Choudhury Mahmood Hasan	10	0.000002%
Total	**67,000,000**	**100%**

On the basis of the above, The IBN SINA API Industry Ltd. holds the status of a subsidiary of The IBN SINA Pharmaceutical Industry PLC.

Board of Directors

The Members of the Board of Directors of the Company:

Name	Designation
Prof. Dr. A K M Sadrul Islam	Chairman
Prof. Dr. Choudhury Mahmood Hasan	Managing Director
Kazi Harun or Rashid (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Director
Prof. Col. Dr. Zehad Khan (Retd.) (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Director
Abdus Sadeque Bhuiyan (Nominated by The IBN SINBA Pharmaceutical Industry PLC)	Independent Director

The number of Board meetings of The IBN SINA API Industry Ltd. held during the year under review was 4 (Four).

Capital Expenditure

Several contracts relating to the development of API molecules, civil construction and R&D facility are under execution. The running bills against these contracts have been duly accounted for in this year's financial statements.

Financial Position

The Statement of Financial Position as on June 30, 2026, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the year then ended are annexed herewith.

Dividend Declaration

As the Company is in the early stage of commercial operations and continues to scale up its business activities, the Board of Directors, considering the financial position of the Company for the year under review, has recommended that no dividend be declared for the year. The earnings are proposed to be retained to support the Company's ongoing operations and future business requirements.

Compliance with BSEC's Corporate Governance Code

In accordance with Condition No. 2 of BSEC's Corporate Governance Code (Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated June 3, 2018), the Board duly complied with the required conditions, including:

(a) Provisions relating to the composition of the Board of the holding company, The IBN SINA Pharmaceutical Industry PLC was made applicable to the composition of the Board of the subsidiary company, The IBN SINA API Industry Ltd.;

(b) Mr. Abdus Sadeque Bhuiyan BSS (Hon's) MSS, DU Independent Director of the holding company has been performing the duties as Independent Director of the Company with dedication and sincerity since January 2022 on the Board of The IBN SINA API Industry Ltd.;

(c) The minutes of the Board meeting of The IBN SINA API Industry Ltd. were placed for review at the following Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC;

(d) The minutes of the respective Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC (IPI) duly stated that they (The Board of IPI) have reviewed the affairs of The IBN SINA API Industry Ltd.

(e) The Audit Committee of the holding company reviewed the financial statements, in particular the investments made by the subsidiary company, The IBN SINA API Industry Ltd.

Appointment of Auditors

Malek Siddiqui Wali, Chartered Accountants performed as Statutory Auditors of the Company for the financial year as at June 30, 2026. Malek Siddiqui Wali, Chartered Accountants has given their expression of interest (EOI) to be re-appointed as Auditors for the next financial year.

The profile of the audit firms and their audit works performed in the last year was reviewed by the Audit Committee and suggested to reappoint Malek Siddiqui Wali, Chartered Accountants as Statutory Auditors of the Company for the financial year, 2026-27.

The Board of Directors of The IBN SINA API Industry Ltd. has concurred with the opinion of Audit Committee and hence recommended in favor of Malek Siddiqui Wali, Chartered Accountants to reappoint as Statutory Auditors of the Company for the year 2026-27 with a remuneration of Tk. 75,000/= (Taka Seventy Five Thousand).

Acknowledgement

The Board of Directors expresses its sincere appreciation to all employees of the Company for their hard work, dedication, and commitment. The Board also acknowledges with gratitude the support and cooperation received from the regulators, stakeholders, bankers, contractors, and well-wishers who contributed to the progress of the Company.

Signed on behalf of the Board of Directors.

Prof. Dr. Choudhury Mahmood Hasan
Managing Director

Prof. Dr. A K M Sadrul Islam
Chairman

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Independent Auditor's Report to the Shareholders of

To the Shareholders of The IBN SINA API Industry Ltd.

Report on the Audit of the Financial Statements

Opinion:

We have audited the financial statements of The IBN SINA API Industry Ltd. (the Company), which comprise the statement of financial position as at June 30, 2026, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at June 30, 2026, and of its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the Financial Reporting Council (FRC) of Bangladesh.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements of the Financial Reporting Council together with the ethical requirements of the Institute of Chartered Accountants of Bangladesh (ICAB) Bye-Laws that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matter:

The statutory auditor of the Company for the year ended June 30, 2025 (comparative financial statements for 2025) was S. F. Ahmed & Co., Chartered Accountants, who issued an unmodified audit opinion on the financial statements. As S. F. Ahmed & Co., Chartered Accountants also audited the preceding financial year, we have not expressed a separate opinion on the opening balances of the current year's financial statements.

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the IASB and adopted by the Financial Reporting Council (FRC) of Bangladesh, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

International Affiliation :
Reddy Siddiqui LLP, UK, Chartered Accountatnts
Website: www.reddysiddiqui.com

Branch Office :
Rupayan Shopping Square (9th Floor)
Plot # C-2, Block # G, Bashundhara, Dhaka-1229, Bangladesh

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Report on other Legal and Regulatory Requirements:

In accordance with the Companies Act 1994 and Financial Reporting Act 2015, we also report the following:

a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of these books;

c) The statement of financial position and the statement of comprehensive income dealt with by the report are in agreement with the books of account and returns; and

d) The financial statements have been prepared in accordance with standards, framework, compliance and guidelines adopted and promulgated by the Financial Reporting Council;

Md. Waliullah, FCA, Enrolment No: 0247
Malek Siddiqui Wali, Chartered Accountants
FRC Firm Enlistment No.: CAF - 001 –091
RJSC Firm Registration No: P-50041/2022
Dhaka/ September 27, 2026
DVC: 2610070247AS105682

The IBN SINA API Industry Ltd.

Statement of Financial Position

As at 30 June 2026

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	164,672,352	142,245,156
Capital Work-In-Progress	720,013,896	627,802,179
Investment in API Industrial Park	29,000,000	29,000,000
Total Non- Current Assets	**913,686,247**	**799,047,334**
Current Assets		
Advances, Deposits and Prepayments	3,291,212	19,711,758
Cash and Cash Equivalents	6,930,362	19,918,307
Total Current Assets	**10,221,574**	**39,630,065**
TOTAL ASSETS	**923,907,821**	**838,677,400**
SHAREHOLDERS' EQUITY AND LIABILITIES		
Shareholders' Equity		
Share Capital	670,000,000	670,000,000
Share Money Deposit	130,000,000	-
Retained Earnings/(Accumulated Losses)	(115,493,376)	(74,905,970)
	684,506,624	**595,094,030**
LIABILITIES		
Non-Current Liabilities		
Long Term Finance	207,106,866	221,482,304
Deferred Tax Liabilities	1,375,046	1,205,919
	208,481,912	**222,688,222**
Current Liabilities		
Trade and Other Payables	580,500	74,750
Current Tax Liabilities	1,032,599	909,057
Short Term Finance	29,306,186	19,911,341
Total Current Liabilities	**30,919,285**	**20,895,148**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	**923,907,821**	**838,677,400**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS105682

The IBN SINA API Industry Ltd.

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
REVENUE	-	-
Cost of goods sold	-	-
GROSS PROFIT	-	-
OPERATING EXPENSES	**(40,788,904)**	**(28,456,093)**
Administrative expenses	(40,788,904)	(28,456,093)
Selling and Distribution expenses	-	-
OPERATING PROFIT	**(40,788,904)**	**(28,456,093)**
Finance Cost	-	-
Other Income	494,167	426,685
Profit before WPPF & Welfare fund	**(40,294,737)**	**(28,029,408)**
Workers' P.P. Fund & Welfare Fund	-	-
PROFIT BEFORE TAX	**(40,294,737)**	**(28,029,408)**
Income Tax Expenses	(292,669)	(125,521)
PROFIT FOR THE YEAR	**(40,587,406)**	**(28,154,929)**

The annexed notes form an integral part of these financial statements

Chief Financial Officer | **Company Secretary** | **Director** | **Managing Director** | **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS105682

The IBN SINA API Industry Ltd.

Statement of Changes In Equity

For the year ended 30 June 2026

AMOUNT IN TAKA

Particulars	Share Capital	Share Premium	Retained Earnings/ (Accumulated Losses)	Total
Balance as at 30 June 2025	**670,000,000**	-	**(74,905,970)**	**595,094,030**
Issue during the year	-	130,000,000	-	130,000,000
Net profit/(Loss) for the year	-	-	(40,587,406)	(40,587,406)
Balance as at 30 June 2026	**670,000,000**	**130,000,000**	**(115,493,376)**	**684,506,624**
Balance as at 30 June 2024	**550,000,000**	-	**(46,751,041)**	**503,248,959**
Issue during the year	120,000,000	-	-	120,000,000
Net profit/(Loss) for the year	-	-	(28,154,929)	(28,154,929)
Balance as at 30 June 2025	**670,000,000**	-	**(74,905,970)**	**595,094,030**

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS105682

The IBN SINA API Industry Ltd.

Statement of Cash Flows

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
A. Cash flows from operating activities		
Payment for operation, expenses & others	(14,786,767)	(34,206,699)
Income Tax paid	(165,352)	(128,558)
Net cash used by operating activities	**(14,952,119)**	**(34,335,257)**
B. Cash flows from investing activities		
Acquisition of Property, Plant and Equipment and CWIP	(123,549,401)	(96,393,611)
Bank Profit received	494,167	426,685
Net cash used in investing activities	**(123,055,234)**	**(95,966,926)**
C. Cash flows from financing activities		
Share Capital	-	120,000,000
Share Money Deposit	130,000,000	-
Long term finance received/(paid) from bank (Net)	(14,375,437)	99,999,777
Short term finance received/(paid) from bank (Net)	9,394,845	(100,472,103)
Net cash provided by financing activities	**125,019,408**	**119,527,674**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(12,987,945)	(10,774,509)
Opening cash and cash equivalents	19,918,308	30,692,817
Closing cash and cash equivalents	**6,930,362**	**19,918,308**

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS105682

IBN SINA

The IBN SINA Polymer Industry Ltd.



Directors' Report

Directors' Report to the Shareholders for the year ended June 30, 2026

Dear Shareholders,

The Board of The IBN SINA Polymer Industry Ltd. is hereby presenting the Directors' Report along with the audited financial statements of the Company containing the Statement of Financial Position as on June 30, 2026, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for the year ended June 30, 2026 and the Auditors Report thereon in terms of the provisions of Section 184 of the Companies Act 1994, IAS/IFRS Codes and the guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC).

The Company's principal objective is to carry on manufacturing and selling of basic primary packaging materials for pharma production including PET bottles, compression molding, plastic caps, eye drops plastic vials, plastic drops, douche plastic bottles, polybags, etc. in first phase to ease of backward linkage factory for IBN SINA Pharma production which is related to the pharma packaging supply chain. In second phase, the Company intends to manufacture printed aluminum blister foils, laminated strips foils, PVC films, poly laminated alu foils, etc.

The IBN SINA Polymer Project is located at Chalkpara, Mawna, Gazipur, Bangladesh. Construction work of a two-storied admin building, having total floor area of 7,750 sqf., four-storied Production Building, having total floor area of 122,236 sqf., along with two-storied Generator building, having 6785 sqf., have been completed. Installation and commissioning of production machine is in progress full-swing and trial production will commence by January 2027.

Operational Results

The brief summary of operational performance during the year 2025-26 is as follows:

Particulars	2025-26 July 01 to June 30	2024-25 July 01 to June 30
Turnover	NIL	NIL
Gross Profit	NIL	NIL
NET PROFIT AFTER TAX	**(4,875,501)**	**116,385**
Gross Profit Ratio (%)	NIL	NIL
Net Profit Ratio (%)	NIL	NIL
Net Asset Value (NAV)	**337,483,693**	**202,359,195**

The above result reveals that the project is not yet set into operation. The above expenditure amount mainly incurred in the development stage of the project.

Shareholding

The present shareholding pattern of the Company is as follows: -

Name of the Shareholders	Shareholding (Shares)
The IBN SINA Trust	**100,00,000**
The IBN SINA Pharmaceutical Industry PLC	**200,00,000**
Total	**300,00,000**

Based on above shareholdings, The IBN SINA Polymer Industry Ltd. has the status of subsidiary to The IBN SINA Pharmaceutical Industry PLC.

Board of Directors

The following persons are the Members of the Board of Directors of the Company:

Name	Designation
Prof. Dr. Choudhury Mahmood Hasan (Nominated by The IBN SINA Trust)	Chairman
Kazi Harun or Rashid (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Managing Director
Prof. Dr. A K M Sadrul Islam (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Director
Dr. Mohammad Ayub Mia (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Director
Md. Rafiqul Islam Khan FCA, (Nominated by The IBN SINA Pharmaceutical Industry PLC)	Independent Director

The number of Board meetings of The IBN SINA Polymer Industry Ltd. held during the year was 5 (Five).

Financial Position

The Statement of Financial Position as on June 30, 2026, Statement of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows ended at June 30, 2026 are placed herewith.

Dividend Declaration

The IBN SINA Polymer Industry Ltd. is now project stage. As per audited accounts of the Company as at 30 June 2026, the net profit after tax stood Tk.(4,875,501)/- as profit for the same period.

Hence, the Board of Directors of The IBN SINA Polymer Industry Ltd. has recommended not to declare any dividend for the year under review.

Compliance of BSEC's Code of Governance

As per Condition No. 2 of Corporate Governance Code of BSEC's notification No. BSEC/ CMRRCD/ 2006-158/207/Admin/80 Date: 3 June 2018 relating to Governance of Board of Directors of Subsidiary Company, the Board duly complied with the required conditions of the Code mentioned below -

(a) Provisions relating to the composition of the Board of the holding company, The IBN SINA Pharmaceutical Industry PLC was made applicable to the composition of the Board of the subsidiary company, The IBN SINA Polymer Industry Ltd.;

(b) Md. Rafiqul Islam Khan FCA Independent Director of the holding company is the Independent Director on the Board of The IBN SINA Polymer Industry Ltd.;

(c) The minutes of the Board meeting of The IBN SINA Polymer Industry Ltd. were placed for review at the following Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC;

(d) The minutes of the respective Board meeting of the holding company, The IBN SINA Pharmaceutical Industry PLC duly stated that they (The Board of holding company, IPI) reviewed the affairs of The IBN SINA Polymer Industry Ltd.;

(e) The Audit Committee of the holding company also reviewed the financial statements, in particular the investments made by the subsidiary company, The IBN SINA Polymer Industry Ltd.

Appointment of Auditors

Malek Siddiqui Wali, Chartered Accountants performed as Statutory Auditors of the Company for the financial year as at June 30, 2026. Malek Siddiqui Wali, Chartered Accountants has given their expression of interest (EOI) to be re-appointed as Auditors for the next financial year.

The profile of the audit firms and their audit works performed in the last year was reviewed by the Audit Committee and being eligible as per law, suggested

to reappoint Malek Siddiqui Wali, Chartered Accountants as Statutory Auditors of the Company for the financial year, 2026-27.

The Board of Directors of The IBN SINA Polymer Industry Ltd. has concurred with the opinion of Audit Committee and hence recommended in favor of Malek Siddiqui Wali, Chartered Accountants to reappoint as Statutory Auditors of the Company for the year 2026-27 with a remuneration of Tk.70,000/= (Taka Seventy Thousand).

Acknowledgement

The Board of Directors thankfully acknowledge the devotion and dedication of all the employees without which the Company's development works-in-progress could not have attained satisfactory as reported above.

The Board also record with appreciation the support, services and co-operation rendered by all concerned.

Signed on behalf of the Board of Directors.



Kazi Harun or Rashid
Managing Director



Prof. Dr. Choudhury Mahmood Hasan
Chairman

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Independent Auditor's Report to the Shareholders of

To the Shareholders of The IBN SINA Polymer Industry Ltd.

Report on the Audit of the Financial Statements

Opinion:

We have audited the financial statements of The IBN SINA Polymer Industry Ltd. (the Company), which comprise the statement of financial position as at June 30, 2026, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at June 30, 2026, and of its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and adopted by the Financial Reporting Council (FRC) of Bangladesh.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements of the Financial Reporting Council together with the ethical requirements of the Institute of Chartered Accountants of Bangladesh (ICAB) Bye-Laws that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matter

The statutory auditor of the Company for the year ended June 30, 2025 (comparative financial statements for 2025) was S. F. Ahmed & Co., Chartered Accountants, who issued an unmodified audit opinion on the financial statements. As S. F. Ahmed & Co., Chartered Accountants also audited the preceding financial year, we have not expressed a separate opinion on the opening balances of the current year's financial statements.

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Director's report and other information contained within the annual report except the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover other information and we do not express any form of assurance conclusion thereon.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the IASB and adopted by the Financial Reporting Council (FRC) of Bangladesh, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

International Affiliation :
Reddy Siddiqui LLP, UK, Chartered Accountatnts
Website: www.reddysiddiqui.com

Branch Office :
Rupayan Shopping Square (9th Floor)
Plot # C-2, Block # G, Bashundhara, Dhaka-1229, Bangladesh

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Malek Siddiqui Wali
Chartered Accountants
Since 1965
9-G, Motijheel C/A (L-2), Dhaka-1000, Bangladesh.

Phone : +88-02-9513471
Email : info@msw-bd.com
Website : www.msw-Bd.com

Report on other Legal and Regulatory Requirements:

In accordance with the Companies Act 1994 and Financial Reporting Act 2015, we also report the following:

a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of these books;

c) The statement of financial position and the statement of comprehensive income dealt with by the report are in agreement with the books of account and returns; and

d) The financial statements have been prepared in accordance with standards, framework, compliance and guidelines adopted and promulgated by the Financial Reporting Council;

Md. Waliullah, FCA, Enrolment No: 0247
Malek Siddiqui Wali, Chartered Accountants
FRC Firm Enlistment No.: CAF - 001 –091
RJSC Firm Registration No: P-50041/2022
Dhaka/ September 27, 2026
DVC: 2610070247AS240657

The IBN SINA Polymer Industry Ltd.

Statement of Financial Position

As at 30 June 2026

	AMOUNT IN TAKA	
	30 June 2026	30 June 2025
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	2,380,977	2,288,144
Capital Work-In-Progress	285,986,565	148,734,393
Right-of-Use Assets	3,262,399	3,386,681
Total Non- Current Assets	**291,629,941**	**154,409,218**
Current Assets		
Advances, Deposits and Prepayments	9,563,322	3,698,151
Other Financial Assets	-	-
Deferred Tax Assets	84,714	73,107
Cash and Cash Equivalents	43,065,801	50,790,551
Total Current Assets	**52,713,836**	**54,561,809**
TOTAL ASSETS	**344,343,777**	**208,971,027**
SHAREHOLDERS' EQUITY AND LIABILITIES		
Shareholders' Equity		
Share Capital	300,000,000	200,000,000
Share Money Deposit (Potential Share Capital)	40,000,000	-
Retained Earnings/(Accumulated Losses)	(2,516,307)	2,359,195
	337,483,693	**202,359,195**
LIABILITIES		
Non-Current Liabilities		
Lease Liabilities	3,584,272	3,619,926
Total Non Current Liabilities	**3,584,272**	**3,619,926**
Current Liabilities		
Trade and Other Payables	343,991	74,750
Lease liabilities	35,654	32,596
Current Tax Liabilities	2,896,167	2,884,560
Total Current Liabilities	**3,275,812**	**2,991,906**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	**344,343,777**	**208,971,027**

The annexed notes form an integral part of these financial statements

Chief Financial Officer | **Company Secretary** | **Director** | **Managing Director** | **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS240657

The IBN SINA Polymer Industry Ltd.

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
REVENUE	-	-
Cost of goods sold	-	-
GROSS PROFIT	-	-
OPERATING EXPENSES	**(4,577,979)**	**(2,603,079)**
Administrative expenses	(4,577,979)	(2,603,079)
Selling and Distribution expenses	-	-
PROFIT FROM OPERATION	**(4,577,979)**	**(2,603,079)**
Finance cost on lease	(327,404)	(330,200)
Other income	29,882	3,611,524
Profit before WPPF & Welfare Fund	**(4,875,501)**	**678,245**
Workers' P.P. Fund & Welfare Fund	-	-
PROFIT BEFORE TAX	**(4,875,501)**	**678,245**
Income tax (expenses)/income	-	(561,860)
PROFIT FOR THE PERIOD	**(4,875,501)**	**116,385**

The annexed notes form an integral part of these financial statements

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS240657

The IBN SINA Polymer Industry Ltd.

Statement of Changes In Equity

For the year ended 30 June 2026

AMOUNT IN TAKA

Particulars	Share Capital	Share Premium	Retained Earnings/ (Accumulated Losses)	Total
Balance as at 30 June 2025	**200,000,000**	-	**2,359,195**	**202,359,195**
Issue during the year	100,000,000	-	-	100,000,000
Net profit/(Loss) for the year	-	-	(4,875,501)	(4,875,501)
Balance as at 30 June 2026	**300,000,000**	**-**	**(2,516,306)**	**297,483,694**
Balance as at 30 June 2024	**100,000,000**	-	**2,242,810**	**102,242,810**
Issue during the year	100,000,000	-	-	100,000,000
Net profit/(Loss) for the year	-	-	116,385	116,385
Balance as at 30 June 2025	**200,000,000**	-	**2,359,195**	**202,359,195**

Chief Financial Officer **Company Secretary** **Director** **Managing Director** **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS240657

The IBN SINA Polymer Industry Ltd.

Statement of Cash Flows

For the year ended 30 June 2026

	AMOUNT IN TAKA	
	01 July 2025 to 30 June 2026	01 July 2024 to 30 June 2025
A. Cash flows from operating activities		
Payment for operation, expenses & others	(9,604,824)	(3,347,501)
Income tax paid	(188,771)	(1,233,838)
Net cash used in operating activities	**(9,793,595)**	**(4,581,339)**
B. Cash flows from investing activities		
Realization / (Acquisition) of financial assets	-	76,177,784
Acquisition of property, plant and equipment	(348,865)	(2,351,974)
Acquisition of CWIP	(137,252,172)	(125,548,777)
Bank Profit	29,882	4,725,301
Net cash used in investing activities	**(137,571,154)**	**(46,997,667)**
C. Cash flows from financing activities		
Share Capital	100,000,000	100,000,000
Share Deposit Account	40,000,000	-
Payment of lease liabilities	(360,000)	(360,000)
Net cash from financing activities	**139,640,000**	**99,640,000**
D. Net increase/(decrease) in cash and cash equivalents (A+B+C)	**(7,724,749)**	**48,060,995**
E. Cash and cash equivalents at beginning of year	50,790,551	2,729,556
F. Cash and cash equivalents at end of year (D+E)	**43,065,801**	**50,790,551**

Chief Financial Officer | **Company Secretary** | **Director** | **Managing Director** | **Chairman**

As per our annexed report of same date

Malek Siddiqui Wali Chartered Accountants
RJSC Firm Registration No: P-50041/2022

Md. Waliullah, FCA
Enrolment No: 0247

Dated: Dhaka
September 27, 2026
Document verification code(DVC) No : 2610070247AS240657



Excerpts from 41th Annual General Meeting

The 41th Annual General Meeting of the The IBN SINA Pharmaceutical Industry PLC was held on 23 November, 2025 at Digital (Virtual) Platform. A good number of Shareholders participated the AGM by Digital Platform. Kazi Harun or Rashid, Chairman of the Company presided over the meeting. After recitation from the Holy Quran, the Annual General Meeting was started by the welcome address to the Shareholders by the Chairman.

The Annual General Meeting is a forum through which the Shareholders are informed of Company's activities and progress. The Chairman of the meeting invited comments on Directors' Report and Audited Financial Statements for the year ended 30 June, 2025. In the question and answer session, Shareholders were encouraged to ask questions before approval of the particular agenda. The Shareholders expressed their views on the important activities of the company, its success and progress in the competitive local and overseas markets.

The due process of election and detailed information of "voting results" of each agenda and its resolution was authenticated by Independent Scrutinizer appointed for the purpose as per BSEC's instruction and reported the same to the BSEC within the stipulated time of conclusion of AGM.

The Managing Director Prof. Dr. A K M Sadrul Islam thanked the Shareholders for their constructive suggestions for the sustainable improvement of the Company. Strategies and future stategy of the company had also been discussed. Shareholders put up their valuable recommendations which were discussed and reviwed in the subsequent Board Meeting and proper actions in this respect had duly been taken. The meeting approved @ 64% Cash dividend as against per share of Tk. 10 for the year 2024-25.

Virtual Annual General Meeting (AGM) Logistics

Pursuant to the Bangladesh Securities and Exchange Commission's Directive No. BSEC/ICAD/2024/318/87, dated March 27, 2024, a listed Company can arrange virtual Annual General Meeting via live webcast by using digital platform. Accordingly the 42nd AGM (Virtual Meeting) of The IBN SINA Pharmaceutical Industry PLC has been scheduled to be held on Monday, 23 November 2026 at 9:30 AM by using digital platform and online Shareholders' tools enabling the Shareholders to participate fully, and equally, from any location around the world.



Monday, 23 November 2026



Time 9:30 AM



Live Webcast
https://ibnsinapharma.bdvirtualagm.com

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি

প্রক্সি ফরম

আমি/আমরা..... দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি-এর সদস্য/সদস্যাবৃন্দ.....টি সাধারণ শেয়ারের মালিক। জনাব.....কে আমার/আমাদের প্রক্সি হিসেবে ২৩ নভেম্বর ২০২৬, সোমবার, ডিজিটাল (ভার্চুয়াল) প্লাটফর্মে অনুষ্ঠিতব্য কোম্পানীর ৪২তম বার্ষিক সাধারণ সভায় এবং একই প্লাটফর্মে অনুষ্ঠিতব্য যে কোন মুলতবী সভায় উপস্থিত থাকার জন্য এবং আমার/আমাদের পক্ষে ভোটদানের জন্য নিয়োগ করছি।

১০০ টাকার রেভিনিউ স্ট্যাম্প লাগান

প্রক্সির স্বাক্ষর.....

তারিখ.....

.....

শেয়ারহোল্ডারের স্বাক্ষর

তারিখ.....

ফলিও নং | | | | | | অথবা

বিও নং | | | | | | | | | | | | | | | | |

দ্রষ্টব্য

১. "স্বাক্ষর" কোম্পানী অফিসে রক্ষিত "নমুনা স্বাক্ষর" অনুযায়ী হওয়া বাঞ্ছনীয়।

২. সভা অনুষ্ঠানের নির্ধারিত সময়ের অন্ততঃ ৭২ (বাহাত্তর) ঘন্টা পূর্বে প্রক্সি ফরম ১০০ টাকার রেভিনিউ স্ট্যাম্প সহকারে যথাযথভাবে পূরণ করে কোম্পানীর রেজিস্টার্ড অফিসে জমা দিতে হবে।

৩. প্রক্সি ফরম এর ফটোস্ট্যাট কপি ব্যবহার করা যাবে।

IBN SINA

দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি

হাজিরা পত্র

আমি ২৩ নভেম্বর ২০২৬, সোমবার সকাল ০৯.৩০ টায় ডিজিটাল (ভার্চুয়াল) প্লাটফর্মে অনুষ্ঠিতব্য দি ইবনে সিনা ফার্মাসিউটিক্যাল ইন্ডাস্ট্রি পিএলসি-এর ৪২তম বার্ষিক সাধারণ সভায় আমার উপস্থিতি লিপিবদ্ধ করলাম।

শেয়ারহোল্ডার/প্রক্সির নাম.....শেয়ার সংখ্যা.....

ফলিও নং | | | | | | অথবা

বিও নং | | | | | | | | | | | | | | | | |

.....

শেয়ারহোল্ডার/প্রক্সির স্বাক্ষর



The **IBN SINA**
Pharmaceutical Industry PLC

Corporate Office: Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur
Dhaka-1207, Bangladesh, Tel: +880-2-41022148, 41022150-58, 41022174
Website: www.ibnsinapharma.com, E-mail: shareipi@ibnsinapharma.com
Fax: +880-2-41022140, Factory: Shafipur, Kaliakoir, Gazipur, Bangladesh